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Abstract 
 
 
Mycobacteria are acid fast bacilli responsible for the wide spread global diseases 
tuberculosis and leprosy. The increased persistence of multidrug resistant (MDR) 
mycobacterial strains has led to the focus on discovery of new and under-utilised cellular 
targets such as the cell wall. 
 
Peptidoglycan, the principle structural component of the bacterial cell wall is a hetero-
polymer comprised of alternating monosaccharides cross-linked by pentapeptide chains. 
The cell wall of mycobacteria are inherently resistant to antimicrobials and aid in evasion 
from host immune detection due to modifications to its composition. The hydroxylase 
enzyme NamH has been documented to play a role in the N-glycolylation of peptidoglycan 
monosaccharides, utilizing molecular oxygen during aerobic growth to convert N-acetyl- 
to N-glycolyl groups. This modification is found predominantly in  Actinobacteria, except 
Mycobacterium leprae due to genomic reduction.  The percentage incorporation of N-
acetylated and N-glycolylated saccharides is dependent upon the environment and 
functional characterisation of the impact of each modification is vital to achieving a greater 
understanding into mycobacterial response to a range of factors including dormancy, 
resuscitation and intracellular propagation. 
 
The investigations described in this thesis concern the susceptibility of a M. smegmatis 
DnamH strain, the cell wall of which contains solely N-acetylated cell wall components 
towards: (a) selected hydrolytic enzymes, as a model of the survival of phagocytosed 
mycobacteria within the harsh conditions of the phagolysosome and; (b) new and existing 
antimicrobials commonly used as therapies against infection. The absence of the N-
glycolylated sugar within the peptidoglycan cell wall led to consistently observed increases 
in susceptibility to a range of hydrolytic enzymes and antimicrobials, especially those 
which target the formation of peptidoglycan. Mycobacterial Mur ligases demonstrated 
increased catalytic bias towards N-glycolylated substrates to increase their inclusion into 
the wide peptidoglycan sacculus.  Investigations were expanded to characterize the impact 
of newly discovered known cell wall active compounds against the peptidoglycan 
biosynthesis machinery. 
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Chapter 1: Introduction 
 
1.1 Tuberculosis 
 
Tuberculosis (TB, tubercules bacillus) is a contagious disease affecting approximately a third of 
the human population (Houben and Dodd 2016). The World Health Organisation (WHO) 
categorises TB as the second most preeminent cause of death by an infectious disease (WHO, 
2012). Worldwide occurrences of tuberculosis were diminishing towards the end of the 21st 
century, but the rise of widespread resistance to standard drug therapies and the number of human 
immunodeficiency virus (HIV) co-infections have led to the disease being categorised as a global 
health emergency (WHO, 2011). The rising global impact of tuberculosis coupled with the 
emergence of multiple therapy resistances leads to the requirement of new antimicrobial treatments 
as well as identifying new and re-examining pre-existing targets in mycobacteria such as the 
peptidoglycan (PG) cell wall.  
 
 
1.2 Mycobacteria  
 
Mycobacteria are aerobic unicellular rod organisms noted to include an increased C-G content of 
bases. Commonly aligned with Gram positive bacteria due to genetic similarity, the genus 
Mycobacterium is part of the family Actinobacteria, encompassing 170 species (Fedrizzi, et al. 
2017). Mycobacteria are categorised as Acid-Fast bacilli (AFB) (Riello, et al. 2016), and include 
organisms such as Mycobacterium tuberculosis (M. tuberculosis), Mycobacterium leprae (M. 
leprae) and Mycobacterium smegmatis (M. smegmatis).  
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1.2.1 Mycobacterium tuberculosis complex (MTBC) 
 
Mycobacterium tuberculosis is classified as part of the Mycobacterium tuberculosis complex 
(MTBC), a group of genetically similar mycobacteria (Chimara, et al. 2004), which infect 
numerous hosts with tuberculosis. M. tuberculosis, M. africanum and M. canettii are categorised 
as human pathogens (Somoskovi, et al. 2009, de Jong, et al. 2010), M. bovis infects both bovine 
and human subjects (Vayr, et al. 2018), and M. microti infects rodent species (Vayr, et al. 2018).  
 
 
1.2.1.1 Mycobacterium tuberculosis 
 
In 1882 Robert Koch first discovered the causative agent of tuberculosis in humans, M. 
tuberculosis (Koch, 1882). Koch demonstrated an in vitro method for reproducing the disease 
pathophysiology observed initially in humans by infecting animal cells with M. tuberculosis. The 
mycobacterium was visualised under a microscope utilising a newly conceived staining technique 
(Weigert, 1875), which led to Koch receiving the 1905 Nobel Prize in Medicine for his isolation 
and investigation of tuberculosis.  
 
 
1.2.2 Non-tuberculosis mycobacteria (NTM) 
 
Other members of the genus mycobacteria excluding the MTBC and M. leprae are classified as 
non-tuberculosis mycobacteria (NTM) (Fedrizzi, et al. 2017). NTM reside within a number of 
environments such as soil and water (Falkinham 2015), and though rarely pathogenic can cause 
infection notably in immunosuppressed hosts (Horsburgh, et al. 1993). 
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1.2.2.1 Mycobacterium smegmatis  
 
Due to the laboratory containment procedures required to study M. tuberculosis and the inability 
to easily culture M. leprae (Bailey, et al. 2017), the weakly-pathogenic saprophyte M. smegmatis 
is commonly used as a model to investigate mycobacteria (He and De Buck 2010) due in part to 
the organism’s fast growth and the ease of generating cultures in manufactured media. The original 
M. smegmatis wild type strain displayed a low transformation efficiency, and was resolved by the 
isolation of an efficient-plasmid-transformation (ept) mutant strain, defined as mc2155 (Snapper, 
et al. 1990). 
 
 
1.2.3 Mycobacterium leprae 
 
Leprosy, also known as Hansen’s disease, was identified by Armauer G. Hansen in 1873 (Vera-
Cabrera, et al. 2015). Leprosy is induced by the intracellular pathogen M. leprae and 
acknowledged to be a major public health issue in numerous developing countries (Sales, et al. 
2011). Requiring an extended incubation period within host cells, infection predominantly occurs 
within the skin, the peripheral nervous system and the upper respiratory tract (Ooi and Srinivasan 
2004). There are various methods of categorising leprosy. The World Health Organisation 
separates patients based upon the visible type and number of afflictions on the skin (Gaschignard, 
et al. 2016). Those who display less than five skin lesion with a negative bacterial skin sample are 
termed paucibacillary. Patients with either or both, a greater number of skin lesion than five and/or 
a positive skin test detection of bacteria are termed multibacillary. A second method of 
categorising leprosy is determined by the immune response of the host to the bacilli (Ochoa, et al. 
1996). A robust immune system response contributes only to a smaller number of visible skin 
lesions and a thickening of peripheral nerves, culminating in the patient registering as moderately 
contagious, described as tuberculoid leprosy. An impaired immune system response leads to a 
more pronounced manifestation of skin lesions, a widespread impact on the nervous system and 
additional organs. This disease state is significantly more contagious and denoted as lepromatous 
leprosy. M. leprae is non-culturable long term in vitro on manufactured media and agar (Bailey, 
et al. 2017), requiring study through traditional in vivo animal models (Adams, et al. 2012).  
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The sequencing of the M. leprae genome (Cole, et al. 2001) has revealed extensive genomic 
reduction, with many of the equivalent genes found in M. tuberculosis described as pseudogenes 
displaying no function (Muro, et al. 2011), including of relevance to this thesis, NamH.  With less 
than fifty percent functional genome, M. leprae lacks numerous metabolic systems justifying the 
required incubation period and the requirement of animal model culture systems. Leprosy is 
commonly diagnosed through a skin biopsy (Joshi 2011), and once confirmation of leprosy is 
attained, a lepromin skin test can also determine the form of leprosy (Krotoski, et al. 1993), 
evaluated by the capacity of the host to initiate a cell-mediated immune response to M. leprae 
bacilli. The presence of swelling and redness indicates the presence of tuberculoid leprosy while 
the absence of changes to the skin indicate lepromatous leprosy. Treatment for leprosy is generally 
a twelve-month multidrug therapy that is tailored to the type of leprosy observed (Malathi and 
Thappa 2013). Paucibacillary leprosy requires dapsone and rifampicin, whereas multibacillary 
leprosy requires both previously mentioned antibiotics plus clofazimine. 
 
 
1.3 Bacterial cell wall 
 
Classified upon the composition of the cell wall, bacteria are commonly identified based upon a 
technique known as Gram staining (Beveridge 2001). The stain was developed by Hans Christian 
Gram as a taxonomic tool based solely on the complexity of the bacterial cell wall and the total 
percentage of amassed peptidoglycan within the sacculus (Austrian 1960). The unique structural 
component is located in virtually all eubacteria, excluding Mycoplasma. The 20-80nm broad 
peptidoglycan layer of gram-positive organisms such as Staphylococcus aureus and Streptococcus 
pneumoniae consists of between 30-70% of the total structure of the cell wall (Schleifer and 
Kandler 1972). Gram-negative bacteria have a minimal 2-3nm peptidoglycan layer along with 
lipoproteins, phospholipids and lipopolysaccharides which are surrounded by an outer membrane 
(Beveridge 1999). Certain bacteria such as mycobacteria do not conform to identification through 
Gram-staining. 
 
The cell wall of mycobacteria is impermeable to different commonly utilised identification 
techniques and the ability to resist decolourisation by acid alcohol is due in part to the inclusion of 
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mycolic acids, a structural component of the mycobacterial cell wall found predominantly in 
Actinobacteria (Kragelund, et al. 2007). Comprised of long chain, branched fatty acids, mycolic 
acids combine with arabinogalactan (AG) and peptidoglycan to form the mycolic acid, 
arabinogalactan and peptidoglycan (mAGP) complex, an integral part of mycobacterial cell wall 
architecture (Alderwick, et al. 2015). The varying components of the bacterial cell wall of Gram-
positive, Gram-negative and acid-fast bacilli are depicted in Figure 1.1. 
 
 
 
Figure 1.1 Cross-section of the major components of the bacterial cell wall of (a) gram-positive, (b) gram-
negative and (c) Acid-Fast bacilli. Gram-positive bacteria contain a greater percentage of peptidoglycan. Gram-
negative bacteria contain a smaller percentage of peptidoglycan and an outer membrane. Acid-Fast Bacilli contain the 
mycolic acid-arabinogalactan-peptidoglycan complex and an outer membrane comprised of glycopeptides and lipids. 
Abbreviations: CM – Cytoplasmic membrane, PG – Peptidoglycan, OM – Outer membrane, CLM – Capsule like 
material, AG – Arabinogalactan, MA – Mycolic acids, LP – Lipopolysaccharides. Adapted from Cabeen and Jacobs-
Wagner (2005), Crick (2001) and Abrahams (2018).  
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1.3.1 Peptidoglycan 
 
Peptidoglycan also known as murein (Vollmer and Holtje 2004) is present in virtually all known 
species of bacteria, excluding select examples such as Mycoplasma and archaebacteria (Kim, et 
al. 2015). Peptidoglycan is not found in eukaryotic cells and is therefore a well-regarded site of 
antimicrobial investigation (Yount and Yeaman 2013). The purpose of the polymer is as a scaffold 
for the bacterial cell; preserving the overall shape, rigidity and stability of the cell membrane to 
protect from outside forces such as osmotic pressures, yet permitting steady bacterial growth, 
expansion and division (Vollmer, et al. 2008). 
 
 
1.3.2 The structure of peptidoglycan 
 
The fundamental structure of peptidoglycan, observed in the majority of bacteria consist of glycan 
strands interconnected by short cross-linked peptide side chains as depicted in Figure 1.2. 
 
 
Figure 1.2: The structure of peptidoglycan in mycobacteria. Alternating N-acetylglucosamine (GlcNAc) and either 
N-acetylmuramic acid (MurNAc) or N-glycolylmuramic acid (MurNGlyc) sugars form glycan chains (blue lines) by 
b-1,4 glycosidic bonds. Chains are interconnected by cross-linking (red lines) amino acid 3 and 4 of parallel peptide 
stems. Position 3 is commonly L-Lysine for Gram-positive organisms and meso-DAP in Gram-negative and Acid-
Fast bacilli. Abbreviations: MurNAc – N-acetylmuramic acid, GlcNAc – N-acetylglucosamine,  L-Ala – L-Alanine, 
D-Glu – D-Glutamate, L-Lys – L-Lysine, m-DAP – meso-diaminopimelic acid.  Adapted from Bugg, et al. (1999). 
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The mycobacterial peptidoglycan backbone is constructed from alternating N-acetylglucosaminyl 
(GlcNAc) and either N-acetylmuramyl (MurNAc) or N-glycolylmuramyl (MurNGlyc) sugar 
residues bound via b(1®4) linkages (Mihelic, et al. 2017). The cross linked bridges are formed 
initially from five bacterial specific amino acids. The formation of peptidoglycan involves the 
implementation of distinct phases to construct the overall sacculus. These are the cytosolic 
assembly of the UDP-MurNAc/NGlyc-pentapeptide subunits, the intracellular membrane-bound 
transport across the plasma membrane and integration into the interweaved sacculus architecture 
(Vollmer 2008). 
 
 
1.3.3 The cytoplasmic steps of peptidoglycan synthesis 
 
Uridine diphospho-N-acetylglucosamine (UDP-GlcNAc), the initial precursor of the cytosolic 
pathway is obtained from glucosamine biosynthesis, a product of carbohydrate metabolism (Spiro 
1958). The first committed enzymatic step in the pathway involves MurA (Rv1315), an UDP-N-
acetyl-glucosamine enolpyruvyl transferase catalyzing the transfer of an enolpyruvate group from 
phosphoenolpyrvate (PEP) to the C3 position of the glucosamine sugar ring of GlcNAc, 
culminating in UDP-GlcNAc-enolpyruvate (Babajan, et al. 2011). The subsequent enzyme in the 
pathway, MurB (Rv0482), an UDP-N-acetylenolpyruvylglucosamine reductase, permits the 
reduction of the enolpyruvate double bond utilising the transfer of electrons from NADPH via 
FAD to form the lactyl group of MurNAc, creating one of the two main subunits of peptidoglycan, 
linked to UDP (UDP-N-acetyl-muramic acid; UDP-MurNAc) (Eniyan, et al. 2018).  
 
The remainder of the pathway appends selected amino acids to UDP-MurNAc to generate the 
pentapeptide stem. The residues appended to the subunit are specific to individual organisms. The 
four amino acid ligases MurC (Rv2151c), MurD (Rv2144c), MurE (Rv2158c) and MurF 
(Rv2157c) are ATP dependent enzymes (Munshi, et al. 2013) which employ an identical reaction 
mechanism involving a high-energy tetrahedral intermediate to react with the relevant amino acid 
to extend the peptidoglycan precursor by up to five amino acids. The standard pentapeptide stem 
is composed from L-Alanine, D-Glutamate, the third position for most Gram-positive organisms 
is L-Lysine or diaminopimelic acid (DAP) whereas most Gram-negative organisms and Acid-fast 
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bacilli incorporate DAP at this position (Consaul, et al. 2004). Variations to this sequence are 
observed in M. leprae. The mycobacterium incorporates L-Glycine into position one of the peptide 
stem as opposed to L-Alanine observed in other members of the mycobacterium genus (Mahapatra, 
et al. 2005). The final two residues are D-alanyl-D-alanine. D-amino acids are not natural cellular 
products, D-Alanine is generated from L-Alanine by a pyridoxal 5’-phosphate (PLP) cofactor 
dependent catalysis of alanine racemase (Alr), while D-Glutamate is isomerized from L-glutamate 
by glutamate racemase (MurI) which deprotonates the a-carbon of L-Glutamate with one active 
site thiol, and reprotonates the intermediate with a second thiol to bring about the L ® D 
conversion of glutamate (Glavas, et al. 2001). ATP dependent D-alanyl-D-alanine ligase (Ddl) 
combines two D-Alanine residues to incorporate them into the UDP-MurNAc peptide stem (Walsh 
1989).  
 
The cytosolic phase of peptidoglycan synthesis is tightly regulated to aid in mycobacterial 
pathogenesis and antibiotic survival. The activity of MurA is regulated by interaction with CwlM, 
an peptidoglycan amidase homologue which when phosphorylated by the Serine/Threonine 
protein kinase PknB increases MurA activity 30 fold (Boutte, et al. 2016). Direct phosphorylation 
of the cytosolic Mur ligases in mycobacteria (Thakur, et al. 2008) is also implemented by PknA 
and PknB to regulate the formation of the pentapeptide stem attached to UDP-MurNAc subunit 
against host stimuli (Munshi, et al. 2013). The cytosolic phase of peptidoglycan synthesis is 
depicted in Figure 1.3. 
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Figure 1.3 The formation of UDP-MurNAc-pentapeptide from the peptidoglycan cytosolic biosynthesis pathway. Cytosolic enzymes MurA and MurB 
transform UDP-GlcNAc into UDP-MurNAc. Four ATP dependent amino acid ligases MurC-F adhere bacterial specific residues (Black – Gram-positive, Blue – 
Gram-negative/Acid-Fast bacilli) to UDP-MurNAc creating UDP-MurNAc-pentapeptide. Abbreviations: NAM – N-acetylmuramic acid, NAG – N-
acetylglucosamine, UDP – Uridine diphosphate, PEP – Phosphoenolpyruvate, ATP – Adenosine triphosphate, Alr – Alanine Racemase, DdlB – D-Ala-D-Ala 
ligase, AFB – Acid Fast Bacilli, L-Ala – L-Alanine, D-Glu – D-Glutamate, L-Lys – L-Lysine, m-DAP – meso-diaminopimelic acid. Adapted from Teo, et al. 
(2015).  
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1.3.4 Formation of Lipid II 
 
Phospho-MurNAc-pentapeptide is translocated from UDP-MurNAc-pentapeptide to a prenyl 
phosphate which in most bacteria is the C55 prenyl phosphate, undecaprenyl phosphate (Chen, et 
al. 2016). Mycobacteria are unique however in that they utilise the C50 prenyl phosphate, 
decaprenyl phosphate for this purpose in a reaction catalysed by MurX (Rv2156c) to form Lipid I 
(decaprenyl diphospho-MurNAc-pentapeptide) (Mahapatra, et al. 2005). The enzyme MurG 
(Rv2153c), a glycosyltransferase is coupled to this reaction and transfers a GlcNAc subunit onto 
the C4 position of the muramyl sugar ring culminating in the formation of Lipid II (decaprenyl 
pyrophosphoryl-MurNAc-(GlcNAc)-pentapeptide (Bouhss, et al. 2008). The decaprenyl 
phosphate carrier is acquired from two sources, the enzymatic phosphorylation of decaprenol or 
the dephosphorylation of decaprenyl pyrophosphate (Touz and Mengin-Lecreulx 2008). 
 
 
1.3.5 Traversal of Lipid II to the extracellular face of the cytoplasmic 
membrane 
 
Before incorporation into the peptidoglycan sacculus, Lipid II must be transported across the 
cytoplasmic membrane by a ‘flippase’. Currently the exact mechanism is unknown but two 
proteins have been reported to flip Lipid II. The first identified by Mohammadi et al. (2011)  was 
E. coli FtsW corresponding to mycobacterial Rv2154c. This protein is important in cell division, 
and has the ability to move peptidoglycan subunits across proteoliposomes and membrane vesicles. 
The mechanism of transport involved a size-restricted pore-like structure with substrate specificity 
for Lipid II. The second protein (Sham et al. 2014) identified by in vivo experiments was MurJ, 
corresponding to mycobacterial Rv3910 as the unidentified flippase. Sham et al. (2004) also 
demonstrated that FtsW was unable to transport Lipid II in vivo. Coordination between a number 
of proteins is currently the suggested mechanism.  
 
The formation of Lipid II and the traversal across the plasma membrane are depicted in Figure 1.4. 
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Figure 1.4 The formation of Lipid II and the traversal of Lipid II across the plasma membrane. UDP-MurNAc-pentapeptide synthesised within the cytoplasm 
is bound to a lipid carrier by MurX, generating Lipid I. MurG adheres GlcNAc to Lipid I forming Lipid II. Lipid II is transported between the cytoplasm and 
extracellular space/periplasmic space (Gram-positive/Gram-negative) by the plasma membrane bound ‘flippase’ FtsW or MurJ. Abbreviations: NAM – N-
acetylmuramic acid, NAG – N-acetylglucosamine, UMP – Uridine monophosphate, UDP – Uridine diphosphate, L-Ala – L-Alanine, D-Glu – D-Glutamate, L-Lys 
– L-Lysine, m-DAP – meso-diaminopimelic acid. Adapted from Teo et al. (2015). 
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1.3.6 Extracellular peptidoglycan integration 
 
Once Lipid II has been transferred across the plasma membrane it is integrated within the existing 
peptidoglycan chains. Penicillin binding proteins (PBPs) are extracellular enzymes, which are 
categorised by activity and molecular weight (Waxman and Strominger 1983). Select PBPs are 
unique in function whereas other display a redundancy (Sassine, et al. 2017). PBPs are divided 
into high molecular weight PBPs with either bifunctional transglycosylase and transpeptidase 
domains or monofunctional transpeptidases and low molecular weight PBPs, which are typically 
carboxypeptidases (Strobel, et al. 2014). Transglycosylation (TG) is the polymerisation of Lipid 
II to form the individual glycan chains that comprise peptidoglycan strands (Galley, et al. 2014). 
Transpeptidation (TP) is the cross-linking of the peptide stems to rigidify the glycan chain 
structures (Sauvage and Terrak 2016). Carboxypeptidation cleaves the terminal D-alanine residues 
from non-cross-linked peptide stems (Sauvage, et al. 2008).  
 
In M. tuberculosis single stands of peptidoglycan are formed from Lipid II monomers along with 
the essential bifunctional PBPs PonA1/PBP1 (Rv0050) and PonA2/PBP2 (Rv3682) (Kieser, et al. 
2015) which adhere the terminal 4’-OH of GlcNAc from one Lipid II onto a second Lipid II 
terminal MurNAc forming a b-1,4 glycosidic bond. The decaprenyl phosphate group is then 
displaced from Lipid II. Regulation of the mycobacterial PBP activity is modulated through 
phosphorylation of the cytoplasmic tail by the serine/threonine protein kinase PknB (Kieser, et al. 
2015), a unique mechanism not observed currently in other organisms (Prisic, et al. 2010) and 
required to alter the rate of mycobacterial growth and cellular elongation (Kieser, et al. 2015). 
 
The transpeptidation of parallel peptidoglycan strands occurs in two variations, either (4®3) or 
(3®3) cross-linking. Bifunctional PBPs contain TP domains that as far as have been observed, 
exclusively catalyse (4®3) cross-linking (Patru, et al. 2017). Transpeptidases that implement 
(3®3) cross-linking have not been found to possess TG activity (Hugonnet, et al. 2016). The most 
common form of cross-linking is (4®3) (Vollmer, et al. 2008), meaning the e-amino group of the 
third position peptide of the stem, m-DAP in mycobacteria is connected to the a-carbonyl of the 
fourth position peptide, D-Alanine of a parallel glycan strand. Transpeptidation involves the 
formation of an acyl-enzyme intermediate (Sauvage, et al. 2008), a noncovalent complex between 
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the a-carbonyl carbon atom of the fourth position D-Alanine residue within the peptide stem of 
the donor peptidoglycan strand and the active site serine of the PBP transpeptidase domain. The 
TP active site utilises a lysine residue to abstract a proton to activate the nucleophilic activity of 
the active site serine (Kumarasiri, et al. 2014), causing the release of the terminal D-Alanine 
residue from the donor stem during acylation. Deacylation occurs through interaction of the acyl-
enzyme intermediate with the e-amino group of the third position amino acid of a secondary 
acceptor peptidoglycan strand displacing the PBP and forming a covalent bond with the donor 
strand resulting in transpeptidation (Macheboeuf, et al. 2007). The mechanism for (4®3) peptide 
stem cross-linking is depicted in Figure 1.5. 
 
 
 
Figure 1.5 Transpeptidase activity of PBPs against parallel mycobacterial peptidoglycan strands forming a 
(4®3) cross-link between peptide stems. The PBP active site lysine residue abstracts a proton to aid the formation 
of an acyl-enzyme intermediate implemented by the PBP active site serine residue against the a-carbonyl carbon atom 
of the fourth position D-Alanine of the donor stem. The terminal D-Alanine of the donor stem is released. Deacylation 
occurs through displacement of the PBP by the e-amino acid group of the third position DAP of the acceptor peptide 
stem forming a covalent bond between the (4®3) cross-link. 
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The second configuration of transpeptidation involves (3®3) cross-linking. The more rigid PG 
structure that results from (3®3) cross-linking is believed to aid against environmental stresses 
such as hypoxia and increase antimicrobial resistance (Peddireddy, et al. 2017). The peptide cross-
links are constructed from transpeptidation by L,D-transpeptidases LdtMt1 (Rv0116c) and LdtMt2 
(Rv2518c) (Correale, et al. 2013), containing an active site cysteine residue instead of the serine 
residue observed within the TP domain of PBPs (Magnet, et al. 2008). The tetrapeptide donor stem 
cleaved by carboxypeptidases interacts with the active site cysteine residue forming an acyl-
intermediate with the third position DAP residue, and releasing the fourth position D-Alanine. 
Deacylation transpires when the enzyme is displaced by the e-amino acid group of the third 
position DAP residue of the acceptor peptide stem forming a (3®3) cross-link covalent bond 
between the two DAP residues. The mechanism of (3®3) cross-linking of peptide stems is 
depicted in Figure 1.6. 
 
 
 
Figure 1.6 L,D-transpeptidase activity against parallel mycobacterial peptidoglycan strands forming a (3®3) 
cross-link between peptide stems. The L,D-transpeptidase active site cysteine residue forms an acyl-enzyme 
intermediate against the a-carbonyl carbon atom of the third position DAP residue of the donor stem. The terminal 
fourth position D-Alanine of the donor stem is released. Deacylation occurs through displacement of the transpeptidase 
by the e-amino acid group of the third position DAP of the acceptor peptide stem forming a covalent bond between 
the (3®3) cross-link. 
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PBPs do not have a eukaryotic equivalent which makes them a key target of antibacterial 
investigations. As noted by the name penicillin binding proteins (Tipper and Strominger 1965), 
penicillins and other b-lactams such as cephalosporins interact with PBPs, specifically inhibiting 
the transpeptidase activity of the enzyme due to the structural similarity of these antibiotics to the 
donor substrate as well as the intrinsic reactivity of the b-lactam ring of penicillin, cephalosporin 
and related antibiotics. Lipid II integration into the polymerised peptidoglycan cell layer is 
depicted in Figure 1.7.
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Figure 1.7 Nascent Lipid II incorporated into the overall peptidoglycan architecture by penicillin binding proteins. Translocated Lipid II synthesised within 
the cytoplasm is integrated by transglycosylation to extend the peptidoglycan glycan chain and parallel chains are cross-linked to improve structural stability by 
transpeptidation of the peptide stems. The lipid carrier is removed and recycled by traversing across the plasma membrane. Abbreviations: NAM – N-acetylmuramic 
acid, NAG – N-acetylglucosamine. Adapted from Teo et al. (2015).  
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1.3.7 Recycling and maintenance of peptidoglycan 
 
The peptidoglycan sacculus is not a static structure. It is constantly being remodelled as new glycan 
monomers are incorporated and existing strands are cleaved to permit peptidoglycan turnover and 
cell division (Vollmer, et al. 2008). The localised removal of glycan strands is tightly regulated by 
peptidoglycan hydrolases. Those that cleave the b-1,4 glycosidic bonds of glycan strands are 
termed glycosidases and those who cleave the (4®3) or (3®3) peptide linkages are 
endopeptidases (Harty, et al. 2000). Once cleaved, the peptidoglycan disaccharides are recycled 
and redistributed as either a source of energy or reprocessed back into peptidoglycan biosynthesis 
(Park and Uehara 2008). Recycling of PG has traditionally been investigated in E. coli, as gram-
positive bacteria lack an outer cell wall therefore it was initially assumed that PG was not recycled 
but instead lost (Park 1995), this is not a currently held belief (Borisova, et al. 2016), though the 
mechanisms for recycling in gram-positive organisms have not yet been identified. The membrane 
protein AmpG has been determined as the cytoplasmic transporter of PG monomers within E. coli 
(Lindquist, et al. 1993). A homologue of AmpG has yet to be classified in mycobacteria. 
 
 
1.3.8 Modifications to peptidoglycan facilitating resistance to hydrolytic 
enzymes 
 
The host’s immune response to invading mycobacteria involves the release of hydrolytic enzymes 
such as lysozyme (Ragland, et al. 2017) to degrade the mycobacterial cell wall and aid immune 
signalling towards infected macrophages (Amaral, et al. 2016). Mycobacteria and other organisms 
attempt to mitigate these actions and evade recognition through specific peptidoglycan 
modifications to alter the composition of the bacterial cell (Ragland, et al. 2017) wall as depicted 
in Figure 1.8.  
 
 18 
 
Figure 1.8 Modifications to the bacterial peptidoglycan monomer Lipid II to decrease susceptibility to host 
hydrolytic enzymes. Bacteria can utilise various alterations to the Lipid II structure to disrupt conventional enzyme 
binding. (a) The standard structure of Lipid II, (b) Amidation of D-glutmate to D-isoglutamine (Blue), (c) N-
glycolylation of MurNAc to MurNGlyc (Pink), (d) O-acetylation of MurNAc (Red), (e) N-deacetylation of MurNAc 
to MurN (Green), (f) N-deacetylation of GlcNAc to GlcN (Green). Adapted from Ragland et al. (2017). 
 
 
1.3.8.1 O-acetylation 
 
O-acetylation is a ubiquitous peptidoglycan modification observed in numerous bacteria involving 
the appendance of an acetyl group to the C-6 hydroxyl of N-acetylmuramic acid sugars. The 
addition is administered by an O-acetyltransferase (OatA) within gram-positive bacteria 
(Moynihan and Clarke 2010) and coordination through a transmembrane bound acetate transporter 
(PatA) and a periplasmic O-acetyltransferase (PatB) in Gram-negative bacteria (Bernard, et al. 
2011). The modification is implemented on nascent peptidoglycan strands and perturbs lysozyme 
binding through steric hindrance without altering the host immune NOD (Nucleotide-binding 
oligomerisation domain-containing protein) recognition of peptidoglycan (Moynihan and Clarke 
2010). 
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1.3.8.2 N-deacetylation 
 
The removal of the C-2 acetyl group from either the GlcNAc or MurNAc moieties within the 
polymerised peptidoglycan, known as N-deacetylation is catalysed by the deacetylase PgdA 
(Rv1096), creating glucosamine, GlcN and muramic acid, MurN moieties (Vollmer and Tomasz 
2000). This modification aids virulence by decreasing host immune NOD recognition of 
peptidoglycan (Boneca, et al. 2007) and reduces lysozyme activity by removing the proposed 
interaction between the acetyl groups and the lysozyme active site (Callewaert and Michiels 2010).  
 
 
1.3.8.3 Amidation 
 
Resistance towards hydrolytic enzymes can also be instigated through modification of the cross-
linked peptide stem of peptidoglycan chains. The second and third residues of the peptidoglycan 
peptide stem D-Glutamate and m-DAP can be amidated (Ngadjeua, et al. 2018) with the D-
Glutamate residue becoming D-Isoglutamine. This modification is predominantly found within 
gram-positive and acid-fast organisms and implemented by enzymes such as the mycobacterial 
amidotransferase GatCAB (Su, et al. 2016) to reduce the overall net negative charge of the cell 
envelope which attracts lysozymes (Figueiredo, et al. 2014). 
 
 
1.3.8.4 N-glycolylation 
 
N-glycolylation is a unique structural alteration of the muramic acid sugar predominantly found in 
all mycobacteria and members of the Actinobacteria family (Vollmer 2008), except M. leprae 
where the orthologue of MTB NamH in this organism (ML0085c) is a pseudogene (Mahapatra, et 
al. 2008). N-glycolylation differs from O-acetylation and N-deacetylation by the cellular region in 
which each modification takes place, occurring solely within the cytoplasm of the mycobacteria 
whereas the other two mentioned modifications occur in the extracellular region solely to 
polymerised PG. The methyl group of the N-acetyl moiety of UDP-MurNAc is oxidised to its 
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corresponding alcohol to form the N-glycolyl moiety by the hydroxylase, NamH (Rv3818) to form 
the N-glycolyl modification of peptidoglycan. (Raymond, et al. 2005), as depicted in Figure 1.9. 
 
 
Figure 1.9: The hydroxylase activity of NamH. Molecular oxygen is fixed (highlighted in red) to the second position 
of the muramic acid ring of UDP-MurNAc due in part to the hydroxylase NamH oxidising the methyl group of the N-
acetyl moiety into the N-glycolyl moiety generating UDP-MurNGlyc.  
 
 
Categorised as a Rieske type monooxygenase enzyme (Rieske, et al. 1964), NamH catalyses the 
addition of a hydroxyl group to the muramic acid from oxygen molecules attained within an 
aerobic environment. NamH enzymes contain a 2Fe-2S centre to catalyse the reaction of oxygen 
with UDP-MurNAc substrates (Liu, et al. 2014). The active site is a flat rhombic cluster of two 
inorganic sulphide ions constructing a bridge with two Fe ions. One of the Fe ions interacts with 
two NamH cysteine residues while the other with two histidine residues. Utilising a reductase and 
cofactors such as NADPH permit the reduction of oxygen (D’Ordine, et al. 2009). 
 
The mycobacterial cell wall incorporates both variants of muramic acid within the PG layer 
(Mahapatra, et al. 2005). The percentage incorporated can differ depending upon factors such as 
phase of cellular growth as well as location within host macrophages. The standard ratio of 
MurNGlyc:MurNAc sugars located within the peptidoglycan of exponentially growing M. 
smegmatis cells was observed by chromatographic and mass spectrometric analysis to be 7:3. 
(Raymond, et al. 2005). Though the addition of the N-glycolyl muramic acids within the 
peptidoglycan structure can mitigate against hydrolytic enzymes, the unique structural 
modifications permits increased immune recognition. The N-glycolylation of muramic acids was 
observed to significantly increase the stimulation of NOD2 receptor recognition during 
mycobacterial infection (Coulombe, et al. 2009). The innate host immune response to 
mycobacterial infection requires pattern recognition molecules such as Nod-like receptors and 
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Toll-like receptors coordinating to recognise the architecture relating to the invading bacilli and 
induce proinflammatory cytokine production (Bodar, et al. 2008). The findings reported by 
Coulombe et al. (2009) indicate that NOD2 pathway maybe precisely focused to recognise specific 
N-glycolylated mycobacterial cellular debris. The implementation of N-glycolylated 
peptidoglycan has however been demonstrated to not impact the pathogenicity of M. tuberculosis 
(Hansen, et al. 2014) 
 
 
1.4 Tuberculosis infection 
 
The obligate pathogen is transmitted from infectious patients in droplets of sputum, residing 
airborne for several hours (Singh, et al. 2016). Bacilli traverse the respiratory tract of hosts, 
invading the macrophages of lung alveoli (Guirado, et al. 2013).  
 
 
1.4.1 Innate immune response 
 
The first point of contact between the immune system of the host and invading bacilli, involves 
recognition of mycobacterial cell wall components such as lipoproteins (LprA) and 
lipoarabinomannans (LAM) (Welin, et al. 2008) by pattern recognition receptors (Toll-like 
receptors (TLR)) of the innate immune system (Takeda and Akira 2005). TLR-2 initiates a pro-
inflammatory immune response, culminating in the activation of nuclear transcription factor (NF)-
κB within the macrophage and secretion of pro-inflammatory cytokines and chemokines to signal 
infection (Domingo-Gonzalez, et al. 2016).  
 
The innate immune system identifies specific structures unique to bacteria such as the 
peptidoglycan cell wall, termed pathogen-associated molecular patterns (PAMPs) to activate 
pattern recognition receptors NOD1 and NOD2 (Fritz, et al. 2006). NOD1 is a receptor for 
muramyl peptides containing meso-diaminopimelic acid (DAP) within the peptide stem of released 
peptidoglycan fragments (Chamaillard, et al. 2003). NOD2 is a receptor for muramyl dipeptide 
ligands (Inohara, et al. 2003) (Mo, et al. 2012). 
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The bacilli are engulfed by phagocytes such as macrophages, neutrophils and dendritic cells 
forming a vacuole from the enclosed plasma membrane, known as a phagosome (Pauwels, et al. 
2017). The internalised environment of the phagosome must undergo significant alterations to pH, 
hydrolytic enzyme content and nitric oxide concentration to successfully lyse the enclosed 
mycobacterial cell (Canton, et al. 2014). This maturation of the phagosome is a key component of 
the innate immune system. Once the bacilli has been phagocytosed two outcomes may transpire, 
favouring either the mycobacterium or the immune system as depicted in Figure 1.10.  
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Figure 1.10 The antibacterial mechanisms of the phagosome to aid (a) host microbial factors, or (b) against bacterial defence mechanisms. Phagocytosed 
bacteria within the host macrophage phagosome attempt to prevent the activation of host antimicrobial activity such as the generation of reactive oxygen species 
(ROS), antimicrobial peptides, proteases and proton pumps. Bacteria utilise their own proteases to break down antimicrobial peptides, bacterial enzymes to alter 
harmful compounds, and inhibit recruitment of vital host protein complexes to synthesize ROS. Abbreviations: SOD - Superoxide dismutase, MPO - 
Myeloperoxidase, ROS - Reactive oxygen species, INOS - inducible Nitric Oxide synthase, Ara4N - 4-amino-4-deoxy-arabinose, NADPH - Nicotinamide adenine 
dinucleotide phosphate. Adapted from Flannagan (2009). 
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1.4.1.1 Arresting phagosome maturation 
 
The primary goal of the invading mycobacteria once phagocytosed is to prevent the maturation of 
the phagosome into the phagolysosome, forged by combining with lysosomes (Zimmerli, et al. 
1996). Lipoarabinomannan (LAM), a glycolipid incorporated within the mycobacterial cell wall 
recognises and binds to both mannose and complement receptors (Kang, et al. 2005). The 
interaction aids mycobacterial virulence by preventing cytosolic increases in Ca2+ concentration, 
causing the incorporation of mannose capped with LAM onto the cell membrane of infected 
macrophages, impeding recognition. Mannose capped LAM ligands within dendritic cells bind to 
host mannose receptors and Dendritic cell specific intracellular adhesion molecule-3-grabbing 
nonintegrin (DC-SIGN) receptors suppress phagolysosome maturation, membrane antigen 
integration and macrophage apoptosis (Halder, et al. 2015). M. tuberculosis emits other targeted 
ligands to modulate macrophage response, for example phosphatidylinositol mannoside (PIM) 
binds Toll-like receptor-4 (TLR4) and inhibits the regulation the signalling pathways of infected 
macrophages (Doz, et al. 2009). Phagosome maturation suppression is essential to ensure 
mycobacterial reproduction and survival within host macrophages. Invading mycobacteria also 
diminish cytosolic phosphatidylinositol 3-phosphate (PI(3)P) concentration to delay phagosome 
maturation, by secreting the phosphatase SapM to hydrolyse PI(3)P (Vergne, et al. 2003). 
Unimpeded bacilli replicate and rupture the host cell macrophages to infect neighbouring cells 
(Simeone, et al. 2012). The halting of phagosome maturation is a key component for M. 
tuberculosis survival and proliferation within host macrophages (Welin, et al. 2008). 
 
 
1.4.1.2 Phagosome maturation 
 
If the innate immune system is unobstructed by the phagocytosed mycobacterium then 
phagolysosomal formation is established. The phagosome once formed is gradually integrated with 
other macrophage vesicles, firstly with an early endosome, then a late endosome and finally the 
lysosome (Desjardins, et al. 1994). The function of the phagolysosome is to provide a toxic 
environment to mycobacteria and ultimately lead to cell lysis. Mechanisms include the application 
of vacuolar proton transporting ATPase (vH+-ATPase) along with initiation of a Ca2+ signalling 
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cascade in order to reduce internal pH (Forster and Kane 2000), the generation of nitric oxide (von 
Bargen, et al. 2011) and ubiquitin derived autophagy (Bah, et al. 2016). The intrinsic pH of the 
phagolysosome measured at pH 5 (Flannagan, et al. 2009), optimises the lysosome derived acid 
hydrolysis of mycobacterium. The integrity of the mycobacterial cell membrane is destabilised by 
the generation of ubiquitin-derived peptides permitting generated nitric oxide to permeate the cell 
(Purdy, et al. 2009). Once cells are lysed within apoptotic vesicles, antigens derived from the 
mycobacterial architecture are integrated and distributed within the cell membrane of dendritic 
cells (Espinosa-Cueto, et al. 2017). Cytokine secretion initiated during recognition of bacteria 
attract a number of immune cells such as monocytes, neurophils and lymphocytes to the site of 
infection (Lyadova 2017) and due to integration of mycobacterial antigens on the cell membrane, 
infected macrophages are recognised. 
 
Macrophages release various cytokines and proteolytic enzymes as part of the innate immune 
response to M. tuberculosis invasion (Domingo-Gonzalez, et al. 2016). Over 50 distinct 
degradative enzymes such as proteases, glycosidases and phosphatases capable of impeding 
various cellular components are produced by the lysosome (Flannagan, et al. 2009), the majority 
of which are noted to display optimum enzymatic activity at acidic pH ranges (Odaka and 
Mizuochi 1999). These proteins vary in their roles from lactoferrin which prevents bacterial 
growth by sequestering iron within the phagosomal lumen (Masson, et al. 1969), to defensins 
which impact the integrity and permeability of the pathogen cell membrane (Lehrer, et al. 1993). 
 
This thesis focusses on two specific hydrolytic enzymes secreted by the phagolysosome, lysozyme 
and b-hexosaminidase. 
 
 
1.4.1.2.1 Lysozyme 
 
Lysozymes are also known as either muramidases or N-acetylmuramide glycanhydrolases. They 
are characterised by their ability to hydrolyse the b-1,4 glycosidic bonds between either N-
acetylmuramyl or N-glycolylmuramyl residues and N-acetylglucosaminyl residues of the 
carbohydrate components of the peptidoglycan of  Gram-positive, Gram-negative or Acid-fast 
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organisms (Ragland and Criss 2017). Lysozyme was identified in numerous biological secretion 
and characterised as bacteriolytic (Fleming 1922). The structure of lysozyme was the first ever 
enzyme solved by x-ray diffraction (Blake, et al. 1967). 
 
Found throughout bacterial, plant, animal species as well as in viruses, lysozymes are highly 
conserved anti-microbial enzymes and vital components of the innate immune response against 
microbial infection (Ragland and Criss 2017). The broad phylogenetic distribution of lysozymes 
is responsible for the evolution of bacterial mechanisms of resistance to these enzymes, either by 
modifying their peptidoglycan sacculus or through the utilisation of specific inhibitors (Ragland 
and Criss 2017). Lysozymes are sub divided into three main groups, c-type (Chicken), g-type 
(Goose) and i-type (Invertebrate), although other lysozyme variants from plants, bacteria and 
phages do occur (Jolles and Jolles 1984, Fastrez 1996). C-types include both the chicken and 
human lysozyme variants and are also noted to be standard models in the study of protein structure 
and function (Gourbatsi, et al. 2016). C-type lysozymes comprise two domains bridged by an alpha 
helix, where those enzymes have an optimal activity range of between pH 6-9, with an active site 
located in a deep cleft within the enzyme (Pincus, et al. 1977). 
 
 
1.4.1.2.1.1 Human lysozyme 
 
The human lysozyme consists of 130 residues with a molecular weight of 14.7 kDa. It shares 
around 58% amino acid sequence identity with the chicken homologue although the noted anti-
bacterial activity is threefold greater (Wu, et al. 2015) as a result of variation in cationic residues 
and tri-dimensional structures. Human lysozyme, along with other C-type lysozymes are cationic 
(Callewaert and Michiels 2010), attracted to the negative charge of the targeted bacterial cell 
envelope, human lysozyme embeds itself within the cell membrane and forms pores to aid 
antibacterial activity (Zhang, et al. 2016). The two mechanisms of lysozyme activity are depicted 
in Figure 1.11. 
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Figure 1.11 Hydrolysis of peptidoglycan by lysozyme. (a) The two proposed roles of lysozyme against microbial 
cells binding either to the peptidoglycan layer to hydrolyse PG monomers or embedded into the plasma membrane to 
disrupt integrity. (b) the hydrolysis reaction of lysozyme against the b-1,4-glycosidic bond between MurNAc and 
GlcNAc sugar monomers. The essential active site residues of the lysozyme active site, aspartic acid (red) and glutamic 
acid (blue) are depicted. Abbreviations: MurNAc – N-acetylmuramic acid, GlcNAc – N-acetylglucosamine, PG – 
Peptidoglycan, CM – Cytoplasmic membrane. Adapted from Ragland, et al. (2007). 
 
 
Lysozyme plays a key role in the activation of the innate immune system. Macrophages secrete 
extracellular lysozyme during infection to produce PAMPs from the lysed bacterial peptidoglycan 
layer to initiate pattern recognition receptors (Davis, et al. 2011). The peptidoglycan of 
phagocytosed bacteria are hydrolysed by lysozyme within the phagolysosome and these 
peptidoglycan monomer ligands are transferred across the endosomal membrane of macrophages 
to NOD receptors to further increase immune recognition (Lee, et al. 2009). Occasionally viewed 
as an aid in disease diagnosis, raised concentrations of human lysozyme are observed in both the 
urine and serum of leukaemia patients (Osserman and Lawlor 1966). Lysozyme is a common 
antibacterial agent located within the blood and saliva as well as secreted by certain organs and 
cells such as the spleen, kidneys and white blood cells where specific missense mutation in the lyz 
gene can culminate as inheritable renal amyloidosis (Yazaki, et al. 2003). 
 
 
1.4.1.2.2 b-hexosaminidase 
 
b-hexosaminidase is the second enzyme produced by the lysosome (Koo, et al. 2008) to be 
investigated in this thesis. The enzyme has a similar mode of action to lysozyme although it cleaves 
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the b-1,4-linked glycosidic bond between MurNAc and GlcNAc subunits from the non-reducing 
end of oligosaccharide chains. The fully functional enzyme is comprised from one a and one b 
subunit transcribed from the genes hexA and hexB respectively. b-hexosaminidase is vital to 
regulating the central nervous system (Beutler 1979). It forms a complex with the cofactor GM2 
activator protein within lysosomes, where it catalyses the decomposition of the ganglioside GM2 
(Ganglioside monosialic 2). Mammalian b-hexosaminidases are organised into two functional 
isoforms composed of dimers from either a or b subunits (Dersh, et al. 2016). One isoform is b-
hexosaminidase A, an a/b heterodimer which degrades GM2 gangliosides in neurons, whereas the 
other isoform, b-hexosaminidase B is a b/b homodimer secreted to degrade glycosphingolipids in 
the visceral organs. The role of the enzyme is vital as mutations in the genes of either the a or b 
subunits lead to accumulation of GM2 gangliosides within neurons concurrent with 
neurodegenerative disorders such as GM2 gangliosidosis. Gene mutation specific to the a subunit 
lead to Tay-Sachs disease (Myerowitz 1997), conversely b subunit gene mutations lead to 
Sandhoff disease (GM2-gangliosidosis type II) (Yamada, et al. 2013). Both disease states produce 
a debilitating ganglioside accumulation in lysosomes, especially those within neurons.  
 
Recent investigations into b-hexosaminidase knockout mice indicate that the enzyme is an 
essential factor of innate immunity for the host, reducing mycobacterial infection and survival 
within macrophages (Koo, et al. 2008). M. tuberculosis infection has also been shown to impact 
regulation of specific hydrolytic enzyme expression within lysosomes. Infection leads to 
significant down-regulation of both a- and b-hexosaminidase subunits by a factor of 20- and 25-
fold respectively (Hare, et al. 2017). 
 
Patients who are carriers of the Tay-Sachs gene have been recognised as presenting an increased 
resistance to tuberculosis (Spyropoulos 1988). These patients, who are unable to form the 
functional a-chain and therefore have a deficiency of the a/b heterodimer form of b-
hexosaminidase have significantly increased production of brain and fibroblast b-hexosaminidase 
B (b/b) by upwards of 200%. This has led to the understanding that the b/b homodimer is an 
important component of the host immune response to M. tuberculosis infection. 
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1.5 Dormancy 
 
Dormancy is the process by which M. tuberculosis cells enter a reversible state of reduced 
metabolic activity to endure cellular stresses and the immune response of the host (Gengenbacher 
and Kaufmann 2012). This state known as non-replicating persistence (NRP) (Wayne 1994) is 
initiated by specific environmental factors such as immune response, pH and nutrient availability 
(Peddireddy, et al. 2017) in order for M. tuberculosis cells to persist without cellular division 
within the host for prolonged periods of time. Dormant M. tuberculosis bacilli were first identified 
within pulmonary lesions surgically excised from patients who tested negative to tuberculosis 
smear testing (Canetti 1955). Excised lesions were examined and found to contain both 
populations of viable and non-viable mycobacteria decades after initial infection, hence the term 
NRP. The bacilli contained within these persisting populations are profoundly heterogenic and can 
be divided into three separate categories based upon specific physiological states (Kaprelyants, et 
al. 1993). Bacilli can be described as viable, dormant or differentially culturable based upon their 
ability to propagate in vitro. Viable cells are able to grow readily within nutrient media; dormant 
cells depend upon resuscitation first before normal cellular growth can be obtained and 
differentially culturable cells are completely unable to be cultured in vitro. The immune response 
to mycobacterial invasion leads to the formation of granulomas, an aggregation of infected 
macrophages and activated T-cell lymphocytes encased in necrotic lesions to mitigate the 
pathogenesis of M. tuberculosis (Saunders and Britton 2007) as depicted in Figure 1.12.  
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Figure 1.12 The cellular components and overall structure of a granuloma formed during tuberculosis 
infection. M. tuberculosis infected macrophages are encased with layers of interlinked epithelioid cells. Macrophages 
within the granuloma can combine to form multinucleated giant cells or differentiate into foam cells.  Multiple other 
cell types aggregate to form a granuloma including T-cells, B-cells, NK cells, neutrophil cells and dendritic cells. The 
mycobacteria are localised within the necrotic core and are non-pathogenic to hosts. Adapted from Ramakrishnan 
(2012). 
 
 
The granuloma microenvironment has a reduced pH and deprives the bacilli of oxygen and 
required nutrients for regular aerobic cellular growth. Mycobacteria persist within these necrotic 
granulomas by utilising a metabolic shift initiated by the two component regulatory system 
DosRS/T (Karakousis, et al. 2004). Genes related to this system were originally discovered within 
a virulent Dev strain of M. tuberculosis, leading to the genes for the DosR regulon being designated 
as devR (Rv3133c) and one of the two sensor histidine kinases, DosS being designated as devS 
(Rv3132c). The second kinase DosT, is expressed from the gene dosT (Rv2027c). The low oxygen, 
high nitric oxide (NO) and carbon monoxide (CO) environment of the granulomas stimulates the 
DosR regulon. In vitro, extended periods of stationary phase growth as well as static cultures can 
also lead to an activation of the DosR regulon (Honaker, et al. 2009).  
 
Hypoxic conditions are a requirement for the regulon as even if activation is initiated by nitric 
oxide or carbon monoxide, the recognition of oxygen by the system is an inhibitor to dormancy 
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(Kumar, et al. 2007). The two sensor histidine kinases are activated by different environmental 
stimuli. DosS is a redox sensor, whereas DosT is a hypoxia sensor. The sensors exhibit comparable 
protein sequences although vary in their ability to autophosphorylate and phosphotransfer, with 
DosT more adept than DosS (Roberts, et al. 2004). As found in both eukaryotic and prokaryotic 
organisms, the sensors are known to contain the small-molecule binding, regulatory GAF domains 
(cGMP, adenylyl cyclase, FhlA) (Honaker, et al. 2009). These domains permit the sensors to bind 
heme, (Sivaramakrishnan and de Montellano 2013), which in turn binds the mentioned divalent 
gases, O2, CO and NO and modulates the actions of the kinase response.  
 
During aerobic conditions the redox sensor, DosS is in an inactive state attributed to the constant 
presence of oxygen. Its heme ligand is constantly oxidised to Fe3+, inhibiting kinase signalling. 
The DosT sensor in an aerobic environment is also inactive, bound to oxygen molecules, the kinase 
is able to resist oxidation (Sousa, et al. 2007), explaining the reason why it is able to respond to 
hypoxia, but unable to function as a redox sensor.  
 
During immune response, macrophages produce nitric oxide. If concentrations of nitric oxide 
greatly exceed that of O2, then nitric oxide will out compete the oxygen molecules for the heme 
binding sites of DosS (Voskuil, et al. 2003). Oxygen inhibits the DosS sensor fifty fold more than 
nitric oxide (Tuckerman, et al. 2002). In the absence of O2 the heme bound to DosS is reduced to 
Fe2+, which in turn triggers autokinase activity of the sensor, signalling activation of the regulon. 
In the absence of O2 the hypoxia sensor DosT is deoxygenated, initiating autokinase activity.  
 
The redox/oxygenation state of the DosS/T sensors are used as a means of detecting the shifting 
environment and allowing the bacilli not only to adapt but persist. The induction of DosR is 
contingent upon the auto phosphorylation of either of the kinase sensors culminating in the 
phosphorylation of DosR (Roberts, Liao et al. 2004). DosR only regulates one of the two sensors, 
DosS in the two-hybrid system, due to the dosS gene residing within a region consisting of DosR 
regulon genes. dosT is situated close to one of these regions (Voskuil, et al. 2003) but does not act 
as though regulated by DosR. The expression of dosT is unaltered whether in aerobic or low 
oxygen environments (Saini, et al. 2004).  
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The DosT hypoxia sensor is important for initial recognition of environmental stresses and 
measuring the surrounding O2 concentrations. Once O2 decreases, DosT is induced and signals the 
DosR regulon and in turn increases the expression of dosS. The importance of DosT diminishes 
during hypoxic conditions and DosS is solely responsible for the induction of DosR regulated 
genes (Honaker, et al. 2009). The signalling of the DosR regulon by DosS and DosT is depicted 
in Figure 1.13. 
 
 
 
Figure 1.13 Activation of the M. tuberculosis DosR regulon by kinase sensors DosS (a) and DosT (b) to initiate 
mycobacterial dormancy. Interactions between the kinase sensors sensing divalent gases Oxygen (O2), Nitric Oxide 
(NO) and Carbon Monoxide (CO) regulate the induction of the DosR regulon. (a) In the presence of O2, the heme 
ligand of DosS is oxidised to Fe3+ inactivating signalling, in hypoxic conditions or with the aid of a cellular redox 
couple such as FdxA, DosS can be reduced implementing autokinase activity. DosS activity can also be initiated by 
interaction with NO and CO divalent molecules “locking” the sensor into an reduced active state initiating signalling. 
(b) In the presence of O2, the heme ligand of DosT is oxygenated to Fe-O2 impeding signalling. In hypoxic conditions 
or due to interactions with NO or CO divalent molecules, the sensor is “locked” into a deoxygenated active state 
initiating autokinase activity. The activation of the DosR regulon leads to the upregulation of highly conserved 
dormancy genes. 
 
 
The DosR regulon consists of around 50 co-regulated genes vital for adapting and maintaining 
survival during dormancy (Leistikow, et al. 2010). Many of these genes transcribe hypothetical 
proteins with current unknown function, though specific genes aid in acquiring energy from 
alternative sources during dormancy such as nitrate reduction (Sohaskey 2005) and glyoxylate 
metabolism (Wayne and Lin 1982). The construction of a M. tuberculosis dosR deficient strain has 
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shown that genes upregulated by DosR in hypoxic conditions are contingent upon the regulon for 
induction (Park, Guinn et al. 2003). The majority of these DosR regulated genes have a DNA 
consensus motif preceding the sequence. Investigations have shown that DosR binds directly to 
this motif (Park, et al. 2003). Other environmental conditions known to induce the regulon include 
hydrogen peroxide (H2O2) and ethanol (C2H5OH) (Kendall, et al. 2004, Voskuil, et al. 2011). 
Dormant mycobacteria are not solely located within granulomas, and mycobacterial DNA have 
been identified from within adipose tissue (Neyrolles, et al. 2006). This type of tissue is also noted 
as a high nitric oxide/low oxygen environment. The physiological differences between aerobically 
cultured M. tuberculosis and dormant bacilli also impact treatment for patient. Those with latent 
tuberculosis require more tailored therapeutics as dormant cells are more resistant towards 
common antimicrobials (Aguilar-Ayala, et al. 2018). Dormant mycobacteria are non-infectious 
and can persist with the host several years until conditions within the granulomas change. 
 
 
1.5.1 In vitro dormancy models 
 
A number of models have been created to investigate dormancy in vitro, the most well-known 
being the Wayne model of non-replicating persistence characterises the impact of microaerophilic 
conditions on the growth and dormancy of M. tuberculosis (Wayne and Lin 1982). Previous 
methods noted that the sudden transfer of aerobically grown mycobacteria to an instantly anaerobic 
environment led solely to cell death but the gradual reduction of oxygen induced dormancy 
(Wayne 1994). The Wayne model identified two separate stages of non-replicating persistence 
(NRP) depending upon the oxygen concentration. NRP stage 1 was categorised once diminishing 
oxygen saturation had reached 1%. This stage involved a significant and constant formation of 
glycine dehydrogenase and a steady production and maintenance of ATP concentration. The 
turbidity of the culture slowly increased during this period though the cause was not attributed to 
an increase in CFU.  
 
NRP stage 2 required 0.06% O2 saturation. During this almost anaerobic stage the turbidity seen 
in stage 1 did not increase and the previously observed high production of glycine dehydrogenase 
was notably reduced. The survival of mycobacteria within NRP stage 2 was greatly increased by 
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acclimatising for an extended time period within NPR stage 1. The Wayne model also observed 
that NRP bacilli from either stage could be immediately resuscitated once introduced to optimal 
aerobic and nutrient conditions (Wayne 1994).  
 
Other models of in vitro dormancy include nutrient starvation in PBS (Betts, et al. 2002), 
incubation in extended stationary phase (Smeulders, et al. 1999, Shleeva, et al. 2002) as well as 
the multiple stress model (Deb, et al. 2009). 
 
 
1.5.2 In vivo dormancy models  
 
Standard in vivo animal models of M. tuberculosis infection involve either rabbit, guinea pig or 
most commonly mouse hosts (Gupta and Katoch 2009) due to the similarity to the human immune 
response. Mouse models initially demonstrated the relationship between the immune response to 
infection and the triggering of mycobacterial dormancy, depicting the switch as not solely nutrient 
derived (Wayne and Sohaskey 2001). 
 
Animals can be infected by aerosols to imitate the standard infection route in humans with low-
dose bacterial loads or injected intravenously with high-dose bacterial loads such as the Cornell 
model (McCune and Tompsett 1956). Predominantly a study of chronic infection, the Cornell 
model in mice causes mycobacterial infection (1-3 x 106 dose) led by an extended antimicrobial 
therapy of isoniazid and pyrazinamide to produce bacilli that are non-culturable. The disease state 
can be reactivated through suppression of the host immune system (McCune, et al. 1956). The 
mouse model displays a number of drawbacks to investigating latent tuberculosis infection. The 
granulomas created within mice lack the rigid formation and composition found in the human host, 
leading to a lack of necrosis at the core of the granuloma, vital for mycobacterial dormancy 
(Munoz-Elias, et al. 2005).  To mimic human mycobacterial infection with greater accuracy, 
artificial granulomas are implanted within mice models subcutaneously to induce the latent 
mycobacterial disease state (Karakousis, et al. 2004).  
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1.5.3 Resuscitation 
 
M. tuberculosis bacilli can remain in a state of dormancy for decades as long as the encased 
granuloma environment remains constant (Kapoor, et al. 2013). Maintaining the stability of 
granulomas requires tumour necrosis factor (TNF- α) activity (Keane, 2005) in signalling innate 
immunity. In vivo investigations in mouse models (Mohan, et al. 2001) have concluded that 
employing monoclonal anti-TNF antibodies to constrain the cytokine commences resuscitation. A 
compromised immune system constraining T-cells results during immunosuppression; common 
causes include advanced age (Montecino-Rodriguez, et al. 2013), treatment for autoimmune 
disease (Stenger, 2005) or HIV infection (Paige and Bishai 2010). Co-infection of TB and HIV 
leads to an active tuberculosis state as HIV infection diminishes the total number of CD4+ and/or 
CD8+ T-cells primed to respond to M. tuberculosis infection (Wells, et al. 2007).  
 
Once the granuloma environment changes from an anaerobic to aerobic state, the mycobacteria 
must initiate resuscitation procedures in order to become a metabolically active infectious 
pathogen. Oxygen molecules once again outcompete other divalent gases and bind to the heme 
groups of DosS/T kinase sensors, terminating signalling to the dormancy regulon DosR 
(Tuckerman, et al. 2002).  
 
Resuscitation is also instigated by lytic transglycosylases defined as resuscitation promoting 
factors (Rpfs) (Telkov, et al. 2006) and RipA (Rpf-interacting protein A), an endopeptidase (Hett, 
et al. 2007). Rpfs not only permit bacilli to revert back to an active state but also stimulate growth 
(Rosser, et al. 2017). Five rpf gene homologues, rpfA-E have been identified within the genome 
of M. tuberculosis (Mukamolova, et al. 2002), each possessing muralytic activity towards the b-
1,4 glycosidic bonds of peptidoglycan in a similar method to c-type (chicken) lysozyme (Cohen-
Gonsaud, et al. 2005). The homologues display a functional redundancy and are known to be non-
essential for mycobacterial growth (Downing, et al. 2004). Non-culturable dormant M. 
tuberculosis rpf-deficient strains have been examined and determined to be significantly impaired 
during resuscitation (Downing, et al. 2005). Individual Rpfs form a two protein complex with 
RipA at the septa of cells undergoing cellular division (Hett, et al. 2007). The mechanism by which 
resuscitation is enacted is still undetermined. 
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1.6 Diagnosis 
 
Basic laboratory identification of mycobacteria is obtained through Acid-fast Ziehl-Neelsen 
staining of acquired sputum samples (Riello, et al. 2016). A fuchsine based dye combined with the 
presence of phenol is used to penetrate the lipid layer, cells are decolourised by an acid-alcohol 
solution and counter stained for identification under microscopy. The relatively inexpensive 
diagnostic test has certain disadvantages including the inability to detect extrapulmonary TB 
(Purohit and Mustafa 2015). Frequently polymerase chain reaction (PCR) testing is coordinated 
with acid fast bacilli (AFB) staining to increase diagnostic precision and reduce false negative 
diagnoses (Ryu 2015). The oldest currently used technique is the tuberculin skin test, otherwise 
known as the Mantoux test (Nayak and Acharjya 2012), an intracutaneous tuberculin injection, 
instigating a delayed hypersensitivity reaction. The original hypothesis for the test was determined 
in 1890 by Robert Koch and the standard intradermal technique was pioneered by Charles 
Mantoux in 1907 (Yang, et al. 2012) utilising purified protein derivative (PPD) from M. 
tuberculosis cells. The methodology for amassing PPD was revised and standardised in 1934 by 
Seibert (Seibert 1934). PPD is no-longer acquired solely from MTB, instead less pathogenic 
alternatives have been developed, denoted by a suffix letter such as PPD-A for M. avium. Other 
common methods for evaluating pulmonary TB in patients include chest x-rays (Woodring, et al. 
1986) and computed tomography (CT) scans to locate and define lesions (Lee, et al. 1993). 
Interferon-g release assays (IGRAs) provide a twenty-four-hour outcome from initial testing 
(Banaei, et al. 2016). The assays measure the interferon-g (IFN-g) immune response of patients to 
specific M. tuberculosis antigens. The known drawback to IGRA testing is the inability to 
distinguish between active and dormant tuberculosis (Sharma, et al. 2017). 
 
 
1.7 Antimicrobial Discovery 
 
At the beginning of the 20th century the potential of antimicrobials was being hypothesised. A 
German physician, Paul Ehrlich ascertained that specific chemical dyes stained selective bacterial 
cells but not others, and extrapolated that certain compounds may kill selective cells (Bosch and 
Rosich 2008). The first antimicrobial, Arsphenamine was discovered in 1909 for the treatment of 
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syphilis (Williams 2009). In 1928, Alexander Fleming inadvertently discovered the antibiotic, 
Penicillin (Tan and Tatsumura 2015), secreted from the fungi Penicillium notatum. The mould 
prevented growth of Staphylococcus, creating a bacteria-free zone. The isolation and purification 
of the antibiotic by Florey and Chain (Gaynes 2017) led to penicillin being the first mass produced 
antimicrobial utilised to treat infection during the second world war. These discoveries led to the 
global effort during the 1900s to purify and distribute antimicrobial products to medicate against 
bacterial infection. Early antimicrobial discoveries include Sulphonamide (1935) (Jesman, et al. 
2011), Cephalosporins (1945) (Nakajima 2003), Chloramphenicol (1947) (Wiest, et al. 2012), and 
Aminoglycosides (1943) (Vong and Auclair 2012). Predominant targets of antimicrobial therapies 
include DNA replication, protein synthesis and the bacterial cell wall (Kohanski, et al. 2010). 
 
 
1.7.1 Tuberculosis treatment 
 
The primary protection from M. tuberculosis infection in humans was the production of a vaccine 
(Luca and Mihaescu 2013). The Bacillus Calmette Guérin (BCG) vaccine containing a living 
attenuated strain of M. bovis is commonly administered to both infants and adults to present 
mycobacterial antigens to the immune system. Vaccination unfortunately impedes certain methods 
of tuberculosis detection in patients such as the tuberculin test (Buddle, et al. 1999). The standard 
antimicrobial treatment for tuberculosis is a six to nine-month multidrug combination (Kerantzas 
and Jacobs 2017), synergising the activities of four anti-tuberculosis therapies. Isoniazid (INH), a 
prodrug activated by the mycobacterial heme enzyme, KatG (Metcalfe, et al. 2008) inhibits the 
formation of mycolic acids (Quemard, et al. 1991). Targeting the fatty acid synthetase II (FAS-II) 
system, Isoniazid inactivates InhA, a 2-trans-enoyl-acyl carrier protein reductase (Marrakchi, et 
al. 2000). Rifampicin (RIF) is primarily a derivative of rifamycin B, a product of the bacterium 
Amycolatopsis mediterrani (Nigam, et al. 2014). An inhibitor of bacterial DNA transcription to 
RNA, rifampicin binds to the b-subunits of the RNA polymerase RpoB. Pyrazinamide (PZA) is 
active as an anti-tuberculosis therapy once hydrolysed to pyrazinoic acid (POA) by a 
pyrazinamidase enzyme PncA expressed by M. tuberculosis. The mode of action of the prodrug 
once activated by PncA is currently unknown but was initially believed to obstruct metabolism 
and the mycobacterial plasma membrane (Zhang, et al. 2003). Currently it is thought that POA 
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impacts trans-translation and ribosomal protein S1 (RpsA) (Shi, et al. 2011), although this has 
been disputed (Dillon, et al. 2017). The efficacy of Pyrazinamide is elevated against slow and non-
replicating bacilli (Pullan, et al. 2016). Ethambutol (EMB) is a antimicrobial targeting the 
mycobacterial cell wall (Alderwick, et al. 2015). A known inhibitor of several key components of 
the complex; ethambutol prevents the transport of mycolic acid into the cell wall, as well as the 
inhibition of arabinogalactan and lipoarabinomannan biosynthesis (Goude, et al. 2009).  
 
The multidrug therapy administration can vary depending upon the stage of tuberculosis infection 
as certain treatments have greater efficacy against solely latent or active TB. Latent TB infection 
is commonly treated with a monotherapy of isoniazid, or rifampicin if isoniazid resistance is 
detected (Norton and Holland 2012). If resistance towards one or all of the first-line therapies 
occurs, then second-line therapies are implemented. Second-line treatments include 
fluoroquinolones and aminoglycosides (Falzon, et al. 2013) which inhibit DNA gyrase (Hooper 
1999) and protein synthesis (Eustice and Wilhelm 1984) respectively.  
 
Select antimicrobials utilised against standard drug resistant tuberculosis strains target the 
mycobacterial peptidoglycan biosynthesis pathway. D-cycloserine, another secondary TB therapy 
inhibits the enzymes Alr and Ddl responsible for the synthesis of D-Ala-D-alanyl, the fourth and 
fifth amino acids of the UDP-MurNAc/NGlyc-pentapeptide stem (Chen, et al. 2017). Vancomycin, 
a glycopeptide antibiotic enacts hydrogen bonding with the terminal D-Ala-D-Alanyl residues of 
UDP-MurNAc-pentapeptide, preventing incorporation of the precursor into the peptidoglycan 
layer (Soetaerta, et al. 2015).  
 
 
1.7.2 Antimicrobial resistance 
 
The prevalence of antimicrobial resistance (AMR) is impacting all aspects of antimicrobial therapy 
and research, rapidly becoming a global health threat (Gootz 2010). Current estimates predict 
AMR will supersede cancer as the leading global cause of death annually by the year 2050 (O'Neill 
2015). Basic standard treatments to common infections are insufficient, with selected bacterial 
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strains becoming multidrug resistant (Zhang and Yew 2009). It is vital that new and existing targets 
be explored in order to develop contemporary antimicrobials to implement against AMR. 
 
 
1.7.3 Mechanisms of Antimicrobial resistance 
 
The acquisition and implementation of resistance to antimicrobial products is an evolutionary 
requirement and plays a key role in the survival of bacteria within a microenvironment (Miller, et 
al. 2016). The natural selection of resistance used to occur over an extended time period but recent 
advances in drug discovery and global application of therapies have produced a number of man-
made selection pressures to pathogens, that have increased resistance acquisition (Kapil 2005). 
Resistance to antimicrobials can be gained, through acquiring genes such as methicillin resistance 
in Staphylococcus aureus (MRSA) (Lee, et al. 2018) the altering of genes such as pneumococcal 
penicillin resistance (Hakenbeck, et al. 2012), or inherently such as impermeable membranes 
(Gotoh 2001) and efflux pumps (Poole 2007).  
 
The time frame for adaption of targets to therapies can vary. Resistance towards the antibiotic 
vancomycin, a peptidoglycan biosynthesis inhibitor, (Hammes and Neuhaus 1974) was identified 
30 years after its original development (Launay, et al. 2006); whereas sulphonamide resistant 
streptococcal strains were identified within three years of the drug first being prescribed (Finland, 
et al. 1976).  
 
The most basic instance of resistance is a mutation to the genetic sequence of an antimicrobial 
target. Examples include the simplest single point mutations, along with insertions, deletions and 
inversions of genes (Nollau and Wagener 1997). The alteration of a single nucleotide can 
significantly impact not only the amino acid sequence but also the 3-dimensional structure of the 
folded protein, altering the drug target.  
 
A consequence of being unable to utilise the exchange of genetic material termed horizontal gene 
transfer, M. tuberculosis cultivates resistance to prevailing therapies such as rifampicin and 
streptomycin by genetic mutation (Ramaswamy and Musser 1998). Other methods of resistance 
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include impacting the efficacy of the antimicrobial through either hydrolysis (Tao, et al. 2012) or 
modification (Lambert 2005), inactivating the drug. b-lactamases hydrolyse the b-lactam ring, the 
functional group of b-lactam antibiotics such as penicillin (Heesemann 1993). Modifications of 
drug structure to impede activity are the focus of phosphoryltransferases and acetyltransferases 
which catalyse O-phosphorylation and N-acetylation respectively to impact aminoglycosides 
(Morita, et al. 2014) and chloramphenicol (Shaw 1983). The final noted bacterial mechanism to 
influence drug concentration are efflux pumps. Located ubiquitously within the membranes of all 
bacteria, efflux pumps diminish the intracellular concentration of administered antimicrobials 
(Poole 2007).   
 
 
1.7.4 Antimicrobial resistant Tuberculosis 
 
Aside from acquired resistance to selected antimicrobials, mycobacteria are inherently resistant to 
various therapies, that target the mycobacterial cell wall (Hett and Rubin 2008). The reduced rate 
of diffusion traversing the mAGP complex coupled with efflux pumps, antimicrobial degrading 
enzymes and response regulators impedes drug efficacy (Chambers, et al. 1995). Tolerance 
towards an antimicrobial is not equivalent to resistance. Tolerance is not a genetic predisposition 
(Murakami, et al. 2017), but avoidance of mycobacterial lysis instigated by dormant or non-
replicating cells (Fattorini, et al. 2013) along with numerous drug resistance pumps (Poole 2007). 
Isoniazid, ethambutol and rifampicin tolerance has been established in vitro (Tudo, et al. 2010, de 
Keijzer, et al. 2016). Antimicrobial resistance to drug therapies can be separated into primary 
resistance, infection acquired through a resistant strain and acquired resistance, observed during 
drug treatment (Jenkins, et al. 2018). Acquired resistance to one of the standard multi-drug 
therapies to tuberculosis can be obtained through inadequate drug adherence, management or 
selection pressures (Kapil 2005).  
 
Generally evoked due to genetic mutation, there are four classifications of mycobacterial resistance 
states (Chan, et al. 2009). The first state is when a strain is mono-resistant to a single first-line 
therapy. Poly-resistant when immune to two or more therapies excluding isoniazid and rifampicin. 
A strain identified as resistant to both isoniazid and rifampicin is termed multidrug-resistant 
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(MDR). The final classification encompasses both MDR, a fluoroquinolone and one other second-
line therapy, deemed as extensively drug-resistant (XDR) (Zhang and Yew 2009).  
 
Resistance towards Isoniazid treatment can be induced through a number of methods. A mutation 
in the peroxidase, KatG which activates isoniazid from the prodrug state. An increase in the 
expression of the target of inhibition, InhA or alterations to either NADH affinity or the NADH 
dehydrogenase enzyme (Miesel, et al. 1998, Tseng, et al. 2015). Rifampicin resistant M. 
tuberculosis is frequently the result of genetic mutations to the b-subunit of the mycobacterial 
RNA polymerase (Alifano, et al. 2015).  
 
Antimicrobials resistance has also been observed towards therapies which target the peptidoglycan 
cell wall biosynthesis pathway. Fosfomycin is the sole administered antimicrobial which targets 
the cytoplasmic phase of peptidoglycan synthesis, inhibiting the first enzyme in the pathway MurA 
(Nasiri, et al. 2017). The active site of MurA commonly contains a cysteine residue which 
fosfomycin modifies to inhibit peptidoglycan synthesis in fosfomycin sensitive organisms. 
Mycobacteria are intrinsically resistant to a broad range of antimicrobials including fosfomycin 
due specifically to the active site cysteine being replaced with an aspartate residue (De Smet, et al. 
1999). D-cycloserine resistance in mycobacteria is displayed either by overexpression of either of 
the targeted enzymes, Alr and Ddl (Feng, et al. 2003) or by mutations observed predominantly in 
the Alr enzyme (Chen, et al. 2017). 
 
Synergy between existing antimicrobials has been shown to combat mycobacterial mechanisms of 
resistance. The genome of M. tuberculosis encodes the b-lactamase BlaC, expressed to hydrolyse 
standard b-lactam antimicrobials (Hugonnet, et al. 2009). Recent investigations have shown that 
co-administering clavulanate, an inhibitor of b-lactamases along-side common b-lactam classes 
such as penicillin, carbapenems and cephalosporin aid in therapy against previously resistant 
strains (Hugonnet and Blanchard 2007) (Kumar, et al. 2012).  
 
The prevalence of drug resistance within strains of tuberculosis illustrate the raison d’etre of an 
extended therapy period and underlines the requirement for additional anti-tuberculosis 
antimicrobials or modifications to existing treatments. 
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1.8 Thesis aim 
 
The overall objective of this thesis is to evaluate the role of mycobacterial N-glycolylation on 
peptidoglycan and peptidoglycan precursors, in order to gain a better understanding of the 
observed resilience endowed by this modification towards a range of both hydrolytic enzymes and 
antimicrobial therapies. Furthermore this thesis will examine what variation the modification has 
on peptidoglycan synthesis flux, aiding mycobacteria against external pressures as well as 
investigating the role of newly discovered cell wall active treatments to combat the increasing 
spread of antimicrobial resistance towards standard therapies.  
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Chapter 2. Materials and Methods 
 
2.1 Buffers and solutions 
 
All buffers and solutions were prepared using Milli-Q purified water sterilised before use by 
autoclave or with a 0.2 µm filter. A WPA pH meter CD720 from Hanna instruments measured the 
pH of all solutions against pH buffer standards at pH 4, pH 7 and pH 10. Analytical grade 
chemicals were acquired from either Acros Organics (USA), Bachem (Germany), Calbiochem 
(USA), Chembridge (USA), Fisher Scientific (USA), Novabiochem (Germany) or Sigma-Aldrich 
(USA). Synthesised oligonucleotides were acquired from Integrated DNA Technologies (UK). 
 
 
2.2 Growth media 
 
The following growth media were utilized throughout this thesis. 
 
 
2.2.1 7H9 media  
 
7H9 medium was used for propagation of mycobacteria (Sigma Aldrich) 
 
0.5% (w/v) (NH4)2SO4, 0.5% (w/v) L-glutamic acid, 0.1% (w/v) Sodium citrate, 0.001% (w/v) 
Pyridoxine, 0.0005% (w/v) Biotin, 2.5% (w/v) Na2HPO4, 1% (w/v) KH2PO4, 0.001% (w/v) Ferric 
ammonium citrate and 0.001% (w/v) CuSO4, adjusted to pH 6.8. Media was sterilised by 
autoclave.  
 
7H9 media was supplemented with 10% (v/v) ADC (comprising 5% (w/v) Bovine serum albumin, 
2% (w/v) Dextrose, 0.8% (w/v) Sodium chloride, 0.003% (w/v) Catalase) and 0.05% (v/v) Tween 
80, passed through at 0.2 µm filter. The complete medium was stored at 4°C. 
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2.2.2 Lysogeny broth (LB) broth  
 
LB broth used for E. coli growth. 
 
1% (w/v) Tryptone, 0.5% (w/v) NaCl and 0.5% (w/v) Yeast extract were combined and 
autoclaved. LB broth was stored at 4°C. 
 
 
2.2.3 Super Optimal broth with Catabolite repression (SOC) media 
 
SOC medium was used to promote growth of competent E. coli following transformation with a 
plasmid vector. 
 
2% (w/v) Peptone, 0.5% (w/v) Yeast extract, 0.6% (w/v) NaCl, 1.9% (w/v) KCl, 1% (w/v) MgCl2, 
1.2% (w/v) MgSO4, were combined and autoclaved. Media was supplemented with 3.6% (v/v) 
Glucose passed through at 0.2 µm filter. Combined medium was stored at 4°C.  
 
 
2.2.4 Minimal growth media  
 
Minimal growth media was used for B. subtilis growth. 
 
1% (w/v) (NH4)2SO4, 7% (w/v) K2HPO4, 3% (w/v) KH2PO4, and 1% (w/v) Sodium Citrate, were 
combined and autoclaved. Medium was combined with 0.2% (w/v) MgSO4 0.2% (w/v) Casein 
hydrolysate and 1% (w/v) Glucose passed through at 0.2 µm filter. Completed medium was stored 
at 4°C. 
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2.2.5 Tryptic soy agar  
 
Tryptic soy agar was used for M. smegmatis growth. 
 
1.5% (w/v) Casein peptone (pancreatic), 0.5% (w/v) Soya peptone (papain digest), 0.5% (w/v) 
NaCl was adjusted to pH 7.3, supplemented with 1.5% (w/v) Agar, and sterilized by autoclaving. 
Once cooled to 50°C, agar media was poured into sterile petri dishes and stored at 4°C.  
 
 
2.2.6 LB-agar 
 
LB-agar was used for E. coli growth. 
 
1% (w/v) Tryptone, 0.5% (w/v) NaCl, 0.5% (w/v) Yeast extract, 1.5% (w/v) Bacto-agar was 
sterilized by autoclaving, selected antibiotics were incorporated into agar media once it had cooled 
to 50°C and poured into sterile petri dishes. It was stored at 4°C.  
 
 
2.2.7 Minimal media agar  
 
Minimal media agar was used for M. smegmatis growth. 
 
1% (w/v) (NH4)2SO4, 7% (w/v) K2HPO4, 3% (w/v) KH2PO4, 1% (w/v) Sodium Citrate, 0.2% (w/v) 
MgSO4 were combined, adjusted to pH 7.4, supplemented with 1.5% (w/v) Agar and autoclaved. 
Once cooled to 50°C, medium was supplemented with 0.2% (w/v) Casein hydrolysate and 1% 
(w/v) Glucose passed through at 0.2 µm filter. Media was poured into sterile petri dishes and stored 
at 4°C.  
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2.3 Bacterial strains 
 
Organism Strain Genotype Reference 
M. 
smegmatis 
PM965 (Wild type)  ept-1 rpsL4 DblaS1 Raymond, et al. (2005) 
M. 
smegmatis 
PM979 (DnamH) ept-1 rpsL4 DblaS1 DnamH1 Raymond, et al. (2005) 
E. coli Top 10 F- mcrA Δ(mrr-hsdRMS-
mcrBC) φ80lacZΔM15 
ΔlacX74 deoR recA1 
araD139 Δ (ara-leu)7697 
galU galK rpsL (StrR) 
endA1 nupG 
Grant, et al. (1990) 
E. coli BL21 (DE3) F- ompT gal dcm lon 
hsdSB(rB-mB-) l(DE3 [lacI 
lacUV5-T7p07 ind1 sam7 
nin5]) [malB+]K-12(lS) 
Studier and Moffatt, 
 (1986) 
E. coli BL21 (DE3) 
pRosetta 
F-ompT hsdSB(rB–, mB–) 
gal dcm (DE3) and pRosetta 
plasmid for rare codon 
overexpression 
Studier and Moffatt, 
 (1986) 
E. coli Tuner (DE3) F-ompT hsdSB(rB–, mB–) 
gal dcm lacY1 (DE3) 
Compaan and  
Ellington (2003) 
B. subtilis 168 trpC2 Spizizen (1958) 
S. aureus ATCC 27664 see, selq Bergdoll and Borja 
(1971) 
Table 2.1 Bacterial strains utilised within this thesis 
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2.4 Bacterial growth 
 
2.4.1 Generation of glycerol stocks  
 
5 mL of LB media with antibiotic as required was inoculated with a single colony from solid 
media. Cultures were incubated with shaking at 180 rpm at 37°C. Exponentially grown cells were 
transferred to 1.8 mL Corning cyro-vials and aseptically mixed with growth media plus between 
20-50% (v/v) glycerol, depending on the organism and frozen in liquid nitrogen. Purity of stocks 
were assessed through serial dilution and growth on nutrient agar. Stocks were stored at -80°C. 
 
 
2.4.2 Generation of competent cells 
 
E. coli expression strains of interest were inoculated from single isolated colonies in LB media 
with an antibiotic if required and incubated at 37°C with 180 rpm agitation overnight. Overnight 
cultures were then used as a 10% (v/v) inoculum of sterile LB, supplemented with 20 mM MgSO4 
and preferred antibiotic and grown as above until an optical density (OD600nm) within the range of 
0.4 to 0.6 was reached. Cells were pelleted by centrifugation at 4°C at 4500 x g for 10 minutes in 
a Beckman JA-14 rotor. Pellets were resuspended gradually in 100 mL of ice cold TFB1 (30 mM 
Potassium acetate, 10 mM Calcium chloride, 50 mM Manganese chloride, 100 mM Rubidium 
chloride, 15% (v/v) Glycerol pH 5.8). This suspension was incubated on ice for 5 minutes then 
pelleted by centrifugation at 4500 x g for 5 minutes at 4°C in a Beckman JA-14 rotor. Isolated 
pellets were resuspended in ice cold TFB2 buffer (10 mM MOPS, pH 6.5, 75 mM Calcium 
chloride, 10 mM Rubidium chloride, 15% (v/v) Glycerol) and incubated on ice for 1 hour. 
Competent cells were aliquoted, and frozen in liquid nitrogen. Stored at -80°C. 
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2.4.3 Aerobic growth of M. smegmatis 
 
Frozen stocks of mycobacteria were cultured at 37°C with 180 rpm agitation in 250 mL baffled 
flasks to oxygenate the media for 30 hours. Once samples reached exponential phase, cultures 
were diluted to an OD600nm of 0.1. Cells were passed through a 26-gauge needle to disrupt clumps 
and further diluted by a factor of 104. 100 µL of diluted cultures were pipetted in triplicate into 96-
well microtiter plates. As required concentrations of hydrolytic enzymes/antibiotics were added. 
Triplicate control wells containing media were used as negative and contamination controls. 
Microtiter plates were covered by gas permeable membrane barrier seals (4titude). Microtiter 
plates were incubated and analysed in a Varioskan flash multimode reader (Thermo Scientific) at 
37°C with intermittent shaking, where growth was measured at OD600nm at 3 hour intervals for 48-
60 hours. 
 
 
2.4.4 Determination of Minimal bactericidal concentration (MBC) 
 
Cells which failed to produce observable growth in the presence of hydrolytic enzymes/antibiotics 
were pipetted in 10 µL volumes onto segmented nutrient agar plates. Plates were incubated at 37°C 
in aerobic conditions for 72 hours. Presence of growth used to inform MBC values. 
 
 
2.4.5 Anaerobic growth of M. smegmatis 
 
Cultures were grown as in Section 2.4.3 and then diluted to an OD600nm of 0.1. Cultures were serial 
diluted ten-fold in media until an OD600nm of 10-8 was reached. 20 µL from each dilution was 
pipetted onto tryptic soy agar (Section 2.2.5) and minimal agar (Section 2.2.7) plates. Plates were 
initially incubated in an anaerobic cabinet for 21 days at 30°C. The agar plates were then 
transferred to an aerobic 37°C incubator for six days. Control plates were incubated in aerobic 
conditions for six days.  
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2.5 Assessment of hydrolytic enzyme activity against modified mycobacterial 
peptidoglycan  
 
2.5.1 Mycobacterial agar colonisation against hydrolytic enzyme incubation 
 
M. smegmatis was cultured to exponential phase and centrifuged at 3,200 x g for 10 minutes. The 
supernatant was removed and pellets were resuspended twice in incomplete Hank’s balanced salt 
solution (HBSS) buffer (8% (w/v) NaCl, 0.4% (w/v) KCl, 0.05% (w/v) Na2HPO4, 1% (w/v) 
Glucose, 0.06% (w/v) KH2PO4 and 0.035% (w/v) NaHCO3) minus Mg2+ and Ca2+. Cells were 
passed through a 26-gauge needle (Sigma Aldrich) to break down aggregates. Samples were 
diluted to 105 Colony forming units (CFU).mL-1 using complete HBSS buffer composed of 
chemicals mentioned above in addition to MgSO4 (0.12% (w/v)) and CaCl2 (0.14% (w/v)). 90 µL 
of diluted cells were pipetted into 96-well microtiter plates in triplicate and incubated with 10 µL 
of increasing concentrations 128-0.03 µg.mL-1) of hydrolytic enzymes. Microtiter plates were 
coated with a gas permeable membrane barrier seal and incubated for 1.5 hours unless stated 
otherwise at 37°C. Aliquots of wells were pipetted onto TSB agar plates in triplicate. Plates were 
incubated for 72 hours at 37°C and the percentage of viable colonies were counted, averaged, 
imaged and analysed. Standard concentrations of lysozyme were dissolved in media. Standard 
concentrations of b-hexosaminidase were prepared in media, based upon units of activity per 
milligram specified by the acquired sample. 
 
 
2.6 Cloning and editing of DNA 
 
DNA plasmids and gene constructs utilised during this thesis are outlined in Appendix 1. 
 
Primer sequences to introduce cleavable TEV and poly-Histidine tag sequences are stated in Table 
2.2. Denaturing temperature was 98°C, annealing temperature was 48°C and extension 
temperature was 72°C unless otherwise stated. 
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Primer Sequence 
MurA Forward GCGCGCCATATGGTGGCTGAACGCTTT 
GTTGTTACGGGCGGCAATCG 
MurA Reverse C-term + TEV GCGCGCGGATTGAAAGTACAGGTTCTC 
CAGACACACACGTTC 
MurA Reverse C-term + TEV + 
His 
GCGCGCCTCGAGCTAGTGGTGGTGGTGG 
TGGTGGGATTGAAAGTACAGG 
MurC Forward GCGCGCCATATGAACGCTGGTCAACTGCC 
MurC Reverse + TEV GCGCGCGGATTGGAAATACAGGTTCTC 
TTGCAGGACACCGCTACAGCC 
MurC Reverse + TEV + His GCGCGCCTCGAGCTAGTGGTGGTGGTGG 
TGGTGGGATTGGAAATACAGG 
Table 2.2 Primer sequence modifications to M. leprae MurA and MurC genes. Forward and reverse primers to 
include a C-terminal cleavable TEV sequence, a poly-histidine tag and enzyme restriction sites to pCOLD-M. leprae 
MurA and pCOLD-M. leprae MurC plasmids. 
 
 
2.6.1 Polymerase Chain Reaction (PCR) 
 
Reagents and primer concentrations specified by the manufacturer were combined in accordance 
with the requirements of the Phusion® polymerase at a scale depending upon the number of PCR 
samples required. Samples were transferred into the Mastercycler Gradient thermocycler and pre-
programmed temperature cycles for primer denaturation, annealing and extension were selected. 
Annealing temperatures were dependent upon length and GC content of synthesized 
oligonucleotides.   
 
 
2.6.2 DNA digestion by restriction enzymes  
 
Based upon the plasmid utilised and the available restriction sites contained within the 
cloning/expression region, vectors were digested by specific New England Biolabs (NEB) 
restriction enzymes. Digestion of plasmid DNA or PCR products were optimised by incubation of 
500 ng of DNA with the desired restriction enzyme in a suitable NEB buffer (provided by 
manufacturer) at 37°C for a minimum of 3 hours. Restriction enzymes utilised in this project are 
noted in Table 2.3. 
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Restriction enzyme Sequence 
NdeI CA^TATG 
GTAT^AC 
XhoI C^TCGAG 
GAGCT^C 
Table 2.3 Restriction enzymes utilized for restriction digest of M. leprae Mur enzymes and the vector pCOLD. 
Genetic sequences targeted for enzyme digestion are indicated. Enzymes were incubated for 4 hours at 37°C in 
manufacturer’s recommended NEB buffer 4. 
 
 
2.6.3 DNA purification  
 
PCR, digestion and ligation products were purified using a Qiagen QIAquick® PCR Purification 
kit. Purification was conducted to manufacturer’s specifications.  
 
 
2.6.4 DNA ligation  
 
Digested plasmid DNA were incubated at 37°C for 1 hour with Shrimp alkaline phosphatase to 
dephosphorylate. The enzyme was denatured following incubation at 65°C for 30 minutes and the 
digested plasmid was purified. Digested PCR products and plasmid DNA with reciprocal sticky 
nucleotide ends were ligated together in a final volume of 10 µL by T4 DNA ligase from NEB 
according to the manufacturer’s instructions. A negative control without enzyme was also 
produced. Ligations were incubated at 37°C for 1 hour and resulting ligated plasmids were 
transformed in E. coli TOP10 cells and grown on LB agar at 37°C overnight. 
 
 
2.6.5 Quantification of DNA concentration  
 
A NanoDrop ND-1000 spectrophotometer (Thermo Scientific) was used to quantify 1 µL DNA 
samples at A260/280. 
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2.6.6 Site directed mutagenesis 
 
Complementary oligonucleotides between 25-45 base pairs in length with a greater than 78°C 
melting temperature were synthesized. The point mutation was located within the centre of the 
synthesised oligonucleotides. Whole PCR amplification to generate the newly mutated plasmid 
was conducted with an Aligent QuikChange II Site-Directed Mutagenesis Kit in accordance with 
the manufacturer’s instructions. 
 
Primer Sequence (5’-3’) 
MurA Forward D-C  
active site 
CGCGTGGCACTGCCGGGCGGTT 
GCGCAATCGGCTCTCGTCCG 
MurA Reverse D-C  
active site 
CGGACGAGAGCCGATTGCGCAA 
CCGCCCGGCAGTGCCACGCG 
Table 2.4 Sequences of primers used for site directed mutagenesis of M. leprae MurA gene. Forward and reverse 
genetic overlapping primers to substitute a cysteine residue (Highlighted in bold) for the aspartate residue within the 
active site of MurA. 
 
 
2.6.7 Agarose gel electrophoresis 
 
The size and purity of plasmids, digests and PCR products were determined with a 1% (w/v) 
agarose gel. 1 g of agarose (Sigma) was combined with 100 mL of 1 x Tris-acetate EDTA buffer 
(TAE, 40 mM Tris acetate, 1 mM EDTA, pH 8.3), the agarose was melted using microwave 
heating. A gel cast was constructed containing an inserted comb indicating the required number 
and size of sample wells. Proceeding only once the solution was cooled enough to be held, 
Ethidium bromide was carefully added, 3 µL per 100 mL solution to a final concentration of 0.5 
µg.mL-1. The final solution was then thoroughly mixed and poured into the pre-made cast to set. 
The agarose gel was excised from the cast and placed within a geneflow gel tank and immersed 
completely in 1 x TAE buffer. DNA samples were combined in eppendorfs with 1 x DNA loading 
dye (Fermentas 6 x stock: 0.25% (w/v) bromophenol blue, 0.25% (w/v) xylene cyanol FF and 15% 
(v/v) Ficoll 400). Samples were loaded into individual wells alongside a DNA ladder (Fermentas) 
comprising DNA fragments of lengths appropriate for estimation of the presumed size of samples 
and a negative control absent of DNA. The voltage and duration of electrophoresis was dependent 
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upon the size of gel. Standard agarose gels (100mm by 100mm) were electrophoresed at 90 volts 
(V) for 45 minutes. Gels were analysed under ultraviolet light with a Syngene GeneSnap G:Box 
gel illuminator. 
 
 
2.6.8 DNA sequencing  
 
Isolated DNA plasmids were sequenced by submission to GATC Biotech (Germany). Samples 
were submitted as 10 µL aliquots containing 80-100 ng.µL-1 of plasmid DNA and 5 pmol.µL-1 of 
DNA primer, usually the vector promoter or terminator sequence. Plasmid primer sequences used 
during this project are recorded in Table 2.5.  
 
Primer Sequence (5’-3’) 
pUC57 forward GTAAAACGACGGCCAGTG 
pUC57 reverse GGAAACAGCTATGACCATG 
T7 promoter TAATACGACTCACTATAGGG 
T7 Terminator GCTAGTTATTGCTCAGCGG 
pCOLD forward GCACGCCATATCGCCGAAAGGC 
pCOLD reverse GGCAGGGATCTTAGATTCTGTGC 
Table 2.5. The nucleotide bases of upstream and downstream sequences encompassing the cloning/expression 
region within selected plasmids. These sequences were used to amplify plasmid genes during PCR for DNA 
sequencing/cloning techniques.  
 
The DNA sequences obtained from submitted samples were analysed and aligned against the 
known complete nucleotide sequence of the relevant genes using the plasmid editor software ApE 
(http://jorgensen.biology.utah.edu/wayned/ape/).  
 
 
2.6.9 Transformation  
 
2 µL of plasmid DNA (50-100 ng) was added to a 30 µL suspension of competent E. coli cells and 
incubated on ice for 30 minutes. Incubations were then heat-shocked at 42°C for 45 seconds and 
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cooled on ice for 2.5 minutes. Cells were then supplemented with 200 µL of SOC medium (Section 
2.2 Growth media) and incubated for 1 hour at 37°C at 180 rpm. Successfully transformed cells 
were identified by aseptic plating onto LB-agar containing the appropriate antibiotic selection and 
incubated at 37°C overnight.   
 
 
2.6.10 Isolation of plasmid DNA 
 
Plasmids propagated in E. coli TOP10 cells cultured in LB media plus plasmid specific antibiotic 
overnight were purified by the manufacturer’s instructions outlined within a Fermentas GeneJetTM 
miniprep extraction kit. 
 
 
2.7 Expression and purification of recombinant proteins 
 
Any deviation from the methods described are stated in the relevant chapter. 
 
Plasmids containing genes of interest were transformed into competent E. coli cells grown on 
antibiotic selective agar. Individual colonies were inoculated and incubated overnight at 37°C and 
180 rpm agitation and grown in a 5 mL volume of LB media with any required antibiotics. 
Overnight cultures were then used to inoculate 1 litre volumes of LB media plus the required 
antibiotic at 37°C until culture optical density achieved OD600nm 0.5-0.7. Recombinant protein 
expression was induced by addition of 1 mM Isopropyl-b-D-thiogalactopyranoside (IPTG) at 
which point incubation was continued unless otherwise stated at 37°C for 4 hours. Small volume 
expression trials were conducted with newly constructed plasmids to identify optimal induction 
temperatures to elicit the greatest quantity of recombinant protein. IPTG-induction conditions that 
were investigated included 37°C and 25°C for 4 hours and 16°C overnight. Cells were pelleted by 
centrifugation in a Beckman JLA-8.1000 rotor at 10,000 x g, and resulting cell pellets were 
transferred to containers and stored at -20°C. 
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2.7.1 Recombinant protein over-expression with E. coli tuner (DE3) cells  
 
Expression of recombinant proteins transformed within E. coli tuner (DE3) cell lines aid in protein 
folding leading to increasing soluble protein concentrations by induction of protein chaperones 
and the ability to titrate target protein expression with IPTG concentration. Cells were cultured at 
37°C as described in Section 2.7, with one exception. Cells were grown in the presence of two 
antibiotics, one determined by the resistance of the transformation plasmid and chloramphenicol 
to retain an intrinsic pLacl plasmid until optical density reached OD600nm 0.5-0.7. Tetracycline and 
arabinose at final concentrations 6 ng.mL-1 and 2 mg.mL-1 respectively were added to express 
different sets of chaperones. Tetracycline induced GroES/GroEL chaperones and arabinose 
induced DnaJ, DnaK and GrpE chaperones. Culture flasks were then incubated at 16°C for 1 hour, 
at which point, cultures were induced by 1 mM IPTG overnight at 16°C. Cells were pelleted at 
4°C by 10,000 x g centrifugation in a Beckman JLA-8.1000 rotor, and the resulting cell pellets 
were transferred to suitable containers and stored at -20°C. 
 
Small volume expression trials were conducted with newly constructed plasmids to identify 
optimal concentration of IPTG to elicit the greatest concentration of recombinant protein. 
 
 
2.7.1.1 SDS-Polyacrylamide Gel Electrophoresis  
 
A polyacrylamide resolving gel was cast in a Hoeffer Mighty Small gel kit, comprising 12% 
acrylamide:bis-acrylamide (37.5:1), 375 mM Tris pH8.8 and 0.4% (w/v) SDS. Once the resolving 
gel had set, a stacking gel (4% acrylamide:bis-acrylmide (37.5:1), 125 mM Tris pH 6.8, 0.4% 
(w/v) SDS) was cast above the solving gel. Both gels were polymerised by 10% (w/v) Ammonium 
persulphate (APS) and N,N,N,’,N’-Tetramethylethylenediamine (TEMED). To enable a straight 
interface between both gels, 96% (v/v) ethanol was overlain on the resolving gel while it set. The 
ethanol was then removed and the stacking gel was poured. A well-shaped comb was inserted into 
the unpolymerised stacking gel to create wells of selected size and number within the gel. Protein 
samples were mixed 5:1 with a 6 x sample buffer (6 x; 2.5% (w/v) bromophenol blue, 5% (v/v) b-
mercaptoethanol, 20% (v/v) glycerol, 63.5 mM Tris pH 6.8, 0.4% (w/v) SDS). 5-10 µg protein 
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samples and molecular weight standards were heat-denatured by 10-minute incubation using an 
Eppendorf Mastercycler Gradient thermocycler at 95°C. 20 µL maximum sample volume was 
pipetted into SDS-PAGE wells. SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE) utilised a 
Tris-glycine buffer system (Laemmli 1970). Gels were run at 180 volts (V) once submerged in 
SDS-PAGE running buffer (25 mM Tris pH 8.3, 190 mM glycine, 0.1% (w/v) SDS). The 
procedure was concluded once the dye front has migrated to the bottom of the gel. 
 
 
2.7.1.2 Development of SDS-PAGE 
 
Detection of separated protein were visualized by staining overnight with Instant Blue (Sigma-
Aldrich). Stained gels were rinsed in H2O and analysed using the Syngene GeneSnap G:Box Gel 
Documentation and analysis system. 
 
 
2.7.1.3 Western blotting 
 
Poly-histidine tagged recombinant proteins were initially separated by SDS-PAGE (Section 
2.7.1.1) along with histidine tagged protein markers (Invitrogen). The resolving gel was incubated 
in transfer buffer (25 mM Tris pH 8.3, 192 mM Glycine, 20% methanol (v/v) and 0.05% SDS) 
and layered on a PVDF membrane (Hybond-P, GE Healthcare) which was pre-soaked in methanol 
followed by a subsequent wash in deionising water followed by submersion in transfer buffer. The 
membrane and gel were placed within an electroblotting kit (BioRad) for one hour and thirty 
minutes at 120 V. To prevent non-specific binding, membranes were incubated at room 
temperature for 1 hour in 10% milk powder TBS solution plus 0.1% (w/v) Tween-20 (TBS-T). 
Membrane were then placed overnight still within the milk TBS-T solution at 4°C. 
 
Membranes were washed on three occasions with TBS-T for 10 minutes each followed by 
incubation in 5% milk TBS-T solution plus 20 µL of primary antibody (Anti-His IgG mouse 
monoclonal) (Roche) for one hour. Performed three 10 minutes TBS-T washed followed by 
incubation in 5% milk TBS-T solution plus 10 µL of secondary antibody (Anti-mouse IgG) and 
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horseradish peroxidase (Sigma) for 2 hours. Concluded with three final 15 minutes washes within 
TBS-T.  
 
The ECL solutions A and B (GE Healthcare) were mixed together within a darkroom and applied 
to the membrane for two minutes. Remove Excess solution was removed from the membrane and 
inserted within an cassette. The membrane was exposed to x-ray film for 5 minutes and then 
developed. 
 
 
2.7.2 Fractionation of lysed E. coli cells  
 
Weighted frozen cell pellets containing cells that over-expressed proteins of interest were thawed 
on ice and were resuspended per gram at 4°C with 3 mL of phosphate buffer saline (PBS) 
containing 20 µg.mL-1 DNAse, 1 µM of protease inhibitors leupeptin and pepstatin and 2.5 mg.mL-
1 chicken egg white lysozyme.  
 
Dependent upon the total volume of the resuspended cell solution, cells were lysed by two 
methods. Small volumes less than 10 mL such as those used in expression trials were sonicated 
using a Bandelin Sonoplus sonicator at 30% power on ice in three sets of 10 second periods 
interspaced by 20 seconds of cooling on ice. An aliquot of lysed cells was retained from each 
sample, and the remaining cell lysate was pelleted by centrifugation at 3,200 x g in an Eppendorf 
centrifuge 5810R for 10 minutes at 4°C. A consistent volume aliquot of the soluble phase of the 
eppendorf sample was isolated and run on an SDS-PAGE gel (Section 2.7.1.1 SDS-Page Gel 
Electrophoresis) along with the isolated whole cell lysate aliquot to determine percentage of 
soluble protein expressed.  
 
Large volume cell suspensions greater than 100 mL were lysed by gradual passage through a 4°C 
30 kpsi continuous cell disruptor (Constant Cell Disruption Systems) three times on ice. The 
resultant lysate was then pelleted by centrifuged at 4°C for 40 minutes at 25,000 x g. The 
suspension from this step contained solubly expressed proteins and membranes. The membrane 
fraction was further purified if required by further centrifugation in a Beckman Ti45 rotor at 4°C, 
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at 100,000 x g for 1 hour. The resulting pellet was isolated and resuspended using a glass 
homogenizer in a membrane resuspension buffer (25 mM Tris pH 7.5, 10 mM MgCl2, 1 M NaCl, 
20 mM (v/v) Glycerol). Proteins were extracted from the membrane fractions with 2% (v/v) Triton 
X-100 with gentle agitation gently at 4°C for 2 hours. The samples were then ultracentrifuged at 
150,000 x g at 4°C for 1.5 hours. 
 
 
2.7.3 Recombinant protein purification 
 
Any deviation from the methods described are stated in the relevant chapter. 
 
 
2.7.3.1 Affinity chromatography 
 
Immobilised metal affinity chromatography (IMAC) was utilised to purify poly-histidine tagged 
proteins. Two IMAC methods were implemented within this thesis using either a pre-packed 5 mL 
Nickel or Colbalt HisTrap column (GE healthcare) or a 5 mL column TALON Colbalt Metal 
Affinity Resin (Clontech) packed within an Econo-Pac® Chromatography column (BioRad). In the 
former case, equilibration, sample loading, column washing and final elution of the target protein 
was performed with the column as poured. In the latter case, the TALON resin was equilibrated, 
mixed with the protein sample with gentle agitation and then poured as a column, subsequent to 
which it was washed and then eluted to obtain the desired protein. 
 
For both IMAC methods, the metal resin was washed with 10 column volumes (CV) of sterile 
water, followed with 10 CV of purification buffer A (25 mM Tris pH 7.5, 10 mM MgCl2, 1 M 
NaCl, 20% (v/v) glycerol, 0.25 (v/v) TritonX-100) supplemented with 15 mM Imidazole. Pre-
packed columns were loaded with sample. Alternatively sample was mixed with 5 mL TALON 
Cobalt beads and incubated at 4°C for 1 hour, at which point the resin was poured as a column. 
Both IMAC methods then followed the same protocol. 
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Flow through sample loading for both column types was collected and columns were washed with 
a further 10 CV of purification buffer A plus 15 mM Imidazole before purified proteins were eluted 
in convenient volume fractions by a purification buffer A plus 1 M Imidazole gradient at 1 mL.min-
1 over 10 CV unless otherwise stated. Protein elutions were monitored by absorbance at 280 nm 
by the AKTA 10/100 system. Identification of protein fractions of interest and assessment of 
sample purity was achieved using SDS-PAGE. 
 
Pre-packed columns were cleaned with 10 CV of purification buffer A followed by 10 CV of 20% 
(v/v) Ethanol and stored at 4°C. 
 
 
2.7.3.2 Size exclusion chromatograph 
 
Samples were separated at room temperature by size either through the use of a Bio-gel® P200 
column (Bio-Rad) for peptidoglycan precursors or a Superdex 200 (GE Healthcare) for protein 
purification.  
 
A Bio-gel® P200 column (dimensions: diameter 2.5 cm/height 80 cm/volume 393 mL) was 
attached to the AKTA 10/100 system (GE healthcare) and equilibrate overnight in 2 CV of sterile 
water at a flow rate of 1 mL.min-1. Samples were resuspended after freeze-drying in 2 mL of sterile 
water and loaded onto the column with a 5 mL injection loop. The column was then eluted at a 
flow rate of 1 mL.min-1 where 5 mL fractions were collected. Elutions of species of interest were 
monitored by absorbance measured at 254 and 280 nm. 
 
The Superdex 200 column was attached to the AKTA 10/100 system (GE healthcare) and 
equilibrated in 2 CV of Gel filtration buffer (20 mM Tris pH 8.0, 100 mM NaCl and 10% (v/v) 
Glycerol). Samples were concentrated (Section 2.7.5) to 2 mL and loaded onto the column with a 
5 mL injection loop. The column was eluted at a flow rate of 1 mL.min-1 where 0.5 mL fractions 
were collected. Elutions were monitored by absorbance measured at 254 and 280 nm. 
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2.7.3.3 Ion exchange chromatography 
 
Purified protein samples were further purified by anion exchange chromatography. A MonoQ 5/50 
column (Sigma Aldrich), packed with the beads of the strong anion exchanger MonoQ, containing 
quaternary amine groups, mounted on an AKTA 10/100 system was washed with 10 CV of sterile 
water. The column was equilibrated with 10 CV of MonoQ buffer A (20 mM HEPES pH 7.6, 10 
mM NaCl, 10% (v/v) Glycerol), 10 CV of MonoQ buffer B (20 mM HEPES pH 7.6, 1 M NaCl, 
10% (v/v) Glycerol) and finally 10 CV of MonoQ buffer A. Samples were either concentrated or 
resuspended in MonoQ buffer A to a 2 mL final volume. Samples were injected onto the column 
followed by 10 CV of MonoQ buffer A. All flow through volumes were collected. Bound samples 
were eluted by a gradual NaCl concentration increase due to the percentage of MonoQ buffer B 
present. Small volume fractions were collected and samples identified by absorbance measured at 
218/254/280 nm or by SDS-PAGE.  
 
Peptidoglycan precursor samples resulting from fractionation by Bio-Gel P200 by size exclusion 
chromatography (Section 2.7.3.2) were further purified using the same method with alternate 
buffer compositions. Buffer A consisted of 10 mM Ammonium acetate pH 7.6 and buffer B 
consisted of 1 M Ammonium acetate pH 7.6. Small volume fractions were collected and samples 
identified by absorbance measured at 218/254/280 nm. 
 
 
2.7.4 Buffer exchange dialysis of recombinant protein  
 
Proteins purified in one buffer were often required to be transferred to another buffer. Specific 
buffers are stated within the relevant chapters. Generally, a 1 litre dialysis buffer was assembled 
and stored at 4°C. Dialysis tubing sufficient in length to contain the protein sample was washed in 
H2O and tied at one end and clipped to prevent leakage. The protein sample was added to the 
tubing and the other end was tied and clipped. The dialysis tubing was submerged in the required 
dialysis buffer and placed overnight at 4°C with a magnetic stirring bar on a magnetic stirrer. The 
buffer was gently and continually stirred overnight, to facilitate buffer exchange by dialysis.  
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2.7.5 Concentration of recombinant protein 
 
Dilute proteins were concentrated through a Satorius Vivaspin® centrifugal concentrator. 
Concentrator selection was dependent upon the molecular weight of the protein, being 
concentrated. Concentrators with molecular weight cut offs of 10, 30 or 100 kDa were used as 
appropriate. Large volumes were concentrated in stages within a 4°C centrifuge (Eppendorf 
Centrifuge 5810R) at 1,800 x g until the requisite protein volumes and concentrations were 
obtained. 
 
 
2.7.6 Quantification of recombinant protein 
 
There were two methods used to quantify protein concentration, the choice of either depending 
upon the presence of detergents. 
 
 
2.7.6.1 Bio-rad protein quantification 
 
Purified proteins in the absence of detergents were quantified using a Bio-rad colorimetric assay 
to determine concentration. 1 mL of diluted Bio-rad reagent (1:5; Bio-rad:H2O) plus 2 µL of the 
protein sample buffer was used as a blank control in plastic semi-micro cuvettes where absorbance 
was measured with a Jenway 6306 UV-visible spectrophotometer at 595 nm. 2 µL of purified 
protein sample was mixed with the reagent and absorbance measured. Samples exceeding the 
measureable range were diluted and multiple readings were taken to acquire an average. The 
formula for calculating protein concentration of a known sample is noted below; 
 
[Protein] (µg.mL-1) = (A595nm/0.1) x 1.95 x dilution factor x (1000/2). 
 
Formula based on a linear response of the assay between 0-20 µg bovine serum albumin (BSA) 
where an A595 of 0.1 was generated by 1.95 µg protein in the assay. 
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2.7.6.2 Bicinchoninic acid (BCA) protein quantification 
 
Purified protein in the presence of detergents were quantified using a Thermo Scientific Pierce 
BCA protein assay kit to determine concentration. Manufacturer’s instructions were followed. 25 
µL serial dilutions of a known BSA protein standard were combined with 1000 µL working BCA 
reagent (reagent A and B mixed at a 50:1 ratio) such that 10, 20, 30, 40 and 50 µg BSA were added 
to each assay. Solutions were incubated at 37°C for 30 minutes and absorbance was measured at 
562 nm using a Jenway 6306 UV-visible spectrophotometer. Standard values obtained were 
plotted against known standard concentrations and the concentration of the unknown sample 
treated identically to the BSA samples was interpreted from the resulting calibration curve. 
 
 
2.8 Synthesis of Lipid II and intermediates 
 
2.8.1 Biosynthesis of cytoplasmic peptidoglycan intermediates 
 
The protocol for production of individual cytoplasmic peptidoglycan precursors employed here 
was developed from the method described by Lloyd et al. (2008). Dependent upon the precursor 
required specific components of the cytosolic peptidoglycan pathway were incubated for 18 hours 
at 37°C within a final 2 mL reaction volume. The production of N-glycolylated variants of any 
described precursor was obtained by the exchanging of UDP-MurNAc from the reaction mixture 
with UDP-MurNGlyc (GVK biosciences). 
 
For the production of UDP-MurNAc-L-Ala, synthesis contained: 50 mM HEPES pH 7.5, 10 mM 
MgCl2, 50 mM KCl, 1 mM dithiothreitol (DTT), 200 µM NADPH, 6 mM ATP, 25 mM isocitrate, 
40 units isocitrate dehydrogenase (Sigma Aldrich), 500 units pyruvate kinase (Sigma Aldrich), 
200 mM PEP, 10 mM UDP-GlcNAc, 30 mM L-Ala, 300 µg MurA, 2000 µg MurB and 750 µg 
MurC. 
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For the production of UDP-MurNAc-L-Ala-D-Glu, synthesis contained the previously mentioned 
components plus 30 mM D-Glu and 1000 µg MurD. For the production of UDP-MurNAc-L-Ala-
D-Glu-L-Lys/m-DAP, synthesis contained the previously mentioned components plus 30 mM L-
Lys/m-DAP and 1250 µg MurE. For the production of UDP-MurNAc-L-Ala-D-Glu-L-Lys/m-
DAP-D-Ala-D-Ala, synthesis contained the previously mentioned components plus 30 mM D-
Alanyl-D-Ala and 1500 µg MurF. 
 
After incubation, synthesis were diluted with 5 mL of sterile water and the protein components 
were filtered out using a 10 kDa Vivaspin® centrifugal concentrator. 
 
 
2.8.1.1 Purification of cytoplasmic peptidoglycan intermediates 
 
Purification of the synthesised intermediates were performed by anion exchange chromatography 
as described in Section 2.7.3.3. Removal of acquired ammonium acetate was by size exclusion 
chromatography as described in Section 2.7.3.2 or more usually by three rounds of lyophilisation 
from water (Section 2.8.2). 
 
 
2.8.1.2 Quantification of cytoplasmic peptidoglycan intermediates 
 
The peptidoglycan precursors were quantified using the absorbance of the uracil ring (extinction 
coefficient at 260 nm = 10,000 M-1cm-1) permitting the measurement of produced precursor 
concentration within a quartz cuvettes using a Jenway 6303 UV-visible spectrophotometer. 
 
 
2.8.1.3 Biotinylation of UDP-MurNAc-pentapeptide 
 
UDP-MurNAc-pentapeptide and UDP-MurNGlyc-pentapeptide were synthesised as described in 
Section 2.8.1. Synthesised precusors were biotinylated using the EZ-linkTM Sulfo-NHS-LC-
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Biotinylation Kit (Sigma Aldrich) following the manufacturer’s instructions. Samples were freeze 
dried, resuspended in 50 mL sterile water and freeze dried again. Labelled and unlabelled 
monosaccharides were isolated by ion exchange chromatography. Lipid synthesis was conducted 
as described in Section 2.8.4. 
 
 
2.8.2 Lyophilisation of peptidoglycan intermediates 
 
Excess liquid was removed from dissolved peptidoglycan/lipid/protein solutions by freeze-drying. 
Solutions were transferred to round bottomed flask able to sufficiently accommodate the volume 
contained. Flasks were placed within liquid nitrogen and rotated constantly to evenly distribute the 
frozen solution throughout the inside of the flask. Flasks were placed onto the freeze-dryer and the 
vacuum pressure applied.  
 
 
2.8.3 Preparation of bacterial cell membrane enzymes for Lipid II synthesis  
 
Single colonies of M. flavus/ B. subtilis were inoculated in either LB or minimal media 100 mL 
overnight at 37°C with 180 rpm agitation. 800 mL of either fresh media was re-inoculated with 4 
mL 20% (w/v) glucose and 15 mL of overnight bacterial culture in 2 litre flasks. Flasks were 
subsequently incubated at 37°C and 180 rpm. The optical density at 600 nm of the cell culture was 
evaluated every hour and cells were harvested at 10,000 x g for 20 minutes at 4°C once cells 
entered log phase. The supernatant was discarded and pellets were resuspended in cold 
resuspension buffer (20 mM Tris pH 7.5, 1 mM MgCl2, 2 mM b-mercaptoethanol).  
 
Samples were centrifuged at 15,000 x g for 20 minutes at 4°C, the supernatant was removed and 
the pellet was resuspended in buffer at a ratio of 3 mL per gram of cells. 2.5 mg per mL of chicken 
egg lysozyme was added to the resuspended cells. The cells were incubated at 4°C with steady 
agitation for 20 minutes. Bacterial cells were lysed by repeated processing through a continuous 
cell disruptor (Constant Cell Disruption Systems) at 4°C and a constant pressure of 30 kpsi. Lysed 
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samples were transferred to centrifuge tubes and centrifuged at 10,000 x g for 1 hour at 4°C. The 
resulting supernatant was centrifuged again at 75,000 x g for 1 hour at 4°C. The pellet containing 
the cell membranes was retained and resuspended in a small volume (2.5 mL) of resuspension 
buffer. Protein concentration was determined with the Bio-rad protein assay (Section 2.7.6.1). 
Resuspended membranes were stored at -80°C. 
 
 
2.8.4 Small-scale synthesis of Lipid II  
 
Based upon published work by Breukink et al. (2003). 0.654 µg of extracted cellular membranes, 
0.57 mg.mL-1 MurG, 6 mM UDP-GlcNAc (Sigma-Aldrich), 4 mM UDP-MurNAc-pentapeptide 
or UDPMurNGlyc-pentapeptide, 4.8 µmol undecaprenyl phosphate and 40 µL buffer (100 mM 
Tris.HCl pH 8, 5 mM MgCl2, 1% (v/v) Triton X-100) were combined in a final volume of 200 µL 
and were incubated for 4 hours at 37°C. To isolate synthesized lipids, an equal volume of 6 M 
pyridine-acetate pH 4.2 and two volumes of N-butanol were added to the incubated synthesis. 
Reactions were transferred to glass tubes and centrifuged at 3,000 x g for 10 minutes. The upper 
phase (N-butanol) was retained, and washed with an equal volume of H2O. The upper lipid phase 
was subjected to rotary evaporation and frozen at -80°C. 
 
 
2.8.4.1 Purification of Lipid II 
 
Purification of synthesized lipids was conducted by anion exchange chromatography. 15 mL glass 
pipettes were clamped upright, glass wool was placed inside the base and 4 mL DEAE-Sephacel 
resin was poured into each. Columns were then washed with 40 mL of 1 M ammonium acetate, 
followed by 60 mL of H2O and finally 38 mL of solvent A (chloroform:methanol:water; 2:3:1). 
The flow-through for each wash was disposed of. Dried down synthesized lipids were resuspended 
completely in 6 mL of solvent A and loaded onto a DEAE-Sephacel column. The subsequent 
column flow through was collected for TLC analysis. Unbound contaminants were eluted from the 
column with 3 column volumes of solvent A. Separation of Lipid II from unreacted undecaprenyl 
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phosphate was achieved by eluting the column isocratically with increasing concentrations of 
ammonium bicarbonate (AB) between 50 mM to 1 M in solvent A. Aliquots from each elution 
were rotary evaporated and stored at -80°C for TLC analysis. 
 
 
2.8.4.2 Thin layer chromatography (TLC) of synthesized Lipid II 
 
A TLC tank was pre-warmed at 37°C. TLC plates were marked in pencil to evenly separate out 
pipetted samples. Marks were drawn 2.5 cm from the bottom of the plate and 1.5 cm from the side. 
The TLC plates were pre-heated at 60°C for 20 minutes prior to use. Purified dried lipid fractions 
were resuspended in a small volume (15 µL) of solvent A, and pipetted onto marked spots on the 
TLC plates in 2 µL aliquots and permitted to air dry. TLC mobile phase 
(chloroform:methanol:water:ammonia (88:48:10:1)) was poured into the TLC tank to a depth of 1 
cm. The loaded TLC plates were placed into the TLC tank which was then covered. Thin layer 
chromatography was allowed to run at 25°C for around 3 hours until the mobile phase was within 
1 cm of the top of the TLC plate. To visualize the separated species, plates were stained in a sealed 
container with iodine vapours. Results were scanned immediately as the stain faded rapidly. 
 
 
2.8.4.3 Quantification of Lipid II 
 
Two small 50 µL aliquots of Lipid II were dried down using nitrogen to remove the 
chloroform/methanol/water (2:3:1). A control aliquot of chloroform/methanol/ water (2:3:1) was 
also dried down. The contents of each vial were resuspended in a total of 50 µL volume of 50 mM 
HEPES, 10 mM MgCl2, 30 mM KCl, 1.5% (w/v) CHAPS pH 7.6 and supplemented with 50 µL 1 
M HCl. Vials were then boiled for 20 minutes, followed by a 5 minute 3,000 x g centrifugation. 
The pH of each vial was adjusted by addition of 1 M NaOH to pH 7.6. 
 
Quantification of Lipid II was measured as a function of phosphate released in the above acid 
hydrolysis. The structure of Lipid II contains two equivalents of Pi which were released from the 
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lipid in the form of inorganic pyrophosphate and probably also phosphate during acid hydrolysis. 
Therefore samples were treated with inorganic pyrophosphatase (IPP) to convert all remaining 
pyrophosphate to free Pi which was then measured using purine nucleoside phosphorylase (PNP) 
to catalyse the phosphorolysis of 7-methyl-6-guanosine (MESG) (Berry and Associates, USA) to 
ribose 1-phosphate and 7-methyl-6-thioguanine with the concomitant increase in absorbance at 
360 nm (A360 = 10000 M-1 cm-1 per Molar phosphate). 
 
The assay consists of 50 mM HEPES pH 7.6, 10 mM MgCl2, 1 units of Inorganic Pyrophosphatase, 
0.2 mM MESG and 1 unit of Purine Nucleoside Phosphorylase. 
 
 
2.9 Peptidoglycan intermediate accumulation 
 
2.9.1 B. subtilis peptidoglycan intermediate accumulation 
 
Single B. subtilis colonies were inoculated in minimal media (Section 2.2 Growth media) and 
grown overnight at 37°C. Subsequent cultures were then used to inoculate 1 L of minimal media, 
grown at 37°C and 180 rpm. OD600nm readings were taken until cells reached OD600nm 1.0. Pywac 
reporter screened cell wall active compounds and the positive control antibiotic vancomycin, were 
added at twice their MIC values and cultures were incubated for a further three hours. Cells were 
harvested by centrifugation at 3,200 x g for 10 minutes, the supernatant was then removed and the 
cell pellets were stored at 4°C. 
 
 
2.9.2 Trichloroacetic acid extraction of peptidoglycan intermediates 
 
Harvested pellets were cooled on ice and resuspended in ice cold 10% (w/v) Trichloroacetic acid 
(TCA), at a ratio of five mLs TCA per gram of pellet wet weight and incubated at 4°C with 
agitation for 30 minutes. Concurrent with the incubation, a Beckman JA 25.5 centrifuge rotor was 
also cooled at 4°C. After incubation, samples were centrifuged at 48,000 x g for 10 minutes at 
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4°C. The resulting supernatant was retained on ice. The TCA preciptitation protocol was repeated 
twice more on the pellet of the first extraction, with the volume of TCA half of the first extraction. 
The three supernatants were then combined.  
 
 
2.9.3 Di-ethyl ether extraction of TCA of peptidoglycan intermediate pool 
 
The total TCA supernatant was poured into a separating funnel and equal volume of ice cold di-
ethyl ether was added. The combined volume was mixed gently to extract the TCA. The ethanol 
and aqueous phases were separated. The aqueous phase was retained while the ether phase 
containing the TCA was discarded. The aqueous phase was reextracted twice more with equal 
volumes of ether. The pH of the aqueous phase was then adjusted to pH 7.2. The sample was rotary 
evaporated to remove residual solvents and freeze dried. Cell wall intermediates were isolated by 
size exclusion chromatography (Section 2.7.3.2) and ion exchange chromatography (Section 
2.7.3.3) and identified by Mass spectrometry (Section 2.12). 
 
 
2.10 Assessment of antimicrobial binding against biotinylated Lipid II 
variants 
 
2.10.1 Surface Plasma Resonance (SPR) 
 
Streptavidin coated SPR chips (GE healthcare) were analysed at 25°C using a Biacore T200 (GE 
healthcare). Individual labelled vials were inserted into the system containing 20 µg.mL-1 
biotinylated N-acetylated Lipid II DAP, biotinylated N-glycolylated Lipid II DAP, and biocytin to 
act as a control. The four flow cells of the SPR chip were washed three times with degassed and 
filtered HBS-EP buffer (0.01 M HEPES pH 7.4, 0.15 M NaCl, 3 mM EDTA and 0.005% (v/v) 
Surfactant P20). Each flow cell was prepared by immobilizing the specific biotinylated lipid or 
biocytin control onto the surface and washed once more with HBS-EP buffer. Investigated 
antimicrobials were prepared by serial dilution from concentrated stocks, with the DMSO 
 
 
69 
concentration, if required for antimicrobial solubility maintained across the concentration range. 
The antimicrobial dilutions were aliquoted into individual vials, labelled and randomized within 
the Biacore T200. The sensorgram was performed by injection of antimicrobials at 20 µL.min-1 
across all concentrations. Increasing concentrations of NaCl (0.5-5 M) were present to remove 
bound ligands if required to completely regenerate the SPR chip.  
 
 
2.10.2 Bio-Layer Interferometry (BLI)  
 
Biosensors coated in streptavidin or nickel-charged tris-nitriloacetic acid (Ni-NTA) were 
submerged in selected assay buffers for 10 minutes. The streptavidin assay buffer for Lipid II 
variants consisted of 25 mM Tris pH 8.0 and 0.1% (v/v) Triton X-100. The Ni-NTA assay buffer 
for PBP enzymes PonA1/A2 consisted of 50 mM Bis-Tris pH 8.0, 20 mM NaCl and 0.1% (v/v) 
Triton X-100. Within a 96 well black opaque microtiter plates known concentrations of 
biotinylated Lipid II variants and antimicrobials of interest were aliquoted into columns. 
Biosensors and the microtiter plate were inserted and integrated into the Octet RED96 biolayer 
interferometer system (FortéBio, Pall Inc.). The sensors were sequentially programmed to be 
submerged first into the wells containing the 2 µg.mL-1 biotinylated lipid II or  2 µM poly-histidine 
tagged PonA1/A2, to reversibly immoblise the ligands to the sensor. The bound sensors were 
washed three times in assay buffer.  The BLI assay was performed at 30°C and consisted of a 60 
second baseline measurement in assay buffer, a 120 second association step against a range of 
selected antimicrobial concentrations and a 120 second disassociation step in assay buffer. 
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2.11 Spectrophotometric assays 
 
2.11.1 Coupled NADH-linked pyruvate kinase/lactate dehydrogenase assay for 
amino acid Mur ligase activity 
 
Amino acid ligase activity was measured at an absorbance of 360 nm in a Varian Cary 100 
spectrophotometer by coupling the ligase catalysis generation of ADP to pyruvate kinase which 
rephosphorylated the ADP to ATP with the concomitant generation of pyruvate. Lactate 
dehydrogenase reduced the pyruvate to lactate oxidising one equivalent of NADH to NAD+ with 
the consequent drop in NADH absorbance at 340 nm. The addition of a single amino acid to the 
UDP-MurNAc/MurNGlyc intermediate consumes ATP releasing ADP and Pi from the reaction. 
ADP was then monitored over time as described above. 
 
The reaction mixture within a quartz cuvette contained 50 mM HEPES pH 7.6, 10 mM MgCl2, 1 
mM DTT, 50 mM KCl, 1 mM ATP, 2 mM PEP, 0.2 mM NADH, 5.8 Units/200 µL of Pyruvate 
kinase/Lactate dehydrogenase mix, 0.4 mM UDP-MurNAc/MurNGlyc intermediate and 40 
µg.mL-1 Mur enzyme. Once a level baseline was established 5 mM of the required amino acid was 
added. Absorbance was read over time at 37°C. 
 
 
2.11.2 Amplex Red assay for transpeptidase activity 
 
Transpeptidase activity was measured at 30°C with a Varian Cary 100 spectrophotometer by 
following the release of the terminal D-Alanine residue from the peptide stem of Lipid II variants. 
Here, D-alanine was oxidatively deaminated to pyruvate and hydrogen peroxide, where the latter 
was consumed by horseradish peroxidase (HRP) with the concomitant conversion of amplex red 
to the chromophore resorufin with an intense absorbance of 555 nm (ɛ1cm, 555 = 55, 000 M-1.cm-1). 
Amplex Red assay measured absorbance at A555nm. The assays were performed in quartz cuvettes 
and were comprised of 50 mM HEPES pH 7.6, 10 mM MgCl2, 50 µM Amplex Red, 33.51 
mM.min-1 d-amino acid oxidase (DAAO), 14.82 mM.min-1 HRP. A level baseline was achieved 
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before individual additions of Lipid II and PBP were inserted into the reaction mixture. Reactions 
were measured at 555 nm, if no activity was observed E. coli PBP 1b was added in excess as a 
positive control to the mixture to prove the reaction mixture was correct. The concentrations 
necessary for the assay for both DAAO and HRP catalytic activity were calculated independently.  
 
DAAO activity was measured by Dr. Adrian Lloyd at an absorbance of A340nm, the variation 
between the absence or addition of the D-amino acid, D-alanine (ɛ1cm, 340 nm = 6,220 M-1.cm-1) 
within the reaction volume. DAAO was prepared by dilution of the enzyme stock with 50 mM Tris 
pH 7.5, 50 mM lactitol, 10% (v/v) Glycerol, 5 mM EDTA, to a starting concentration of 54.13 
nM. The DAAO assay consisted of 50 mM Bis-Tris propane pH 8.5, 0.1% (v/v) Triton X-100, 20 
mM MgCl2, 5.8 units pyruvate kinase/lactate dehydrogenase mix, 0.3 mM NADH, 1.35 nM 
DAAO. The absorbance at 340 nm and 37°C was followed in a Cary UV/Vis spectrophotometer 
and after a control rate was determined, DAAO activity was initiated with 0.1 mM D-alanine. 
 
Horse radish peroxidase catalytic activity was measured at A555nm. The reaction volume consisted 
of 50 mM Bis-Tris propane pH 8.5, 20 mM MgCl2, 50 mM Amplex Red and 18.5 pM HRP. The 
enzyme was initially prepared in 50 mM Bis-Tris propane pH 8.5. Once a level baseline was 
achieved, hydrogen peroxide was added to a final concentration of 20 µM to initiate HRP activity. 
The resorufin extinction coefficient (ɛ1cm, 555 = 55, 000 M-1.cm-1) was used to calculate HRP 
activity. 
 
 
2.12 Mass spectrometry  
 
Purified intermediates and lipids were resuspended in 50% acetonitrile using a Waters Synapt G2 
Q-TOF Mass Spectrometer and analysed by negative or positive ion nanospray ionization mass 
spectrometry (ESI-MS) by Dr Adrian Lloyd and Mrs. Anita Catherwood, conducted within the 
Proteomic Facility RTP (School of Life Sciences, University of Warwick). Data analysis of the 
products were verified using MassLynx (Waters, USA). The instrument was calibrated in either 
ion mode with sodium iodide capillary voltage was 1.5 kV. 
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Chapter 3. The role of the N-glycolylated muramic acid in the  
protection of mycobacteria from host hydrolytic enzymes 
 
 
3.1 Introduction 
 
The core focus of this thesis is the role of the N-glycolylation of mycobacterial peptidoglycan 
against the host immune response of various organisms through utilization of hydrolytic enzymes. 
The unique structural modification identified in the Actinobacteria family (Raymond, et al. 2005) 
by which MurNAc subunits within the peptidoglycan sacculus are modified with oxygen is 
dependent upon the enzyme NamH (Rv3808) (Section 1.3.8.4), which converts UDP-MurNAc to 
UDP-MurNGlyc to form the MurNGlyc residues in the actinobacterial peptidoglycan. 
 
 
3.2 NamH deficient mutant 
 
The namH gene is comprised of 1551 base pairs encoding a 516 amino acid 57 kDa enzyme 
(Reddy, et al. 2009). To establish the function of the protein encoded by the namH gene, the 
construction of a namH mutant from the saprophyte M. smegmatis (Raymond, et al. 2005) was 
achieved. In this instance, excision of the known dominant b-lactamase gene blaS, (Flores, et al. 
2005) led to the formation of the strain PM965 followed by allelic exchange of the namH gene, 
leading to the creation of the blaS-; namH- double mutant PM979. Mass spectrometric analysis of 
the mycobacterial cell wall composition of the two newly created strains indicated that PM979 
produced solely MurNAc sugars throughout the peptidoglycan cell wall layer whereas the PM965 
blaS- strain incorporated both MurNGlyc and MurNAc moieties in a ratio of 7:3 during standard 
aerobic growth conditions (Raymond, et al. 2005). Previous investigations into PM979 concluded 
that namH deficient strains were 2-fold more susceptible to human lysozyme in minimal media 
such as 7H9 and 8-fold more susceptible in rich media such as LB (Raymond, et al. 2005). It was 
therefore proposed that NamH was important in hydrolytic enzyme resistance due in part to the 
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increase in hydrogen bonding along peptidoglycan chains (Raymond, et al. 2005) and interference 
caused by the N-glycolyl modification on recognition by peptidoglycan hydrolases.  
 
 
3.3 Experimental aims 
 
The acquisition of the two strains, PM965 and PM979 permitted the expansion of the investigation 
into the role of the N-glycolyl modification towards the mycobacterial response to various lytic 
hydrolases. Therefore, an investigation into the impact of N-glycolylation of peptidoglycan 
muramyl residues have on the sensitivity of M. smegmatis towards the hydrolytic enzymes, 
lysozyme and b-hexosaminidase was pursued. Further, exploration of peptidoglycan lytic 
properties of these enzymes at pH ranges physiologically similar to those found in and around the 
phagolysosome and plasma membrane was also undertaken. 
 
From this point onwards, M. smegmatis strain PM965 is referred to as wild type and PM979 as 
DnamH. The strains obtained from the Pavelka group were sequenced before delivery. 
 
 
3.4 Aerobic growth characterisation of M. smegmatis strains 
 
In order to characterize the growth kinetics of wild type and namH- M. smegmatis to determine 
any strain-specific variation in aerobic growth, the two M. smegmatis strains were inoculated from 
frozen stocks in nutrient 7H9 media supplemented with ADC and Tween80 (Section 2.2) in baffled 
flasks to maximise aeration during the normal phenotypical mycobacterial growth in aerobic and 
nutrient rich conditions. Results are depicted in Figure 3.1.  
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Figure 3.1 M. smegmatis Wild type and DNamH aerobic growth comparison. Cells were grown in 96 well 
microtiter plates in triplicate at 37°C with intermittent shaking every 20 minutes, absorbance was measured at OD600nm 
at 3 hour intervals for 48 hours. Each well contained 100 µL culture media (7H9, ADC, 0.05% (w/v) Tween 80). The 
cultured M. smegmatis wild type (Black) and DNamH (Blue) strains were standardized to an OD600nm of 1 and diluted 
further by a factor of 103 prior to incubation. Error bars represent standard deviation of triplicate measurements. 
Results show no observable variation between strains under standard growth conditions as defined by a student’s t-
test with a p-value >0.05. Ns = not statistically significant. 
 
 
In the previous investigation by the Pavelka group it was noted that the namH gene was not an 
essential requirement for the cell. The data shown in Figure 3.1 reports the same findings in aerobic 
and nutrient rich conditions. Both strains achieved a normal cellular growth pattern, exiting 
apparent lag phase after 24 hours and reaching stationary phase after 46 hours. The doubling time 
(Td) calculated from the exponential growth phase between hours 24 and 33 for the wild type 
strain (Figure 3.1: Black line) was 6.81 hours and for the DNamH strain (Figure 3.1: Blue line) 
was 6.96 hours. The Td variation between the two strains during exponential phase led to a 
measurable difference when comparing the area under the curve (AUC) for each strain. The 
DNamH produced an area under the curve value 8% less than the wild type. The growth curves of 
the wild type and NamH deficient strains were statistically analysed using an unpaired t-test to 
observe if there was a significant statistical difference between the two strains. A p-value less than 
0.05 permits the rejection of the null hypothesis that there is no statistically significant difference 
between two sets of data. The p-value was > 0.5 and so it was accepted that there was no observed 
difference between the two strains during normal cellular growth in nutrient media. 
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3.5 Anaerobic growth characterisation of M. smegmatis strains 
 
The N-glycolyl modification of MurNAc is only possible in the presence of molecular oxygen 
(Mahapatra, et al. 2005) and therefore the function of NamH is only significant in oxygen rich 
environments such as during normal cellular growth or during cellular resuscitation from a 
dormancy-like state amongst degraded granulomas. In a low oxygen environment or one that 
contains the absence of oxygen, the bacterial peptidoglycan sacculus can solely be formed from 
N-acetylated muramic acids. To ascertain the impact of an anaerobic environment on the 
phenotypic growth of the wild type and NamH- strains, the protocol adapted from Cordone, et al. 
(2011) was implemented. Cultures of 7H9 media supplemented with ADC and Tween80 
containing wild type and DNamH M. smegmatis strains were inoculated in baffled flasks in order 
to aerate the media and facilitate the incorporation of a higher percentage of MurNGlyc residues 
into the peptidoglycan of the wild type strain. Once cultures reached exponential phase, both 
strains were diluted to an OD600nm of 1 and 10-fold serial dilutions were pipetted onto both minimal 
media agar and tryptic soy broth (TSB) agar plates. These were incubated in anaerobic conditions 
for an extended period of 21 days to replicate the dormancy-like environment experienced by 
granuloma encased M. tuberculosis in infected macrophages. The strains were selected to be 
cultured on minimal media agar to mimic the nutrient and oxygen deprivation found within 
granulomas, whilst the TSB agar cultures were selected to mimic the absence of oxygen solely. 
Subsequently after 21 days the agar plates were transferred to aerobic conditions and incubated for 
a further 6 days to simulate the resuscitation of cells from the dormancy. The control for this 
experiment involved both media agar plates containing serial dilutions of both strains grown only 
in aerobic conditions for 6 days. The colony propagation controls before and after 6 day 37°C 
aerobic incubation are shown in Figure 3.2. 
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Figure 3.2 M. smegmatis colonization of selective nutrient agar during aerobic incubation. Serial dilutions of M. 
smegmatis strains wild type (top half of each plate) and DNamH (bottom half of each plate) grown on tryptic soy broth 
agar (top row) and minimal media (bottom row) plates for 0-6 days at 37°C in an aerobic environment. Serial dilutions 
labelled 1 (Dilution 101) to 8 (Dilution 108). A1-A2 Serially diluted M. smegmatis strains on TSB agar before 6 day 
aerobic incubation. B1-B2 Serially diluted M. smegmatis strains on TSB agar after 6 day aerobic incubation. C1-C2 
Serially diluted M. smegmatis strains on minimal media agar before 6 day aerobic incubation. D1-D2 Serially diluted 
M. smegmatis strains on minimal media agar after 6 day aerobic incubation. 
 
 
Results from Figure 3.2 indicate that both strains were culturable on both nutrient diverse agar 
plates within similar growth across the six days of aerobic incubation and were similarly able to 
colonise at a 10,000-fold dilution (10-4) from the initial starting OD600nm of 1. The minimal media 
(Figure 3.2: D1-D2) was observed to further permit culturable growth at a 100,000-fold dilution 
(10-5) for both strains. This slight disparity between the nutrient agar is likely due to an increased 
glucose concentration in the minimal media recipe compared to the tryptic soy broth (Section 2.2).  
 
The next stage of this investigation involved repeating the serial dilution of both strains on both 
sets of selected agar plates followed by incubation within an anaerobic environment for 21 days at 
37°C. Images of the serially diluted agar plated were taken before and after anaerobic incubation 
and are displayed in Figure 3.3. 
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Figure 3.3 M. smegmatis colonization of selective nutrient agar during anaerobic incubation. Serial dilutions of 
M. smegmatis strains wild type (top half of each plate) and DNamH (bottom half of each plate) grown on tryptic soy 
broth agar (top row) and minimal media (bottom row) plates for 0-21 days at 37°C in an anaerobic environment. Serial 
dilutions labelled 1 (Dilution 101) to 8 (Dilution 108). A1-A2 Serially diluted M. smegmatis strains on TSB agar before 
21 days anaerobic incubation. B1-B2 Serially diluted M. smegmatis strains on TSB agar after 21 days anaerobic 
incubation. C1-C2 Serially diluted M. smegmatis strains on minimal media agar before 21 days anaerobic incubation. 
D1-D2 Serially diluted M. smegmatis strains on minimal media agar after 21 days anaerobic incubation. 
 
 
The extended incubation period within a solely anaerobic environment led to the both strains being 
unable to visibly colonise the nutrient agar of either selective media at any investigated dilution 
(Figure 3.3). The anaerobically incubated agar plates were then placed within an aerobic incubator 
for six days, the equal time period as the solely aerobic controls at 37°C in Figure 3.2. Once 
completed, images of each plate were taken. The results of this experiment are presented in Figure 
3.4. 
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Figure 3.4 M. smegmatis colonization of selective nutrient agar during aerobic incubation following prolonged 
anaerobic incubation. Serial dilutions of M. smegmatis strains wild type (top half of each plate) and DNamH (bottom 
half of each plate) grown on tryptic soy broth agar (top row) and minimal media (bottom row) plates were incubated 
for 21 days at 37°C in an anaerobic environment. Plates were subsequently incubated aerobically at 37°C for 6 days. 
Serial dilutions labelled 1 (Dilution 101) to 8 (Dilution 108). A1-A2 Serially diluted M. smegmatis strains on TSB agar 
after 21 day anaerobic incubation. B1-B2 Serially diluted M. smegmatis strains on TSB agar after 21 days anaerobic 
incubation followed by 6 days aerobic incubation. C1-C2 Serially diluted M. smegmatis strains on minimal media 
agar after 21 days anaerobic incubation. D1-D2 Serially diluted M. smegmatis strains on minimal media agar after 21 
days anaerobic incubation followed by 6 days aerobic incubation. 
 
 
The results shown in Figure 3.4 show that once the nutrient agar plates incubated initially in 
anaerobic conditions were permitted to be incubated aerobic then the serially diluted aliquots of 
M. smegmatis strains on the surface of each media were able to colonise. Colony growth was 
noticeably reduced in both strains from the aerobic control experiment on the nutrient rich TSB 
agar plates. (Figure 3.4: B1-B2). Both strains demonstrated about a 100-fold decrease in bacterial 
survival from 104 dilution (Figure 3.2: B1) 102 dilution (Figure 3.4: B1) on the TSB nutrient agar 
plates. The ability to colonize at higher dilutions was less pronounced on minimal media agar 
(Figure 3.4: D2). Both strains once again equal displayed the capacity to form a single colony once 
diluted by 105. This was the exact maximum dilution observed in the aerobic control experiment 
(Figure 3.2: D2) for both strains, though the number of colonies was significantly more 
pronounced on the minimal media control plates. The variation in bacterial survival between the 
two selected agar plates after anaerobic incubation is likely due in part to oxygen deprivation being 
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a greater factor in M. smegmatis colonization than nutrient deprivation, as well as the slightly 
increased glucose concentration aiding colonization.  
 
Based on these results it could be concluded that namH is not essential to the viability of the cell, 
as reported by Raymond et al. (2005), not required to assist the resuscitation of dormant cells or 
support normal cellular growth whether during aerobic or anaerobic conditions. With time 
permitting further work could determine whether there had not been any reversion of the namH 
gene to the wild type sequence during colonization.  
 
 
3.6 M. smegmatis sensitivity towards lysozyme 
 
3.6.1 M. smegmatis sensitivity towards chicken egg white lysozyme 
 
The peptidoglycan of both wild type and namH deficient M. smegmatis strains have been shown 
to be substrates for lysozymes. To characterise the response of both strains to specific lytic 
enzymes, the minimal inhibitory concentration (MIC) of both strains challenged with chicken egg 
lysozyme in nutrient 7H9 media was assessed (Section 2.4.3). In short, cells were cultured from 
glycerol stocks in 7H9 nutrient media supplemented with ADC and Tween80 in baffled flasks to 
mid exponential phase to maximise oxygen distribution within the culture. Cells were diluted to 
an OD600nm of 0.1 and passed with a syringe through a 21-gauge needle to disrupt clumps of cells. 
Cells were diluted further by a factor of 103 and incubated in 96-well microtiter plates with 
increasing concentrations of chicken egg lysozyme in triplicate. Plates were incubated at 37°C 
with agitation for 60 hours under a gas permeable seal and OD600nm values were measured routinely 
every 3 hours. The MIC growth curves for both strains is presented in Figure 3.5. 
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Figure 3.5 The hydrolytic activity of chicken egg white lysozyme against the mycobacterial modifications of peptidoglycan. Wild type (a) and (b) DNamH 
M. smegmatis MIC growth curves against chicken egg white lysozyme. Cells were grown in 96-well microtiter plates in triplicate at 37°C with intermittent shaking 
every 20 minutes, where the absorbance was measured at 600nm at 3 hour intervals for 60 hours. Each well contained 100 µL culture media (7H9, ADC, 0.05% 
(w/v) Tween 80) with increasing concentrations of chicken egg white lysozyme. The cultured M. smegmatis wild type (a) and (b) DNamH strains were standardized 
to an OD600nm of 1 and diluted further by a factor of 104 prior to addition of enzyme and incubation. Error bars represent standard deviation of triplicate 
measurements. Chicken egg white lysozyme concentrations: 0 µg.mL-1 (Blue), 2 µg.mL-1 (Green), 4 µg.mL-1 (Pink), 8 µg.mL-1 (Orange), 16 µg.mL-1 (Purple), 32 
µg.mL-1 (Red), 64 µg.mL-1 (Yellow), 128 µg.mL-1 (Black), 256 µg.mL-1 (Brown). Statistically significant results are indicated with * = p-value <0.05, ** = <0.01, 
*** = <0.001 and **** = <0.0001. Results: DNamH displayed greater susceptibility to chicken egg white lysozyme than wild type. MIC results: Wild type (a) 
32µg.mL-1, DNamH (b) 16µg.mL-1. 
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Chicken 
egg 
lysozyme 
(µg.mL-1) 
Wild type M. smegmatis DNamH M. smegmatis (b) vs 
(a) 
p-
values 
Apparent 
Lag 
phase 
(h) 
Td 
(h-1) 
AUC 
(%) 
Stationary 
Phase 
OD600nm 
Wild 
type 
p-
values 
(a) 
Apparent 
Lag 
phase 
(h) 
Td 
(h-1) 
AUC 
(%) 
Stationary 
Phase 
OD600nm 
DNamH 
p-
values 
(b) 
0 21 8.01 - 0.23 - 21 7.9 - 0.23 - >0.05 
2 21 7.96 99.21 0.23 >0.05 24 6.42 86.59 0.21 >0.05 >0.05 
4 21 12.05 74.48 0.22 <0.01 30 8.28 65.34 0.21 <0.01 >0.05 
8 30 10.23 42.58 0.17 <0.0001 42 16.82 12.03 0.11 <0.0001 <0.001 
16 45 12.34 29.66 0.16 <0.0001 60 0.00 0.00 0.00 <0.0001 <0.001 
32 60 0.00 0.00 0.05 <0.0001 60 0.00 0.00 0.00 <0.0001 - 
64 60 0.00 0.00 0.05 <0.0001 60 0.00 0.00 0.00 <0.0001 - 
128 60 0.00 0.00 0.05 <0.0001 60 0.00 0.00 0.00 <0.0001 - 
256 60 0.00 0.00 0.05 <0.0001 60 0.00 0.00 0.00 <0.0001 - 
Table 3.1 Statistical comparisons of M. smegmatis growth curves in the presence of increasing concentrations of chicken egg lysozyme. Wild type and 
DNamH strains incubated for 60 hours at 37°C with selected concentrations of chicken egg lysozyme produced growth curves measured at OD600nm in Figure 3.5. 
Variations between growth curves were measured by time taken to exit apparent lag phase (hours), the doubling time (Td) of cells during exponential phase (hours-
1), the area under the curve (AUC) percentage compared to the 0 µg.mL-1 control (%), the OD600nm value achieved during stationary phase and whether the growth 
curve variations were statistically significant compared to each 0 µg.mL-1 control with p-values <0.05 deemed significant. The statistical significance of DNamH 
(b) growth curves compared to wild type (a) at equivalent chicken egg lysozyme concentrations were determined by p-values <0.05. 
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The standard control growth curve of the M. smegmatis wild type strain under aerobic and nutrient 
conditions displayed in Figure 3.5 (a) (Blue), showed a normal growth progression between phases 
and based on the initial dilution and media acclimatisation achieved observable growth above the 
background of the microtiter plate after 21 hours. The doubling time (Td) of the strain was 8.01 
hours with growth plateauing at OD600nm 0.23 after 45 hours. The statistical significance of the 
results in Figure 3.5 were analysed with a paired Student t-test comparing the standard growth 
phenotype OD values of the wild type control to those in the presence of increasing concentrations 
chicken egg lysozyme. Analysis of the wild type strain (Table 3.1) noted that all growth 
phenotypes except for cells grown in the presence of 2 µg.mL-1 were statistically significant 
compared to the 0 µg.mL-1 control. P-values for each concentration were 2 µg.mL-1 (>0.05), 4 
µg.mL-1 (<0.01) and 8-256 µg.mL-1 (<0.0001). 
 
The addition of 4 µg.mL-1 of chicken egg lysozyme (Figure 3.5 (a): Pink) to the wild type strain 
culminated in the first observable indication of cellular growth inhibition caused by the lysozyme. 
Although the initial apparent lag phase in the presence of 4 µg.mL-1 lysozyme matched the time 
frame of the 0 µg.mL-1 control at 21 hours, the gradient of growth during exponential phase was 
reduced leading to a 50% increase in doubling time to 12.05 hours. Growth plateaued at a similar 
optical density to the control OD600nm 0.22 though the area under the curve (AUC) for the 4 µg.mL-
1 data set was reduced by 25% compared to the control.  
 
Subsequent concentrations of lysozyme: 8 µg.mL-1 (Figure 3.5 (a): Orange) and 16 µg.mL-1 
(Figure 3.5 (a): Purple) differed from the lower concentrations due to the noted extended time 
period with apparent lag phase of 10 and 15 hours respectively. Both concentrations displayed a 
similar Td to 4 µg.mL-1, attaining 10.23 and 12.34 hours respectively. These two concentrations 
plateaued at a similar OD600nm entering stationary phase after 51 hours. The final optical density 
reached by 8 µg.mL-1 and 16 µg.mL-1 data sets was 74% and 69% the value obtained by the control. 
The AUC for both 8 µg.mL-1 and 16 µg.mL-1  concentrations were 57% and 69% relative to the 
control data set. The sixty-hour time frame of the experiment was insufficient to observe growth 
present in those wells containing 32 µg.mL-1 lysozyme, (Figure 3.5 (a): Red) leading to the MIC 
of the wild type strain being recorded as 32 µg.mL-1.  
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As noted in Figure 3.1 the DNamH strain demonstrated a comparable growth curve to the wild 
type under normal conditions. In  Figure 3.5 the DNamH control experiment (Figure 3.5 (b): Blue), 
presented a similar growth phenotype to the wild type control (Figure 3.5 (a)). Exponential growth 
was observed after 21 hours and the cell cultures within the triplicate wells reached stationary 
phase after 45 hours. The Td during exponential phase was also equivalent to the wild type strain 
at 7.9 hours. A student’s t-test analysis of the DNamH strain (Table 3.1) against chicken lysozyme 
indicated that all measured growth curves were statistically significant compared to the 0 µg.mL-
1 lysozyme absent control. P-values for each concentration were 2 µg.mL-1 (>0.05), 4 µg.mL-1 
(<0.01) and 8-256 µg.mL-1 (<0.0001). 
 
The addition of 2 µg.mL-1 chicken egg white lysozyme (Figure 3.5 (b): Green) led to an almost 
20% decrease in Td to 6.42 hours. A reason for this variation from the control data may be due in 
part to very low concentrations of lysozyme disrupting remaining mycobacterial cell clumps, not 
separated sufficiently by growth within media containing Tween80 or by not adequately passing 
through a narrow syringe before incubation. Other observed differences from the wild type strain 
in the 2 µg.mL-1  data set were more in keeping with previous incubation with lysozyme. The 
apparent lag phase was extended to 24 hours and the AUC data showed a reduction by 14% 
compared to the control.  
 
Doubling the enzyme concentration to 4 µg.mL-1 (Figure 3.5 (b): Pink) increased the Td to 8.28 
hours and extended the apparent lag phase to 30 hours but did not impact the maximum optical 
density reached during the stationary phase compared to 2 µg.mL-1. The AUC of the curve was 
reduced to 65% of the control which was 10% greater than the equivalent concentration against 
the wild type (Figure 3.5 (a): Pink). The final lysozyme concentration for which a measurable 
growth phenotype for the DNamH M. smegmatis strain could be measured was 8 µg.mL-1 (Figure 
3.5 (b): Orange), where the growth curve plateaued at 47.8% of the maximum optical density 
reached by the control. The Td of 8 µg.mL-1 lysozyme doubled from the control data set to 16.82 
hours and achieved an AUC of 14% relative to the control. All other lysozyme concentrations were 
sufficient to completely inhibit growth, leading to the conclusion that the MIC for chicken egg 
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white lysozyme against M. smegmatis DNamH cells was 16 µg.mL-1 (Figure 3.5 (b): Purple), 
which is half the MIC of the wild type (Figure 3.5 (a): Red).  
 
Student’s t-test analysis comparing the inhibition of growth curves for both M. smegmatis strains 
at equivalent chicken lysozyme concentrations (Table 3.1) indicated that concentrations below 4 
µg.mL-1 were not significant with p-values >0.05. Contrasting the two strains at equivalent chicken 
lysozyme concentrations at 8 µg.mL-1 and 16 µg.mL-1 which permitted observable growth in the 
wild type did demonstrate statistically significant data producing p-values for both concentrations 
of <0.001.  
 
Wells containing MIC or greater for both wild type and DNamH strains were pipetted onto TSB 
agar plates and incubated for 72 hours to determine the minimal bactericidal concentration (MBC). 
The findings are presented in Figure 3.6. 
 
 
 
Figure 3.6 Minimal bactericidal concentration of chicken egg white lysozyme against M. smegmatis strains. M. 
smegmatis wild type (a) and ∆NamH (b) cells incubated in liquid media with increasing concentrations of lysozyme 
that did not produce growth (Figure 3.5) were pipetted in duplicate onto TSB agar to determine MBC. Each quadrant 
denotes the enzyme concentration in µg.mL-1. Results: Wild type MBC 64 µg.mL-1, ∆NamH MBC 32 µg.mL-1.  
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Although no growth was observed at these concentrations in the microtiter plates (Figure 3.5), 
once transferred to nutrient agar both strains incubated with 16 µg.mL-1 of chicken egg white 
lysozyme were able to colonise the agar plate (Figure 3.6). The wild type strain (Figure 3.6 (a)) 
also achieved colonisation after incubation with 32 µg.mL-1 of lysozyme, although the DNamH 
did not. The two remaining highest concentrations, 64 µg.mL-1 and 128 µg.mL-1 were sufficient 
to prevent any observable measurement of growth either within the microtiter plate or subsequently 
on agar. These results lead to the conclusion that the MBC values for both strains, 64 µg.mL-1 for 
the wild type and 32 µg.mL-1 for the DNamH are double the MIC concentrations for each strain. 
 
 
3.6.1.1 M. smegmatis sensitivity towards human lysozyme 
 
The human lysozyme variant has been shown to be significantly more potent than the chicken egg 
equivalent in cleaving sugar residues (Wu, et al. 2015). Previous investigations by the Pavelka 
group (Raymond, et al. 2005) noted the MIC for the newly constructed wild type (PM965) and the 
DNamH (PM979) M. smegmatis strains against human lysozyme were 16 µg.mL-1 and 8 µg.mL-1 
respectively. The MIC activity for both strains against human lysozyme was re-evaluated here 
(Figure 3.7). As the MIC assessment of chicken egg lysozyme showed that the lysozyme MIC was 
32 µg.mL-1, the decision was taken to change the investigated concentration range from 2-256 
µg.mL-1 to 1-128 µg.mL-1.  
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Figure 3.7 The hydrolytic activity of human lysozyme against the mycobacterial modifications of peptidoglycan. Wild type (a) and DNamH (b) M. smegmatis 
MIC growth curves against human lysozyme. Cells were grown in 96-well microtiter plates in triplicate at 37°C with intermittent shaking every 20 minutes, where 
the absorbance was measured at 600nm at 3 hour intervals for 60 hours. Each well contained 100 µL culture media (7H9, ADC, 0.05% (w/v) Tween 80) with 
increasing concentrations of human lysozyme. The cultured M. smegmatis wild type (a) and DNamH (b) strains were standardized to an OD600nm of 1 and diluted 
further by a factor of 104 prior to addition of enzyme and incubation. Error bars represent standard deviation of triplicate measurements. Human lysozyme 
concentrations: 0 µg.mL-1 (Blue), 1 µg.mL-1 (Green), 2 µg.mL-1 (Pink), 4 µg.mL-1 (Orange), 8 µg.mL-1 (Purple), 16 µg.mL-1 (Red), 32 µg.mL-1 (Yellow), 64 µg.mL-
1 (Black), 128 µg.mL-1 (Brown). Statistically significant results are indicated with * = p-value <0.05, ** = <0.01, *** =  <0.001 and **** = <0.0001.  Results: 
DNamH displayed greater susceptibility to human lysozyme than wild type. MIC results: Wild type 16 µg.mL-1, DNamH 8 µg.mL-1.  
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Human 
lysozyme 
(µg.mL-1) 
Wild type M. smegmatis DNamH M. smegmatis (b) vs 
(a) 
p-
values 
Apparent 
Lag 
phase 
(h) 
Td 
(h-1) 
AUC 
(%) 
Stationary 
Phase 
OD600nm 
Wild 
type 
p-
values 
(a) 
Apparent 
Lag 
phase 
(h) 
Td 
(h-1) 
AUC 
(%) 
Stationary 
Phase 
OD600nm 
DNamH 
p-
values 
(b) 
0 21 6.95 - 0.25 - 21 6.95 - 0.23 - >0.05 
1 21 7.16 84.58 0.22 <0.01 21 8.88 79.04 0.20 <0.01 <0.01 
2 27 11.71 54.09 0.19 <0.001 27 13.2 46.85 0.16 <0.001 <0.01 
4 33 12.42 36.60 0.15 <0.0001 33 19.2 25.92 0.12 <0.0001 <0.001 
8 36 15.40 26.29 0.13 <0.0001 60 0.00 0.00 0.05 <0.0001 <0.001 
16 60 0.00 0.00 0.05 <0.0001 60 0.00 0.00 0.05 <0.0001 - 
32 60 0.00 0.00 0.05 <0.0001 60 0.00 0.00 0.05 <0.0001 - 
64 60 0.00 0.00 0.05 <0.0001 60 0.00 0.00 0.05 <0.0001 - 
128 60 0.00 0.00 0.05 <0.0001 60 0.00 0.00 0.05 <0.0001 - 
Table 3.2 Statistical comparisons of M. smegmatis growth curves in the presence of increasing concentrations of human lysozyme. Wild type and DNamH 
strains incubated for 60 hours at 37°C with selected concentrations of human lysozyme produced growth curves measured at OD600nm in Figure 3.7. Variations 
between growth curves were measured by time taken to exit apparent lag phase (hours), the doubling time (Td) of cells during exponential phase (hours-1), the area 
under the curve (AUC) percentage compared to the 0 µg.mL-1 control (%), the OD600nm value achieved during stationary phase and whether the growth curve 
variations were statistically significant compared to each 0 µg.mL-1 control with p-values <0.05 deemed significant. The statistical significance of DNamH (b) 
growth curves compared to wild type (a) at equivalent human lysozyme concentrations were determined by p-values <0.05. 
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The growth kinetics of the wild type control correlated with the data obtained from the previous 
experiment involving chicken egg lysozyme (Figure 3.5 (a)). Growth was measurable after 21 
hours, the Td during exponential phase was 6.95 hours and the control reached a maximum optical 
density of 0.25 during stationary phase after 45 hours (Figure 3.7 (a): Blue). A student’s t-test 
analysis of the growth of wild type strain (Table 3.2) against human lysozyme demonstrated that 
all concentrations were statistically significant compared to the 0 µg.mL-1 lysozyme absent control. 
P-values for the wild type strain were 1 µg.mL-1 (<0.01), 2 µg.mL-1 (<0.001) and 4-128 µg.mL-1 
(<0.0001). 
 
The presence of 1 µg.mL-1 human lysozyme (Figure 3.7 (a) Green) did not impact the length of 
apparent lag phase or the time taken to reach stationary phase, which remained 45 hours, but did 
slightly increase the Td to 7.16 hours. The final optical density achieved by the 1 µg.mL-1  data set 
during stationary phase was reduced by 12% of the control and also impacted the AUC, calculated 
as 85% of the area obtained by the wild type control.  
 
The variation in the impact on growth of the wild type M. smegmatis strain between the human 
and chicken egg white lysozymes was most clearly evident with 2 µg.mL-1 of the enzyme (Figure 
3.7 (a): Pink). Whereas the chicken egg lysozyme did not impact upon the growth of M. smegmatis 
at this concentration, the human enzyme extended the apparent lag phase of M. smegmatis by 6 
hours, increased the Td to 11.71 hours and reduced the stationary phase OD by 22% and the AUC 
to 55% of the control value. Treatment of M. smegmatis with 4 µg.mL-1 human lysozyme (Figure 
3.7 (a): Orange) significantly extended the apparent lag phase of the organism to 33 hours, 
increased the Td to 12.42 hours where the corresponding AUC was reduced by 62% compared to 
the control. The final concentration of human lysozyme permitting an observable growth 
phenotype was 8 µg.mL-1 (Figure 3.7 (a): Purple), exiting apparent lag phase after 36 hours with 
a two-fold increase in the doubling time to 15.40 hours and a reduction by 72% of the AUC 
compared to the control. The 60-hour time frame was just insufficient to register growth from the 
16 µg.mL-1 (Figure 3.7 (a): Red) triplicate, leading the MIC to be observed to be 16 µg.mL-1. This 
concentration was half of the MIC result from chicken egg lysozyme against the wild type strain 
(Figure 3.5 (a)).  
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The human lysozyme MIC results for the DNamH strain (Figure 3.7 (b)) as with the wild type fell 
similarly in line with the results obtained against the chicken egg lysozyme variant (Figure 3.5 
(b)), although the potency of enzyme activity had notably increased. The DNamH control data was 
identical to the wild type M. smegmatis growth phenotype, producing observable growth after 21 
hours, with a Td of 6.95 hours and an entrance into stationary phase with an OD600nm of 0.24 after 
45 hours. Similarly, to the wild type strain, all concentrations of human lysozyme impacted the 
growth phenotype of the DNamH strain in a statistically significant manner (Table 3.2). P-values 
for each concentration were 1 µg.mL-1 (<0.01), 2 µg.mL-1 (<0.001) and 4-128 µg.mL-1 (<0.0001). 
 
The addition of 1 µg.mL-1 human lysozyme (Figure 3.7 (b): Green) did not extend the apparent lag 
phase but impacted the doubling time, increasing it to 8.88 hours. The AUC decreased by 11% and 
maximum stationary OD was 85% of the control data value.  
 
2 µg.mL-1 of human lysozyme (Figure 3.7 (b): Pink) was adequate enough to almost double the 
Td to 13.2 hours, reduce measurable growth such that the AUC total was 48%, extended the 
apparent lag phase by 6 hours and diminished the maximum OD reached during stationary phase 
to 69% of the control. The final concentration of human lysozyme to permit cellular growth was 4 
µg.mL-1 (Figure 3.7 (b): Orange). The growth curve AUC represented 30% of the control, the 
apparent lag phase and Td were increased to 32 hours and 19.2 hours respectively and culminated 
in a 53% maximum OD during stationary phases compared to the control. The MIC of the DNamH 
strain was 8 µg.mL-1 (Figure 3.7 (b): Purple).  
 
Student’s t-test analysis comparing the two M. smegmatis strains at equivalent human lysozyme 
concentrations indicated statistical significance variation between growth curves at each 
investigated concentration (Table 3.2). The significance increased as the concentration of human 
lysozyme increased. P-values produced at each concentration were <0.01 (1 and 2 µg.mL-1) and 
<0.001 (4 and 8 µg.mL-1).  
 
These values were consistent with the initial experiments reported by Raymond, et al. (2005), 
where the human lysozyme MIC of the wild type (PM965) strain was 16 µg.mL-1 and that of the 
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DNamH (PM979) was 8 µg.mL-1. Those human lysozyme concentrations from both strains (Figure 
3.7) which did not produce any visible sign of growth were transferred to nutrient agar to determine 
the MBC values for each strain. The results are shown in Figure 3.8. 
 
 
 
Figure 3.8 Minimal bactericidal concentration of human lysozyme against M. smegmatis strains. M. smegmatis 
wild type (a) and ∆NamH (b) cells were incubated in liquid media with increasing concentrations of lysozyme that 
did not produce growth (Figure 3.7) were pipetted in duplicate onto TSB agar to determine MBC values. Each quadrant 
denotes the enzyme concentration in µg.mL-1. Results: Wild type MBC 32 µg.mL-1, ∆NamH MBC 16 µg.mL-1.  
 
Plating onto agar those wells that did not produce any visible signs of growth (Figure 3.7), led to 
an MBC values of 32 µg.mL-1 for the wild type and 16 µg.mL-1 for the DNamH (Figure 3.8). These 
values are double the minimal inhibitory concentrations observed in Figure 3.7, and once again 
show that the DNamH strain is more susceptible to lysozyme than the wild type strain. 
 
 
3.6.1.2 Impact of pH on the sensitivity of M. smegmatis towards human 
lysozyme  
 
The standard pH for in vitro growth of mycobacteria is pH 6.8, commonly cultured within 7H9 
media. The pH range over which hydrolytic enzymes released from the phagolysosome are active 
can range between low acidic to slightly basic conditions. Since the phagolysosome is a low pH 
environment, pH 5 (Levitz, et al. 1999) the effects of enzyme activity during these extremes is 
important to analyse. M. smegmatis cells are unable to grow at a low pH as observed by their 
switch into a state of dormancy once encased within granulomas (Section 1.5). The protocol to 
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investigate mycobacterial survival at lower pH values with viable cells was described by Eric 
Brown’s group (Koo, et al. 2008). In short, incubated cells that had grown to exponential phase 
were diluted and passed through a syringe to break up any aggregated clumps. Cells were incubated 
in Hank’s Balanced Salt Solution (HBSS) buffer at specific pH ranges in the absence of specific 
nutrients to prevent growth along with the varying concentrations of hydrolytic enzymes. (Section 
2.5.1) After a selected time period of 1.5 hours the wells were pipetted onto agar plates in triplicate, 
incubated at 37°C for 72 hours and the resulting colonies counted and averaged.  
 
Before assessment of the hydrolytic enzymes was undertaken, serial dilutions of cell cultures were 
investigated to determine the range of visible colony separation necessary to accurately distinguish 
and count viable single colonies. As previously described, cells from both wild type and DNamH 
strains were cultured and once growth entered exponential phase, cultures were isolated from the 
nutrient growth by centrifugation and resuspended in HBSS buffer pH7. The optical density of 
each strain was diluted to OD600nm 0.1, from which serial 10-fold dilutions were prepared in HBSS, 
ranging from OD600nm 10-2 to 10-7. A 100 µL aliquots from each dilution were pipetted onto TSB 
agar plates and incubated at 37°C for 72 hours. Once incubation was complete the plates were 
examined and assessed for ease of visualising individual colonies. The serial dilutions of M. 
smegmatis cells are depicted in Figure 3.9. 
 
   
Figure 3.9 Colony count visibility of serially diluted M. smegmatis strains. Wild type (a) and DNamH (b) cells 
cultured to exponential phase in nutrient media, centrifuged and resuspended in HBSS buffer pH 7. Cells from both 
strains were diluted to OD600nm 0.1 and subsequently serially diluted 10-fold from OD600nm 10-2 to 10-7 to assess colony 
count viability. Result: OD600nm 10-5 dilution for both strain produced the most visible colony separation. 
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The results of Figure 3.9 depict that utilising a final dilution below OD600nm 10-5 for both strains 
leads to an insufficient number of colonies forming on the agar plates as a control in the absence 
of hydrolytic enzymes. Utilising a dilution above OD600nm 10-5 inversely leads to significant 
colonisation of the agar plate preventing the ability to distinguish between individual colonies. 
Based upon the results depicted in Figure 3.9 the standard final dilution utilised during the chapter 
for both strains was OD600nm 10-5 (0.00001).  
 
The controls for each experiment involved the wild type and DNamH strains incubated for the 
equivalent time period in HBSS buffer in the absence of enzyme as cells incubated in the presence 
of enzyme. To assess the difficulty of accurately counting single colonies in untreated controls on 
triplicate agar plates, both strains were diluted to OD600nm 10-5 and 100 µL pipetted onto individual 
agar plates. Plates were incubated for 72 hours and the resulting colonies were counted by hand. 
The results are displayed in Figure 3.10. 
 
 
 
Figure 3.10 Assessment of M. smegmatis strain serial dilution and HBSS incubation. M. smegmatis (a) wild type 
and (b) DNamH cells were incubated in 100 µL HBSS in a 96 well microtiter plate. After 1.5 hour incubation at 37°C 
bacterial survival was determined. Wells were pipetted on TSB agar plates and incubated at 37°C for 72 hours.  Colony 
forming units were counted and averaged from triplicate plates.  
 
 
The OD600nm 10-5 dilutions for both strains in Figure 3.10 were sufficient to permit an abundant 
number of viable colonies during control conditions. Each plate produced over 200 visible colonies 
with no signs of contamination.  
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The previously mentioned Brown (2008) protocol was applied to investigate the impact of varying 
concentrations of human lysozyme on M. smegmatis cells buffered to different pH values. The pH 
of the buffer was measured before and after the experiment to maintain accuracy. The initial 
experiment determined the effect of lysozyme at pH 7 at selected concentrations for both strains. 
The colony forming units (CFU) were counted and averaged and the percentage survival of each 
strain during incubation with each concentration of lysozyme was compared to the 0 µg.mL-1 
control. This data is demonstrated in Figure 3.11. 
 
 
 
Figure 3.11 In vitro human lysozyme assay for bactericidal activity against M. smegmatis at pH 7. M. smegmatis 
wild type (Black) and DNamH (Blue) cells were incubated with 0, 256, 1024, 4096 and 16384 µg.mL-1 of human 
lysozyme in 100 µL HBSS in a 96 well microtiter plate. After 1.5 hour incubation at 37°C bacterial survival was 
determined. Wells were pipetted on TSB agar plates and incubated at 37°C for 72 hours.  Colony forming units were 
counted and averaged from triplicate plates. Error bars represent standard deviation of these data. Statistically 
significant results are indicated with * = p-value <0.05, ** = <0.01, *** = <0.001 and **** = <0.0001.  Result: The 
DNamH strain was more susceptible at each human lysozyme concentration, producing fewer colonies than the wild 
type strain. 
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Lysozyme 
concentration 
(µg.mL-1) 
Wild type % (1) 
Survival (mean ± 
SD, n=3)  
DNamH % (2) 
Survival (mean ± SD, 
n=3)   
Significance student’s 
t-test (2) v (1) 
0.0 100.00 ± 8.74 100.00 ± 13.13 N/A 
256 98.27 ± 17.24 91.55 ± 11.95 p >0.05 
1024 101.14 ± 8.84 70.22 ± 3.35 p <0.005 
4096 85.63 ± 12.47 52.00 ± 4.00 p <0.05  
16384 29.88 ± 8.67 5.33 ± 1.33 p <0.01  
Table 3.3 Average bacterial survival by M. smegmatis wild type and DNamH strains against human lysozyme 
at pH 7. Results depicted in a graph in Figure 3.11. Standard deviation is of triplicate measurements. Statistically 
significant results were indicated by p-values <0.05. 
 
 
The initial CFU averages for the wild type strain in the absence of enzyme (0 µg.mL-1) was 77 ± 
6.76 (n=3) colonies per plate, 23% less than the equivalent result, 100 ± 13.13 (n=3) colonies for 
the DNamH strain. The percentage obtained from the initial experiment demonstrated that at pH 7 
(Figure 3.11) the difference between the two strains in terms of lysozyme susceptibility was visible 
from the lowest incubated concentration (Table 3.3). At 256 µg.mL-1 human lysozyme, the wild 
type showed a 1.7% decrease in bacterial survival count compared to the wild type control whereas 
the DNamH survival decreased by 8.5% compared to its control. 1024 µg.mL-1 human lysozyme 
failed to significantly impact upon the survival of wild type M. smegmatis strain, the bacterial 
survival was identical compared to the control within the margin of error. The DNamH strain 
incubated with 1024 µg.mL-1 suffered a notable drop in survival to 70% of the total colonies 
present in the control. 4096 µg.mL-1 was the lowest concentration of human lysozyme that altered 
bacterial survival of wild type cells, where the total number of colonies present decreased by 15% 
at this concentration. The DNamH strain on the other hand continued to display greater 
susceptibility with a 48% decrease in cell survival at this lysozyme concentration. The highest 
concentration of 16,384 µg.mL-1 human lysozyme tested reduced the survival of wild type M. 
smegmatis to below 30% total survival, whereas the NamH deficient strain to only 5% total 
bacterial survival.  
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A student’s t-test comparative analysis of the percentage survival of both strains against human 
lysozyme at pH 7.0 (Table 3.3) demonstrated that that initial survival variation at 256 µg.mL-1 was 
not deemed statistically significant with a p-value >0.05. Subsequent comparisons between strains 
at concentration greater than 256 µg.mL-1 were deemed statistically significant with p-values of 
<0.005 (1024 µg.mL-1), <0.05 (4096 µg.mL-1) and <0.01 (16384 µg.mL-1). This experiment 
successfully underlines the difference between the two stains first described by the Pavelka group 
as well as to indicate that the protocol published by the Brown group is applicable for this 
investigation.  
 
The standard protocol outlined in Figure 3.11 was subsequently repeated, except that the pH of the 
HBSS buffer was altered to pH 6.5, 6.0, 5.5 and 5.0. Due to the stark difference in survival of the 
DNamH strain observed between human lysozyme concentrations 4096 µg.mL-1 and 16384 
µg.mL-1 at pH 7.0 (Figure 3.11), a mid-point concentration of 8192 µg.mL-1 was selected to collect 
more data related to decline in bacterial survival to enzyme concentration. The following data sets 
were formed from triplicate colony counts on agar plates. The data was analysed and average 
colony counts obtained were equated against the 0 µg.mL-1 control of each data set as percentages, 
as depicted in Figure 3.12. 
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Figure 3.12 In vitro human lysozyme bacterial survival percentage assay for bactericidal activity against M. 
smegmatis wild type at selected pH. M. smegmatis wild type cells were incubated with 0, 256, 1024, 4096, 8192 and 
16384 µg.mL-1 of human lysozyme in 100 µL HBSS at pH 5.0 (Purple), 5.5 (Red), 6.0 (Blue) and 6.5 (Black) in a 96 
well microtiter plate. After 1.5 hrs incubation at 37°C bacterial survival was determined. Wells were pipetted onto 
TSB agar plates and incubated at 37°C for 72 hours.  Colony forming units were counted and averaged from triplicate 
plates. Error bars represent standard deviation of triplicate measurements. Averages at each concentration were 
compared to the control 0 µg.mL-1 as a percentage. Statistically significant results are indicated with * = p-value <0.05, 
** = <0.01, *** = <0.001 and **** = <0.0001. Result: Percentage survival at each pH was consistent as human 
lysozyme concentration increased except pH 6.5 at higher concentrations which were significantly reduced. 
 
 
The initial data obtained from the colony counts of CFU from the wild type produce three similar 
sets of data and one outliner. The total colony count for the wild type in the absence of human 
lysozyme at pH 6.5 was reduced by 13% compared to the other conditions with an average of 238 
± 12.12 (n=3) colonies across the triplicate plates. The reason for this reduction is not due to the 
pH as 6.5 is the highest and nearest to neutral pH of the four investigated conditions. The nutrient 
media commonly used to culture M. smegmatis in vitro is stated as pH 6.8 (Section 2.2.1). A likely 
reason for this discrepancy is an initial pipetting error during the serial dilution of cells to achieve 
OD600nm 10-4. Each additional pH condition began similarly with an initial total near 280 single 
colonies per plate and concluded with 100 fewer colonies after 16384 µg.mL-1 human lysozyme 
incubation. The initial CFU average for the remaining pH conditions were 274.66 ± 10.26 (n=3) 
for pH 6.0, 275.00 ± 10.53 (n=3) for pH 5.5 and 289 ± 15.13 (n=3) for pH 5.0. 
 
The percentage bacterial survival of the wild type strain at each selected pH condition (Figure 
3.12) displayed a similar decline in bacterial survival against the two lowest investigated 
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concentrations, 256 µg.mL-1 and 1024 µg.mL-1. Each average bacterial survival percentage 
regardless of pH decreased by 15% compared to the 0 µg.mL-1 control once incubated with 1024 
µg.mL-1, indicating that although the colony count average was reduced for cells incubated at pH 
6.5 the effect of lysozyme activity was equivalent at all pH conditions. As observed in Figure 3.12 
increasing the concentration of human lysozyme above 4096 µg.mL-1 at pH 6.5 aided lysozyme 
activity (Figure 3.12: Black), decreasing the percentage survival compared to the corresponding 
results at pH 6.0 (Figure 3.12: Blue), by 19% at 4096 µg.mL-1, 17% at 8192 µg.mL-1 and 13% at 
16384 µg.mL-1. The final total survival for the wild type strain at 16384 µg.mL-1 was 50% at pH 
6.5, these results coupled with Figure 3.11 shows that reduction of the pH from pH 7 to pH 6.5 
decrease lysozyme activity and increased survival of the strain by 50% (Table 3.3). The activity 
of the enzyme is believed to be at its optimum at pH 7 (Yang, et al. 2011). The percentages 
obtained at pH 6.5 were statistically compared to those obtained at the lower pH conditions to 
determine their significance. The bacterial survival at the initial two lysozyme concentrations, 256 
and 1024 µg.mL-1 were deemed insignificant (p-value >0.05) where-as the three highest 
concentrations generating statistically significant results compared to the other conditions, with p-
values of <0.05 (4096 µg.mL-1), <0.001 (8192 µg.mL-1) and <0.01 (16384 µg.mL-1). 
 
The three remaining pH conditions, 6.0 (Figure 3.12: Blue), 5.5 (Figure 3.12: Red) and 5.0 (Figure 
3.12: Purple) mirror each other’s survival at each concentration with only slight deviation around 
the standard error. The gradual decline for each condition was not impacted significantly by pH or 
lysozyme concentration, where each condition permitted around 65% bacterial survival at the 
highest concentration 16384 µg.mL-1. The data from Figure 3.12 indicated that lysozyme activity 
towards the wild type strain did not alter between pH 6.0 and 5.0. 
 
The DNamH CFU survival frequency averages were plotted as % CFU viability relative to the  0 
µg.mL-1 lysozyme control for each pH against increasing lysozyme concentration as depicted in 
Figure 3.13. 
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Figure 3.13 In vitro human lysozyme bacterial survival percentage assay for bactericidal activity against M. 
smegmatis DNamH at selected pH. M. smegmatis DNamH cells were incubated with 0, 256, 1024, 4096, 8192 and 
16384 µg.mL-1 of human lysozyme in 100 µL HBSS at pH 5.0 (Purple), 5.5 (Red), 6.0 (Blue) and 6.5 (Black) in a 96 
well microtiter plate. After 1.5 hrs incubation at 37°C bacterial survival was determined. Wells were pipetted onto 
TSB agar plates and incubated at 37°C for 72 hours.  Colony forming units were counted and averaged from triplicate 
plates. Error bars represent standard deviation of triplicate measurements. At each pH averages at each lysozyme 
concentration were compared to the 0 µg.mL-1 control as a percentage. Statistically significant results are indicated 
with * = p-value <0.05, ** = <0.01, *** = <0.001 and **** = <0.0001. Result: Percentage survival at each pH was 
unchanged as human lysozyme concentration increased except pH 5.5 at lower concentrations. 
 
 
The average colony counts for the DNamH strain demonstrated greater deviation between pH 
conditions than the wild type strain. The initial 0 µg.mL-1 control averages for pH 6.5 and pH 5.5 
produced the greatest number of colonies per plate with an average of 381.33 ± 14.57 (n=3) and 
380.33 ± 15.63 (n=3) respectively. pH 6.0 supported growth of 339.66 ± 5.13 (n=3) colonies per 
plate, an 11% decrease from the other two pH values. The final pH test was 5.0, which produced 
the fewest number of DNamH strain colonies with an average count of 237 ± 14.73 (n=3). The 
reduction in the average of colonies at pH 5.0 compared to either pH 6.5 or pH 5.5 was 38%. The 
DNamH mutation of the knockout strain may have led to a decrease in cell tolerance to pH and 
increased lysis. This reduction at pH 5.0 was not observed in the wild type CFU which produced 
a similar CFU average to cells incubated at pH 6.0 and 5.5.  
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Combining the percentage survival of the DNamH strain at each incubated pH value (Figure 3.13) 
demonstrated the similar effect incubation with increasing concentrations of human lysozyme had 
on cells exposed to each pH value. The two extremes of the pH values investigated, pH 6.5 (Figure 
3.13: Black) and pH 5.0 (Figure 3.13: Purple) displayed the same propensity towards lysozyme 
susceptibility regardless of concentration, maintaining only a 3% difference in average bacterial 
survival. Each of the four pH values resulted in a final total bacterial survival percentage of close 
to 33% at 16384 µg.mL-1 human lysozyme, demonstrating that the alteration in pH conditions from 
pH 6.5 to pH 5.0 did not impact the activity of human lysozyme, similarly to the equivalent result 
obtained in the wild type in Figure 3.12. pH 5.5 (Figure 3.13: Red) was the only condition which 
demonstrated initial increased susceptibility towards 256 µg.mL-1 and 1024 µg.mL-1 to a greater 
degree with reductions of 10% and 15% respectively than other conditions, although once 
lysozyme concentration increased above 4096 µg.mL-1 the percentage bacterial survival at pH 5.5 
matched that observed at the other pH. The greater susceptibility was not visible during incubation 
with pH 5.0 (Figure 3.13: Purple), and is not believed to be caused by altering lysozyme activity. 
The percentage survival at pH 5.5 at 256 and 1024 µg.mL-1 lysozyme was compared to their 
equivalent results at other pH conditions and deemed statistically significant with p-values of 
<0.05 (256 µg.mL-1) and <0.005 (1024 µg.mL-1) respectively.  
 
The percentage bacterial survival results for human lysozyme incubation against both M. 
smegmatis strains at the four selected pH values were combined as detailed in Figure 3.14. 
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Figure 3.14 In vitro human lysozyme assay for bactericidal activity against M. smegmatis between pH 6.5 and 5.0. M. smegmatis wild type (Black) and 
DNamH (Blue) cells were incubated with 0, 256, 1024, 4096, 8192 and 16384 µg.mL-1 of human lysozyme in 100 µL HBSS at four specific pH values; (a) pH 6.5, 
(b) pH 6.0, (c) pH 5.5 and (d) pH 5.0 in a 96 well microtiter plate. After 1.5 hour incubation at 37°C bacterial survival was determined. Wells were pipetted on 
TSB agar plates and incubated at 37°C for 72 hours.  Colony forming units were counted and averaged from triplicate plates. Error bars represent standard deviation 
of triplicate measurements. Statistically significant results are indicated with * = p-value <0.05, ** = <0.01, *** = <0.001 and **** = <0.0001. Result: The DNamH 
strain was more susceptible at each human lysozyme concentration and each selected pH to varying degrees.
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Lysozyme 
concentration 
(µg.mL-1) 
Wild type % (1) 
Survival (mean ± 
SD, n=3)  
DNamH % (2) 
Survival (mean ± SD, 
n=3)   
Significance student’s 
t-test (2) v (1) 
0.00 100.00 ± 5.09 100.00 ± 3.82 N/A 
256 93.97 ± 9.13 89.33 ± 4.84 p >0.05 
1024 85.43 ± 6.52 78.23 ± 3.73 p >0.05 
4096 64.14 ± 2.70 61.36 ± 3.43 p >0.05 
8192 53.08 ± 3.49 45.19 ± 4.03 p >0.05 
16384 49.71 ± 0.64 33.39 ± 4.36 p <0.005 
Table 3.4 Average bacterial survival by M. smegmatis wild type and DNamH strains against human lysozyme 
at pH 6.5. Results depicted in a graph in Figure 3.14 (a). Standard deviation is of triplicate measurements. Statistically 
significant results were indicated by p-values <0.05.  
 
 
The highest pH condition investigated pH 6.5 (Figure 3.14 (a)) was still in the range of normal 
cellular growth for M. smegmatis (Piddington, et al. 2000). The decrease in pH from the initial 
investigation at pH 7 (Figure 3.11) eliminated the noted variation between the two strains towards 
human lysozyme. The decrease in survival for each strain at each selected lysozyme concentration 
were relatively equal to each other, as opposed to the observed survival deviation at pH 7. 
Incubation with the selected lysozyme concentrations at pH 6.5 lead to a gradual decline in 
bacterial survival by both strains (Table 3.4) as the lysozyme concentration increased, leading to 
49.71% and 33.39% total bacterial survival of the wild type and DNamH strains respectively at the 
highest investigated concentration, 16384 µg.mL-1. The decrease in wild type survival at pH 6.5 
between 256 and 4096 µg.mL-1 could be due to an increased activity of the enzyme compared to 
pH 7.0, although this was considered unlikely as this increased lysozyme activity was not also 
viewed in the DNamH strain data at pH 6.5 (Figure 3.14 (a)). The DNamH strain has previously 
been shown to be more susceptible to lysozyme than the wild type at pH 7.0 (Figure 3.11). The 
comparative survival between the two strains at the highest lysozyme concentration 16384 µg.mL-
1, increased by 20% in the wild type strain (49.71%) and 28% in the DNamH strain (33.39%) 
respectively at pH 6.5 compared to the equivalent results at pH 7 (Figure 3.11).  This indicated 
that the lysozyme had reduced hydrolytic activity at pH 6.5 compared to pH 7.0. The standard 
deviation for the wild type was greatest against incubation with the two lowest enzyme 
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concentrations at pH 6.5.  It is therefore possible that greater than normal variation between data 
points from these averages is the cause of discrepancy between the pH 7 and pH 6.5 data.  
 
A student’s t-test analysis (Table 3.4) of the human lysozyme concentrations against both strains 
at pH 6.5 indicate that bacterial survival variation between the two strains below 16384 µg.mL-1 
was statistically insignificant with p-values > 0.05. The p-value of 16384 µg.mL-1 was <0.005, 
which was deemed statistically relevant.   
 
 
Lysozyme 
concentration 
(µg.mL-1) 
Wild type % (1) 
Survival (mean ± 
SD, n=3)  
DNamH % (2) 
Survival (mean ± SD, 
n=3)   
Significance student’s 
t-test (2) v (1) 
0.00 100.00 ± 3.73 100.00 ± 1.51 N/A 
256 88.23 ± 2.92 88.12 ± 5.23 p >0.05 
1024 85.31 ± 6.47 74.58 ± 3.38 p >0.05  
4096 83.85 ± 6.61 61.13 ± 2.08 p <0.005 
8192 70.99 ± 4.13 52.11 ± 3.31 p <0.005 
16384 62.98 ± 2.74 37.09 ± 4.12 p <0.001 
Table 3.5 Average bacterial survival by M. smegmatis wild type and DNamH strains against human lysozyme 
at pH 6.0. Results depicted in a graph in Figure 3.14 (b). Standard deviation is of triplicate measurements. Statistically 
significant results were indicated by p-values <0.05. 
 
 
Further reducing the pH to 6.0 led to a clear distinction between wild type and DNamH M. 
smegmatis strains as the lysozyme concentration increased (Figure 3.14 (b)). Initial colony counts 
at the lowest concentration, 256 µg.mL-1 for both strains culminated in an identical percentage 
survival (88%) (Table 3.5), however, the two strains deviated in their sensitivity to lysozyme from 
this point onwards. The DNamH strain demonstrated a gradual decline in bacterial survival as 
lysozyme concentration increased similar to the DNamH data obtained at pH 6.5 (Figure 3.14 (a)), 
culminating in a final 37% total bacterial survival at pH 6.0 at 16384 µg.mL-1 human lysozyme. 
The wild type displayed a slight increase in susceptibility towards the lysozyme at 256 µg.mL-1 
compared to the equivalent result at pH 6.5, reducing the percentage CFU to 88% of the control 
compared to 93% at pH 6.5. The wild type strain was unaffected as shown in Table 3.5 by the 
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subsequent increases in enzyme concentration, 85.31% survival at 1024 µg.mL-1 and 83.85% 
survival at 4096 µg.mL-1. The wild type strain resisted the activity of the lysozyme to a greater 
degree than previously demonstrated at pH 6.5, producing data more equivalent during incubation 
at pH 7 (Figure 3.11) terminating in a final bacterial survival at the highest lysozyme concentration 
13% greater than pH 6.5.  
 
The statistical significance between the two M. smegmatis strains at pH 6.0 were analysed (Table 
3.5). P-values determined that bacterial survival at concentrations 256 µg.mL-1 (>0.05) and 1024 
µg.mL-1 (>0.05) were not statistically significant whereas bacterial survival variations between 
concentrations 4096 µg.mL-1 (<0.005), 8192 µg.mL-1 (<0.005) and 16384 µg.mL-1 (<0.001) were 
statistically significant. 
 
 
Lysozyme 
concentration 
(µg.mL-1) 
Wild type % (1) 
Survival (mean ± 
SD, n=3)  
DNamH % (2) 
Survival (mean ± 
SD, n=3)   
Significance student’s 
t-test (2) v (1) 
0.00 100.00 ± 3.83 100.00 ± 4.10 N/A 
256 96.72 ± 5.71 77.30 ± 4.23 p <0.01 
1024 88.72 ± 2.27 59.51 ± 3.62 p <0.0005 
4096 84.00 ± 7.51 52.93 ± 1.84 p <0.005 
8192 76.36 ± 2.18 40.31 ± 3.68 p <0.0005 
16384 62.06 ± 4.00 33.82 ± 1.84 p <0.0005 
Table 3.6 Average bacterial survival by M. smegmatis wild type and DNamH strains against human lysozyme 
at pH 5.5. Results depicted in a graph in Figure 3.14 (c). Standard deviation is of triplicate measurements. Statistically 
significant results were indicated by p-values <0.05. 
 
 
The bacterial survival shown in Table 3.6 of both M. smegmatis strains was the most divergent at 
pH 5.5 (Figure 3.14 (c)). From the lowest concentration of human lysozyme, 256 µg.mL-1 the 
bacterial survival of the two strains immediately diverged. This result differed from the other 
investigated pH conditions, with wild type and DNamH diminishing by equivalent percentages at 
pH 6.5 (Figure 3.14 (a)), 6.0 (Figure 3.14 (b)) and 5.0 (Figure 3.14 (d)) at the lowest investigated 
concentration 256 µg.mL-1. The wild type strain demonstrated almost the exact same relationship 
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between bacterial survival and human lysozyme concentration as the strain did at pH 6.0 (Figure 
3.14 (b)) except with an initial 6% increase in survival at the lowest enzyme concentration of 
96.7%. The DNamH strain was more sensitive to initial lysozyme concentrations demonstrating 
77% total survival at 256 µg.mL-1. This percentage survival was 10% reduced from equivalent 
values at pH 6.5 and 6.0. The knockout strain exhibited 59% total bacterial survival at 1024 µg.mL-
1 compared to 78% and 74% from the previous pH 6.5 (Figure 3.14 (a)) and pH 6.0 (Figure 3.14 
(b)) conditions.  
 
The more pronounced deviation between the bacterial survival percentages of two strains at pH 
5.5 than was observed during the two previously investigated pH conditions, did not continue with 
the final investigated concentration 16384 µg.mL-1. The variation between growth inhibition of 
each strain at pH 5.5 at the highest lysozyme concentration was equivalent to totals shown at pH 
6.0 (Figure 3.14 (b)), with 62% survival for wild type and 34% for DNamH. The equivalent total 
survival at 16384 µg.mL-1 for both strains at pH 6.0 (Figure 3.14 (b)) and pH 5.5 (Figure 3.14 (c)) 
indicate that enzyme activity may not alter between these two conditions and cell tolerance towards 
pH may be the reason for the greater variation observed at lower concentrations.  
 
All bacterial survival percentages for M. smegmatis DNamH compared to the wild type were 
measured to be statistically significant (Table 3.6). P-values for each concentration were 256 
µg.mL-1 (<0.01), 1024 µg.mL-1 (<0.0005), 4096 µg.mL-1 (<0.005), 8192 µg.mL-1 (<0.0005) and 
16384 µg.mL-1 (<0.0005).  
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Lysozyme 
concentration 
(µg.mL-1) 
Wild type % (1) 
Survival (mean ± 
SD, n=3)  
DNamH % (2) 
Survival (mean ± SD, 
n=3)   
Significance student’s 
t-test (2) v (1) 
0.00 100.00 ± 5.23 100.00 ± 6.21 N/A 
256 91.58 ± 5.73 92.68 ± 6.54 p >0.05 
1024 85.12 ± 4.90 74.12 ± 5.50 p >0.05  
4096 79.23 ± 3.61 58.08 ± 3.51 p <0.005 
8192 77.97 ± 3.63 43.60 ± 6.83 p <0.005 
16384 67.24 ± 6.83 32.77 ± 1.70 p <0.001 
Table 3.7 Average bacterial survival by M. smegmatis wild type and DNamH strains against human lysozyme 
at pH 5.0. Results depicted in a graph in Figure 3.14 (d). Standard deviation is of triplicate measurements. Statistically 
significant results were indicated by p-values <0.05. 
 
 
The results obtained in Table 3.7 of the final and lowest pH condition, pH 5.0 (Figure 3.14 (d)) 
correlated strongly with the findings of human lysozyme activity at pH 6.0 (Figure 3.14 (b)). Both 
wild type and NamH deficient strains were equally susceptible to the lowest initial lysozyme 
concentration of 256 µg.mL-1, where CFU survival was 91.5% and 92.6% respectively compared 
to the lysozyme absent controls. Subsequent increases in lysozyme concentration led to an 
observable divergence between the two strains. As noted previously the wild type strain was more 
resilient to lysozyme with measurable bacterial survival diminishing gradually, to a final count 
32% less than the control at the highest concentration 16384 µg.mL-1. The DNamH strain survival 
decreased steadily by almost 15% with each increasing concentration, concluding with a final 
colony total 67% less than the control at 16384 µg.mL-1.  
 
The statistical significance of the pH 5.0 data (Table 3.7) also matched results obtained at pH 6.0. 
Concentrations 256 µg.mL-1 and 1024 µg.mL-1 were deemed statistically insignificant with p-
values >0.05. The three highest concentrations were deemed statistically significant with p-values 
<0.005 (4096 µg.mL-1), <0.005 (8192 µg.mL-1) and <0.005 (16384 µg.mL-1). 
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3.6.1.3 Impact of extended incubation on the sensitivity of M. smegmatis 
towards human lysozyme 
 
The other aspect of the protocol published by Eric Brown’s group, detailing methods to investigate 
mycobacterial susceptibility towards lytic enzymes is the effect of incubation time at a set pH 
(Koo, et al. 2008). To evaluate the impact of prolonged exposure to lysozyme, pH 5.0 was selected 
as this resembled the intra-phagolysosomal within infected macrophages (Flannagan, et al. 2009). 
The three separate incubation periods chosen were, 1.5 hours (Figure 3.15 (a)), 3 hours (Figure 
3.15 (b)) and 4.5 hours (Figure 3.15 (c)) using the same human lysozyme concentrations as 
mentioned previously.  
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Figure 3.15 Effect of duration of exposure of M. smegmatis to human lysozyme at pH 5.0. M. smegmatis wild type (Black) and DNamH (Blue) cells were 
incubated with 0, 256, 1024, 4096, 8192 and 16384 µg.mL-1 of human lysozyme in 100 µL HBSS at pH 5.0 in a 96 well microtiter plate. Microtiter plates were 
incubated for (a) 1.5 hours, (b) 3 hours and (c) 4.5 hours. After incubation at 37°C bacterial survival was determined. Wells were pipetted on TSB agar plates and 
incubated at 37°C for 72 hours.  Colony forming units were counted and averaged from triplicate plates. Error bars represent standard deviation of triplicate 
measurements. Statistically significant results are indicated with * = p-value <0.05, ** = <0.01, *** = <0.001 and **** = <0.0001.  Result: Extended incubation 
led to decreased bacterial survival above 4096 µg.mL-1, variation between strains was not exacerbated.  
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Lysozyme 
concentration 
(µg.mL-1) 
Wild type % (1) 
Survival (mean ± 
SD, n=3)  
DNamH % (2) 
Survival (mean ± SD, 
n=3)   
Significance student’s 
t-test (2) v (1) 
0.00 100.00 ± 6.11 100.00 ± 5.75 N/A 
256 90.96 ± 5.48 83.80 ± 5.07 p >0.05 
1024 85.28 ± 4.16 64.27 ± 3.75 p <0.005  
4096 78.65 ± 4.19 53.58 ± 5.97 p <0.005 
8192 71.73 ± 5.02 44.16 ± 1.55 p <0.001 
16384 65.48 ± 3.87 30.22 ± 3.34 p <0.0005 
Table 3.8 Average bacterial survival by M. smegmatis wild type and DNamH strains against human lysozyme 
at pH 5.0 incubated for 1.5 hours. Results depicted in a graph in Figure 3.15 (a).  Standard deviation of triplicate 
measurements. Statistically significant results were indicated by p-values <0.05. 
 
 
The standard incubation time of 1.5 hours (Figure 3.15 (a)) showed similar results to previous 
incubation data at pH 5.0 in Figure 3.14 (d) with a steady decline in survival as reported by CFU 
as the lysozyme concentration increased across both strains. As previously seen, the wild type 
survival percentages were higher than those seen in the NamH deficient strain (Table 3.8). The 
reduction in survival of M. smegmatis was steady with each concentration of human lysozyme 
leading to a drop of between 10-15% for both strains as concentration increased, culminating in 
final bacterial survival percentages of 65% for the wild type and 30% for DNamH strains. 
 
A student’s t-test comparison (Table 3.8) between wild type and DNamH indicated that all data 
points except for 256 were statistically significant with p-values for the DNamH data set >0.05 
(256 µg.mL-1), <0.005 (1024 µg.mL-1), <0.005 (4096 µg.mL-1), <0.001 (8192 µg.mL-1) and 
<0.0005 (16384 µg.mL-1) compared to the wild type strain. 
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Lysozyme 
concentration 
(µg.mL-1) 
Wild type % (1) 
Survival (mean ± 
SD, n=3)  
DNamH % (2) 
Survival (mean ± SD, 
n=3)   
Significance student’s 
t-test (2) v (1) 
0.00 100.00 ± 2.98 100.00 ± 4.13 N/A 
256 84.82 ± 4.06 88.78 ± 6.50 p >0.1 
1024 76.15 ± 2.86 59.03 ± 5.52 p <0.01  
4096 32.33 ± 4.48 15.84 ± 3.78 p <0.01 
8192 22.85 ± 2.57 11.20 ± 2.58 p <0.01 
16384 21.22 ± 2.25 7.87 ± 1.98 p <0.005 
Table 3.9 Average bacterial survival by M. smegmatis wild type and DNamH strains against human lysozyme 
at pH 5.0 incubated for 3 hours. Results depicted in a graph in Figure 3.15 (b).  Standard deviation of triplicate 
measurements. Statistically significant results were indicated by p-values <0.05. 
 
 
Doubling the incubation period to 3 hours (Figure 3.15 (b)) in the presence of human lysozyme 
was observed to have smallest effect on survival of either strain at the lowest concentration of 
lysozyme, 256 µg.mL-1 with both wild type and DNamH strains of M. smegmatis being within 5% 
(Table 3.9) of the previous percentage survival after lysozyme exposure for 1.5 hours (Figure 3.15 
(a)). The wild type strain after 3 hour incubation with 256 µg.mL-1 produced 5% fewer colonies 
and the DNamH strain produced 5% more colonies than the equivalent result after 1.5 hours (Figure 
3.15 (a)). At 1024 µg.mL-1 human lysozyme, the DNamH strain colony percentage decreased by 
29%, though this result is 5% less than the equivalent result at 1.5 hours. The wild type survival 
after 3 hours decreased by 8% at the same concentration, 9% less than the equivalent result after 
1.5 hours. In the presence of 4096 µg.mL-1 lysozyme, the survival of the wild type and the 
knockout were 32% and 15% respectively after 3 hours of incubation (Figure 3.15 (b)), compared 
to 78% and  53% respectively after 1.5 hours of incubation (Figure 3.15 (a)).  
 
The dramatic decrease in survival did not continue as the concentrations of lysozyme doubled. 
Exposure to 8192 µg.mL-1 lysozyme led to the survival of wild type strain further decreasing in 
survival percentage by 10%, leading to a 22% total survival compared to the 0 µg.mL-1 control. 
Survival of the DNamH strain diminished only by a further 4% after treatment with 8192 µg.mL-1 
lysozyme to a total of 11% CFU present relative to that in the absence of lysozyme. Doubling the 
concentration of human lysozyme to 16384 µg.mL-1 did not significantly alter the survival 
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percentage of either strain compared to that observed at 8192 µg.mL-1 lysozyme, where wild type 
and NamH strain survival percentage decreased only by a further 1%, to 21% final CFU and 4% 
final CFU respectively. The final percentage results for both strains are both less than a third of 
the equivalent results after a 1.5 hour incubation (Figure 3.15 (a)). 
 
The DNamH 3-hour incubation data set mirrors the statistical significance of the 1.5-hour 
incubation with all except the initial 256 µg.mL-1 human lysozyme concentration achieving 
statistical significance (Table 3.9) compared to the wild type. P-values for the data set include 
>0.05 (256 µg.mL-1), <0.01 (1024 µg.mL-1), <0.01 (4096 µg.mL-1), <0.01 (8192 µg.mL-1) and 
<0.005 (16384 µg.mL-1). 
 
 
Lysozyme 
concentration 
(µg.mL-1) 
Wild type % (1) 
Survival (mean ± 
SD, n=3)  
DNamH % (2) 
Survival (mean ± SD, 
n=3)   
Significance student’s 
t-test (2) v (1) 
0.00 100.00 ± 3.62 100.00 ± 2.78 N/A 
256 86.44 ± 4.33 76.46 ± 4.00 p <0.05 
1024 76.03 ± 4.21 42.12 ± 4.67 p <0.001 
4096 22.31 ± 1.54 11.23 ± 1.46 p <0.005 
8192 11.90 ± 1.78 7.16 ± 1.74 p <0.05 
16384 10.57 ± 2.23 5.04 ± 1.15 p <0.05 
Table 3.10 Average bacterial survival by M. smegmatis wild type and DNamH strains against human lysozyme 
at pH 5.0 incubated for 4.5 hours. Results depicted in a graph in Figure 3.15 (c).  Standard deviation of triplicate 
measurements. Statistically significant results were indicated by p-values <0.05. 
 
 
The final duration of exposure for wild type and DNamH strains of M. smegmatis to increasing 
human lysozyme concentration was extended to 4.5 hours (Figure 3.15 (c)). The survival of the 
wild type strain was identical to the 3 hour exposure to 256 and 1024 µg.mL-1 lysozyme (86% at 
256 µg.mL-1 and 76% at 1024 µg.mL-1 lysozyme respectively) (Figure 3.15 (b)). The data depicted 
in table 3.10 indicates that at the two lowest concentrations evaluated there was little effect on 
increasing the incubation time from 3 to 4.5 hours for the wild type strain. Reminiscent of the data 
obtained on three hour exposure to human lysozyme, exposure of wild type M. smegmatis to 4096 
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µg.mL-1 lysozyme lead to a significant drop in survival to 22 % of the original control colony 
population. Matching the data obtained after 3 hour incubation, doubling the concentration of 
lysozyme to 8192 µg.mL-1 reduced the survival of the wild type strain by 10%, and doubling the 
concentration again to 16384 µg.mL-1 lysozyme reduced its survival by only 1%, culminating in a 
final percentage survival of 10%. The final three highest concentrations 4096 µg.mL-1, 8192 
µg.mL-1 and 16384 µg.mL-1 lysozyme impacted the wild type in a similar manner after 3 hour and 
4.5 hours with the only notable difference being the halving in percentage survival of these 
lysozyme concentrations obtained after 4.5 hours. 
 
The DNamH strain on the other hand showed greater initial susceptibility at 4.5 hours (Figure 3.15 
(c)) than during the three hour exposure to lysozyme (Figure 3.15 (b)). At 256 µg.mL-1 lysozyme 
reduced survival of the DNamH strain by 24% compared to the control, which was 12 % greater 
than the survival after a 3 hour incubation. Increasing the lysozyme concentration to 1024 µg.mL-
1 reduced survival by 57.88% indicating that while the wild type strain was more resilient even 
over longer periods such as 3 and 4.5 hours exposed to lower lysozyme concentrations, 256 and 
1024 µg.mL-1 the knockout was more susceptible after an extended period. The 50% increase in 
incubation time to 4.5 hours did not impact DNamH survival at the highest three concentrations. 
As seen previously a significant drop in colonies occurred during incubation with 4096 µg.mL-1 
lysozyme by 84%, relative to the survival percentages plateauing at 8192 µg.mL-1 (7%) and 16384 
µg.mL-1 lysozyme (5%). The percentage survival at the three highest lysozyme concentrations 
only deviated by 2-4% at 4.5 hours compared to their corresponding 3 hour values. 
 
The 4.5 hours data sets from both M. smegmatis strains were deemed to be entirely statistically 
significant from one another in the presence of human lysozyme (Table 3.10). P-values for the 
DNamH data set were <0.05 (256 µg.mL-1), <0.001 (1024 µg.mL-1), <0.005 (4096 µg.mL-1), <0.05 
(8192 µg.mL-1) and <0.05 (16384 µg.mL-1). 
 
The data sets from Figure 3.15 for each individual strain were compiled and analysed, to compare 
the wild type (Figure 3.16) and ∆NamH (Figure 3.17) strains resilience with respect to increasing 
lysozyme concentrations at pH 5.0 at 1.5, 3 and 4.5 hour exposure to the enzyme. 
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Figure 3.16 Compilation of the effect of various durations of exposure to increasing lysozyme concentrations 
on the survival of M. smegmatis wild type at pH 5.0. M. smegmatis wild type cells were incubated with 0, 256, 
1024, 4096, 8192 and 16384 µg.mL-1 of human lysozyme in 100 µL HBSS at pH 5.0  in a 96 well microtiter plate. 
After 1.5 (Black), 3 (Blue) and 4.5 (Purple) hours incubation at 37°C bacterial survival was determined. Wells were 
pipetted on TSB agar plates and incubated at 37°C for 72 hours.  Colony forming units were counted and averaged 
from triplicate plates. Error bars represent standard deviation of triplicate measurements. Averages at each 
concentration were compared to the relevant 1.5, 3 or 4.5 hour control at 0 µg.mL-1 lysozyme as a percentage. 
Statistically significant results are indicated with * = p-value <0.05, ** = <0.01, *** = <0.001 and **** = <0.0001. 
Result: Increasing incubation period for wild type strain does not greatly impact at lysozyme concentrations below 
1024 µg.mL-1 but greatly impact at higher concentrations. Little difference between 3 hour and 4.5 hour incubations. 
 
Wild type M. smegmatis was resilient to lysozyme treatment regardless of the incubation time at 
the lowest two enzyme concentrations tested (Figure 3.16: 256 µg.mL-1 and 1024 µg.mL-1), 
indicating tolerance to the activity of lysozyme for extended periods under these conditions. Only 
once the lysozyme concentration exceeded 1024 µg.mL-1 did the period for which the organism 
was exposed to lysozyme become significant. At 1.5 hours (Figure 3.16: Black) the relationship 
between lysozyme concentration and survival was essentially a linear gradual decline.  However, 
during incubations extended to 3 (Figure 3.16: Blue) and 4.5 (Figure 3.16: Purple) hours, where 
the concentrations of human lysozyme the wild type strain was exposed to exceeded 1024 µg.mL-
1, there was a dramatic reduction in bacterial survival. As previously mentioned after both 3 and 
4.5 hour incubations with 4096 µg.mL-1 the colony count for both strains significantly reduced by 
over 65% and 78% respectively. The lysozyme activity plateaued after 4096 µg.mL-1, but survival 
was never fully prevented even at the highest lysozyme concentration of 16384 µg.mL-1 survival 
 
 
113 
remained at 21% after 3 hours and 10% after 4.5 hours. Little variation was obtained by increasing 
incubation from 3 to 4.5 hours for the wild type strain. 
 
The statistical significance of the three incubation periods on wild type survival against human 
lysozyme concentrations was investigated. The 3 and 4.5 hour survival percentages were compared 
against those obtained during a 1.5-hour incubation. The survival measured during 3 and 4.5 hour 
incubations against 256 and 1024 µg.mL-1 were deemed non statistically significant with p-values 
>0.05. All three subsequent human lysozyme concentrations for both extended incubations were 
deemed statistically significant. P-values for the 3-hour incubation were <0.001 (4096 µg.mL-1), 
<0.001 (8192 µg.mL-1) and <0.001 (16384 µg.mL-1). The 4.5-hour incubation produced p-values 
of <0.0001 (4096 µg.mL-1), <0.0001 (8192 µg.mL-1) <0.0005 (16384 µg.mL-1). 
 
The combined incubation results for the DNamH strain are shown in Figure 3.17. 
 
 
Figure 3.17 Compilation of the effect of various durations of exposure to increasing lysozyme concentrations 
on the survival of M. smegmatis DNamH at pH 5.0. M. smegmatis DNamH cells were incubated with 0, 256, 1024, 
4096, 8192 and 16384 µg.mL-1 of human lysozyme in 100 µL HBSS at pH 5.0  in a 96 well microtiter plate. After 1.5 
(Black), 3 (Blue) and 4.5 (Purple) hours incubation at 37°C bacterial survival was determined. Wells were pipetted on 
TSB agar plates and incubated at 37°C for 72 hours.  Colony forming units were counted and averaged from triplicate 
plates. Error bars represent standard deviation of triplicate measurements. Averages at each concentration were 
compared to the relevant 1.5, 3 or 4.5 hour control at 0 µg.mL-1 lysozyme as a percentage. Statistically significant 
results are indicated with * = p-value <0.05, ** = <0.01, *** = <0.001 and **** = <0.0001.  Result: Increasing 
incubation period for wild type strain does not greatly impact low concentrations but greatly impact high 
concentrations. Little difference between 3 hour and 4.5 hour incubations. 
 
 
114 
Comparing the data sets from only the DNamH strain (Figure 3.17), shows that the percentage 
survival of the strain is equal after both 1.5 (Figure 3.17: Black) and 3 hour (Figure 3.17: Blue) 
incubations against 256 µg.mL-1 and 1024 µg.mL-1 lysozyme, whereas extending the incubation 
to 4.5 hours (Figure 3.17: Purple) reduces the initial survival by 12% and 17% at these lysozyme 
concentrations respectively. Similarly, as with the wild type (Figure 3.16) after a 1.5 hour 
incubation the increase in lysozyme concentration lead to a gradual decrease in survival, whereas 
3 and 4.5 hour incubations decrease rapidly once exposed to greater than 4096 µg.mL-1. The 
variation between the two longest incubation periods is minimal after 4096 µg.mL-1, with each 
plateauing in a similar manner to the wild type. 
 
The statistical significance of the DNamH strain survival at various incubation time frames were 
analysed with a student’s t-test. The 3 and 4.5 hour incubation periods were compared to those 
obtained during the 1.5 hour incubation in a similar manner to the wild type strain. Each of the two 
lowest human lysozyme concentrations 256 and 1024 µg.mL-1 were deemed statistically 
insignificant (p-value >0.05) after extending the incubation to 3 hours and the three highest 
lysozyme concentrations were deemed statistically significant with p-values <0.001 (4096 µg.mL-
1), <0.0001 (8192 µg.mL-1) <0.001 (16384 µg.mL-1). Incubation for 4.5-hours produced a greater 
initial divergence in survival, relative to survival of DNamH cells incubated for 1.5 hours at all 
lysozyme concentrations except 256 µg.mL-1. P-values for the 4.5-hour incubation were <0.05 
(256 µg.mL-1), <0.005 (1024 µg.mL-1), <0.0005 (4096 µg.mL-1), <0.0001 (8192 µg.mL-1) and 
<0.0005 (16384 µg.mL-1). 
 
 
3.7 M. smegmatis sensitivity towards b-hexosaminidase 
 
The second hydrolytic enzyme released by the phagolysosome to be investigated in this chapter 
was b-hexosaminidase (Section 1.4.1.2.2). This enzyme is produced by both prokaryotes and 
eukaryotes (Hossain and Roslan 2014)  and the impact of hexosaminidases from both kingdoms 
was investigated on M. smegmatis.  
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3.7.1 M. smegmatis sensitivity towards Streptomyces plicatus b-hexosaminidase 
 
Initial experiments were conducted with S. plicatus b-hexosaminidase recombinantly expressed in 
E. coli. (Source NEB). The stock concentration of the enzyme was related to its activity in 
Units.mL-1, where one unit was defined as the amount sufficient to cleave 95% of the terminal b-
D-N-acetyl-galactosamine from 1 nmol of GalNAcb1-4Galb1-4Glc-7-amino-4-methyl-coumarin 
in 1 hour at 37°C in a total reaction volume of 10 µL. Knowledge of the activity of the S. plicatus 
b-hexosaminidase allowed the impact of known amounts of enzyme activity on M. smegmatis 
growth. Both M. smegmatis wild type and DNamH strains growth under standard aerobic 
conditions at pH 6.8 were measured in in the presence of increasing concentrations of S. plicatus 
b-hexosaminidase activity to observe enzymatic impact on cellular growth (Figure 3.18). 
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Figure 3.18 The hydrolytic activity of S. plicatus b-hexosaminidase against the mycobacterial modifications of peptidoglycan. Wild type (a) and DNamH 
(b) M. smegmatis MIC growth curves against S. plicatus b-hexosaminidase. Cells were grown in 96-well microtiter plates in triplicate at 37°C with intermittent 
shaking. Absorbance was measured at OD600nm at 3 hour intervals for 45 hours. Each well contained 100 µL culture media (7H9, ADC, 0.05% (w/v) Tween 80) 
with increasing concentrations of S. plicatus b-hexosaminidase. The cultured M. smegmatis wild type (a) and DNamH (b) strain was standardized to an OD600nm of 
1 and diluted further by a factor of 104 prior to addition of enzyme and incubation. Error bars represent standard deviation of triplicate measurements. Streptomyces 
plicatus b-hexosaminidase concentrations: 0 Units.mL-1 (Blue), 30 Units.mL-1 (Black), 60 Units.mL-1 (Red). Statistically significant results are indicated with * = 
p-value <0.05, ** = <0.01, *** = <0.001 and **** = <0.0001.   Results: DNamH strain displays greater susceptibility to S. plicatus b-hexosaminidase than Wild 
type.  
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S. plicatus 
b-
hexosaminidase 
(Units.mL-1) 
Wild type M. smegmatis DNamH M. smegmatis (b) vs 
(a) 
p-
values 
Apparent 
Lag 
phase 
(h) 
Td 
(h-1) 
AUC 
(%) 
Stationary 
Phase 
OD600nm 
Wild 
type 
p-
values 
(a) 
Apparent 
Lag 
phase 
(h) 
Td 
(h-1) 
AUC 
(%) 
Stationary 
Phase 
OD600nm 
DNamH 
p-
values 
(b) 
0.00 21 5.88 - 0.31 - 21 6.19 - 0.31 - >0.05 
30 24 5.60 83.66 0.27 <0.05 24 5.88 70.01 0.25 <0.01 <0.05 
60 27 5.58 71.74 0.23 <0.01 27 7.60 28.97 0.15 <0.001 <0.01 
Table 3.11 Statistical comparisons of M. smegmatis growth curves in the presence of increasing concentrations of S. plicatus b-hexosaminidase. Wild type 
and DNamH strains incubated for 60 hours at 37°C with selected concentrations of S. plicatus b-hexosaminidase produced growth curves measured at OD600nm in 
Figure 3.18. Variations between growth curves were measured by time taken to exit apparent lag phase (hours), the doubling time (Td) of cells during exponential 
phase (hours-1), the area under the curve (AUC) percentage compared to the 0 µg.mL-1 control (%), the OD600nm value achieved during stationary phase and whether 
the growth curve variations were statistically significant compared to each 0 µg.mL-1 control with p-values <0.05 deemed significant. The statistical significance 
of DNamH (b) growth curves compared to wild type (a) at equivalent S. plicatus b-hexosaminidase concentrations were determined by p-values <0.05. 
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The growth phenotypes produced by M. smegmatis wild type (Figure 3.18 (a): Black) and DNamH 
(Figure 3.18 (b): Black) strains in the absence of S. plicatus β-hexosaminidase match those 
observed previously in the rest of the chapter. Both strains produced visible signs of growth, 
exiting apparent lag phase after 21 hours, the Td measured during exponential phase was 5.88 
hours for the wild type and 6.19 hours for the DNamH. Stationary phase was reached after 42 hours 
at an OD600nm of 0.3.  
 
The 30 and 60 Units.mL-1 concentrations of Streptomyces b-hexosaminidase employed in this 
experiment equated to addition of 3 µg.mL-1 and 6 µg.mL-1 β-hexosaminidase protein respectively. 
The addition of 30 Units.mL-1 of Streptomyces b-hexosaminidase to the wild type strain (Figure 
3.18 (a): Blue) altered apparent lag phase relative to the 0 Units.mL-1 control by 3 hours to 24 
hours. The 30 Units.mL-1 result produced a slight decrease in Td between 27 and 36 hours to 5.60 
hours with the addition of b-hexosaminidase. The AUC of M. smegmatis wild type growth curves 
in the presence of 30 Units.mL-1 b-hexosaminidase was reduced to 83.66% and although the curve 
similarly plateaued after 42 hours, the OD600nm reached by stationary phase was 90% of the control. 
Increasing the b-hexosaminidase concentration to 60 Units.mL-1 (Figure 3.18 (a): Purple) extended 
the apparent lag phase by 6 hours to 27 hours. This data set was characterized by a similar Td to 
the control of 5.58 hours at 60 Units.mL-1 treated, though its AUC total was 71.74% of the 0 
Units.mL-1 control. The wild type strain entered stationary phase at a 22% lower optical density 
relative to when incubated in the absence of b-hexosaminidase. Both of the two b-hexosaminidase 
concentration data sets were identified as statistically significant (Table 3.11) when compared 
against the 0 Units.mL-1 wild type control with p-values of <0.05 (30 Units.mL-1) and <0.01 (60 
Units.mL-1) respectively. 
 
The M. smegmatis DNamH strain displayed an increase in susceptibility towards b-
hexosaminidase (Figure 3.18 (b)). The addition of b-hexosaminidase altered the apparent lag phase 
of the knockout strain at 30 Units.mL-1 by 3 hours to 24 hours (Figure 3.18 (b): Blue), and at 60 
Units.mL-1 (Figure 3.18 (b): Purple) by 6 hours to 27 hours. The Td of this strain in the presence 
of 30 Units.mL-1 b-hexosaminidase was 5.88 hours, equivalent to the Td of the 0 Units.mL-1 
control (Figure 3.18 (b): Black). The Td of the strain incubated with 60 Units.mL-1 b-
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hexosaminidase was increased to 7.60 hours. The stationary phase maximum optical density 
obtained by the DNamH control after 42 hours was decreased by 17% with the addition of 30 
Units.mL-1 b-hexosaminidase and by 52% with 60 Units.mL-1 relative to the 0 Units.mL-1 control. 
The AUC for the DNamH strain in the presence of 30 Units.mL-1 b-hexosaminidase was 70.01% 
of that of the 0 Units.mL-1 control. The DNamH strain incubated with 60 Units.mL-1 b-
hexosaminidase produced an AUC of 28.97% of the 0 Units.mL-1 control. These AUC values were 
reduced by 13.65% and 42.77% respectively, compared to the wild type strain. The growth curves 
produced by the DNamH strain in the presence of S. plicatus β-hexosaminidase were analysed by 
a student’s t-test (Table 3.11) to determine statistical significance compared to the 0 Units.mL-1 
control . Both concentrations produced statistically significant inhibition to DNamH growth curves 
with p-values of <0.01 (30 Units.mL-1) and <0.001 (60 Units.mL-1) respectively.  
 
Comparisons between the two M. smegmatis strains at equivalent β-hexosaminidase 
concentrations were also analysed and both of the variations depicted from growth curves at 30 
(<0.05) and 60 (<0.01) Units.mL-1 were deemed statistically significant between each strain. 
 
 
3.7.2 M. smegmatis sensitivity towards human b-hexosaminidase 
 
The human equivalent of b-hexosaminidase shares only 25% sequence similarity to the S. plicatus 
version (www.ncbi.nih.gov/BLAST). According to Koo et al. (2008) the minimum concentration 
of human b-hexosaminidase  required to achieve a significant decrease in survival was only 4 
Units.mL-1. The impact of between 0.5 to 4 Units.mL-1 of human b-hexosaminidase on the growth 
of M. smegmatis wild type and DNamH strains was evaluated (Figure 3.19).  
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Figure 3.19 The hydrolytic activity of human b-hexosaminidase against the mycobacterial modifications of peptidoglycan. Wild type (a) and DNamH (b) 
M. smegmatis MIC growth curves against human b-hexosaminidase. Cells were grown in 96-well microtiter plates in triplicate at 37°C with intermittent shaking, 
absorbance was measured at OD600nm at 3 hour intervals for 48 hours. Each well contained 100 µL culture media (7H9, ADC, 0.05% (w/v) Tween 80) with 
increasing concentrations of human b-hexosaminidase. The cultured M. smegmatis wild type (a) and DNamH (b) strains were standardized to an OD600nm of 1 and 
diluted further by a factor of 104 prior to addition of enzyme and incubation. Error bars represent standard deviation of triplicate measurements. Human b-
hexosaminidase concentrations: 0 Units.mL-1 (Blue), 0.5 Units.mL-1 (Green), 1 Units.mL-1 (Pink), 2 Units.mL-1 (Orange), 4 Units.mL-1 (Red). Statistically 
significant results are indicated with * = p-value <0.05, ** = <0.01, *** = <0.001 and **** = <0.0001.   Results: DNamH displays greater susceptibility to human 
b-hexosaminidase than wild type at each concentration. MIC results: Wild type 4 Units.mL-1, DNamH 4 Units.mL-1. 
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Human 
b-
hexosaminidase 
(Units.mL-1) 
Wild type M. smegmatis DNamH M. smegmatis (b) vs 
(a) 
p-
values 
Apparent 
Lag 
phase 
(h) 
Td 
(h-1) 
AUC 
(%) 
Stationary 
Phase 
OD600nm 
Wild 
type 
p-
values 
(a) 
Apparent 
Lag 
phase 
(h) 
Td 
(h-1) 
AUC 
(%) 
Stationary 
Phase 
OD600nm 
DNamH 
p-
values 
(b) 
0 21 6.93 - 0.31 - 21 6.41 - 0.31 - >0.05 
0.5 24 7.35 87.21 0.30 <0.05 24 10.37 45.02 0.19 <0.001 <0.001 
1 24 11.90 50.92 0.20 <0.001 24 13.45 29.59 0.14 <0.001 <0.05 
2 27 11.36 36.73 0.17 <0.001 27 14.96 25.73 0.13 <0.001 <0.05 
4 60 0.00 0.00 0.05 <0.0001 60 0.00 0.00 0.05 <0.0001 - 
Table 3.12 Statistical comparisons of M. smegmatis growth curves in the presence of increasing concentrations of human b-hexosaminidase. Wild type and 
DNamH strains incubated for 60 hours at 37°C with selected concentrations of human b-hexosaminidase produced growth curves measured at OD600nm in Figure 
3.19. Variations between growth curves were measured by time taken to exit apparent lag phase (hours), the doubling time (Td) of cells during exponential phase 
(hours-1), the area under the curve (AUC) percentage compared to the 0 µg.mL-1 control (%), the OD600nm value achieved during stationary phase and whether the 
growth curve variations were statistically significant compared to each 0 µg.mL-1 control with p-values <0.05 deemed significant. The statistical significance of 
DNamH (b) growth curves compared to wild type (a) at equivalent human b-hexosaminidase concentrations were determined by p-values <0.05. 
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The human b-hexosaminidase concentration range identified by Koo, et al. (2008) was appropriate 
for evaluation of the MIC of human b-hexosaminidase. Based upon the specific activity of the 
enzyme, 20 Units.mg-1 amount of enzyme activity used in Figure 3.19 equated to additions in 
µg.mL-1 was 25 µg.mL-1, 50 µg.mL-1, 100 µg.mL-1 and 200 µg.mL-1 human b-hexosaminidase 
respectively. The human b-hexosaminidase MIC for the wild type M. smegmatis was 4 Units.mL-
1 (Figure 3.19 (a) Red). The control data, wild type growth in the presence of 0 Units.mL-1 b-
hexosaminidase (Figure 3.19 (a): Blue) was characterised by a apparent lag phase of 21 hours, a 
Td of 6.93 hours and an entrance into stationary phase at OD600nm 0.31 after 45 hours. Significance 
student’s t-test of the wild type strain against human b-hexosaminidase (Table 3.12) demonstrated 
that the results depicted by the addition of all investigated concentrations were statistically 
significant compared to the 0 Units.mL-1 control. P-values for each concentration were <0.05 (0.5 
Units.mL-1), <0.001 (1 and 2 Units.mL-1) and <0.0001 (4 Units.mL-1) respectively.  
 
The addition of 0.5 Units.mL-1 of enzyme (Figure 3.19 (a) Green) had a slight impact on the growth 
phenotype of the strain, compared to the growth of wild type M. smegmatis in the absence of  b-
hexosaminidase. The lowest investigated concentration led to an apparent lag phase duration of 24 
hours, an increase in Td to 7.35 hours and the reduction of the AUC percentage to 87.21%. The 
incubation of wild type cells with either 1 (Figure 3.19 (a) Pink) or 2 (Figure 3.19 (a) Orange) 
Units.mL-1 of human b-hexosaminidase had similar effects on reducing growth. Both data sets 
demonstrated observable growth after 24 and 27 hours respectively, 3 and 6 hours longer than the 
control. The Td for both data sets was 11.90 hours and 11.36 hours respectively, and the AUC of 
each growth curve in the presence of 1 or 2 Units.mL-1 b-hexosaminidase were respectively 
50.92% and 36.73% that of the control.  
 
The M. smegmatis DNamH strain 0 Units.mL-1 control (Figure 3.19 (b) Blue) demonstrated a 
similar growth curve to the wild type control (Figure 3.19 (a) Blue) with a 21 hour apparent lag 
phase a Td of 6.41 hours and a final stationary phase OD600nm value of 0.31. All of the investigated 
concentrations of human b-hexosaminidase inhibited growth to a statistically significant degree 
with p-values of <0.001 (0.5, 1 and 2 Units.mL-1) and <0.0001 (4 Units.mL-1) respectively. 
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The M. smegmatis NamH strain was more sensitive to growth inhibition by b-hexosaminidase at 
every concentration of the enzyme investigated (Figure 3.19 (b)) compared to the wild type (Figure 
3.19 (a)).  This was exemplified most clearly by the impact of 0.5 Units.mL-1 of b-hexosaminidase 
on growth of the DNamH. Whereas this concentration of b-hexosaminidase minimally impaired 
growth of the wild type strain (Figure 3.19 (a) Green), the growth of the DNamH strain (Figure 
3.19 (b) Green) was significantly attenuated with respect to all currently used measures of growth. 
DNamH cells did not display visible signs of growth in the presence of 0.5 Units.mL-1 b-
hexosaminidase until 3 hours after the control, the AUC was 45.02% of the value obtained by the 
0 Units.mL-1 control absence of the enzyme, and the cells achieved an OD600nm of 0.19. The Td 
was also almost two-fold greater, requiring 10.37 hours compared to 6.41 hours for the control.  
 
Raising the b-hexosaminidase concentration to 1.0 Units.mL-1 b-hexosaminidase (Figure 3.19 (b) 
Pink) further impaired growth, the cells exited apparent lag phase after 24 hours the AUC was 
measured at 29.59% relative to the untreated control, and the Td was raised to 13.45 hours 
culminating in a final OD600nm value during stationary phase of 0.14. The addition of 2 Units.mL-
1 b-hexosaminidase (Figure 3.19 (b) Orange) as seen in the wild type did not significantly increase 
the inhibition of growth over that caused by 1 Units.mL-1 of b-hexosaminidase producing only a 
5% difference in AUC (25.73%) and a Td only 1.5 hours greater (14.96 hours) compared to 1 
Units.mL-1. The MIC for the DNamH strain was 4 Units.mL-1 (Figure 3.19 (b) Red), identical to 
that of the wild type, sufficient to inhibit observable growth. The true difference between the two 
strains was most evident from a comparative student’s t-test. Each of the investigated 
concentrations of human b-hexosaminidase which permitted cell growth were deemed statistically 
significant (Table 3.12) between each M. smegmatis strain. P-values for each concentration were 
<0.001 (0.5 Units.mL-1), <0.05 (1 Units.mL-1) and <0.05 (2 Units.mL-1). 
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3.7.2.1 The relationship between M. smegmatis sensitivity towards human b-
hexosaminidase and pH 
 
As with previous experiments, the activity of the human b-hexosaminidase enzyme was studied 
according to Koo, et al. (2008) at pH conditions representative of the of the enzyme within the 
phagolysosome at pH 5.0 and throughout the cytoplasm of the macrophage at pH 7.0 (Koo, et al. 
(2008). The concentrations of human b-hexosaminidase that M. smegmatis was exposed to were 
between 0.5-4 Units.mL-1. The average colony counts for each strain were converted into 
percentage survival at each concentration of human b-hexosaminidase compared to the 0 
Units.mL-1 control. The results are shown in Figure 3.20. 
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Figure 3.20. Effect of exposure of M. smegmatis to increasing concentration of human b-hexosaminidase at pH 5.0 and 7.0. M. smegmatis wild type (Black) 
and DNamH (Blue) cells were incubated with 0, 0.5, 1, 2 and 4 Units.mL-1 of human b-hexosaminidase in 100 µL HBSS at (a) pH 7.0 and (b) pH 5.0 in a 96 well 
microtiter plate. Microtiter plates were incubated for 1.5 hours. After incubation at 37°C bacterial survival was determined. Wells were pipetted on TSB agar plates 
and incubated at 37°C for 72 hours.  Colony forming units were counted and averaged from triplicate plates. Error bars represent standard deviation of triplicate 
measurements. Statistically significant results are indicated with * = p-value <0.05, ** = <0.01, *** = <0.001 and **** = <0.0001. Result: DNamH was more 
susceptible to b-hexosaminidase at each pH but variation between strains was less pronounced at pH 5.0.  
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b-hexosaminidase 
concentration 
(Units.mL-1) 
Wild type % (1) 
Survival (mean ± 
SD, n=3)  
DNamH % (2) 
Survival (mean 
± SD, n=3)   
Significance 
student’s t-test 
(2) v (1) 
0.0 100.00 ± 6.55 100.00 ± 8.03 N/A 
0.5 91.15 ± 6.78 67.10 ± 10.91 p <0.05 
1.0 80.16 ± 10.65 50.41 ± 6.84 p <0.05 
2.0 54.42 ± 8.26 29.91 ± 9.67 p <0.05 
4.0 36.86 ± 7.24 9.58 ± 6.23 p <0.01 
Table 3.13 Average bacterial survival by M. smegmatis wild type and DNamH strains against 
human b-hexosaminidase at pH 7.0 incubated for 1.5 hours. Results depicted in a graph in Figure 
3.20 (a). Standard deviation of triplicate measurements. Statistically significant concentrations indicated 
with p-values <0.05. 
 
 
The colony count for both strains at pH 7.0 was above 200 CFU, with the wild type 
producing a triplicate average of 248 ± 16.28 (n=3) colonies per plate and the DNamH 
strain an average of 202 ± 16.19 (n=3). At pH 7.0, the survival of the DNamH strain 
was consistently 25-30% less than that of the wild type strain (Figure 3.20 (a)). The 
decline in survival of wild type M. smegmatis with increasing b-hexosaminidase 
concentration was gradual, decreasing between 10-15% over every incremental 
increase in b-hexosaminidase concentration (Table 3.13). The wild type strain survival 
was diminished by 4 Units.mL-1 human b-hexosaminidase to 36% of the average CFU 
obtained in the 0 Units.mL-1 control.  
 
The most significant reduction in survival of the DNamH knockout was achieved by 
incubation with the lowest concentration of 0.5 Units.mL-1 b-hexosaminidase (Figure 
3.20 (a)). Once incubated with the enzyme survival of the DNamH strain decreased by 
33%, three times greater than the impact of this concentration of b-hexosaminidase on 
the wild type. The survival decreased in a dose dependant manner decreasing by almost 
20% with each increasing enzyme concentration, culminating in 9.58% survival of 
DNamH cells relative to that of untreated DNamH cells at 4 Units.mL-1 b-
hexosaminidase. Each of the human b-hexosaminidase concentrations produced 
statistically significant variation between the two strains at pH 7.0 (Table 3.13), with 
p-values of <0.05 (0.5, 1 and 2 Units.mL-1) and <0.01 (4 Units.mL-1). 
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b-hexosaminidase 
concentration 
(Units.mL-1) 
Wild type % (1) 
Survival (mean ± 
SD, n=3)  
DNamH % (2) 
Survival (mean 
± SD, n=3)   
Significance 
student’s t-test 
(2) v (1) 
0.0 100.00 ± 4.68 100.00 ± 6.13 N/A 
0.5 87.02 ± 2.99 68.00 ± 2.95 p <0.005 
1.0 65.34 ± 2.35 47.76 ± 2.72 p <0.005 
2.0 45.78 ± 3.58 29.25 ± 2.05 p <0.005 
4.0 28.12 ± 2.27 12.31 ± 1.84 p <0.001 
Table 3.14 Average bacterial survival by M. smegmatis wild type and DNamH strains against 
human b-hexosaminidase at pH 5.0 incubated for 1.5 hours. Results depicted in a graph in Figure 
3.20 (b). Standard deviation of triplicate measurements. Statistically significant concentrations indicated 
with p-values <0.05. 
 
 
Both strains produced triplicate average CFU counts above 300 at pH 5.0, with the wild 
type cultivating an average CFU of 303 ± 14.17 (n=3) and the DNamH a CFU average 
of 365 ± 22.36 (n=3). When the growth response of wild type and DNamH M. 
smegmatis to b-hexosaminidase was evaluated at pH 5.0 (Figure 3.20 (b)), the more 
observable variation between strains at pH 7.0 (Figure 3.20 (a)) was less apparent at 
pH 5.0 with both strain producing similar declines in total averages at each selected 
concentration. Previously the wild type strain maintained a difference in survival of 25-
30% in excess of that displayed by the DNamH strain regardless of the b-
hexosaminidase concentration. This discrepancy was reduced to 18-16% between the 
two strains at pH 5.0 (Table 3.14).  
 
The greatest change between the two pH conditions was the effect on the survival of 
the wild type strain, not the DNamH, as has previously been observed in this chapter. 
Although the bacterial survival percentages remained higher for the wild type compared 
to the DNamH, the wild type strain displayed more pronounced susceptibility to b-
hexosaminidase at all measured concentrations at pH 5.0 than the previously 
investigated pH 7.0 (Table 3.13). The difference was most pronounced at 1 Units.mL-1 
with a 15% drop in bacterial survival for the wild type at pH 5.0 relative to that seen at 
pH 7.0. The change of pH from pH 7.0 to 5.0 once again diminished the DNamH 
survival, most notably during incubation with the lowest enzyme concentrations, 
however subsequently the DNamH strain produced only slight variations in survival 
 128 
percentages when comparing the strain’s survival at both pH 7.0 and pH 5.0 conditions. 
Though the variation between the two strains was narrower at pH 5.0 than at pH 7.0, 
the standard deviation between triplicate results was also narrower leading to the 
percentage bacterial survival of both strain at all investigated concentrations being 
statistically more significant than at pH 7.0. P-values for each concentration were 
<0.005 (0.5, 1 and 2 Units.mL-1) and <0.001 (4 Units.mL-1). 
 
The data sets from the wild type and DNamH strains were considered separately and 
comparisons were made on enzyme activity and bacterial survival between each 
selected pH condition. The wild type strain survival percentage is shown in Figure 3.21. 
 
 
 
Figure 3.21. Impact of pH on wild type M. smegmatis survival of b-hexosaminidase treatment. M. 
smegmatis wild type cells were incubated with 0, 0.5, 1, 2 and 4 Units.mL-1 of human b-hexosaminidase 
in 100 µL HBSS at pH 7.0 (Black) and pH 5.0 (Blue) in a 96 well microtiter plate for 1.5 hours at 37°C. 
Bacterial survival was then determined. Wells were pipetted on TSB agar plates and incubated at 37°C 
for 72 hours.  Colony forming units were counted and averaged from triplicate plates. Error bars represent 
standard deviation of triplicate measurements. Averages at each concentration were compared to the 
control 0 µg.mL-1 as a percentage. Statistically significant results are indicated with * = p-value <0.05, 
** = <0.01, *** = <0.001 and **** = <0.0001. Ns = not statistically significant. Result: The wild type 
strain showed increased susceptibility for each concentration at pH 5.0. Any impact of pH on survival 
was most noticeable at 1 Units.mL-1.  
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The wild type strain in Figure 3.21 showed a greater resilience to b-hexosaminidase at 
pH 7.0 (Figure 3.21: Black) than pH 5.0 (Figure 3.21: Blue). At pH 7.0 the percentage 
of bacterial survival, indicated that cells resisted lysis to a greater extent especially at 
1.0 Units.mL-1 than at pH5.0. The strain was observed to be more susceptible to the 
human b-hexosaminidase after incubation at pH 5.0 with each concentration indicating 
that the enzyme is more active towards the wild type at the lower pH condition, 
equivalent to the known pH of the phagolysosome than at neutral conditions. At pH 5.0 
the survival percentage of the wild type strain is most similar to pH 7.0 at 0.5 Units.mL-
1 with survival deviating by only 3%. This  percentage reduction increased to 14% at 
1.0 Units.mL-1 compared to pH 7.0. The final two investigated concentrations 2.0 and 
4.0 Units.mL-1 reduced percentage survival each equally by a further 9% as the 
concentration doubled. A student’s t-test determined than the variation between 
percentage bacterial survival of the wild type strain at pH 7.0 and 5.0 at each human b-
hexosaminidase concentration was not statistically significant with p-values >0.05. 
 
The DNamH strain pH comparison data is depicted in Figure 3.22. 
 
 
Figure 3.22. Impact of pH on DNamH M. smegmatis survival of human b-hexosaminidase 
treatment. M. smegmatis DNamH cells were incubated with 0, 0.5, 1, 2 and 4 Units.mL-1 of human b-
hexosaminidase in 100 µL HBSS at pH 7.0 (Black) and pH 5.0 (Blue) in a 96 well microtiter plate for 
1.5 hours at 37°C. Bacterial survival was then determined. Wells were pipetted on TSB agar plates and 
incubated at 37°C for 72 hours.  Colony forming units were counted and averaged from triplicate plates. 
Error bars represent standard deviation of triplicate measurements. Averages at each concentration were 
compared to the control 0 µg.mL-1 as a percentage. Statistically significant results are indicated with * = 
p-value <0.05, ** = <0.01, *** = <0.001 and **** = <0.0001. Ns = not statistically significant. Result: 
DNamH strain was equally susceptible to b-hexosaminidase at each pH.  
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Figure 3.22 shows an equivalency between data sets at each investigated pH condition. 
The impact of b-hexosaminidase activity on the survival of the DNamH M. smegmatis 
strain did not alter between the two pH values, maintaining the same measured 
reduction in percentage bacterial survival as hexosaminidase concentration increased. 
Percentage survival for each data point was within 3% and the standard error, therefore 
none of the human b-hexosaminidase concentrations against the DNamH strain at the 
two investigated pH conditions were deemed statistically significant (p-values >0.05). 
 
The human variant of b-hexosaminidase was difficult to reliably acquire and available 
only from a single source (Sigma-Aldrich). The low quantity provided and the 
infrequent availability meant that further investigations with human b-hexosaminidase 
were not possible within the time available. An alternative variant was procured to 
attempt to extend this line of investigation. 
 
 
3.7.3 M. smegmatis sensitivity towards bovine b-hexosaminidase 
 
The final version of b-hexosaminidase tested for its impact on M. smegmatis growth 
was the bovine variant, as mycobacterial infection in cattle is caused by M. bovis and 
is a significant issue in agriculture (Mathews, et al. 2006). The sequence similarity 
between the human and bovine alpha and beta b-hexosaminidase subunits are 84% and 
70% respectively (www.ncbi.nih.gov/BLAST). The bovine b-hexosaminidase had an 
enzymatic activity of around 50 Units.mg-1. Based on this information, mycobacterial 
strains were incubated with bovine b-hexosaminidase concentrations of 2.5, 5 and 10 
Units.mL-1 at pH 5.0. The specific enzyme activity equates these concentrations to 50, 
100 and 200 µg.mL-1.  
 
The percentage bacterial survival data for both strains against bovine b-hexosaminidase 
was analysed and depicted in Figure 3.23. 
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Figure 3.23. Impact of bovine b-hexosaminidase on the survival of M. smegmatis at pH 5.0. M. 
smegmatis wild type (Black) and DNamH (Blue) cells were incubated with 0, 2.5, 5 and 10 Units.mL-1 
of bovine b-hexosaminidase in 100 µL HBSS at pH 5.0 in a 96 well microtiter plate. for 1.5 hours at 
37°C. Bacterial survival was then determined. Wells were pipetted on TSB agar plates and incubated at 
37°C for 72 hours.  Colony forming units were counted and averaged from triplicate plates. Error bars 
represent standard deviation of triplicate measurements. Averages at each concentration were compared 
to the control 0 µg.mL-1 as a percentage. Statistically significant results are indicated with * = p-value 
<0.05, ** = <0.01, *** = <0.001 and **** = <0.0001. Ns = not statistically significant. Result: 
Concentrations of bovine b-hexosaminidase investigated were insufficient to impact bacterial survival 
of either strain. 
 
 
b-hexosaminidase 
concentration 
(Units.mL-1) 
Wild type % (1) 
Survival (mean ± 
SD, n=3)  
DNamH % (2) 
Survival (mean 
± SD, n=3)   
Significance 
student’s t-test 
(2) v (1) 
0.0 100.00 ± 3.16 100.00 ± 2.03 N/A 
2.5 100.24 ± 5.96 99.89 ± 5.98 p >0.05  
5.0 102.73 ± 2.84 97.65 ± 2.50 p >0.05 
10.0 98.72 ± 10.32 103.10 ± 5.67 p >0.05 
Table 3.15 Average bacterial survival by M. smegmatis wild type and DNamH strains against 
bovine b-hexosaminidase at pH 5.0 incubated for 1.5 hours. Results depicted in a graph in Figure 
3.23. Standard deviation of triplicate measurements. Statistically significant concentrations indicated 
with p-values <0.05. 
 
 
The control colony count totals for both strains were robust enough to compare colony 
count survival with increasing concentrations of bovine b-hexosaminidase. Total 
averages achieved by the wild type and DNamH strain were 270 ± 8.50 (n=3) and 325 
± 6.65 (n=3) CFU respectively. The addition of bovine b-hexosaminidase at the 
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concentrations investigated (Figure 3.23) were unable to reduce the colony count in 
either strain.  
 
The percentage survival for both strains remained steady regardless of enzyme 
concentration. The exposure of wild type M. smegmatis to bovine b-hexosaminidase 
concentrations (Figure 3.23 (a)) more than double the Units.mL-1 MIC of the human 
counterpart reduced survival by only 1.28% (Table 3.15) after incubation with 10 
Units.mL-1 equivalent to 200 µg.mL-1. The DNamH strain (Figure 3.23 (b)) increased 
in the number of viable colonies present during 10 Units.mL-1 incubation to 103% of 
the total achieved by the strain in the absence of enzyme although this was not 
statistically significant (Table 3.15). The concentrations of hydrolytic enzymes may 
have been too low to significantly impact survival of M. smegmatis but may have 
disrupted remaining clumps of cells not homogenised sufficiently during cell 
preparation. None of the investigated concentration produced statistically signifcant 
data. It is impossible to determine if whether the inactivity of the hexosaminidase was 
due to substrate specificity, low enzyme activity or an inactive batch of enzyme. 
 
The human and bovine variants of b-hexosaminidase was difficult to procure compared 
to the variants of lysozyme investigated, therefore avenues of the investigation 
undertaken were narrower than expected. Outstanding experiments will be outlined in 
further work (Section 3.9).  
 
 
3.8 Discussion  
 
 
3.8.1 N-glycolyl modification during aerobic and anaerobic growth 
 
The absence of the namH gene prevents the incorporation during mostly aerobic 
incorporation of N-glycolylated sugars into the wider peptidoglycan layer. This 
deficiency does not significantly impact upon the aerobic phenotypic growth profile of 
the DNamH mutant compared to the wild type strain (Figure 3.1), suggesting that the 
presence of the modification does not positively or negatively impact growth alone 
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(Raymond, et al. 2005). The NamH enzyme utilises molecular oxygen but was shown 
to not be essential for cellular propagation on nutrient rich or deficient agar during 
resuscitation from an anaerobic environment (Figure 3.2). The incorporation of N-
glycolylated Lipid II which occurs solely during aerobic conditions, does not lead to 
the conclusion that the expression of namH is vital in aiding cell reanimation from 
dormancy within newly ruptured granulomas initiating a more active disease state in 
the previously latent mycobacteria (Cordone, et al. 2008). Based upon these results, the 
purpose of NamH does not appear to accelerate growth when oxygen concentrations 
are the only limiting factor. 
 
 
3.8.2 N-glycolyl modification against lysozyme 
 
Based upon the previous investigated documented by Raymond, et al. (2005) the 
absence of N-glycolylated saccharides within the peptidoglycan structure of M. 
smegmatis led to a greater susceptibility towards lysozyme. The previously observed 
M. smegmatis MIC for human lysozyme (Raymond, et al. 2005) was successfully 
repeated for both strains (Figure 3.7), with the DnamH deficient variant susceptible at 
half the concentration of the wild type. MIC experiments were conducted at pH 6.8 for 
optimal growth of the mycobacteria, which is also within the optimal range of human 
lysozyme activity (Pincus, et al. 1977). Interactions between mycobacteria and 
lysozyme at this pH would take place surrounding the plasma membrane of host’s 
macrophages (Koo, et al. 2008) and based upon results the absence of N-glycolylated 
peptidoglycan in the DNamH strain would impede mycobacterial growth two-fold 
compared to wild type due in part to the steric hindrance of N-glycolylation preventing 
lysozyme binding. MIC assessment of hen egg white lysozyme (Figure 3.5) 
demonstrated a requirement for a two-fold greater required concentration of this protein 
compared to that of the human lysozyme for inhibition of phenotypic growth in both 
strains. Chicken lysozyme MIC variation matched the findings of human lysozyme 
with the namH deficient mutant displaying a lack of growth at half the MIC of the wild 
type. MBC values for both investigated lysozymes were consistently double the MIC 
result for each strain (Figure 3.6 and Figure 3.8).  
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Assessment of mycobacterial bacterial survival on nutrient agar after human lysozyme 
incubation at optimal activity pH 7 (Figure 3.11), demonstrated similar findings to the 
MIC investigation (Figure 3.7). The percentage bacterial survival was more 
pronounced in the DnamH strain than the wild type although the percentage difference 
between each strain at increasing concentrations remained equivalent. Increasing the 
human lysozyme concentration greater than 256 µg.mL-1 equally impacted the survival 
of both strains, indicating that the absence of N-glycolylation does not lead to more 
susceptible organism in excess lysozyme concentrations.  
 
The reduction of the pH of the incubation to 6.5 reduced the efficacy of the lysozyme 
and increased the survival of both strains, a characteristic most pronounced in the 
DNamH strain, narrowing the previously observed disparity between wild type and 
DNamH strain susceptibility to lysozyme (Figure 3.14). The effectiveness of human 
lysozyme did not measurably diminish as pH was reduced from pH 6.0 to pH 5.0 
(Figure 3.14) more in keeping with the acidic environment generated within the 
phagolysosome (Flannagan, et al. 2009). These results imply that human lysosome 
activity would not be greatly impacted by the gradual decrease in pH within the 
phagolysosome to around pH 5.0 caused by H+ ion pumps (Forster and Kane 2000), 
although as shown the lysozyme would have the greatest activity within a more neutral 
environment such as near the cell membrane. Variations observed to bacterial survival 
in the NamH deficient mutant at pH 5.5 demonstrated decreased survival at the lowest 
investigated human lysozyme concentrations, indicating increased enzyme activity, 
although this effect was not observed at either pH 6.0 or pH 5.0 and was likely caused 
by a discrepancy during the generation of diluted enzyme stocks.  
 
Extending the incubation time frame above 1.5 hours (Figure 3.15) was not deemed 
necessary to increase the variation in survival between the two strains and based upon 
the findings of this investigation increasing the incubation above 3 hours was not 
necessary unless required to measure low human lysozyme concentrations. The lack of 
variation in human lysozyme activity at decreasing pH conditions appears to be due in 
part to the length of incubation. Wild type survival was especially greatly impacted by 
extending the incubation phase decreasing at a more pronounced degree at high 
concentrations, though the gulf in susceptibility between strain remains constant. 
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Prolonged exposure to hydrolytic enzymes at acidic pH conditions mimics the purpose 
of the phagolysosome. If mycobacteria are unable to escape through the rupture of the 
phagosomal membrane by type VII secretion systems (van der Wel, et al. 2007), the 
combination of synergistic conditions aid in cell lysis by hydrolytic activity. 
 
 
3.8.3 N-glycolyl modification against b-hexosaminidase 
 
Initial b-hexosaminidase investigations were conducted with S. plicatus b-
hexosaminidase. The organism is commonly identified within soil (Hasani et al. 2014) 
which is also the habitat for non-tubercular mycobacteria such as M. smegmatis 
(Tsukamura, et al. 1976). Though focus of this thesis was primarily towards host 
macrophage invasion of mycobacteria, the b-hexosaminidase from S. plicatus 
permitted in vitro assessment of Streptomyces-secreted enzymes on mycobacteria. Due 
to similarity of targeting by both b-hexosaminidase and lysozyme, the presence of 
solely N-acetylated peptidoglycan of the DNamH strain once again correlated with 
growth impairment compared to the wild type (Figure 3.18). The MIC for both strains 
was not established due to insufficient concentrations of available stocks of S. plicatus 
b-hexosaminidase. 
Human b-hexosaminidase was ten-fold more active than the S. plicatus variant, and 
impeded the growth phenotype of both strains to produce an MIC (Figure 3.19). In the 
first instance, during the MIC assessment of hydrolytic enzymes against wild type and 
DNamH M. smegmatis mycobacterial strains the MIC was equal. Both strains displayed 
growth at 2 Units.mL-1 but not at 4 Units.mL-1. These results do not indicate 
equivalency, however. Comparisons between both strains at each investigated human 
b-hexosaminidase concentration demonstrated statistically significant variation in their 
enzyme susceptibility. Further investigation at 3 Units.mL-1 would likely lead to MIC 
variation between strains. 
 
Measuring the strain survival of treatment by human b-hexosaminidase at the two 
extreme host pH conditions, pH 7.0 and pH 5.0 showed that the wild type maintained 
its resilience to inactivation by b-hexosaminidase inhibition over DNamH regardless of 
pH condition (Figure 3.20). Though comparisons between each strain at pH 5.0 
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appeared to show a narrower gulf between strain survival (Figure 3.20), analysis of 
each strain at both pH conditions (Figure 3.21 and Figure 3.22) presented no 
statistically significant alteration in bacterial survival at pH 7.0 compared to 5.0. This 
indicated that the alteration of pH does not impact the enzyme. Other factors therefore 
must be important to increase mycobacterial lysis within the phagolysosome. Both the 
human b-hexosaminidase MIC assessment (Figure 3.19) and the bacterial survival 
utilised the equivalent enzyme concentration range. The 60 hour time frame of the MIC 
data led to complete growth inhibition at 4 Units.mL-1 compared to the 1.5 hour 
incubation for bacterial survival leading to 10% survival in both strains. The 
requirement for extended enzyme incubation periods requires further study to ascertain 
significance.  
  
The data reported here indicated that human b-hexosaminidase activity was stable 
between both pH 7 and 5, which would be advantageous in vivo to the enzyme once 
located with a newly formed phagolysosome as the pH of the compartment is gradually 
reduced to aid mycobacterial cell lysis.  
 
Human b-hexosaminidase is also known to be located at both the more pH neutral cell 
membrane (Koo, et al. 2008) therefore, the ability to maintain a stable activity 
regardless of its cellular location would be important to aid in the immune response 
whether during initial contact with the mycobacteria or during phagolysosome 
degradation.  
 
The initial investigations into bovine b-hexosaminidase at equivalent concentrations to 
the human variant failed to produce an impact on growth of wild type or DNamH M. 
smegmatis at pH 5.0. The optimal conditions for enzyme activity needs to be identified 
before further investigations can be conducted.  
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3.9 Further work 
 
 
• Equivalent enzyme comparison 
 
The investigations made against bovine b-hexosaminidase were insufficient to reduce 
survival of either M. smegmatis strains (Figure 3.23). These concentrations were 
equivalent to active concentrations of human b-hexosaminidase (Figure 3.20) and 
acquiring increased quantities of the enzyme are required to determine the optimum 
active concentration of bovine b-hexosaminidase. Initial investigations have been made 
into a selection of both lysozymes and b-hexosaminidases from a range of hosts to 
make broad comparisons between enzymatic activity towards mycobacterial 
interactions. It would be useful to standardise the activity of all investigated enzymes 
to ensure equivalent activities of enzymes were being used to draw important 
comparisons such as between the two mammalian host’s immune responses during 
extended incubation or at selected pH conditions resembling the conditions within the 
phagolysosome of host’s macrophages. One possible method to determine equivalency 
could be adapted from Koo et al. (2008) measuring alterations in the optical density of 
set M. smegmatis cultures at selected time points with various enzyme concentrations.  
 
 
• Enzyme stability 
 
Aerobic growth phenotypes of M. smegmatis strains were assessed against hydrolytic 
enzymes at 37°C for up to 60 hours due to the slow growth rate of mycobacteria. During 
the experiment sub MIC concentrations led to cells remaining within apparent lag phase 
for extended periods before demonstrating exponential growth. To ascertain whether 
measurement of growth is due to each strain overcoming a stable enzyme concentration 
or whether extended incubation periods lead to a denaturing and reduced efficacy of 
the enzyme which in turn permits cellular growth, control experiments utilising each 
investigated enzyme will be incubated at 37°C in the absence of mycobacteria prior to 
repeating the hydrolytic enzyme susceptibility of mycobacteria and contrast the results 
with non-preincubated enzymes to determine overall stability.  
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• Synergy between lysozyme and b-hexosaminidase 
 
Release of enzymes by the phagolysosome impacts the cell wall of invading 
mycobacteria. Synergy between b-hexosaminidase and lysozyme would aid in 
increasing mycobacterial cell lysis thereby priming the innate immune system (Weiss 
and Schaible 2015). Lysozyme and b-hexosaminidase both cleave the b-1,4 glycosidic 
bonds between MurNAc/MurNGlyc and GlcNAc within the peptidoglycan, although it 
has been suggested that b-hexosaminidase targets terminal sugar rings (Fernandes, et 
al. 1997). Based on this differential specificity, the possibility of synergy between b-
hexosaminidase and lysozyme should be investigated to complement the investigations 
made for each isolated enzyme, with respect to their antimycobacterial activity. 
 
 
• Other lytic enzymes 
 
Expanding upon the initial work involving the organism S. plicatus b-hexosaminidase  
(Figure 3.18), examining the role of other secreted hydrolytic enzymes from organisms 
and phages is an important area of investigation. Lytic bacteriophages release 
endolysins (Schmelcher, et al. 2012) which has a similar hydrolytic mode of action 
against peptidoglycan as other investigated enzymes to bypass the bacterial cell wall to 
invade and utilise the replication mechanisms of the host to propagate. There has been 
interest in the exploitation of mycobacteriophage endolysins in the regard (Catalão and 
Pimentel 2018). Resuscitation promoting factors (RPFs) are secretory protein encoded 
by MTB (Kana, et al. 2008) which cleave peptidoglycan monomers to signal the 
presence of an aerobic environment to previously dormant cells. Studies involving RFP 
knockout, in a wild type and DNamH background might reveal relationship between N-
glycolylation and RPF function and any possible relationship with emergence from 
dormancy. 
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• M. tuberculosis DNamH 
 
Collaborators in the Mukamolova lab at the University of Leicester have generated an 
MTB DNamH strain. Once obtained, the investigations made in M. smegmatis against 
variants of lysozyme and b-hexosaminidase will be repeated, to evaluate the difference 
between the low pathogenic M. smegmatis and the more highly pathogenic MTB as it 
relates to incorporation of the N-glycolyl modification into tubercular PG. Similar to 
the work done with M. smegmatis DNamH the percentage of N-glycolyl PG 
incorporation will be measured by methods outlined by Raymond, et al. (2005) 
isolating the peptidoglycan layer of aerobically grown cells and analysing the 
components by mass spectrometry. These experiments could be complemented by 
anaerobic studies to analysis more closely the relationship between dormancy, NamH 
activity and environmental oxygen tension. 
 
 
• Survival within amoeba  
 
The ability to probe intracellular survival of mycobacteria within various hosts is 
important. Non-tuberculosis mycobacteria are commonly isolated from water and soil 
environments containing free-living amoeba (Hu, et al. 2017). Many of the intracellular 
survival mechanisms adopted by mycobacteria within macrophages were likely honed 
against amoeba, as the Mycobacterium tuberculosis complex organisms have been 
identified as amoeba-resistant. Collaborators in the Wellington lab at the University of 
Warwick are investigating the relationship between amoeba and intracellular bacteria. 
Experiments would include measuring at a range of environmental conditions the 
survival difference within the amoeba between the wild type and NamH strains, as 
MTB has been demonstrated to survive for 14 days (Medie, et al. 2011).  
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3.10 Conclusion 
 
The mycobacterial incorporation of MurNGlyc into the peptidoglycan sacculus has 
been demonstrated in this chapter to enable resistance to the activities of lytic enzymes 
such as lysozyme and b-hexosaminidase from a range of potential hosts and competing 
organisms. The absence of namH is not essential to cell propagation in aerobic 
conditions but dramatically impacts upon the resilience of the organism to hydrolytic 
enzymes at low pH environments and during extended incubation periods. Initial 
assessment of enzyme activity ranges were established in all expect bovine b-
hexosaminidase, with comparisons between equivalent activities yet to be determined. 
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Chapter 4. The role of the N-glycolylated muramic acid in the 
protection of mycobacteria from antimicrobial susceptibility  
 
 
4.1 Introduction 
 
As previously stated (Section 1.2) mycobacteria are attributed to a number of global 
diseases such as tuberculosis and leprosy. The standard antimicrobial therapies against 
mycobacterial infection are becoming increasingly less potent as the percentage of 
antimicrobial resistance rises (Section 1.7.4). A number of key antimicrobials target 
specific synthetic steps or structures of the bacterial cell wall which have no eukaryotic 
equivalents (Yount and Yeaman 2013).  
 
Mycobacteria are inherently resilient to cell wall targeting antimicrobials due to the 
composition of the cell wall structure containing the mycolyl-arabinogalactan-
peptidoglycan (mAGP) complex (Hett and Rubin 2008) and due to the expression of 
antimicrobial degrading enzymes like b-lactamases such as BlaS (Flores, et al. 2005). 
The standard treatment for tuberculosis infection (Section 1.7.1) is a combination 
therapy of four antimicrobials, isoniazid, rifampicin, ethambutol and pyrazinamide. 
The increase in widespread resistance to standard treatments had led to utilization of 
second-line antimicrobials like vancomycin (Soetaerta, et al. 2015). 
 
The N-glycolylation of mycobacterial peptidoglycan monosaccharides has been shown 
in the previous chapter to be important in aiding mycobacterial tolerance towards 
hydrolytic enzymes such as lysozyme.  
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4.2 Chapter Aim 
 
The importance of the N-glycolyl modification in determining the activity of cell wall 
targeted antimicrobials was evaluated utilizing clinically well-established antibiotics as 
well as the newly discovered antimicrobial teixobactin (Ling, et al. 2015) and its 
derivative Arg-teixobactin (Jad, et al. 2015).  
 
 
4.3 DMSO tolerance of M. smegmatis strains 
 
Standard investigations into the antimicrobial activity of compounds against bacterial 
strains are commonly performed in nutrient media (EUCAST 2000). Many 
antimicrobials utilised within this chapter were insufficiently soluble in aqueous 
solution and required dissolution initially in dimethyl sulfoxide (DMSO), a dipolar 
aprotic solvent (Alastruey-Izquierdo, et al. 2012). To acertain mycobacterial tolerance 
for DMSO increasing percentages of the latter were incubated with growing M. 
smegmatis wild type and NamH deficient cells. The impact of DMSO on mycobacterial 
proliferation is shown in Figure 4.1. 
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Figure 4.1 DMSO tolerance of M. smegmatis. Wild type (a) and NamH deficient (b) cells were grown in the presence of increasing concentrations of DMSO to identify 
optimal tolerance for the solvent, in 96 well microtiter plates in triplicate at 37°C with intermittent shaking. Absorbance was measured at OD600nm at 3 hour intervals for 60 
hours. Each well contained 100 µL 7H9 media supplemented with ADC + Tween80. The cultured M. smegmatis cells were standardized to an OD600nm of 1 and diluted further 
by a factor of 104 prior to incubation. Error bars represent standard deviation of triplicate measurements. DMSO concentration (v/v): 0% (Blue), 1% (Pink), 2% (Green), 3% 
(Orange), 4% (Purple), 5% (Red). Statistically significant results of comparisons of growth at increasing DMSO concentrations compared to 0% (v/v) DMSO for each strain 
are indicated with * = p-value <0.05, ** = <0.01, *** = <0.001 and **** = <0.0001. Ns = not statistically significant. Result: DMSO concentrations below 2% (v/v) did not 
alter growth whereas DMSO concentration above 2% (v/v) significantly reduced growth.  
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DMSO 
Conc 
(v/v) 
(%) 
Wild type M. smegmatis DNamH M. smegmatis (b) vs 
(a) 
p-
values 
Apparent 
Lag 
phase 
(h) 
Td  
(h-1) 
AUC  
(%) 
Stationary 
Phase  
OD600nm 
Wild 
type 
p-values 
(a) 
Apparent 
Lag 
phase  
(h) 
Td  
(h-1) 
AUC  
(%) 
Stationary 
Phase  
OD600nm 
DNamH 
p-
values 
(b) 
0 21 7.03 - 0.26 - 21 6.76 - 0.25 - >0.05 
1 21 6.91 104.31 0.26 >0.05 21 6.73 101.50 0.25 >0.05 >0.05 
2 21 6.84 103.67 0.25 >0.05 21 6.69 101.50 0.24 >0.05 >0.05 
3 27 6.81 82.26 0.24 <0.01 27 6.71 80.66 0.24 <0.01 >0.05 
4 30 7.19 62.23 0.21 <0.001 30 6.96 60.29 0.20 <0.001 >0.05 
5 45 15.61 12.12 0.13 <0.0001 45 19.25 8.76 0.11 <0.0001 >0.05 
Table 4.1 Statistical comparisons of M. smegmatis growth curves in the presence of increasing concentrations of DMSO. Wild type and DNamH strains incubated for 60 
hours at 37°C with selected concentrations of DMSO (v/v) produced growth curves measured at OD600nm in Figure 4.1. Variations between growth curves were measured by 
time taken to exit apparent lag phase (hours), the doubling time (Td) of cells during exponential phase (hours-1), the area under the curve (AUC) percentage compared to the 0 
% control (%), the OD600nm value achieved during stationary phase and whether the growth curve variations were statistically significant compared to each 0 % control with p-
values <0.05 deemed significant. The statistical significance of DNamH (b) growth curves compared to wild type (a) at equivalent DMSO concentrations were determined by 
p-values <0.05. 
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The impact of DMSO concentration was investigated in order to ascertain the maximum 
percentage of DMSO compatible with normal cellular growth of M. smegmatis. Both 
wild type and NamH deficient strains responded to DMSO equally, with no significant 
variation noted between the strains (Table 4.1). The standard growth phenotype of the 
wild type (Figure 4.1 (a) Blue) and DNamH (Figure 4.1 (b) Blue) strains both exited 
apparent lag phase after 21 hours, achieved a Td of 7.03 and 6.76 hours respectively 
and reached stationary phase at OD600nm 0.26 and 0.25 respectively after 45 hours.  
 
The growth curves produced for each strain were analysed separately by a Student’s t-
test (Table 4.1) to compare the growth inhibition observed with increasing 
concentrations of DMSO against the 0% (v/v) DMSO control. Results indicated that 
growth variation by DMSO concentrations below 3% (v/v) in both strains were not 
deemed statistically significant with p-values >0.05 (Table 4.1). The growth inhibition 
measured by addition of 3% (v/v) DMSO or greater were equally statistically 
significant against both M. smegmatis strains with p-values of <0.01 (3% (v/v)), <0.001 
(4% (v/v)) and <0.0001 (5% (v/v)) respectively. T-test comparisons of M. smegmatis 
strains at equivalent DMSO concentrations determined that any variation between wild 
type and DNamH growth curves was not statistically significant with p-values >0.05. 
 
The first deviation from the growth phenotype was observed with the addition of 3% 
(v/v) DMSO (Figure 4.1 Orange) equally in both M. smegmatis strains. The M. 
smegmatis cells incubated with 3% (v/v) DMSO differed most notably from the 0% 
(v/v) control during apparent lag phase, which with the presence of the solvent 
increased by a further 6 hours resulting in a 27 hour duration before growth was 
observed. 3% (v/v) DMSO did not impact the Td or final OD600nm value reached during 
stationary phase in both strains, but due to the extended apparent lag phase reduced the 
AUC to around 80% (Table 4.1) of the 0% (v/v) control.  
 
The addition of 4% (v/v) DMSO (Figure 4.1 Purple), extended apparent lag phase of 
both wild type and DNamH M. smegmatis strains to 30 hours, increased the Td 
marginally to 7.19 hours in the wild type and 6.96 hours in the DNamH strain and 
decreased the AUC to 62.23% and 60.29% respectively. At 5% (v/v) DMSO (Figure 
4.1 Red) the most noted impact on phenotypic growth was observed. The apparent lag 
 146 
phase for both strains was extended to 45 hours, the Td during exponential phase 
doubled to 15.61 hours in the wild type and 19.25 hours in the DNamH strain. The AUC 
of both M. smegmatis strains was significantly impacted with values of 12.12% (wild 
type) and 8.76% (DNamH) respectively. 
 
Based upon the findings shown in Figure 4.1 The decision was taken to utilize 2% (v/v) 
DMSO for all required investigations. Therefore 2% (v/v) DMSO was also added to 
control wells in the absence of antibiotic.  
 
 
4.4 Antimicrobial MIC assessment of the M. smegmatis wild type and 
DNamH strains  
 
The two M. smegmatis strains acquired from the Pavelka group (Raymond, et al. 2005) 
were generated initially by removal of the dominant b-lactamase gene blaS, (Flores, et 
al. 2005) creating the strain PM965 denoted as “wild type” in this chapter. Strain 
PM979 deemed “DNamH” was subsequently formed by allelic exchange of the namH 
gene from PM965 creating the double mutant blaS- namH-. Mass spectrometric analysis 
of the composition of the mycobacterial cell wall structures constructed by the wild 
type strain detailed a 7:3 ratio of N-glycolylated monosaccharides to N-acetylated 
monosaccharides (Raymond, et al. 2005) within the peptidoglycan chains. The DNamH 
mutant strain produced peptidoglycan chains containing solely N-acetylated 
monosaccharides. Raymond, et al. (2005) assessed antimicrobial susceptibility of both 
strains against single concentrations of amoxicillin (20 µg), ampicillin (10 µg), 
isoniazid (5 µg) and ethambutol (50 µg). The average zones of inhibition for both 
strains were equal against isoniazid and ethambutol, with the DNamH strain more 
susceptible to both amoxicillin and ampicillin. This effect on the DNamH strain was 
caused by the deletion of the blaS- gene. This permitted assessment of b-lactam 
antimicrobials as M. smegmatis blaS+ strains exposed to the ampicillin disk diffusion 
assay exhibited no zone of inhibition (Flores, et al. (2005)). Additionally, here the 
absence of blaS+ in the PM965 strain permitted comparison of the impact of the NamH 
knockout and therefore N-glycolylation on b-lactam sensitivity of M. smegmatis. 
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Known antibiotics with distinct cellular targets were evaluated with respect to their 
MIC and MBC values against both M. smegmatis strains. 
 
 
4.4.1 Ampicillin MIC assessment of M. smegmatis wild type and 
DNamH strains 
 
Ampicillin is a b-lactam antibiotic due to its structure containing a b-lactam ring (Kong, 
et al. 2010) as demonstrated in Figure 4.2. 
 
  
Figure 4.2: The structure of the b-lactam antibiotic Ampicillin. Molecular weight: 349.41; Chemical 
formula: C16H19N3O4S. The above schematic was created using ChemBioDraw. The coloured 
substructure (Blue) is the portion of the b-lactam that mimics the D-alanyl-D-alanine terminus of the 
PBP substrate. 
 
The targets of ampicillin are the transpeptidase domains of penicillin binding proteins 
(PBPs) due to the structural similarity of the D-alanyl-D-alanine dipeptide terminus of 
the pentapeptide stem of peptidoglycan saccharides to the b-lactam (Figure 4.2 
highlighted blue) (Hujer, et al. 2005). The PBP active site serine forms a covalent bond 
with the antibiotic impeding the construction of the overall peptidoglycan sacculus. 
Both M. smegmatis strains have had the blaS gene excised, removing the dominant M. 
smegmatis b-lactamase, BlaS. The enzyme is targeted specifically to degrade and 
inactivate b-lactam antibiotics such as ampicillin by hydrolysing the b-lactam ring 
(Abraham, et al. 1988). The M. smegmatis blaS+ strain had an ampicillin MIC of 128 
µg.mL-1 whereas removal of the blaS gene reduced the MIC to 2 µg.mL-1 (Flores, et al. 
2005). Antimicrobial analysis of the two M. smegmatis PM965 and PM979 strains 
revealed that the double knockout DNamH mutant was more susceptible towards 
ampicillin (Raymond, et al. 2005). Both blaS- M. smegmatis strains were reassessed in 
Figure 4.3 against increasing concentrations of ampicillin to evaluate the MIC of the 
antibiotic.  
O
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Figure 4.3 The impact of N-glycolylation of peptidoglycan on sensitivity of M. smegmatis growth to ampicillin. Wild type (a) and (b) DNamH M. smegmatis MIC growth 
curves against ampicillin. Cells were grown in 96-well microtiter plates in triplicate at 37°C with intermittent shaking, OD600nm was measured at 3 hour intervals for 60 hours. 
Each well contained 100 µL culture media (7H9, ADC, 0.05% (w/v) Tween 80) with increasing concentrations of ampicillin at a total DMSO concentration of 2% (v/v). M. 
smegmatis wild type (a) and (b)  NamH strains were standardized to an OD600nm of 1 and diluted further by a factor of 104 prior to addition to wells and incubation. Error bars 
represent standard deviation of triplicate measurements. Ampicillin concentrations: 0 µg.mL-1 (Blue), 0.015 µg.mL-1 (Green), 0.03 µg.mL-1 (Pink), 0.06 µg.mL-1 (Orange), 
0.125 µg.mL-1 (Purple), 0.25 µg.mL-1 (Red), 0.5 µg.mL-1 (Yellow), 1 µg.mL-1 (Black) and 2 µg.mL-1 (Brown). Statistically significant results of comparisons of growth of 
increasing ampicillin concentrations compared to growth at 0 µg.mL-1 ampicillin for each strain are indicated with * = p-value <0.05, ** = <0.01, *** = <0.001 and **** = 
<0.0001. Ns = not statistically significant. Results: DNamH displayed greater susceptibility to ampicillin than wild type. MIC results: Wild type (a) 0.5 µg.mL-1, DNamH (b) 
0.25 µg.mL-1. 
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Ampicillin 
(µg.mL-1) 
Wild type M. smegmatis DNamH M. smegmatis (b) vs (a) 
p-values Apparent 
Lag 
phase 
(h) 
Td  
(h-1) 
AUC  
(%) 
Stationary 
Phase  
OD600nm 
Wild 
type 
p-values 
(a) 
Apparent 
Lag 
phase  
(h) 
Td  
(h-1) 
AUC  
(%) 
Stationary 
Phase  
OD600nm 
DNamH 
p-
values 
(b) 
0 21 6.54 - 0.30 - 21 7.35 - 0.30 - >0.05 
0.015 21 8.13 77.15 0.25 <0.001 24 8.35 73.53 0.24 <0.001 >0.05 
0.03 24 7.95 52.45 0.19 <0.001 24 8.63 59.89 0.20 <0.001 >0.05 
0.06 27 9.04 36.38 0.17 <0.0001 30 11.25 31.42 0.14 <0.0001 <0.01 
0.125 36 11.90 23.46 0.15 <0.0001 42 18.43 12.08 0.11 <0.0001 <0.01 
0.25 36 26.45 9.95 0.10 <0.0001 60 0.00 0.00 0.05 <0.0001 <0.01 
0.5 60 0.00 0.00 0.05 <0.0001 60 0.00 0.00 0.05 <0.0001 - 
1 60 0.00 0.00 0.05 <0.0001 60 0.00 0.00 0.05 <0.0001 - 
2 60 0.00 0.00 0.05 <0.0001 60 0.00 0.00 0.05 <0.0001 - 
Table 4.2 Statistical comparisons of M. smegmatis growth curves in the presence of increasing concentrations of ampicillin. Wild type and DNamH strains incubated for 
60 hours at 37°C with selected concentrations of ampicillin produced growth curves measured at OD600nm in Figure 4.3. Variations between growth curves were measured by 
time taken to exit apparent lag phase (hours), the doubling time (Td) of cells during exponential phase (hours-1), the area under the curve (AUC) percentage compared to the 0 
µg.mL-1 control (%), the OD600nm value achieved during stationary phase and whether the growth curve variations were statistically significant compared to each 0 µg.mL-1 
control with p-values <0.05 deemed significant. The statistical significance of DNamH (b) growth curves compared to wild type (a) at equivalent ampicillin concentrations 
were determined by p-values <0.05. 
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The MIC assessment of the wild type (Figure 4.3 (a)) and DNamH (Figure 4.3 (b)) 
demonstrated that the absence of N-glycolylated peptidoglycan moderately sensitised 
M. smegmatis to ampicillin. This results reinforced the findings of Raymond, et al. 
(2005), emphasising the increased resilience of the wild type strain. 
 
The normal growth phenotype of the wild type (Figure 4.3 (a) Blue) and DNamH 
(Figure 4.3 (b) Blue) strains were used as controls to compare against growth in the 
presence of ampicillin. The normal cell growth of both strains exited apparent lag phase 
after 21 hours, during exponential phase demonstrated a doubling time (Td) of 6.54 
(wild type) and 7.35 (DNamH) hours respectively and plateaued during stationary phase 
at a maximum optical density of OD600nm 0.3 after 45 hours.  
 
The presence of increasing concentrations of ampicillin led to a gradual increase in the 
duration of apparent lag phase and the Td within exponential phase as well as a 
reduction in the final stationary phase OD600nm and the AUC compared to the 0 µg.mL-
1 strain control. The four lowest ampicillin concentrations 0.015 µg.mL-1 (Figure 4.3 
Pink), 0.03 µg.mL-1 (Figure 4.3 Green), 0.06 µg.mL-1 (Figure 4.3 Orange) and 0.125 
µg.mL-1 (Figure 4.3 Purple) permitted M. smegmatis growth of both strains, but 
displayed a more pronounced effect on the growth of the DNamH strain. Variation 
between the two strains was most evident after the incubation of cells with 0.25 µg.mL-
1 (Figure 4.3 Red) ampicillin. The wild type strain demonstrated observable growth 
after 36 hours (Table 4.2) whereas the DNamH strain did not show any measurable 
growth in nutrient media during the 60 hour experiment. The ampicillin MIC for the 
DNamH strain was therefore concluded as 0.25 µg.mL-1, half the 0.5 µg.mL-1 MIC 
(Figure 4.3 (a) Yellow) of the wild type. 
 
The growth curves in Figure 4.3 were analysed with a Student’s t-test against the 
normal cellular phenotype expressed in the 0 µg.mL-1 control (Table 4.2) of each strain. 
This showed that the inhibition towards wild type growth attributed to ampicillin at 
each investigated concentration was deemed statistically significant with p-values 
<0.001 (0.015 and 0.03 µg.mL-1) and <0.0001 (0.06-2 µg.mL-1) respectively. DNamH 
strain inhibition attributed to all ampicillin concentrations were also deemed 
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statistically significant with p-values of <0.001 for ampicillin concentrations 0.015 and 
0.03 µg.mL-1 and <0.0001 for all remaining concentrations between 0.06 to 2 µg.mL-1.  
 
The significance of the observed variation in the responses of the wild type (Figure 4.3 
(a)) and DNamH (Figure 4.3 (b)) M. smegmatis strains to equivalent ampicillin 
concentrations showed that variation in antimicrobial inhibition caused by addition of 
less than 0.03 µg.mL-1 ampicillin to both strains was not statistically significant with a 
p-value >0.05. The variation observed at concentrations greater than 0.03 µg.mL-1 were 
deemed statistically significant from one another with p-values at each concentration 
(0.06, 0.125 and 0.25 µg.mL-1) of <0.01. 
 
To determine if no growth equates to bacterial killing, microtiter plate well contents at 
the 60 hour time point were pipetted onto TSB agar plates to evaluate ampicillin MBC 
for both M. smegmatis strains. Results are shown in Figure 4.4. 
 
 
 
Figure 4.4 Minimal bactericidal concentration of ampicillin against M. smegmatis strains. M. 
smegmatis wild type (a) and ∆NamH (b) cells incubated in liquid media with increasing concentrations 
of ampicillin that did not produce growth (Figure 4.3) were pipetted in duplicate onto TSB agar to 
determine the MBC. Each quadrant denotes the ampicillin concentration in µg.mL-1. Results: Wild type 
MBC 1 µg.mL-1, ∆NamH MBC 0.5 µg.mL-1.  
 
The MBC assessment of wild type (Figure 4.4 (a)) and DNamH (Figure 4.4 (b)) cells 
after incubation with MIC or greater concentrations of ampicillin showed that the 
DNamH strain remained more susceptible to the antimicrobial, with an MBC half the 
value obtained in the wild type. The MBC values were 1 µg.mL-1 (wild type) and 0.5 
µg.mL-1 (DNamH), which were double the corresponding MIC values for each strain.  
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4.4.2 Isoniazid MIC assessment of M. smegmatis wild type and DNamH 
strains 
 
Isoniazid is one of the four standard first-line antimicrobials against tuberculosis 
infection (Metcalfe, et al. 2008). A prodrug activated within mycobacteria by the heme 
enzyme KatG (Metcalfe, et al. 2008). Once active, the drug targets mycolic acid 
synthesis, a major component of the mycobacterial cell wall which forms the mAGP 
complex (Quemard, et al. 1991). The structure of isoniazid is shown in Figure 4.5. 
 
 
 
Figure 4.5: The structure of the antibiotic Isoniazid. Molecular weight: 137.14; Chemical formula: 
C6H7N3O.The above schematic was created using ChemBioDraw. 
 
Raymond, et al. (2005) assessed isoniazid activity against the M. smegmatis PM965 
and PM979 strains and concluded that no variation in susceptibility was observed in 
the DNamH strain compared to the wild type. These finding were reassessed to 
determine the isoniazid MIC for both strains in Figure 4.6. 
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Figure 4.6 The impact of N-glycolylation of peptidoglycan on sensitivity of M. smegmatis growth of isoniazid. Wild type (a) and (b) DNamH M. smegmatis MIC growth 
curves against isoniazid. Cells were grown in 96-well microtiter plates in triplicate at 37°C with intermittent shaking, OD600nm was measured at 3 hour intervals for 60 hours. 
Each well contained 100 µL culture media (7H9, ADC, 0.05% (w/v) Tween 80) with increasing concentrations of isoniazid at a total DMSO concentration of 2% (v/v). M. 
smegmatis wild type (a) and (b) ∆NamH strains were standardized to an OD600nm of 1 and diluted further by a factor of 104 prior to addition to wells and incubation. Error bars 
represent standard deviation of triplicate measurements. Isoniazid concentrations: 0 µg.mL-1 (Blue), 0.125 µg.mL-1 (Green), 0.25 µg.mL-1 (Pink), 0.5 µg.mL-1 (Orange), 1 
µg.mL-1 (Purple), 2 µg.mL-1 (Red), 4 µg.mL-1 (Yellow). Statistically significant results of comparisons of growth at increasing isoniazid concentrations compared to growth at 
0 µg.mL-1 isoniazid for each strain are indicated with * = p-value <0.05, ** = <0.01, *** = <0.001 and **** = <0.0001. Ns = not statistically significant. Results: Both strains 
display equal susceptibility to isoniazid. MIC results: Wild type (a) 2 µg.mL-1, DNamH (b) 2 µg.mL-1. 
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Isoniazid 
(µg.mL-1) 
Wild type M. smegmatis DNamH M. smegmatis (b) vs (a) 
p-values Apparent 
Lag 
phase 
(h) 
Td  
(h-1) 
AUC  
(%) 
Stationary 
Phase  
OD600nm 
Wild 
type 
p-values 
(a) 
Apparent 
Lag 
phase  
(h) 
Td  
(h-1) 
AUC  
(%) 
Stationary 
Phase  
OD600nm 
DNamH 
p-
values 
(b) 
0 21 7.14 - 0.30 - 21 7.19 - 0.29 - >0.05 
0.125 21 7.10 99.89 0.30 >0.05 21 7.02 94.28 0.28 >0.05 >0.05 
0.25 21 7.10 76.28 0.24 <0.01 21 7.18 91.01 0.26 <0.05 <0.05 
0.5 24 7.80 57.68 0.19 <0.001 24 8.85 63.69 0.21 <0.001 >0.05 
1 45 13.75 9.48 0.12 <0.0001 45 14.29 9.28 0.12 <0.0001 >0.05 
2 60 0.00 0.00 0.05 <0.0001 60 0.00 0.00 0.05 <0.0001 - 
4 60 0.00 0.00 0.05 <0.0001 60 0.00 0.00 0.05 <0.0001 - 
Table 4.3 Statistical comparisons of M. smegmatis growth curves in the presence of increasing concentrations of Isoniazid. Wild type and DNamH strains incubated for 
60 hours at 37°C with selected concentrations of isoniazid produced growth curves measured at OD600nm in Figure 4.6. Variations between growth curves were measured by 
time taken to exit apparent lag phase (hours), the doubling time (Td) of cells during exponential phase (hours-1), the area under the curve (AUC) percentage compared to the 0 
µg.mL-1 control (%), the OD600nm value achieved during stationary phase and whether the growth curve variations were statistically significant compared to each 0 µg.mL-1 
control with p-values <0.05 deemed significant. The statistical significance of DNamH (b) growth curves compared to wild type (a) at equivalent isoniazid concentrations were 
determined by p-values <0.05. 
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The absence of the N-glycolyl modification did not appear to impact the isoniazid MIC, 
with both wild type and DNamH strains producing equivalent growth curves at equal 
concentrations of isoniazid (Table 4.3). In this data set, the growth curves for the wild 
type (Figure 4.6 (a) Blue) and DNamH (Figure 4.6 (b) Blue) strains in the absence of 
isoniazid were virtually identical to the equivalent data in the ampicillin experiment 
(Figure 4.3) whereby strains demonstrated an apparent lag phase of 21 hours, produced 
Td of 7.14 and 7.19 hours respectively and entered stationary phase around OD600nm 
0.3 after 45 hours.  
 
The addition of the lowest investigated isoniazid concentration 0.125 µg.mL-1 (Figure 
4.6 Green) to both strains did not alter the normal distribution of growth compared to 
the equivalent 0 µg.mL-1 control. The duration of apparent lag phase, the Td and the 
final OD600nm during stationary phase demonstrated no observable inhibition towards 
cellular growth at 0.125 µg.mL-1 isoniazid (Table 4.3). Doubling the concentration of 
isoniazid to 0.25 µg.mL-1 (Figure 4.6 Pink) in both strains only impacted the final 
OD600nm value during stationary phase. Both the duration of apparent lag phase and Td 
remained constant to their respective 0 µg.mL-1 controls. This variation caused by 0.25 
µg.mL-1 isoniazid reduced the AUC of both strains to 76.28% (wild type) and 91.01% 
(DNamH) respectively (Table 4.3). 
 
The subsequent isoniazid concentrations 0.5 µg.mL-1 (Figure 4.6 Orange) and 1 µg.mL-
1 (Figure 4.6 Purple) were insufficient to prevent growth during the 60 hour experiment 
and equally effected both M. smegmatis strains increasing apparent lag phase, Td and 
reducing stationary phase OD (Table 4.3). The AUC values during 0.5 µg.mL-1 
isoniazid incubation were 57.68% (wild type) and 63.69% (DNamH) respectively, 
whilst during 1 µg.mL-1 isoniazid incubation were reduced significantly to 9.48% (wild 
type) and 9.28% (DNamH) (Table 4.3) respectively. The isoniazid MIC for both M. 
smegmatis strains was 2 µg.mL-1. Both the wild type (Figure 4.6 (a): Red) and DNamH 
(Figure 4.6 (b): Red) were completely inhibited at this concentration. 
 
A Student’s t-test analysis of both strains comparing the inhibition observed in the 
presence of increasing concentrations of the antimicrobial isoniazid to the 0 µg.mL-1 
control for each strain produced matching results at almost all investigated 
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concentrations (Table 4.3). The addition of 0.125 µg.mL-1 to either strain inhibited 
growth in a manner than was not deemed statistically significant with p-values >0.05. 
The presence of 0.25 µg.mL-1 isoniazid produced statistically significant results in both 
strains compared to their 0 µg.mL-1 controls with p values of <0.01 (Wild type) and 
<0.05 (DNamH) respectively. Isoniazid concentrations greater than 0.25 µg.mL-1 
resulted in equally statistically significant inhibition in both strains culminating in p-
values of <0.01 (0.5 µg.mL-1) and <0.001 (1-4 µg.mL-1) respectively. 
 
T-test comparisons made between strains during incubation with equivalent isoniazid 
concentrations determined than any strain specific variation in growth curves was 
deemed not be statistically significant with p-values >0.05 in all concentrations except 
at 0.25 µg.mL-1 isoniazid due to the difference noted in measured AUC (Table 4.3), 
which led to growth curve variation between strains at this sole concentration deemed 
significant with a p-value of <0.05. 
 
Wells containing the MIC and higher isoniazid concentrations incubated with both M. 
smegmatis strains were transferred onto TSB agar plates and incubated for 72 hours to 
determine the MBC values. The results are shown in Figure 4.7.  
 
 
 
Figure 4.7 Minimal bactericidal concentration of isoniazid against M. smegmatis strains. M. 
smegmatis wild type (a) and ∆NamH (b) cells incubated in liquid media with increasing concentrations 
of isoniazid that did not produce growth (Figure 4.6) were pipetted in duplicate onto TSB agar to 
determine MBC. Each quadrant denotes the isoniazid concentration in µg.mL-1. Results: Wild type MBC 
8 µg.mL-1, ∆NamH MBC 8 µg.mL-1.  
 
 
 158 
As observed in the MIC growth curve analysis (Figure 4.6) the isoniazid MBC for both 
strains was 8 µg.mL-1. Therefore, the presence of the N-glycolyl modification present 
in the wild type M. smegmatis peptidoglycan did not alter MBC relative to the DNamH 
strain which possessed exclusively MurNAc based peptidoglycan. The isoniazid MBC 
was 4 times greater than the isoniazid MIC values of 2 µg.mL-1. 
 
 
4.4.3 Ramoplanin MIC assessment of M. smegmatis wild type and 
DNamH strains 
 
Ramoplanin is a gram-positive-directed, broad spectrum antimicrobial which inhibits 
transglycosylase activity of PBPs by binding specifically to Lipid II and preventing the 
extension of peptidoglycan chains (Fang, et al. 2006). Ramoplanin was initially 
proposed to inhibit MurG through binding of Lipid I (Reynolds, et al. 1990), although 
due to its size and high solubility is unlikely that ramoplanin would easily traverse the 
cell membrane (Fang, et al. 2006). The structure of ramoplanin is detailed in Figure 
4.8. 
 
 
Figure 4.8: The structure of the glycolipodepsipeptide antibiotic Ramoplanin. Molecular weight: 
2524.04; Chemical formula: C117H150ClN21O40. The above schematic was created using ChemBioDraw. 
 
The MIC of ramoplanin with respect to inhibition of growth of both M. smegmatis 
strains was assessed in Figure 4.9. 
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Figure 4.9 The impact of N-glycolylation of peptidoglycan on sensitivity of M. smegmatis growth of ramoplanin. Wild type (a) and (b) DNamH M. smegmatis MIC growth 
curves against ramoplanin. Cells were grown in 96-well microtiter plates in triplicate at 37°C with intermittent shaking, OD600nm was measured at 3 hour intervals for 60 hours. 
Each well contained 100 µL culture media (7H9, ADC, 0.05% (w/v) Tween 80) with increasing concentrations of ramoplanin with a total DMSO concentration of 2% (v/v). 
The cultured M. smegmatis wild type (a) and (b) DNamH strains were standardized to an OD600nm of 1 and diluted further by a factor of 104 prior to addition to wells and 
incubation. Error bars represent standard deviation of triplicate measurements. Ramoplanin concentrations: 0 µg.mL-1 (Blue), 0.125 µg.mL-1 (Green), 0.25 µg.mL-1 (Pink), 0.5 
µg.mL-1 (Orange), 1 µg.mL-1 (Purple), 2 µg.mL-1 (Red), 4 µg.mL-1 (Yellow), 8 µg.mL-1 (Black) and 16 µg.mL-1 (Brown). Statistically significant results of comparisons of 
growth at increasing ramoplanin concentrations compared to growth at 0 µg.mL-1 ramoplanin for each strain are indicated with * = p-value <0.05, ** = <0.01, *** = <0.001 
and **** = <0.0001. Ns = not statistically significant. Results: Both strains display equal susceptibility to ramoplanin. MIC results: Wild type (a) 2 µg.mL-1, DNamH (b) 2 
µg.mL-1.  
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Ramoplanin 
(µg.mL-1) 
Wild type M. smegmatis DNamH M. smegmatis (b) vs 
(a) 
p-
values 
Apparent 
Lag 
phase 
(h) 
Td  
(h-1) 
AUC  
(%) 
Stationary 
Phase  
OD600nm 
Wild 
type 
p-values 
(a) 
Apparent 
Lag 
phase  
(h) 
Td  
(h-1) 
AUC  
(%) 
Stationary 
Phase  
OD600nm 
DNamH 
p-
values 
(b) 
0 21 7.22 - 0.29 - 21 7.81 - 0.29 - >0.05 
0.125 21 8.43 77.34 0.25 <0.01 24 9.53 62.07 0.21 <0.001 <0.01 
0.25 30 9.04 48.99 0.20 <0.0001 33 8.80 38.96 0.19 <0.0001 <0.01 
0.5 30 10.20 33.26 0.15 <0.0001 42 10.40 14.59 0.15 <0.0001 <0.001 
1 54 11.32 5.36 0.12 <0.0001 54 11.12 1.89 0.09 <0.0001 <0.05 
2 60 0.00 0.00 0.05 <0.0001 60 0.00 0.00 0.05 <0.0001 - 
4 60 0.00 0.00 0.05 <0.0001 60 0.00 0.00 0.05 <0.0001 - 
8 60 0.00 0.00 0.05 <0.0001 60 0.00 0.00 0.05 <0.0001 - 
16 60 0.00 0.00 0.05 <0.0001 60 0.00 0.00 0.05 <0.0001 - 
Table 4.4 Statistical comparisons of M. smegmatis growth curves in the presence of increasing concentrations of Ramoplanin. Wild type and DNamH strains incubated 
for 60 hours at 37°C with selected concentrations of Ramoplanin produced growth curves measured at OD600nm in Figure 4.9. Variations between growth curves were measured 
by time taken to exit apparent lag phase (hours), the doubling time (Td) of cells during exponential phase (hours-1), the area under the curve (AUC) percentage compared to the 
0 µg.mL-1 control (%), the OD600nm value achieved during stationary phase and whether the growth curve variations were statistically significant compared to each 0 µg.mL-1 
control with p-values <0.05 deemed significant. The statistical significance of DNamH (b) growth curves compared to wild type (a) at equivalent Ramoplanin concentrations 
were determined by p-values <0.05. 
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The control growth curves demonstrated by the wild type (Figure 4.9 (a) Blue) and 
DNamH (Figure 4.9 (b) Blue) strains in the absence of the ramoplanin during this 60 
hour incubation was used as a marker to compared the incubation of increasing 
antimicrobial concentrations. In this set of experiments, cells exited apparent lag phase 
after 21 hours, produced a Td of 7.22 (wild type) and 7.81 (DNamH) hours respectively 
and both reached an OD600nm of 0.29 after 45 hours during stationary phase (Table 4.4).  
 
The addition of increasing concentrations of ramoplanin resulted in an equivalent MIC 
of 2 µg.mL-1 (Figure 4.9 Red) for both strains during the 60 hour experiment. The lower 
preceding ramoplanin concentrations 0.125 µg.mL-1 (Figure 4.9 Green), 0.25 µg.mL-1 
(Figure 4.9 Pink), 0.5 µg.mL-1 (Figure 4.9 Orange) and 1 µg.mL-1 (Figure 4.9 Purple) 
demonstrated a gradual decline in growth measured by the reduction in the AUC of 
both strains compared to their respective 0 µg.mL-1 controls (Table 4.4), although 
inhibition was observed to a greater degree in the DNamH strain.  
 
The growth curves of both wild type and DNamH strains in the presence of increasing 
concentrations of ramoplanin were analysed with a Student’s t-test against the 
equivalent growth curve of each strain in the absence of the antimicrobial to determine 
where observed inhibition was statistically significant (Table 4.4). Results show that all 
investigated concentrations of ramoplanin produced statistically significant inhibition 
compared to the strain’s respective 0 µg.mL-1 control. The addition of the lowest 
investigated concentration 0.125 µg.mL-1 led to significant inhibition in both strains 
with p-values of <0.01 (Wild type) and <0.001 (DNamH) respectively. Subsequent 
concentrations (0.25-16 µg.mL-1) of ramoplanin produced equivalent statistical 
significance in both strains with p-values of <0.0001 for each investigated 
concentration. 
 
Comparative Student’s t-tests between the wild type and DNamH strains at equivalent 
concentrations of ramoplanin were assessed to determine if inter-strain growth curve 
variation was statistically significant (Table 4.4). Results demonstrated that all 
observed differences between strains at matching concentrations were found to be 
statistically significant with p-values of <0.01 (0.125 and 0.25 µg.mL-1), <0.001 (0.5 
µg.mL-1) and <0.05 (1 µg.mL-1) respectively. 
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After the 60 hours incubation period, wells which did not produce observable M. 
smegmatis growth for either strain were pipetted in 10 µL volumes onto TSB agar and 
incubated at 37°C for 72 hours for MBC assessment. Results are shown in Figure 4.10. 
 
 
 
Figure 4.10 Minimal bactericidal concentration of ramoplanin against M. smegmatis strains. M. 
smegmatis wild type (a) and ∆NamH (b) cells incubated in liquid media with increasing concentrations 
of ramoplanin that did not produce growth (Figure 4.9) were pipetted in duplicate onto TSB agar to 
determine MBC. Each quadrant denotes the ramoplanin concentration the M. smegmatis strains were 
exposed to in µg.mL-1. Results: Wild type MBC 4 µg.mL-1, ∆NamH MBC 4 µg.mL-1. 
 
The ramoplanin MBC assessment in Figure 4.10 showed that both M. smegmatis strains 
had the equivalent MBC value of 4 µg.mL-1. Cells incubated at ramoplanin 
concentrations 4 µg.mL-1, 8 µg.mL-1 or 16 µg.mL-1 were unable to propagate on TSB 
agar.  This concentration was double the MIC value (Figure 4.9) for each M. smegmatis 
strain. 
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4.4.4 Tunicamycin MIC assessment of M. smegmatis wild type and 
DNamH strains 
 
Tunicamycin is an antimicrobial that targets numerous cellular processes. The inhibitor 
prevents protein N-glycosylation and  impacts not only peptidoglycan biosynthesis but 
also the bridging of teichoic acids to peptidoglycan (Price, et al. 2005). The 
peptidoglycan biosynthesis target of tunicamycin is the active site of MraY which it 
irreversibly binds to preventing the conversion of undecaprenyl phosphate and UDP-
MurNAc-pentapeptide to Lipid I (Al-Dabbagh, et al. 2008). The structure of 
tunicamycin is shown in Figure 4.11.  
 
 
 
Figure 4.11: The structure of the Tunicamycin. Molecular weight: 844.95; Chemical formula: 
C39H64N4O16. The above schematic was created using ChemBioDraw. 
 
 
To determine the impact of N-glycolylation of peptidoglycan on mycobacterial 
sensitivity to this antibiotic, the tunicamycin MIC for M. smegmatis wild type and 
DNamH strains were determined (Figure 4.12). 
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Figure 4.12 The impact of N-glycolylation of peptidoglycan of peptidoglycan on sensitivity of M. smegmatis growth to tunicamycin. Wild type (a) and (b) DNamH M. 
smegmatis MIC growth curves against tunicamycin. Cells were grown in 96-well microtiter plates in triplicate at 37°C with intermittent shaking, OD600nm was measured at 3 
hour intervals for 60 hours. Each well contained 100 µL culture media (7H9, ADC, 0.05% (w/v) Tween 80) with increasing concentrations of tunicamycin at a total DMSO 
concentration of 2% (v/v). M. smegmatis wild type (a) and (b) ∆NamH strains were standardized to an OD600nm of 1 and diluted further by a factor of 104 prior to addition to 
wells and incubation. Error bars represent standard deviation of triplicate measurements. Tunicamycin concentrations: 0 µg.mL-1 (Blue), 2 µg.mL-1 (Green), 4 µg.mL-1 (Pink), 
8 µg.mL-1 (Orange), 16 µg.mL-1 (Purple), 32 µg.mL-1 (Red) and 64 µg.mL-1 (Yellow). Statistically significant results of comparison of growth at increasing tunicamycin 
concentrations compared to growth at 0 µg.mL-1 tunicamycin for this strain are indicated with * = p-value <0.05, ** = <0.01, *** = <0.001 and **** = <0.0001. Ns = not 
statistically significant. Results: Both strains display equal susceptibility to tunicamycin. MIC results: Wild type (a) 32 µg.mL-1, DNamH (b) 32 µg.mL-1. 
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Tunicamycin 
(µg.mL-1) 
Wild type M. smegmatis DNamH M. smegmatis (b) vs 
(a) 
p-
values 
Apparent 
Lag 
phase 
(h) 
Td  
(h-1) 
AUC  
(%) 
Stationary 
Phase  
OD600nm 
Wild 
type 
p-values 
(a) 
Apparent 
Lag 
phase  
(h) 
Td  
(h-1) 
AUC  
(%) 
Stationary 
Phase  
OD600nm 
DNamH 
p-
values 
(b) 
0 21 6.82 - 0.31 - 21 6.73 - 0.31 - >0.05 
2 21 7.93 97.02 0.30 >0.05 21 7.44 90.34 0.30 >0.05 >0.05 
4 21 7.62 76.78 0.25 <0.01 21 8.19 82.83 0.27 <0.01 >0.05 
8 21 8.69 64.68 0.22 <0.001 21 8.56 60.93 0.21 <0.001 >0.05 
16 30 11.30 42.37 0.18 <0.001 36 13.56 20.50 0.14 <0.0001 <0.001 
32 60 0.00 0.00 0.05 <0.0001 60 0.00 0.00 0.05 <0.0001 - 
64 60 0.00 0.00 0.05 <0.0001 60 0.00 0.00 0.05 <0.0001 - 
128 60 0.00 0.00 0.05 <0.0001 60 0.00 0.00 0.05 <0.0001 - 
Table 4.5 Statistical comparisons of M. smegmatis growth curves in the presence of increasing concentrations of tunicamycin. Wild type and DNamH strains incubated 
for 60 hours at 37°C with selected concentrations of tunicamycin produced growth curves measured at OD600nm in Figure 4.12. Variations between growth curves were measured 
by time taken to exit apparent lag phase (hours), the doubling time (Td) of cells during exponential phase (hours-1), the area under the curve (AUC) percentage compared to the 
0 µg.mL-1 control (%), the OD600nm value achieved during stationary phase and whether the growth curve variations were statistically significant compared to each 0 µg.mL-1 
control with p-values <0.05 deemed significant. The statistical significance of DNamH (b) growth curves compared to wild type (a) at equivalent tunicamycin concentrations 
were determined by p-values <0.05. 
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In this set of experiments, the M. smegmatis wild type (Figure 4.12 (a) Blue) and 
DNamH (Figure 4.12 (b) Blue) control growth curves both exited apparent lag phase 
after 21 hours, with a log phase Td of 6.82 and 6.73 hours respectively and both 
plateaued after 45 hours at an OD600nm of 0.31 (Table 4.5). The addition of the lowest 
concentration to both M. smegmatis strains 2 µg.mL-1 (Figure 4.12 Green), led to 
similar growth curves to the 0 µg.mL-1 controls in terms of apparent lag phase duration 
and final stationary phase OD but differed when measuring exponential phase. The Td 
of each growth curve increased by around an hour to 7.93 (wild type) and 7.44 
(DNamH) hours respectively. The subsequent tunicamycin concentrations 4 µg.mL-1 
(Figure 4.12 Pink) and 8 µg.mL-1 (Figure 4.12 Orange) did not impact apparent lag 
phase which remained constant at 21 hours (Table 4.5) but reduced the AUC of both 
strains by further increasing Td and reducing stationary phase.  
 
The final sub MIC of tunicamycin investigated for both strains was 16 µg.mL-1 (Figure 
4.12 Purple). At this concentration deviation was observed between the two strains for 
the first time. The previous concentrations of tunicamycin produced a maximum of 7% 
variation between AUC values of each strain at equivalent concentrations compared to 
their respective control (Table 4.5). The addition of 16 µg.mL-1 extended apparent lag 
phase by 6 hours in the NamH strain compared to the wild type resulting in a 21.87% 
difference in AUC values. The tunicamycin MIC for both strains was equivalent at 32 
µg.mL-1 (Figure 4.12 Red). 
 
A Student’s t-test analysis of both the wild type and DNamH strains against increasing 
concentrations of tunicamycin compared to their respective 0 µg.mL-1 control (Table 
4.5), demonstrated that the addition of the antimicrobial at 2 µg.mL-1 produced no 
statistically significant inhibition  (p-value >0.05). Investigated concentrations above 
this 2 µg.mL-1 threshold for both strains were each deemed statistically significant. The 
inhibition observed at 4 and 8 µg.mL-1 tunicamycin produced p-values of <0.01 and 
<0.001 respectively. The statistical significance of the inhibition attributed to 16 
µg.mL-1 tunicamycin against the DNamH (p-value <0.0001) strain was more 
pronounced than the wild type (<0.001). This result was the only observed difference 
between the two strains with all subsequent tunicamycin concentrations (32-128 
µg.mL-1) generating p-values of <0.0001.  
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Comparisons made between the two strains at each concentration of tunicamycin 
indicated that all variations observed between strains at equivalent concentrations was 
not statistically significant (p-values >0.05), except the variation noted between the two 
strains at 16 µg.mL-1 which was deemed statistically significant with a p-value of 
<0.001. 
 
Concentrations of tunicamycin which did not produce observable growth, 32 µg.mL-1 
or greater were transferred onto TSB agar plates to measure the MBC. Results are 
shown in Figure 4.13. 
 
 
 
Figure 4.13 Minimal bactericidal concentration of tunicamycin against M. smegmatis strains. M. 
smegmatis wild type (a) and ∆NamH (b) cells incubated in liquid media with increasing concentrations 
of tunicamycin that did not produce growth (Figure 4.12) were pipetted in duplicate onto TSB agar to 
determine MBC. Each quadrant denotes the tunicamycin concentration in µg.mL-1. Results: Wild type 
MBC 64 µg.mL-1, ∆NamH MBC 64 µg.mL-1.  
 
Tunicamycin MBC assessment (Figure 4.13) showed that although 32 µg.mL-1 
tunicamycin (Figure 4.12 Red) was the MIC sufficient to inhibit growth during 
antimicrobial incubation, this concentration was not completely bactericidal towards 
M. smegmatis cells. Increasing the tunicamycin concentration to 64 µg.mL-1 led to a 
lack of observable growth for both strains and was therefore defined as the MBC.  
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4.4.5 Mersacidin MIC assessment of M. smegmatis wild type and 
DNamH strains 
 
Mersacidin is an antimicrobial peptide made from 20 amino acids including uncommon 
residues such as lanthionine and is therefore termed as a lantibiotic (Schmitz, et al. 
2006). The structure of mersacidin is shown in Figure 4.14. 
 
 
 
Figure 4.14: The structure of the lantibiotic Mersacidin. The above schematic was created using 
ChemBioDraw. Unusual amino acid abbreviations: Abu aminobutyric acid: Dha: dehydroalanine.  
 
Mersacidin is targeted towards Lipid II, binding to which inhibits transglycosylase 
activity and the formation of elongated peptidoglycan chains (Appleyard, et al. 2009). 
Mersacidin activity is most pronounced towards Gram-positive organisms due to the 
increased cellular percentage of peptidoglycan (Schleifer and Kandler 1972). 
Assessment of the mersacidin MIC against the two M. smegmatis strains at a 
concentration range of 2 µg.mL-1 to 128 µg.mL-1 is shown in Figure 4.15. 
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Figure 4.15 The impact of N-glycolylation of peptidoglycan on sensitivity of M. smegmatis growth on mersacidin. Wild type (a) and (b) DNamH M. smegmatis MIC 
growth curves against mersacidin. Cells were grown in 96-well microtiter plates in triplicate at 37°C with intermittent shaking, OD600nm was measured at 3 hour intervals for 
60 hours. Each well contained 100 µL culture media (7H9, ADC, 0.05% (w/v) Tween 80) with increasing concentrations of mersacidin with a total DMSO concentration of 
2% (v/v). M. smegmatis wild type (a) and (b) ∆NamH strains were standardized to an OD600nm of 1 and diluted further by a factor of 104 prior to addition to wells and incubation. 
Error bars represent standard deviation of triplicate measurements. Mersacidin concentrations: 0 µg.mL-1 (Blue), 2 µg.mL-1 (Green), 4 µg.mL-1 (Pink), 8 µg.mL-1 (Orange), 16 
µg.mL-1 (Purple), 32 µg.mL-1 (Red), 64 µg.mL-1 (Yellow) and 128 µg.mL-1 (Black). Statistically significant results of comparison of growth at increasing mersacidin 
concentrations compared to growth at 0 µg.mL-1 mersacidin for each strain are indicated with * = p-value <0.05, ** = <0.01, *** = <0.001 and **** = <0.0001. Ns = not 
statistically significant. Results: Both strains were equally susceptibility to mersacidin. MIC results: Wild type (a) 32 µg.mL-1, DNamH (b) 32 µg.mL-1. 
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Mersacidin 
(µg.mL-1) 
Wild type M. smegmatis DNamH M. smegmatis (b) vs 
(a) 
p-
values 
Apparent 
Lag 
phase 
(h) 
Td  
(h-1) 
AUC  
(%) 
Stationary 
Phase  
OD600nm 
Wild 
type 
p-values 
(a) 
Apparent 
Lag 
phase  
(h) 
Td  
(h-1) 
AUC  
(%) 
Stationary 
Phase  
OD600nm 
DNamH 
p-
values 
(b) 
0 21 7.78 - 0.30 - 21 7.72 - 0.29 - >0.05 
2 21 7.99 87.58 0.28 <0.05 21 9.17 92.11 0.26 <0.05 >0.05 
4 24 7.99 76.68 0.25 <0.01 30 9.48 58.99 0.24 <0.001 <0.001 
8 33 9.00 44.44 0.21 <0.001 33 10.69 38.73 0.18 <0.0001 <0.01 
16 42 8.94 24.54 0.16 <0.0001 36 10.31 30.32 0.16 <0.0001 <0.01 
32 60 0.00 0.00 0.05 <0.0001 60 0.00 0.00 0.05 <0.0001 - 
64 60 0.00 0.00 0.05 <0.0001 60 0.00 0.00 0.05 <0.0001 - 
128 60 0.00 0.00 0.05 <0.0001 60 0.00 0.00 0.05 <0.0001 - 
Table 4.6 Statistical comparisons of M. smegmatis growth curves in the presence of increasing concentrations of mersacidin. Wild type and DNamH strains incubated 
for 60 hours at 37°C with selected concentrations of mersacidin produced growth curves measured at OD600nm in Figure 4.15. Variations between growth curves were measured 
by time taken to exit apparent lag phase (hours), the doubling time (Td) of cells during exponential phase (hours-1), the area under the curve (AUC) percentage compared to the 
0 µg.mL-1 control (%), the OD600nm value achieved during stationary phase and whether the growth curve variations were statistically significant compared to each 0 µg.mL-1 
control with p-values <0.05 deemed significant. The statistical significance of DNamH (b) growth curves compared to wild type (a) at equivalent mersacidin concentrations 
were determined by p-values <0.05. 
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In this set of experiments the standard 0 µg.mL-1 mersacidin wild type (Figure 4.15 (a): 
Blue) and DNamH (Figure 4.15 (b): Blue) control growth curves were characterised by 
identical 21 hour apparent lag phases before entering exponential phase with Td values 
of 7.78  (wild type) and 7.72 (DNamH) hours respectively. Growth of both strains 
plateaued after 45 hours at OD600nm of 0.3 (wild type) and 0.29 (DNamH) respectively 
(Table 4.6). 
 
The addition of mersacidin at the lowest investigated concentration, 2 µg.mL-1 (Figure 
4.15 Green)  demonstrated equivalent inhibition towards each strain. The antimicrobial 
at this concentration did not impact the duration of the apparent lag phase, although it 
did marginally increase the Td and reduce the final stationary phase OD. This resulted 
in an AUC reduction to around 90% of their respective 0 µg.mL-1 controls (Table 4.6). 
Doubling the concentration of mersacidin to 4 µg.mL-1 (Figure 4.15 Pink) led to the 
most notable variation between the two strains, demonstrating an increased potency 
towards the DNamH strain not observed during incubation at 2 µg.mL-1.  The two 
strains produced a 6 hour difference in duration of the apparent lag phase with 24 hours 
for the wild type and 30 hours for the DNamH strain. This result combined with the 
wild type Td of 7.99 hours compared to DNamH 9.48 hours led to an AUC difference 
of 17.69% (Table 4.6).  
 
The subsequent mersacidin concentrations 8 µg.mL-1 (Figure 4.15 Orange) and 16 
µg.mL-1 (Figure 4.15 Purple) permitted growth of both M. smegmatis strains. Both 
concentrations led to similar Td values in the wild type (9 hours) and DNamH (10 hours) 
strains, although the apparent lag phase was more pronounced in both strains at the 
highest concentration (Table 4.6). 32 µg.mL-1 (Figure 4.15 Red) mersacidin was 
sufficient to present no observation of M. smegmatis growth of either strain and was 
therefore identified as the MIC value. 
 
Statistical significance of the impact of mersacidin on M. smegmatis wild type was 
determined relative to growth in the absence of the drug by a Student’s t-test (Table 
4.6). The wild type inhibition observed during incubation with all investigated 
concentrations of mersacidin were measured as statistically significant with p-values of 
<0.05 (2 µg.mL-1), <0.01 (4 µg.mL-1), <0.001 (8 µg.mL-1) and <0.0001 (16-128 µg.mL-
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1) respectively. Inhibition attributed to all mersacidin concentrations against M. 
smegmatis DNamH cells were statistically significant (Table 4.6) with p-values <0.05 
(2 µg.mL-1), <0.001 (4 µg.mL-1) and <0.0001 (8-128 µg.mL-1). 
 
Comparative t-test analysis comparing wild type and DNamH growth curves at the same 
concentrations of mersacidin (Table 4.6) demonstrated that growth curve variation at 2 
µg.mL-1 was not statistically significant (p-value >0.05). All subsequent mersacidin 
concentrations demonstrating increased potency towards the DNamH strain were 
statistically significant with p-values of <0.001 (4 µg.mL-1) and <0.01 (8 and 16 µg.mL-
1) respectively. 
 
Wells containing both M. smegmatis strains incubated with mersacidin concentrations 
32, 64 and 128 µg.mL-1 were pipetted onto TSB agar to determine the mersacidin MBC. 
Results are shown in Figure 4.16. 
 
 
 
Figure 4.16 Minimal bactericidal concentration of mersacidin against M. smegmatis strains. M. 
smegmatis wild type (a) and ∆NamH (b) cells incubated in liquid media with increasing concentrations 
of mersacidin that did not produce growth (Figure 4.15) were pipetted in duplicate onto TSB agar to 
determine MBC. Each quadrant denotes the mersacidin concentration in µg.mL-1. Results: Wild type 
MBC 64 µg.mL-1, ∆NamH MBC 64 µg.mL-1. 
 
Mersacidin at 64 µg.mL-1 or greater (Figure 4.16) was bactericidal to both strains 
equally and so 64 µg.mL-1 was determined to be the MBC. 
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4.4.6 Moenomycin MIC assessment of M. smegmatis wild type and 
DNamH strains 
 
Moenomycin is an antimicrobial which reversibly binds directly to the active site of 
peptidoglycan glycosyltransferases (PGTs), preventing the extension of peptidoglycan 
chains by addition of Lipid II (Ostash, et al. 2009). The structure of the 
phosphoglycolipid antibiotic moenomycin shown in Figure 4.17 strongly resembles the 
known structure of Lipid IV, comprised of two Lipid II  subunits. 
 
 
 
Figure 4.17: The structure of the glycosyltransferase antibiotic Moenomycin. Molecular weight: 
1554.62; Chemical formula: C69H111N4O33P. The above schematic was created using ChemBioDraw. 
 
Moenomycin was original identified as a product of Streptomyces ghanaensis (Ostash, 
et al. 2009) and demonstrated potent activity towards gram-positive organisms, but due 
to unsuitable pharmacokinetics more commonly administered in agriculture (Galley, et 
al. 2014). The MIC of moenomycin against both M. smegmatis PM965 and PM979 
strains was assessed in Figure 4.18. 
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Figure 4.18 The impact of N-glycolylation of peptidoglycan on sensitivity of M. smegmatis growth to moenomycin. Wild type (a) and (b) DNamH M. smegmatis MIC 
growth curves against moenomycin. Cells were grown in 96-well microtiter plates in triplicate at 37°C with intermittent shaking, OD600nm was measured at 3 hour intervals for 
60 hours. Each well contained 100 µL culture media (7H9, ADC, 0.05% (w/v) Tween 80) with increasing concentrations of moenomycin at a total DMSO concentration of 2% 
(v/v). M. smegmatis wild type (a) and (b) ∆NamH strains were standardized to an OD600nm of 1 and diluted further by a factor of 104 prior to addition to wells and incubation. 
Error bars represent standard deviation of triplicate measurements. Moenomycin concentrations: 0 µg.mL-1 (Blue), 50 µg.mL-1 (Green), 90 µg.mL-1 (Pink), 130 µg.mL-1 
(Orange), 170 µg.mL-1 (Purple), 210 µg.mL-1 (Red), 250 µg.mL-1 (Yellow). Statistically significant results of comparison of growth at increasing moenomycin concentrations 
compared to growth at 0 µg.mL-1 moenomycin for each strain are indicated with * = p-value <0.05, ** = <0.01, *** = <0.001 and **** = <0.0001. Ns = not statistically 
significant. Results: DNamH was more susceptible to moenomycin than wild type. MIC results: Wild type (a) 210 µg.mL-1, DNamH (b) 170 µg.mL-1. 
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Moenomycin 
(µg.mL-1) 
Wild type M. smegmatis DNamH M. smegmatis (b) vs 
(a) 
p-
values 
Apparent 
Lag 
phase 
(h) 
Td  
(h-1) 
AUC  
(%) 
Stationary 
Phase  
OD600nm 
Wild 
type 
p-values 
(a) 
Apparent 
Lag 
phase  
(h) 
Td  
(h-1) 
AUC  
(%) 
Stationary 
Phase  
OD600nm 
DNamH 
p-
values 
(b) 
0 21 6.95 - 0.30 - 21 7.59 - 0.30 - >0.05 
50 24 9.73 59.84 0.22 <0.001 21 9.97 57.22 0.20 <0.001 >0.05 
90 30 10.67 39.67 0.17 <0.001 33 13.40 24.65 0.16 <0.0001 <0.01 
130 42 13.32 14.92 0.14 <0.0001 42 17.63 5.70 0.10 <0.0001 <0.05 
170 54 28.99 3.17 0.08 <0.0001 60 0.00 0.00 0.05 <0.0001 <0.05 
210 60 0.00 0.00 0.05 <0.0001 60 0.00 0.00 0.05 <0.0001 - 
250 60 0.00 0.00 0.05 <0.0001 60 0.00 0.00 0.05 <0.0001 - 
Table 4.7 Statistical comparisons of M. smegmatis growth curves in the presence of increasing concentrations of moenomycin. Wild type and DNamH strains incubated 
for 60 hours at 37°C with selected concentrations of moenomycin produced growth curves measured at OD600nm in Figure 4.18. Variations between growth curves were measured 
by time taken to exit apparent lag phase (hours), the doubling time (Td) of cells during exponential phase (hours-1), the area under the curve (AUC) percentage compared to the 
0 µg.mL-1 control (%), the OD600nm value achieved during stationary phase and whether the growth curve variations were statistically significant compared to each 0 µg.mL-1 
control with p-values <0.05 deemed significant. The statistical significance of DNamH (b) growth curves compared to wild type (a) at equivalent moenomycin concentrations 
were determined by p-values <0.05. 
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In this set of experiments, the 0 µg.mL-1 control included to compared against wild type 
(Figure 4.18 (a) Blue) and DNamH (Figure 4.18 (b) Blue) growth curves inhibited by 
addition of increasing concentration of moenomycin, both exited apparent lag phase 
after 21 hours, generated a Td within exponential phase of 6.95 and 7.59 hours 
respectively and plateaued during stationary phase at OD600nm 0.3 (Table 4.7).  
 
The addition of the lowest investigated concentration of moenomycin 50 µg.mL-1 
(Figure 4.18 Green) to both strains similarly altered growth, increasing the Td to 9.73 
(Wild type) and 9.97 (DNamH) hours respectively and significantly reduced the AUC 
to 59.84% (Wild type) and 57.22% (DNamH) compared to their respective controls 
(Table 4.7). Subsequent moenomycin concentrations, 90 µg.mL-1 (Figure 4.18 Pink) 
and 130 µg.mL-1 (Figure 4.18 Orange) permitted measurable growth from both strains 
but demonstrated greater potency towards the DNamH strain. The most noted variation 
between the two M. smegmatis strains was most evident in cells incubated for 60 hours 
with 170 µg.mL-1 (Figure 4.18 Purple) moenomycin. This time frame was sufficient for 
the wild type (Figure 4.18 (a) Purple) to demonstrate measurable growth after a 54 hour 
duration within apparent lag phase. The DNamH strain on the other hand was unable to 
display observable growth (Figure 4.18 (b) Purple), therefore the MIC for namH- 
deficient strain was 170 µg.mL-1. Increasing the moenomycin concentration to 210 
µg.mL-1 (Figure 4.18 (a) Red) prevent the wild type from propagating within the 
nutrient microtiter wells and was therefore determined to be the MIC. 
 
A Student’s t-test was done for the growth curves produced from each individual M. 
smegmatis strain with increasing concentrations of moenomycin against the 
corresponding 0 µg.mL-1 control. All moenomycin concentrations for both strains were 
deemed statistically significant. For the wild type strain moenomycin concentrations 50 
and 90 µg.mL-1 produced growth curves with p-values of <0.001. For each subsequent 
concentration the wild type growth curve inhibition resulted in p-values of <0.0001 
(130-250 µg.mL-1). For the DNamH strain the inhibition attributed to 50 µg.mL-1 led to 
a statistically significant growth curve with a p-value of <0.001. All subsequent 
moenomycin concentrations possessed p-values of <0.0001 (90- 250 µg.mL-1). 
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Moenomycin impacted the DNamH strain to a greater degree than the wild type at 
equivalent concentrations based upon the AUC values generated. A Student’s t-test 
analysis of the variation between the two strains at equal concentrations was conducted 
and determined that the disparity between growth curves from each strain was 
statistically significant above 50 µg.mL-1 (p-value >0.05). All subsequent moenomycin 
concentrations produced p-values of <0.01 (90 µg.mL-1) and <0.05 (130 and 170 
µg.mL-1) respectively.  
 
Wells containing cells incubated with moenomycin concentrations at the MIC or 
greater were pipetted onto TSB agar plates to determine the MBC in Figure 4.19. 
 
 
 
Figure 4.19 Minimal bactericidal concentration of moenomycin against M. smegmatis strains. M. 
smegmatis wild type (a) and ∆NamH (b) cells incubated in liquid media with increasing concentrations 
of moenomycin that did not produce growth (Figure 4.18) were pipetted in duplicate onto TSB agar to 
determine MBC. Each quadrant denotes the moenomycin concentration in µg.mL-1. Results: Wild type 
MBC 250 µg.mL-1, ∆NamH MBC 210 µg.mL-1.  
 
The variation between the two M. smegmatis strains observed during moenomycin MIC 
determination (Figure 4.18) continued into MBC assessment in Figure 4.19. Both 
strains were able to propagate on TSB agar after incubation with 170 µg.mL-1 
moenomycin. Increasing the concentration to 210 µg.mL-1 did not impact the wild type 
which still grew but the DNamH strain was unable to colonize the agar plate therefore 
indicating that the MBC for the DNamH strain was 210 µg.mL-1. The highest 
concentration of moenomycin, 250 µg.mL-1 was sufficient to prevent mycobacterial 
growth in both strains and was therefore the MBC value for the wild type strain. 
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4.4.7 Vancomycin MIC assessment of M. smegmatis wild type and 
DNamH strains 
 
Vancomycin is a first generation glycopeptide antibiotic and common therapy against 
gram-positive organisms (Chua, et al. 2009) and a secondary therapy to numerous drug 
resistant M. tuberculosis infections (Soetaerta, et al. 2015)). The mode of action of 
vancomycin is to form hydrogen bonds towards D-alanyl-D-alanine (Wang, et al. 
2018), the terminal dipeptide residues of the peptide stem of extracellular disaccharide 
pentapeptides, preventing their incorporation into the wider peptidoglycan architecture 
(Ge, et al. 1999). The structure of vancomycin is depicted in Figure 4.20. 
 
 
 
Figure 4.20: The structure of the antibiotic Vancomycin. Molecular weight: 1447.27; Chemical 
formula: C66H75Cl2N9O24. The above schematic was created using ChemBioDraw. 
 
The MIC of vancomycin was determined for each of the two M. smegmatis strains in 
Figure 4.21. 
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Figure 4.21 The impact of N-glycolylation of peptidoglycan on the sensitivity of M. smegmatis growth to vancomycin. Wild type (a) and (b) DNamH M. smegmatis MIC 
growth curves against vancomycin. Cells were grown in 96-well microtiter plates in triplicate at 37°C with intermittent shaking, OD600nm was measured at 3 hour intervals for 
60 hours. Each well contained 100 µL culture media (7H9, ADC, 0.05% (w/v) Tween 80) with increasing concentrations of vancomycin to a total DMSO concentration of 2% 
(v/v). M. smegmatis wild type (a) and (b) ∆NamH strains were standardized to an OD600nm of 1 and diluted further by a factor of 104 prior to addition to wells and incubation. 
Error bars represent standard deviation of triplicate measurements. Vancomycin concentrations: 0 µg.mL-1 (Blue), 0.06 µg.mL-1 (Green), 0.125 µg.mL-1 (Pink), 0.25 µg.mL-1 
(Orange), 0.5 µg.mL-1 (Purple), 1 µg.mL-1 (Red), 2 µg.mL-1 (Yellow) and 4 µg.mL-1 (Black). Statistically significant results are indicated with * = p-value <0.05, ** = <0.01, 
*** = <0.001 and **** = <0.0001. Ns = not statistically significant. Results: DNamH displays greater susceptibility to vancomycin than wild type. MIC results: Wild type (a) 
2 µg.mL-1, DNamH (b) 1 µg.mL-1.  
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Vancomycin 
(µg.mL-1) 
Wild type M. smegmatis DNamH M. smegmatis (b) vs 
(a) 
p-
values 
Apparent 
Lag 
phase 
(h) 
Td  
(h-1) 
AUC  
(%) 
Stationary 
Phase  
OD600nm 
Wild 
type 
p-values 
(a) 
Apparent 
Lag 
phase  
(h) 
Td  
(h-1) 
AUC  
(%) 
Stationary 
Phase  
OD600nm 
DNamH 
p-
values 
(b) 
0 21 7.12 - 0.31 - 21 6.81 - 0.30 - >0.05 
0.06 21 7.33 97.30 0.29 >0.05 24 7.30 81.92 0.26 <0.05 <0.01 
0.125 24 7.10 81.86 0.28 <0.05 27 7.94 65.15 0.25 <0.01 <0.01 
0.25 30 7.79 54.61 0.24 <0.01 33 8.32 40.60 0.19 <0.001 <0.01 
0.5 36 9.10 32.38 0.16 <0.001 48 9.98 10.78 0.15 <0.0001 <0.001 
1 42 10.72 18.50 0.14 <0.0001 60 0.00 0.00 0.05 <0.0001 <0.001 
2 60 0.00 0.00 0.05 <0.0001 60 0.00 0.00 0.05 <0.0001 - 
4 60 0.00 0.00 0.05 <0.0001 60 0.00 0.00 0.05 <0.0001 - 
Table 4.8 Statistical comparisons of M. smegmatis growth curves in the presence of increasing concentrations of vancomycin. Wild type and DNamH strains incubated 
for 60 hours at 37°C with selected concentrations of vancomycin produced growth curves measured at OD600nm in Figure 4.21. Variations between growth curves were measured 
by time taken to exit apparent lag phase (hours), the doubling time (Td) of cells during exponential phase (hours-1), the area under the curve (AUC) percentage compared to the 
0 µg.mL-1 control (%), the OD600nm value achieved during stationary phase and whether the growth curve variations were statistically significant compared to each 0 µg.mL-1 
control with p-values <0.05 deemed significant. The statistical significance of DNamH (b) growth curves compared to wild type (a) at equivalent vancomycin concentrations 
were determined by p-values <0.05. 
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The wild type (Figure 4.21 (a) Blue) and DNamH (Figure 4.21 (b) Blue) 0 µg.mL-1 
controls were utilised during this experiment to compare against vancomycin inhibition 
of growth curves. Both strains exited apparent lag phase after 21 hours, produced a Td 
of 7.12 (Wild type) and 6.81 (DNamH) hours respectively and reached stationary phase 
after 45 hours achieving a final OD600nm during stationary phase of 0.30 (Table 4.8). 
 
Vancomycin at each investigated concentration impacted the growth of DNamH M. 
smegmatis cells to a greater degree than the wild type at each equivalent concentration 
(Figure 4.21). The addition of the lowest investigated concentration 0.06 µg.mL-1 
(Figure 4.21 (a) Green) did not alter the duration of apparent lag phase or the Td 
compared to the 0 µg.mL-1 control (Figure 4.21 (a) Blue) in the wild type but did impact 
both measurements in DNamH cells (Figure 4.21 (b) Green) compared to the 0 µg.mL-
1 control (Figure 4.21 (b) Blue). Subsequent vancomycin concentrations 0.125 µg.mL-
1 vancomycin (Figure 4.21 Pink), 0.25 µg.mL-1 vancomycin (Figure 4.21 Orange) and 
0.5 µg.mL-1 vancomycin (Figure 4.21 Purple) each gradually decreased the growth of 
both strains but still permitted observable growth to be measured. The presence of 1 
µg.mL-1 vancomycin (Figure 4.21 Red) completely inhibited growth of the DNamH M. 
smegmatis cells (Figure 4.21 (b) Red) during the 60 hour experiment time frame. The 
wild type cells (Figure 4.21 (a) Red) demonstrated growth after 42 hours (Table 4.8). 
Doubling the vancomycin concentration to 2 µg.mL-1 (Figure 4.21 (a): Yellow) was 
sufficient to completely inhibit growth in the wild type. The MIC of the M. smegmatis 
strains based upon the findings in Figure 4.21 was 2 µg.mL-1 for the wild type and 1 
µg.mL-1 vancomycin for the DNamH strain, half the MIC of the wild type. 
 
The statistical significance (Table 4.8) of the inhibition of wild type growth caused by 
increasing concentrations of vancomycin compared to the 0 µg.mL-1 control was 
analysed with a Student’s t-test. The inhibition attributed to the lowest concentration, 
0.06 µg.mL-1 was deemed not statistically significant with a p-value >0.05. Subsequent 
concentrations of vancomycin were increasingly statistically significant with p-values 
of <0.05 (0.125 µg.mL-1), <0.01 (0.25 µg.mL-1), <0.001 (0.5 µg.mL-1) and <0.0001 (1-
4 µg.mL-1) respectively. The statistical significance (Table 4.8) of the DNamH strain to 
each of the vancomycin concentrations was deemed statistically significant and to a 
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greater degree than their wild type counterparts. The p-values for each concentration 
were <0.05 (0.06 µg.mL-1), <0.01 (0.125 µg.mL-1), <0.001 (0.25 µg.mL-1) and <0.0001 
(0.5-4 µg.mL-1) respectively. 
 
A Student’s t-test analysis comparison (Table 4.8) between the wild type and DNamH 
strains at comparative concentrations of vancomycin determined that all investigated 
concentrations of the glycopeptide produced variable inhibition to DNamH M. 
smegmatis growth curves that was deemed statistically significant with p-values <0.01 
(0.06-0.25 µg.mL-1) and <0.001 (0.5-1 µg.mL-1). Both strains were completely 
inhibited by 2 and 4 µg.mL-1 vancomycin therefore variations were not statistically 
significant (p-value >0.05). 
 
MIC and greater concentrations of vancomycin were pipetted onto TSB agar plates to 
assess MBC values for both strains against the antimicrobial. Results are shown in 
Figure 4.22. 
 
 
 
Figure 4.22 Minimal bactericidal concentration of vancomycin against M. smegmatis strains. M. 
smegmatis wild type (a) and ∆NamH (b) cells incubated in liquid media with increasing concentrations 
of vancomycin that did not produce growth (Figure 4.21) were pipetted in duplicate onto TSB agar to 
determine MBC. Each quadrant denotes the vancomycin concentration in µg.mL-1. Results: Wild type 
MBC 4 µg.mL-1, ∆NamH MBC 2 µg.mL-1. 
 
The variation in susceptibility towards vancomycin noted during antimicrobial 
incubation was also observed during MBC assessment. The wild type strain (Figure 
4.22 (a)) was not able to grow in the presence of 2 µg.mL-1 vancomycin in nutrient 
media, but once cells were isolated and grown in TSB agar growth was observed.  
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The MBC for the wild type was 4 µg.mL-1. Similarly DNamH cells were unable to grow 
in the presence of 1 µg.mL-1 during MIC assessment but were able to propagate on TSB 
agar. The MBC for the DNamH strain was 2 µg.mL-1, half the value observed for the 
wild type. 
 
 
4.4.8 Teixobactin MIC assessment of M. smegmatis wild type and 
DNamH strains 
 
Due to the expanding resistance of micro-organisms towards front-line drug treatments, 
the requirement for alternative candidates have led to antimicrobial peptides as a valid 
source of potential antibiotics (Toke, et al. 2005). Possessing low toxicity and potent 
specific biological activities, the natural product teixobactin and its discovery are 
championed as a unique method of antimicrobial exploration. The structure of 
teixobactin is depicted in Figure 4.23. 
 
 
 
Figure 4.23: The structure of the small molecule antibiotic Teixobactin. Molecular weight: 1242.49; 
Chemical formula: C58H95N15O15. The above schematic was created using ChemBioDraw. 
 
An unconventional depsipeptide, teixobactin contains both methylphenylalanine and 
enduracididine as well as four D-amino acids critical for antimicrobial activity (Ling, 
et al. 2015). The 1242 Dalton peptide elicits a mode of action which differs from 
common therapeutics of bacterial infection (Piddock, et al. 2015), binding the prenyl-
pyrophosphate-GlcNAc region of Lipid II, a highly conserved motif in bacteria. The 
antimicrobial peptide elucidated potent activity (< 1 µg.mL-1) towards both 
mycobacteria and Gram-positive bacteria, in addition to drug resistant strains, although 
it did not exhibit activity towards Gram-negative bacteria (Ling, et al. 2015).  
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Teixobactin is synthesized from a newly identified b-proteobacterium, Eleftheria 
terrae. The natural product was described through a new technique of isolating and 
growing previously unculturable organisms termed iChip (Sherpa, et al. 2015). In short, 
soil samples were diluted to contain approximately a single bacterial cell and 
transferred to a set channel. Two semi-permeable membranes enclosed each channel 
and the whole device was positioned within soil. Dissemination of both nutrients and 
important growth factors across the membranes permitted the secretion of potential 
antibiotics as well as the growth of unculturable bacteria in a natural environment.  
 
The teixobactin compound was acquired from Ling et al. (2015) and the stated MIC 
against M. tuberculosis of 0.125 µg.mL-1 was investigated in M. smegmatis wild type 
and DNamH strains in Figure 4.24.  
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Figure 4.24 The impact of N-glycolylation of peptidoglycan on the sensitivity of M. smegmatis growth to teixobactin. Wild type (a) and (b) DNamH M. smegmatis MIC 
growth curves against teixobactin. Cells were grown in 96-well microtiter plates in triplicate at 37°C with intermittent shaking, OD600nm was measured at 3 hour intervals for 
60 hours. Each well contained 100 µL culture media (7H9, ADC, 0.05% (w/v) Tween 80) with increasing concentrations of teixobactin at a total DMSO concentration of 2% 
(v/v). M. smegmatis wild type (a) and (b)  NamH strains were standardized to an OD600nm of 1 and diluted further by a factor of 104 prior to addition to wells and incubation. 
Error bars represent standard deviation of triplicate measurements. Teixobactin concentrations: 0 µg.mL-1 (Blue), 0.007 µg.mL-1 (Green), 0.015 µg.mL-1 (Pink), 0.03 µg.mL-1 
(Orange), 0.06 µg.mL-1 (Purple), 0.125 µg.mL-1 (Red) and 0.25 µg.mL-1 (Yellow). Statistically significant results of comparison of growth at increasing concentrations of 
teixobactin compared to growth at 0 µg.mL-1 teixobactin for each strain are indicated with * = <0.05, ** = <0.01, *** = <0.001 and **** = <0.0001. Ns = not statistically 
significant. Results: Both strains were equally susceptible to teixobactin. MIC results: Wild type (a) 0.125 µg.mL-1, DNamH (b) 0.125 µg.mL-1.  
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Teixobactin 
(µg.mL-1) 
Wild type M. smegmatis DNamH M. smegmatis (b) vs 
(a) 
p-
values 
Apparent 
Lag 
phase 
(h) 
Td  
(h-1) 
AUC  
(%) 
Stationary 
Phase  
OD600nm 
Wild 
type 
p-values 
(a) 
Apparent 
Lag 
phase  
(h) 
Td  
(h-1) 
AUC  
(%) 
Stationary 
Phase  
OD600nm 
DNamH 
p-
values 
(b) 
0 21 7.36 - 0.29 - 21 7.95 - 0.29 - >0.05 
0.007 24 11.03 53.00 0.22 <0.01 24 10.25 57.16 0.22 <0.01 >0.05 
0.015 36 16.69 20.11 0.13 <0.001 33 16.61 23.41 0.14 <0.001 >0.05 
0.03 48 19.41 4.97 0.1 <0.0001 48 21.47 3.80 0.09 <0.0001 >0.05 
0.06 48 22.42 3.40 0.09 <0.0001 48 19.86 3.32 0.09 <0.0001 >0.05 
0.125 60 0.00 0.00 0.05 <0.0001 60 0.00 0.00 0.05 <0.0001 - 
0.25 60 0.00 0.00 0.05 <0.0001 60 0.00 0.00 0.05 <0.0001 - 
Table 4.9 Statistical comparisons of M. smegmatis growth curves in the presence of increasing concentrations of teixobactin. Wild type and DNamH strains incubated 
for 60 hours at 37°C with selected concentrations of teixobactin produced growth curves measured at OD600nm in Figure 4.24. Variations between growth curves were measured 
by time taken to exit apparent lag phase (hours), the doubling time (Td) of cells during exponential phase (hours-1), the area under the curve (AUC) percentage compared to the 
0 µg.mL-1 control (%), the OD600nm value achieved during stationary phase and whether the growth curve variations were statistically significant compared to each 0 µg.mL-1 
control with p-values <0.05 deemed significant. The statistical significance of DNamH (b) growth curves compared to wild type (a) at equivalent teixobactin concentrations 
were determined by p-values <0.05. 
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In this set of experiments the control (0 µg.mL-1 teixobactin) growth curves of the wild 
type (Figure 4.24 (a) Blue) and DNamH (Figure 4.24 (b) Blue) strains, both produced 
observable growth after 21 hours, with a Td during exponential phase of 7.36 (Wild 
type) and 7.97 (DNamH) hours respectively and both strains plateaued at an OD600nm of 
0.29 during stationary phase after 45 hours.  
 
The introduction of teixobactin at the concentrations investigated impacted both M. 
smegmatis strains equally, producing similar levels of inhibition at equivalent 
concentrations (Table 4.9). The lowest two investigated concentrations of teixobactin 
0.007 µg.mL-1 (Figure 4.24 Green) and 0.0015 µg.mL-1  (Figure 4.24 Pink) significantly 
impacted growth reducing the AUC of both strains to around 55% and 22% of the 
growth obtained by their respective 0 µg.mL-1 controls (Table 4.9). 
 
The final two concentrations that permitted growth were 0.03 µg.mL-1 (Figure 4.24 
Orange) and 0.06 µg.mL-1 (Figure 4.24 Purple). Both teixobactin concentrations once 
incubated with each M. smegmatis strain demonstrated equal growth over the measured 
60 hours. All cells exited apparent lag phase after 48 hours, produced a Td of 20 hours 
and measured greatly reduced AUC values between 3% and 4% total compared to their 
respective 0 µg.mL-1 control (Table 4.9). It is likely these AUC values are under 
estimated because the experiment was terminated before growth under these conditions 
reached stationary phase. The addition of 0.125 µg.mL-1 teixobactin (Figure 4.24 Red) 
was sufficient to completely inhibit growth in both strains and therefore was established 
as the MIC for both the wild type and DNamH strains. This value was the same MIC as 
published by Ling, et al. (2015) against MTB. 
 
Each of the investigated teixobactin concentrations produced M. smegmatis wild type 
and DNamH growth curves which were equally statistically significant compared to the 
0 µg.mL-1 control (Table 4.9). P-values for each teixobactin concentration were <0.01 
(0.007 µg.mL-1), <0.001 (0.015 µg.mL-1) and <0.0001 (0.03-0.25 µg.mL-1) 
respectively. A Student’s t-test (Table 4.9) comparing variations between both strains 
at equivalent concentrations of teixobactin indicated that there was no statistical 
significance at any investigated concentration with all investigated growth curves 
producing p-values >0.05.  
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Wells containing the teixobactin MIC or greater for both strains were transferred onto 
TSB agar plates and incubated for 72 hours to establish MBC values. The results are 
displayed in Figure 4.25. 
 
 
 
Figure 4.25 Minimal bactericidal concentration of teixobactin against M. smegmatis strains. M. 
smegmatis wild type (a) and ∆NamH (b) cells incubated in liquid media with increasing concentrations 
of teixobactin that did not produce growth (Figure 4.24) were pipetted in duplicate onto TSB agar to 
determine MBC. Each quadrant denotes the teixobactin concentration in µg.mL-1. Results: Wild type 
MBC 0.25 µg.mL-1, ∆NamH MBC 0.25 µg.mL-1. 
 
As with the equivalent MIC values (Figure 4.24) for both strains the MBC values were 
also equivalent. Growth was observed for both strains from wells containing the 
teixobactin MIC of 0.125 µg.mL-1 in each of the triplicate results but no growth was 
observed in any quadrant containing cells incubated with 0.25 µg.mL-1 teixobactin. 
Therefore, the teixobactin MBC for both M. smegmatis strains was 0.25 µg.mL-1. 
 
 
4.4.9 Arg-Teixobactin MIC assessment of M. smegmatis wild type and 
DNamH strains 
 
Building upon the identification of the newly discovered teixobactin structure as a 
potent antimicrobial, analogues of the structure were synthesized in vitro by Jad, et al. 
(2015). Arginine-teixobactin (Arg-Teixobactin) substitutes the unique cyclic 
guanidine-based amino acid L-allo-endurcididine residue for the linear L-Arginine 
(Figure 4.26 highlighted in red). The analogue displayed similar but reduced potency 
relative to unmodified teixobactin towards Gram-positive organisms and equivalent 
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inactivity towards Gram-negative organisms. The structure of arg-teixobactin is shown 
in Figure 4.26 highlighting the structural variation between the analogue and 
teixobactin. 
 
 
 
Figure 4.26 The structure of the modified small molecule antibiotic Teixobactin, designated 
Arginine-Teixobactin (Arg-Teixobactin). Molecular weight: 1229.47; Chemical formula: 
C58H94N15O15. The variation in chemical structure from Teixobactin is highlighted (red). The above 
schematic was created using ChemBioDraw. 
 
The teixobactin analogue, although less active than the original towards Gram-positive 
organisms was not tested against mycobacteria. Therefore, the compound was acquired 
from Jad, et al. (2015) and similarly tested to determine MIC values against both M. 
smegmatis strains. These results are shown in Figure 4.27. 
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Figure 4.27 The impact of N-glycolylation of peptidoglycan on the sensitivity of M. smegmatis growth to Arg-teixobactin. Wild type (a) and (b) DNamH M. smegmatis 
MIC growth curves against Arg-teixobactin. Cells were grown in 96-well microtiter plates in triplicate at 37°C with intermittent shaking, OD600nm was measured at 3 hour 
intervals for 60 hours. Each well contained 100 µL culture media (7H9, ADC, 0.05% (w/v) Tween 80) with increasing concentrations of Arg-teixobactin at a total DMSO 
concentration of 2% (v/v). M. smegmatis wild type (a) and (b) DNamH strains were standardized to an OD600nm of 1 and diluted further by a factor of 104 prior to addition to 
wells and incubation. Error bars represent standard deviation of triplicate measurements. Arg-teixobactin concentrations: 0 µg.mL-1 (Blue), 0.03 µg.mL-1 (Green), 0.06 µg.mL-
1 (Pink), 0.125 µg.mL-1 (Orange), 0.25 µg.mL-1 (Purple), 0.5 µg.mL-1 (Red), 1 µg.mL-1 (Yellow) and 2 µg.mL-1 (Black). Statistically significant results of comparison of growth 
at increasing arg-teixobactin concentrations compared to growth at 0 µg.mL-1 arg-teixobactin for each strain are indicated with * = p-value <0.05, ** = <0.01, *** = <0.001 
and **** = <0.0001. Ns = not statistically significant. Results: Both strains were equally susceptible to Arg-teixobactin. MIC results: Wild type (a) 0.5 µg.mL-1, DNamH (b) 
0.5 µg.mL-1.  
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Arg-
Teixobactin 
(µg.mL-1) 
Wild type M. smegmatis DNamH M. smegmatis (b) vs 
(a) 
p-
values 
Apparent 
Lag 
phase 
(h) 
Td  
(h-1) 
AUC  
(%) 
Stationary 
Phase  
OD600nm 
Wild 
type 
p-values 
(a) 
Apparent 
Lag 
phase  
(h) 
Td  
(h-1) 
AUC  
(%) 
Stationary 
Phase  
OD600nm 
DNamH 
p-
values 
(b) 
0 21 7.56 - 0.29 - 21 7.14 - 0.30 - >0.05 
0.03 21 9.46 79.44 0.24 <0.01 24 9.48 61.71 0.24 <0.01 <0.05 
0.06 27 10.64 53.20 0.22 <0.001 33 9.83 42.89 0.19 <0.001 <0.05 
0.125 33 12.61 37.11 0.19 <0.001 36 15.67 26.94 0.14 <0.0001 <0.01 
0.25 36 17.02 15.42 0.12 <0.0001 39 20.32 13.62 0.12 <0.0001 >0.05 
0.5 60 0.00 0.00 0.05 <0.0001 60 0.00 0.00 0.05 <0.0001 - 
1 60 0.00 0.00 0.05 <0.0001 60 0.00 0.00 0.05 <0.0001 - 
2 60 0.00 0.00 0.05 <0.0001 60 0.00 0.00 0.05 <0.0001 - 
Table 4.10 Statistical comparisons of M. smegmatis growth curves in the presence of increasing concentrations of arg-teixobactin. Wild type and DNamH strains 
incubated for 60 hours at 37°C with selected concentrations of arg-teixobactin produced growth curves measured at OD600nm in Figure 4.27. Variations between growth curves 
were measured by time taken to exit apparent lag phase (hours), the doubling time (Td) of cells during exponential phase (hours-1), the area under the curve (AUC) percentage 
compared to the 0 µg.mL-1 control (%), the OD600nm value achieved during stationary phase and whether the growth curve variations were statistically significant compared to 
each 0 µg.mL-1 control with p-values <0.05 deemed significant. The statistical significance of DNamH (b) growth curves compared to wild type (a) at equivalent arg-teixobactin 
concentrations were determined by p-values <0.05. 
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The growth of M. smegmatis in the presence of increasing arg-teixobactin 
concentrations was compared to the wild type (Figure 4.27 (a) Blue) and DNamH 
(Figure 4.27 (b) Blue) strain control growth curves in the absence of the antimicrobial. 
Both controls exited apparent lag phase after 21 hours, established a Td of 7.56 and 
7.14 hours and reached a final stationary phase OD600nm of 0.29 and 0.3 respectively 
after 45 hours (Table 4.10).  
 
The addition of each investigated concentration of arg-teixobactin 0.03 µg.mL-1 (Figure 
4.27 Green), 0.06 µg.mL-1 (Figure 4.27 Pink), 0.125 µg.mL-1 (Figure 4.27 Orange) and 
0.25 µg.mL-1 (Figure 4.27 Purple) gradually increased the duration of the apparent lag 
phase, the Td during exponential phase as well as reduced the AUC of both strains 
(Table 4.10). The potency of the antimicrobial analogue was slightly more pronounced 
against the DNamH strain at each arg-teixobactin concentration except 0.25 µg.mL-1. 
The presence of 0.5 µg.mL-1 arg-teixobactin (Figure 4.27 Red) or greater was sufficient 
to prevent any observation of cell growth in both investigated strains over the 60 hours. 
Therefore, the wild type and DNamH M. smegmatis arg-teixobactin MIC was 
determined to be 0.5 µg.mL-1.  
 
A Student’s t-test analysis to determine the statistical significance of the impact of arg-
teixobactin on M. smegmatis wild type growth curves compared to the 0 µg.mL-1 
control (Table 4.10) was conducted. Each of the arg-teixobactin concentrations were 
deemed statistically significant from the 0 µg.mL-1 wild type control, with p-values of 
<0.01 (0.03 µg.mL-1), <0.001 (0.06 and 0.125 µg.mL-1) and <0.0001 (0.25-2 µg.mL-1) 
respectively. A Student’s t-test of DNamH growth curves comparing the addition of 
arg-teixobactin to the 0 µg.mL-1 control (Table 4.10) showed that as with the wild type 
the inhibition observed by the presence of each concentration was deemed statistically 
significant with p-values <0.01 (0.03 µg.mL-1), <0.001 (0.06 µg.mL-1) and <0.0001 
(0.125-2 µg.mL-1) respectively. 
 
Though the addition of teixobactin did not differentially impact the two M. smegmatis 
strains, the analogue did display a slight increased activity towards the DNamH with all 
but one of the p-values comparing both strains at equivalent arg-teixobactin 
 194 
concentrations statistically significant with p-values of <0.05 (0.03 and 0.06 µg.mL-1) 
and <0.01 (0.125 µg.mL-1) respectively.  
 
Wells containing MIC or greater concentrations of arg-teixobactin were pipetted onto 
TSB agar plates and incubated for 72 hours. MBC values were determined in Figure 
4.28. 
 
 
 
Figure 4.28 Minimal bactericidal concentration of arg-teixobactin against M. smegmatis strains. 
M. smegmatis wild type (a) and ∆NamH (b) cells incubated in liquid media with increasing 
concentrations of arg-teixobactin that did not produce growth (Figure 4.27) were pipetted in duplicate 
onto TSB agar to determine MBC. Each quadrant denotes the arg-teixobactin concentration in µg.mL-1. 
Results: Wild type MBC 2 µg.mL-1, ∆NamH MBC 2 µg.mL-1.  
 
The MBC values for arg-teixobactin in Figure 4.28 were once again equivalent for both 
strains at 2 µg.mL-1. This concentration was 8 times the MBC value of 0.25 µg.mL-1 
for teixobactin (Figure 4.25). The MBC was also 4 times the arg-teixobactin MIC value 
of 0.5 µg.mL-1, unlike the 2 fold increase in MBC over MIC seen in investigation of 
the antimicrobial properties of teixobactin. 
 
 
4.5 Synthesis of Biotinylated Lipid II (MurNAc/NGlyc) 
 
To further probe the role of the N-glycolyl modification in peptidoglycan in vitro 
synthesis of UDP-MurNAc-pentapeptide (DAP) and UDP-MurNGlyc-pentapeptide 
(DAP) were synthesized according to Lloyd et al. (2008) (Section 2.8). In short UDP-
MurNAc and UDP-MurNGlyc were incubated for 18 hours at 37°C within a final 2 mL 
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reaction volume with the L-alanine, D-glutamate, m-DAP and the D-alanyl-D-alanine 
dipeptide and the corresponding MurC-F ligases. Synthesized UDP-MurNAc/NGlyc-
pentapeptides (DAP) were isolated by centrifugal concentrator filtration and purified 
by anion exchange chromatography. 
 
Both UDP muramyl pentapeptide were analysed by mass spectrometry to determine if 
synthesis was successful. The mass spectra for UDP-MurNAc-pentapeptide is found in 
Figure A2.1 (Appendix 2) and for UDP-MurNGlyc-pentapeptide in Figure A2.2 
(Appendix 2). The observed and expected m/z values for each variant are recorded in 
Table 4.11. 
 
 
UDP 
Species 
Observed 
(m-1)/1 
Expected 
(m-1)/1 
Observed 
(m-2)/2 
Expected 
(m-2)/2 
Observed 
(m-3)/3 
Expected 
(m-3)/3 
UDP-
MurNAc-
pentapeptide 
(DAP) 
 
1192.34 
 
1192.33 
 
595.67 
 
595.66 
 
396.77 
 
396.77 
UDP-
MurNGlyc-
pentapeptide 
(DAP) 
 
1208.33 
 
1208.32 
 
603.66 
 
603.66 
 
402.10 
 
402.10 
Table 4.11 The mass/charge ratio for the peptidoglycan precursors UDP-MurNAc-pentapeptide 
(DAP) and UDP-MurNGlyc-pentapeptide (DAP). The observed and expected singly (m-1)/1, doubly 
(m-2)/2 and triply (m-3)/3 charged species of each monosaccharide. 
 
Results determined the sole presence of each correct monosaccharide variant. The 
singly (Observed 1192.34, expected 1192.33), doubly (Observed 595.67, expected 
595.66) and triply (Observed 396.77, expected 396.77)) charged species for UDP-
MurNAc-pentapeptide as well as the singly (Observed 1208.33, expected 1208.33), 
doubly (Observed 603.66, expected 603.66) and triply (Observed 402.10, expected 
402.10) charged species for UDP-MurNGlyc-pentapeptide were detected. 
 
Both UDP muramyl pentapeptides were then labelled on the amino group of their m-
DAP residues with biotin (Section 2.8.1.3). The biotinylated UDP muramyl 
pentapeptides were then purified by ion exchange chromatography with a monoQ 5/50 
resin column to isolate biotin-labelled from unlabelled UDP muramyl pentapeptides. 
 196 
The purification of biotinylated UDP-MurNAc-pentapeptide (DAP) is shown in Figure 
4.29. 
 
 
 
Figure 4.29 Ion exchange chromatography of biotinylated UDP-MurNAc-pentapeptide (DAP) 
from unlabelled UDP-MurNAc-pentapeptide (DAP). (i) Unlabelled UDP-MurNAc-pentapeptide 
(DAP) (conductivity 21.98 mS.cm-1) and (ii) Biotinylated UDP-MurNAc-pentapeptide (DAP) 
(conductivity 30.12 mS.cm-1) were isolated by MonoQ 5/50 GL resin. Red trace is absorbance at 254nm, 
blue trace: absorbance at 280nm and black trace; conductivity. Peak identities were confirmed by mass 
spectrometric analysis. 
 
The ion exchange chromatogram (Figure 4.29) of the biotinylated UDP-MurNAc-
pentapeptide sample resolved two distinct peaks from the initial sample. Peak (i) 
(Figure 4.29: (i)) eluted at a conductivity of 21.98 mS.cm-1. The second noted peak (ii) 
(Figure 4.29: (ii)) eluted once conductivity achieved 30.12 mS.cm-1. Based on the loss 
of the amino group positive charge on the m-DAP moiety on modification with biotin 
increasing the net negative charge, strengthening its binding to an anion exchanger 
relative to the unbiotinylated species it was believed that the biotinylated 
monosaccharide eluted second. To confirm the identity of each isolated species, 
samples were analysed by mass spectrometry. The mass spectra of the first peak is 
evaluated in Figure A2.3 (Appendix 2) and the second peak in Figure A2.4 (Appendix 
2). 
 
Results of mass spectra analysis determined that the initial eluted peak (Figure 4.29: 
(i)) contained UDP-MurNAc-pentapeptide (DAP) singly (Observed 1192.34, expected 
1192.33), doubly (Observed 599.67, expected 595.66) and triply (Observed 396.77, 
expected 396.77) charged species. The second eluted peak (Figure 4.29: (ii)) was 
evaluated to contain biotinylated UDP-MurNAc-pentapeptide (DAP) singly (Observed 
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1418.41, expected 1418.41) and doubly (Observed 708.70, expected 708.70) charged 
species.  
 
The biotinylated UDP-MurNGlyc-pentapeptide (DAP) was purified from unlabelled 
UDP-MurNGlyc-pentapeptide (DAP) by ion exchange chromatography as shown in 
Figure 4.30. 
 
 
 
Figure 4.30 Ion exchange chromatography of biotinylated UDP-MurNGlyc-pentapeptide (DAP) 
from unlabelled UDP-MurNGlyc-pentapeptide (DAP). Noted peaks (i) Unlabelled UDP-MurNGlyc-
pentapeptide (DAP) (conductivity 22.71 mS.cm-1) and (ii) Biotinylated UDP-MurNGlyc-pentapeptide 
(DAP) (conductivity 30.28 mS.cm-1) were isolated by MonoQ 5/50 GL resin. Red trace is absorbance at 
254nm, blue trace: absorbance at 280nm and black trace; conductivity. Peak identities were confirmed 
by mass spectrometric analysis. 
 
The ion exchange purification of the biotin-labelled and unlabelled UDP-MurNGlyc-
pentapeptide (DAP) shown in Figure 4.30 indicates the separation of two nucleotide 
species peaks. The first peak (Figure 4.30: (i)) eluted with a conductivity of 22.71 
mS.cm-1. The second isolated peak (Figure 4.30: (ii)) eluted with a conductivity of 
30.28 mS.cm-1. Based upon the previous UDP-MurNAc-pentapeptide (DAP) ion 
exchange purification in Figure 4.29 the secondary peak is likely to contain the labelled 
monosaccharide and the first peak contains unlabelled UDP-MurNGlyc-pentapeptide 
(DAP). The two isolated peaks were analysed by mass spectrometry to distinguish 
between biotinylated and unbiotinylated UDP N-glycolyl muramyl pentapeptide. The 
mass spectrum of the first isolated peak is shown in Figure A2.5 (Appendix 2) and the 
second peak in Figure A2.6 (Appendix 2). 
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Results demonstrated that the first eluted peak (Figure 4.30: (i)) contained the 
unlabelled UDP-MurNGlyc-pentapeptide (DAP) with singly (Observed 1208.33, 
expected 1208.32) and doubly (Observed 603.66, expected 603.66) charged species 
identified. The mass spectrum analysis of the second isolated elution (Figure 4.30: (ii)) 
confirmed the presence of biotinylated UDP-MurNGlyc-pentapeptide (DAP) with 
singly (Observed 1434.40, expected 1434.40) and doubly (Observed 716.69, expected 
716.69) charged species detected. 
 
Both biotinylated UDP muramyl pentapeptides were utilized to generate biotinylated 
versions of N-acetylated Lipid II (DAP) and N-glycolylated Lipid II (DAP) (Section 
2.8.1.3). The anticipated structure of biotinylated N-acetylated Lipid II (DAP) and 
biotinylated N-glycolylated Lipid II (DAP) is shown in Figure 4.31. 
 
 
 
Figure 4.31 The structure of biotin labelled N-acetylated Lipid II DAP and N-glycolylated Lipid II 
DAP (L-Ala-D-Glu-m-DAP-D-Ala-D-Ala). Biotinylation (labelled red) occurs at the third amino acid 
(m-DAP) position. The N-glycolylation of muramic acid (labelled blue) The above schematic was 
created using ChemBioDraw. 
 
Once Lipid II synthesis was complete and lipid products were extracted with by 
pyridine-acetate and N-butanol separation followed by anion exchange 
chromatography (Section 2.7.3.3) samples were analysed by mass spectrometry to 
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confirm the synthesis of the desired biotinylated Lipid II variants. The results of 
biotinylated N-acetylated Lipid II (DAP) as shown in Figure A2.7 (Appendix 2) and 
biotinylated N-glycolylated Lipid II (DAP) as shown in Figure A2.8 (Appendix 2). 
 
Synthesis of biotinylated N-acetylated Lipid II was successful, as singly (Observed 
2144.13, expected 2144.12), doubly (Observed 1071.56, expected 1071.55) and triply 
(Observed 714.04, expected 714.03) charged species were measured (Figure A1.7). The 
mass spectral analysis of the biotinylated N-glycolylated Lipid II (DAP) in Figure A2.8 
also correctly identified the singly (Observed 2160.11, expected 2160.11), doubly 
(Observed 1079.55, expected 1079.55) and triply (Observed 719.36, expected 719.36) 
charged species of the labelled N-glycolylated lipid (Figure A1.8). 
 
 
4.6 Binding affinity of biotinylated Lipid II variants to antimicrobials 
 
To determine whether N-glycolylation impacted on the binding of antibiotics that act 
through binding to Lipid II, the binding affinity of biotin labelled Lipid II variants were 
measured by interactions with streptavidin coated sensors through surface plasma 
resonance (SPR) and Bio-layer interferometry (BLI) analysis of N-acetylated and N-
glycolylated Lipid II DAP species to ramoplanin, mersacidin and vancomycin. 
 
 
4.6.1 SPR analysis of binding of biotinylated Lipid II variants to 
antimicrobials 
 
Biotin labelled Lipid II (DAP) variants were first assessed by SPR. The technique 
immobilises the biotinylated lipids via binding to streptavidin coated chips. SPR 
measured light refraction between a gold layer within the glass slide and the 
overflowing solution which have two unique refractive indexes (Roper 2007). 
Excitation of the plasmons on the surface by light leads to an electric field intensity 
throughout the gold surface and a subsequent reduction in the reflected light intensity 
at a given incident angle (Tang, et al. 2011). The streptavidin-biotin bound lipid 
molecules produce a measurable baseline SPR angle. The addition of potential binding 
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partners such as antimicrobials can lead to alterations in this SPR angle as interactions 
occur and the mass on the gold surface increases. These interactions result in a 
measurable binding curve (Lund-Katz, et al. 2010). A basic example of this binding 
profile is depicted in Figure 4.32. 
 
 
 
Figure 4.32 Standard SPR sensorgram. An immobilised ligand interaction with a complementary 
binding partner within a flowing solution across the sensor surface alters the SPR angle and forms a 
binding curve. Once partner is remove from flow response is altered and sensor is regenerated. Figure 
source from Biacore – Sensor Surface Handbook (GE Healthcare).  
 
The binding of in this case antimicrobials to immobilised lipids occurs through distinct 
phases within a sensorgram (Figure 4.32). Pre-binding measures the baseline of bound 
biotinylated lipids. The addition of the binding partner to the flow solution leads to a 
measured binding curve from which an association rate (kon) can be measured as 
binding saturation is achieved. Dissociation is then subsequently measured in the 
absence of the binding partner to the flow solution, from which a dissociation rate can 
be obtained (koff). The final step if necessary is then regeneration of the chip to re-
establish the initial baseline. The entire reaction is measured in response units (RU) and 
by comparing the kon and koff rates an equilibrium dissociation constant (Kd) can be 
deciphered for the binding interaction, as a ratio koff/kon.  
 
Biotinylated Lipid II variants were fixed to a streptavidin coated chip as outlined in 
Section 2.10.1. A control run is performed for each antimicrobial tested with a flow 
solution absent of the investigated antimicrobial. The sensorgram produced by this 
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result is subtracted from each sensorgram run at varying antibiotics concentrations to 
remove background alterations to signalling. 
 
 
4.6.1.1 SPR analysis of binding of biotinylated Lipid II variants to 
ramoplanin 
 
MIC assessment of ramoplanin with respect to M. smegmatis indicated that there was 
no statistical significance in terms of sensitivity to the drug between cells which were 
comprised of solely N-acetylated peptidoglycan (DNamH) or both N-acetylated and N-
glycolylated peptidoglycan (wild type) (Figure 4.9). 
 
Immobilised biotin-labelled N-acetylated Lipid II (DAP) and N-glycolylated Lipid II 
(DAP) were exposed to two fold serial dilutions of ramoplanin from 500 µM to 3.90 
µM to measure binding affinity. Flow cells were initially exposed to buffer only for 60 
seconds, ramoplanin was added to the flow solution for 180 seconds followed by solely 
buffer again for a further 240 seconds. The SPR ramoplanin binding curves are shown 
in Figure 4.33. 
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Figure 4.33 SPR binding affinity of ramoplanin to streptavidin-immobilised biotinylated Lipid II (DAP) variants. Sensorgram of (a) biotin labelled muramyl N-acetylated 
Lipid II (DAP) and (b) biotin labelled muramyl N-glycolylated Lipid II (DAP) binding to increasing concentrations of ramoplanin. Binding affinity measured in response units 
(RU) for 180 seconds. Ramoplanin concentrations: 500 µM (Blue), 250 µM (Green), 125 µM (Pink), 62.50 µM (Orange), 31.25 µM (Purple), 15.625 µM (Red), 7.81 µM 
(Yellow) and 3.90 µM (Black).  
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The initial binding response to ramoplanin at all investigated concentrations was 
immediate for both N-acetylated (Figure 4.33: (a)) and N-glycolylated (Figure 4.33: 
(b)) variants of Lipid II (DAP). The addition of ramoplanin to the flow solution at 60 
seconds instantly registered significant alterations in the binding response at each 
concentration. The increase was most notable at 500 µM ramoplanin (Figure 4.33 Blue) 
which instantly measured 800 RU (N-acetylated) and 500 RU (N-glycolylated) 
increases in signal.  
 
Ramoplanin concentrations 500 µM and 250 µM (Figure 4.33 Green) did not appear to 
plateau during the 180 second flow solution in with ramoplanin was present, with both 
reaching their maximum RU value at the conclusion of the run. Ramoplanin 
concentrations 125 µM (Figure 4.33 Pink) and 62.50 µM (Figure 4.33 Orange) 
achieved steady state after 140 seconds for both Lipid II variants, whereas 
concentrations between 32.25 µM (Figure 4.33 Purple) and 3.90 µM (Figure 4.33 
Black) plateaued immediately once ramoplanin was added to the flow solution. Once 
the ramoplanin was removed from the flow solution the binding response for each 
concentration immediately reduced, and returned to near baseline after 400 seconds. 
 
Based upon the apparently concentration-independent immediacy of both ramoplanin 
association and dissociation, the kinetics of association and dissociation of ramoplanin 
from the immobilised Lipid II variants could not be compared. Instead, the maximum 
measured response during ramoplanin binding at equivalent concentrations for each 
Lipid II variant were compared as shown in Figure 4.34. 
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Figure 4.34 SPR steady state response of immobilised biotinylated Lipid II (DAP) variants binding 
to ramoplanin. Comparison of streptavidin bound biotin labelled N-acetylated Lipid II (DAP) (Black) 
and N-glycolylated Lipid II (DAP) (Grey) maximum response units (RU) value to interactions with 
increasing concentrations of ramoplanin. The percentage decrease in relative response compared to the 
500 µM highest concentration for both Lipid II variants is labelled. 
 
The steady state comparisons made in Figure 4.34 demonstrate the clear binding 
preference of ramoplanin binding to the N-acetylated Lipid II over the N-glycolylated 
molecule over the entire ramoplanin concentration range. The percentage difference 
between each biotinylated Lipid II variant remained constant at all ramoplanin 
concentrations, where the N-glycolylated Lipid II (DAP) RU value was consistently 
observed to be 63-65% of the N-acetylated variant. The constant percentage difference 
indicted that even at low concentrations ramoplanin binds more readily to the N-
acetylated Lipid II (DAP). 
 
 
4.6.1.2 SPR analysis of binding of biotinylated Lipid II variants to 
mersacidin 
 
The second investigated antimicrobial whose binding affinity for Lipid II variants were 
determined by SPR was mersacidin. Mersacidin MIC assessment of wild type and 
DNamH strains (Figure 4.15) demonstrated no observable variation in susceptibility to 
the antimicrobial in wild type cells expressing either both N-acetylated and N-
glycolylated peptidoglycan or the DNamH M. smegmatis whose peptidoglycan is solely 
N-acetylated (Raymond, et al. 2005). The binding affinity as revealed by two fold serial  
dilutions of mersacidin from 500 µM to 3.90 µM was assessed in Figure 4.35.  
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Figure 4.35 SPR binding affinity of mersacidin to streptavidin immobilised biotinylated Lipid II (DAP) variants. Sensorgram of (a) biotin labelled muramyl N-acetylated 
Lipid II (DAP) and (b) biotin labelled muramyl N-glycolylated Lipid II (DAP) binding to increasing concentrations of mersacidin. Binding affinity measured in response units 
(RU) for 180 seconds. Mersacidin concentrations: 500 µM (Blue), 250 µM (Green), 125 µM (Pink), 62.50 µM (Orange), 31.25 µM (Purple), 15.625 µM (Red), 7.81 µM 
(Yellow) and 3.90 µM (Black).  
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The observation of an immediate increase in RU once the antimicrobial was added to 
the flowing solution seen in Figure 4.33 was reminiscent of the behaviour of ramoplanin 
although the increase was less pronounced. However the association/dissociation 
kinetics were still too rapid to analyse and therefore estimates of kon, koff and kd could 
not be made. The increase for 500 µM (Figure 4.35 Blue) was 65 RU (N-acetylated) 
and 60 RU (N-glycolylated) respectively. Binding of mersacidin to both lipid II variants 
was not characterised by a steady increase or maintained plateau, at each antibiotic 
concentration (Figure 4.35) with peaks and valleys caused by periods of binding 
association and dissociation during the addition of the antimicrobial to the flowing 
solution. Steady state was achieved for each concentration below 250 µM.  
 
The dissociation of mersacidin after 240 seconds was also immediate at each 
concentration and altered the binding curve, causing it to drop below the baseline of the 
sensorgram due to the analyte absent buffer altering the refractive index of the sensor 
as it is being regenerated to baseline. The maximum RU for each mersacidin 
concentration was plotted versus mersacidin concentration to compare the binding 
affinity of the antibiotic to each immobilised lipid as shown in Figure 4.36. 
 
 
Figure 4.36 SPR steady state response of immobilised biotinylated Lipid II (DAP) variants binding 
to mersacidin. Comparison of streptavidin bound biotin labelled N-acetylated Lipid II (DAP) (Black) 
and N-glycolylated Lipid II (DAP) (Grey) maximum response units (RU) value to interactions with 
increasing concentrations of mersacidin. The percentage decrease in relative response compared to the 
500 µM highest concentration for both Lipid II variants is labelled. 
 
The steady state comparison of mersacidin binding in Figure 4.36 demonstrated an at 
best, marginal preference of the antimicrobial in binding to the N-acetylated Lipid II 
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(DAP) (Figure 4.36 Black) than the N-glycolylated Lipid II (DAP) Figure 4.36 Grey) 
at concentrations less than 31.25 µM. At 500 µM the maximum RU achieved by each 
lipid was 103.87 RU (N-acetylated) and 84.07 RU (N-glycolylated). The percentage 
difference in RU between binding of N-glycolyl and N-acetyl Lipid II species at these 
higher concentrations was 19.07% (500 µM) 12.92% (250 µM), 2.2% (125 µM) and 
7.74% (62.5 µM) although the significance of these differences was too small to rule 
out simple experimental errors as a source of the RU differences. Concentrations below 
62.5 µM demonstrated a greater equivalency between the two lipids with N-
glycolylated lipid producing slight increases in percentage difference at lower RU 
values. Variations between the two lipids were 4.44% (31.25 µM), 13.76% (15.625 
µM), 1.22% (7.81 µM) and 7.79% (3.90 µM). However again, these differences were 
too small to be considered indicative of a genuine influence of N-glycolylation on  
mersacidin binding to Lipid II. 
 
The binding affinity of N-acetylated lipid towards mersacidin decreased gradually at 
the highest concentrations followed by a plateau as the antimicrobial concentration was 
serially diluted. The percentage decreases in RU for the N-acetylated lipid relative to 
the 500 µM value were 29.64% (250 µM), 53.04% (125 µM), 69.35% (62.5 µM), 
78.31% (31.25 µM), 82.99% (15.625 µM), 83.51% (7.81 µM) and 83.82% (3.9 µM)  
 
The binding affinity of the N-glycolylated lipid towards mersacidin also decreased 
gradually at high concentrations and remained constant at low concentrations. The 
percentage decreases in RU for the N-glycolylated lipid were 24.27% (250 µM), 
43.24% (125 µM), 65.06% (62.5 µM), 72.01% (31.25 µM), 76.10% (15.625 µM) and 
79.38% (7.81 µM) and 78.44% (3.9 µM). 
 
 
4.6.1.3 SPR analysis of binding of biotinylated Lipid II variants to 
vancomycin  
 
The MIC assessment of vancomycin showed that cells absent of N-glycolylated 
peptidoglycan were more susceptible to the actions of the antimicrobial, reducing both 
the MIC (Figure 4.21) and MBC (Figure 4.22) by half. The SPR binding analysis of 
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both N-acetylated and N-glycolylated biotinylated Lipid II (DAP) was therefore 
undertaken to determine if N-glycolylation directly affected the binding of this 
antibiotic to Lipid II. SPR results are shown in Figure 4.37. 
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Figure 4.37 SPR binding affinity of vancomycin to streptavidin immobilised biotinylated Lipid II (DAP) variants. Sensorgram of (a) biotin labelled muramyl N-acetylated 
Lipid II (DAP) and (b) biotin labelled muramyl N-glycolylated Lipid II (DAP) binding to increasing concentrations of vancomycin. Binding affinity measured in response units 
(RU) for 180 seconds. Vancomycin concentrations: 500 µM (Blue), 250 µM (Green), 125 µM (Pink), 62.50 µM (Orange), 31.25 µM (Purple), 15.625 µM (Red), 7.81 µM 
(Yellow) and 3.90 µM (Black).  
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Like mersacidin, vancomycin also demonstrated an initial increase in the binding curve 
with the addition of the antimicrobial to either lipids. At 500 µM the response of each 
lipid achieved during steady state was 383.17 RU for the N-acetylated lipid (Figure 
4.37 (a)) and 261.10 RU for the N-glycolylated lipid (Figure 4.37 (b)). Once 
vancomycin was removed from the flowing solution the binding curve at each 
concentration immediately reverted to the baseline, therefore preventing accurate KD 
assessment. The RU values obtained during steady state for each concentration of 
vancomycin bound to each variant of Lipid II (DAP) was compared to assess binding 
affinity (Figure 4.38). 
 
 
  
 
Figure 4.38 SPR steady state response of immobilised biotinylated Lipid II (DAP) variants binding 
to vancomycin. Comparison of streptavidin bound biotin labelled N-acetylated Lipid II (DAP) (Black) 
and N-glycolylated Lipid II (DAP) (Grey) maximum response units (RU) value to interactions with 
increasing concentrations of vancomycin. The percentage decrease in relative response compared to the 
500 µM highest concentration for both Lipid II variants is labelled. 
 
Similar to the results obtained for mersacidin in Figure 4.36, the greater the 
concentration of the antimicrobial the more pronounced the preference for the N-
acetylated variant of Lipid II (DAP). The difference reduced with the decrease in 
vancomycin concentration, where below 15.625 µM vancomycin, both N-glycolylation 
and N-acetylation lipids behaved identically, although the reduced RU values for each 
diluted vancomycin concentration, made estimates of response ratios unreliable. The 
percentage variation between the N-glycolylated and N-acetylated lipids were 31.% 
(500 µM), 27.95% (250 µM), 24.75% (125 µM), 17.20% (62.5 µM), 12.26% (31.25 
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µM), 0.65% (15.625 µM), 11.88% (7.81 µM) and 19.86% (3.90 µM). The greater 
variation observed at 7.81 µM and 3.90 µM was due to the low RU obtained with 
11.88% difference between 28.28 RU (N-acetylated) and 31.64 RU (N-glycolylated). 
 
The binding affinity of N-acetylated lipid towards vancomycin decreased gradually at 
the highest concentrations followed by a plateau as the antimicrobial concentration was 
serially diluted. The percentage decrease in RU for the N-acetylated lipid relative to the 
response at 500 µM vancomycin (0%) were 31.00% (250 µM), 54.55% (125 µM), 
72.58% (62.5 µM), 82.60% (31.25 µM), 89.23% (15.625 µM) 92.61% (7.81 µM) and 
94.12% (3.90 µM).  
 
The binding affinity of the N-glycolylated lipid towards vancomycin also decreased 
gradually at high concentrations and remained constant at low concentrations. The 
percentage decrease in RU for the N-glycolylated lipid were 26.76% (250 µM), 49.81% 
(125 µM), 66.68% (62.5 µM), 77.60% (31.25 µM), 84.09% (15.625 µM), 87.87% (7.81 
µM) and 89.66% (3.90 µM). 
 
 
4.6.2 BLI of biotinylated Lipid II variants to antimicrobials 
 
Biotin labelled Lipid II (DAP) variants were also bound on streptavidin sensors to 
assess antimicrobial binding affinity by bio-layer interferometry. In short, the binding 
of antimicrobials in solution to immobilised lipids on biosensor tips alters the measured 
wavelength (Dl) shifting the interference pattern caused by an increase in the thickness 
of the biological layer (Sultana, et al. 2015). These variations can be detected and 
analysed to assess binding affinity. The major difference between SPR and BLI is the 
formers use of a constantly flowing solution over the coated surface as opposed to the 
BLI transfer of coated sensors between various solutions (Shah, et al. 2015). The stages 
of an example BLI as demonstrated in Figure 4.39. 
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Figure 4.39 Basic BLI binding assessment. Biotin labelled lipids are bound to streptavidin coated 
sensors and exposed to antimicrobials to assess binding association and dissociation by variations to the 
measured wavelength. Figure source 2bind molecular solutions. 
 
 
BLI binding assessment was measured as described by Figure 4.39 by streptavidin 
coated sensors immobilising biotin labelled lipids and the binding 
association/dissociation of antimicrobials measured by alterations in the measured 
wavelength. The BLI protocol outlined in 2.10.2 was utilised against teixobactin, the 
newly synthesised cell wall active antimicrobial and the analogue arg-teixobactin. Each 
compound was assessed at two fold diluted  concentrations between 500 µM and 15.62 
µM. The pre-binding baseline assessment was 30 seconds, antimicrobial association 
was for 60 seconds and antimicrobial dissociation was for 60 seconds. The results are 
shown in Figure 4.40. 
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Figure 4.40. Binding affinity of biotinylated Lipid II variants against newly identified antimicrobial teixobactin and the synthesised analogue arginine-teixobactin. 
Sensorgrams of streptavidin coated sensors bound to N-acetylated Lipid II and N-glycolylated Lipid II were assessed by their affinity towards two-fold serial dilutions from 
500 µM to 15.6 µM of teixobactin and arg-teixobactin (i). Reference sensors were used to remove any non-specific binding (ii). (a) N-acetylated Lipid II (DAP) and teixobactin, 
(b) N-glycolylated Lipid II (DAP) and teixobactin, (c) N-acetylated Lipid II (DAP) and arg-teixobactin and (d) N-glycolylated Lipid II (DAP) and arg-teixobactin. Binding 
constants were measured with the Octet Data Analysis software on an Octet Red, by global fitting the data with the 1:1 heterogenous ligand model. 
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The equilibrium dissociation constants (KD) for both Lipid II (DAP) variants against both 
teixobactin and arg-teixobactin determined from Figure 4.40 are shown in table 4.12. 
 
 
Lipid 
II 
Antimicrobial KD 
(M) 
KD 
Error 
Ka 
(1/Ms) 
Ka 
Error 
Kd  
(1/s) 
Kd 
Error 
NAc Teixobactin 1.55 
10-3 
8.14 
10-4 
1.04 
10+2 
5.38 
10+2 
1.61 
10+0 
1.44 
10-1 
NGlyc Teixobactin 3.30 
10-4 
5.46 
10-5 
5.92 
10+2 
7.02 
10+2 
1.95 
10+0 
2.25 
10-1 
NAc Arg-
Texiobactin 
1.25 
10-3 
1.27 
10-4 
7.40  
10+2 
5.70 
10+1 
9.21 
10-1 
6.10 
10-2 
NGlyc Arg-
Texiobactin 
1.21 
10-3 
1.02 
10-4 
1.08  
10+3 
6.77 
10+1 
1.30  
10+0 
7.42 
10-2 
Table 4.12. The equilibrium dissociation constants, KD for biotinylated Lipid II variants to teixobactin and arg-
teixobactin. N-acetylated  and N-glycolylated Lipid II (DAP) attached to streptavidin biosensors binding measured 
against concentrations of Teixobactin and Arg-teixobactin between 1000 µM and 15.62 µM.  
 
Teixobactin results from table 4.12 indicated that the antimicrobial demonstrated a greater binding 
affinity with the N-glycolylated Lipid II (DAP) with a KD of 0.33 mM, five times greater compared 
to the KD with the N-acetylated Lipid II (DAP) of 1.55 mM. The KD is based upon the relationship 
between the association (ka) and dissociation (kd) of teixobactin towards each lipid. The rate of 
dissociation for each lipid was similar with kd values of 1.61 s-1 (N-acetylated) and 1.95 s-1 (N-
glycolylated). The variation was noted during association with ka values of 104 Ms-1 (N-acetylated) 
and 592 Ms-1 (N-glycolylated) respectively. 
 
The arginine analogue of teixobactin displayed a similar binding affinity towards each of the lipids 
compared to texiobactin with a lower KD of 1.25 mM for the N-acetylated lipid than the 1.22 mM 
for the N-glycolylated lipid. The association constant of each lipid was 74 Ms-1 (N-acetylated) and 
108 Ms-1 (N-glycolylated) respectively, which led to the KD variation observed. The dissociation 
constant for each lipid was 0.9 s-1 (N-acetylated) and 1.30 s-1 (N-glycolylated) respectively. 
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4.7 Discussion 
 
4.7.1 Antimicrobial MIC assessment of DNamH M. smegmatis 
 
Mycobacteria are inherently resistant to antimicrobials (Hett and Rubin 2008) due in part to the 
expression of b-lactamases, efflux pumps and the composition of the mycobacterial cell wall. The 
incorporation of N-glycolylated Lipid II within the mycobacterial peptidoglycan layer was 
previously demonstrated to increase resistance towards hydrolytic enzymes as well as 
antimicrobial therapies. These treatments commonly target unique structural architecture 
displayed solely by bacteria, without a eukaryotic equivalent such as peptidoglycan.  
 
Generation of blaS-, and blaS- namH- strains by Flores, et al. (2005), permitted the probing of 
antimicrobial susceptibility of mycobacteria against standard treatments and measured average 
zones of clearing at set concentrations of antibiotics. Previously published results by Raymond, et 
al. (2005) demonstrated that antimicrobials such as isoniazid and ethambutol which targeted non 
peptidoglycan synthesis components, were equally active towards both mycobacterial strains 
whereas, the b-lactam antibiotics ampicillin and amoxicillin produced greater zones of inhibition 
against namH deficient organisms. Further assessment of antimicrobial efficacy towards these 
strains was required as well as an expansion of investigated targets. 
 
The low aqueous solubility of the antimicrobials considered in this chapter required the 
determination of mycobacterial solvent tolerance. Growth of both blaS-, and blaS- namH- strains 
was equally sensitive to increasing percentages of DMSO. Nevertheless, a solvent concentration 
of 2% (v/v) DMSO (Figure 4.1) effectively solubilised the investigated antimicrobials without 
impacting mycobacterial growth. 
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4.7.1.1 The impact of non-peptidoglycan targeted antimicrobials on M. 
smegmatis growth 
 
Acquisition of the DNamH M. smegmatis knockout mutants led to initial reassessment of standard 
isoniazid antimicrobial treatment. Both wild type and knockout M. smegmatis were equally 
sensitive to this antibiotic to which they responded with the same MIC and MBC values (Figure 
4.6). Mycolic acids form a complex with both peptidoglycan and arabinogalactan (mAGP) 
(Alderwick, et al. 2015) Isoniazid targets mycolic acid synthesis particularly the 2-trans-enoyl-
acyl carrier protein reductase, InhA (Marrakchi, et al. 2000).  Consistent with this therefore, is the 
observation made here that the potency of isoniazid is unaffected by the nature of the N-acyl group 
appended to the muramyl component of the  peptidoglycan. 
 
 
4.7.1.2 The impact of peptidoglycan targeted antimicrobials on M. smegmatis 
growth 
 
Raymond, et al. (2005), observed that growth of  DNamH M. smegmatis with a peptidoglycan 
containing entirely N-acetylated muramyl residues was more sensitive to ampicillin, the 
corresponding wild type strain which contained both N-acetylated and N-glycolylated sugars. 
Ampicillin differentially impacted the growth of wild type and DNamH M. smegmatis strains, 
reducing the MIC and MBC of the DNamH strain to half that of the wild type (Figure 4.3 and 
Figure 4.4). Both the wild type and DNamH cells are blaS- mutants which also increase b-lactam 
susceptibility due to the absence of the b-lactamase BlaS.  
 
Previously studied blaS- M. smegmatis displayed an ampicillin MIC of 2 µg.mL-1 (Flores, et al. 
2005), greater than the corresponding 0.5 µg.mL-1 and 0.25 µg.mL-1 values observed here for the  
wild type and DNamH strains respectively (Figure 4.3). The discrepancy between the two sets of 
findings is unknown though the results obtained by Flores, et al. (2005) was from a separate M. 
smegmatis strain not related to the one used here that was acquired from Raymond, et al. (2005). 
However, there was no indication that ampicillin MIC assessment was measured below 2 µg.mL-
 217 
1 in Flores, et al. (2005), suggesting that differences in ampicillin sensitivity could be artifactual.. 
The functional impact  of N-glycolylation modification of monosaccharides may involve changes 
in  recognition by PBPs of their peptidoglycan precursor substrates or the rapidity with which the 
transglycosylase polymerises the substrate, where this activity is greater with N-glycolylated 
precursors which therefore compete better against  b-lactam challenge, resulting in soothe  wild 
type was more resistant than DNamH to ampicillin. 
 
The pool of investigated antimicrobials was expanded to include a number of inhibitors which 
specifically target either transglycosylase activity of PBPs or MraY. Ramoplanin prevents 
transglycosylation by binding to the head group of Lipid II (Fang, et al. 2006). Its inclusion 
permitted an assessment of whether N-glycolylation impacted the binding affinity of the 
antimicrobial, in part explaining the abundance of MurNGlyc:MurNAc saccharides within the 
peptidoglycan layer (Raymond, et al. 2005). Growth of NamH deficient M. smegmatis was more 
significantly attenuated than wild type by ramoplanin, although, the final MIC was the same (1 
µg.mL-1) for both strains (Figure 4.9). 
 
Generation of biotin labelled N-acetylated (Figure 4.29) and N-glycolylated (Figure 4.30) Lipid II 
allowed for a more detailed SPR investigation into the binding of ramoplanin to the individual 
variants of Lipid II. Here, ramoplanin bound more strongly to N-acetylated lipids than N-
glycolylated lipids (Figure 4.34), maintaining a stable 35% measured response across all 
investigated ramoplanin concentrations. Combining the findings of the MIC assessment and the 
SPR binding affinity show that the decreased susceptibility of the wild type strain could be 
attributed to the increased percentage of N-glycolylated lipids within the peptidoglycan layer, 
resulting in reduced interactions with the antimicrobial. 
 
The transglycosylase inhibitor mersacidin functions by chelation of Lipid II preventing the binding 
to the TG domain of PBPs (Appleyard, et al. 2009). Mersacidin MIC assessment revealed that as 
with ramoplanin, solely N-acetylated peptidoglycan of the DNamH strain was more susceptible 
than the wild type at equivalent mersacidin concentrations (Figure 4.15), though the MIC for both 
strains was the same.  Both antimicrobials bind directly to Lipid II. Data therefore indicates that 
the interactions between both ramoplanin and mersacidin and Lipid II are impeded by the presence 
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of the N-glycolyl group, however, this detriment was not able to solely increase cell antimicrobial 
tolerance at MIC concentrations. The binding affinity  of mersacidin to biotin labelled N-acetylated 
Lipid II were greater than N-glycolylated Lipid II at high concentrations of mersacidin (Figure 
4.36). The N-acetylated binding preference was diminished as investigated antimicrobial 
concentrations were reduced with binding affinity of the two lipid variants remaining equivalent. 
Conclusions drawn from this data were that in high concentrations of mersacidin binding to the N-
acetylated lipid was increased compared to the N-glycolylated lipid leading to the NamH strain 
demonstrating increased susceptibility to this antibiotic..  
 
Tunicamycin targets the active site of MraY located on the cytosolic face of the cytoplasmic 
membrane.  The drug and binds irreversibly to MraY to prevent the formation of Lipid I (Al-
Dabbagh, et al. 2008). As previously stated, N-glycolylation occurs within the cytosol of the 
mycobacteria unlike other common peptidoglycan modifications (Moynihan and Clarke 2010). 
MIC assessment (Figure 4.12) concluded that relative to wild type, the DNamH strain was equally 
impacted by each tunicamycin concentration with no noted statistically significant variation 
between strains, yielding identical with tunicamycin MIC values. Competitive inhibition by 
tunicamycin of  the MraY active site was therefore unaffected by the N-glycolylation of its  UDP-
MurNGlyc-pentapeptide substrate.  
 
The MIC assessment of moenomycin showed that the DNamH strain is more susceptible than the 
wild type and displayed notable variation in comparing the growth phenotype of wild type and 
DNamH M. smegmatis strains. Moenomycin mimics Lipid IV and inhibits peptidoglycan 
glycosyltransferases (Galley, et al. 2014). It is possible that the N-glycolyl modified Lipid II bound 
more tightly than the N-acetylated lipid to these enzymes and so competed better against 
moenomycin for TG active sites. Therefore, removal of the N-glycolyl moiety from the 
mycobacterial peptidoglycan would, as observed, increase the sensitivity to moenomycin 
inhibition, rendering the DNamH strain more sensitive to the drug than the wild type. 
 
The prevalence of antimicrobial resistance in tuberculosis has led to the utilisation of vancomycin 
as a secondary antibiotic therapy (Chua, et al. 2009), targeting the extracellular D-alanyl-D-alanine 
of the amino acid stem of disaccharide pentapeptides (Wang, et al. 2018). The importance of the 
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N-glycolyl group to antimicrobial resistance was clearest during vancomycin MIC assessment 
(Figure 4.21). The DNamH strain demonstrated increased susceptibility at each evaluated 
vancomycin concentration and was entirely inhibited from growth at half the vancomycin 
concentration of the wild type.  
 
These results complemented the findings of the SPR binding affinities towards the antimicrobial 
by each modified Lipid II (Figure 4.38). Mersacidin as observed with other antimicrobial 
preferentially binds to the N-acetylated more readily than the N-glycolylated lipid II equivalent. 
This preference was shown across all but the lowest of concentrations. Vancomycin interacts with 
the terminal residues of the peptide stem, so therefore interactions impeded by the hydroxyl group 
attached to the muramic acid saccharide must depend upon the three dimension structure of the 
intermediate (Figure 1.8).  Alternatively, the rate of synthesis of the N-glycolylated lipid II and/or 
its incorporation into the cell wall might be such that N-glycolylated precursors are better able to 
out-compete the impact of vancomycin (and for that matter other cell wall antibiotics) than N-
acetylated species, accounting for the greater sensitivity of NamH M. smegmatis to vancomycin 
and other peptidoglycan directed antimicrobials. 
 
Antimicrobial resistance towards standard therapies also is leading to the need for new discoveries 
and treatments. The newly isolated teixobactin is being hailed as a major breakthrough with a 
unique target of the prenyl-pyrophosphate-GlcNAc region of Lipid II (Ling, et al. 2015). MIC 
assessment determined that N-glycolylated substrates did not the activity of teixobactin with the 
MIC and MBC values for both the wild type and DNamH strains being equivalent. Teixobactin 
binding affinities towards each variant of lipid were evaluated by BLI (Figure 4.40) which 
demonstrated that the antimicrobial had a five times lower KD for the N-acetylated lipid relative 
to its the N-glycolylated homologue. The observed preferential binding although, did not impede 
the MIC of the DNamH.  Interactions between the antimicrobial and the N-glycolyl may reduce 
binding efficiency but not to a significant enough degree to impede the mycobacterial growth 
phenotype of the DNamH. Again, the impact of the binding affinity of teixobactin may well be 
offset by differential rates of peptidoglycan synthesis driven by N-glycolylated relative to N-
acetylated precursors. 
  
 220 
The teixobactin analogue, arginine-teixobactin has been previously described as possessing more 
modest antimicrobial activity than teixobactin (Jad, et al. 2015), which was demonstrated with an 
MIC four times greater (Figure 4.27) and an MBC eight times greater (Figure 4.28) in the analogue 
compared to the original. Both wild type and DNamH M. smegmatis  strains demonstrated the same 
MIC and MBC values against arg-teixobactin, although sub MIC concentrations impacted the 
DNamH to a more significant degree than the wild type. Binding affinities of the two lipid variants 
were evaluated against the analogue by BLI and findings concluded that arg-teixobactin interacts 
with an equal KD value to both lipids. The analogue is formed by the utilisation of L-arginine 
substituted in place of the original residue, L-allo-endurcididine. This substitution reduces both 
the activity of the antimicrobial and the interactions with the N-glycolyl group of the wild type 
compared to teixobactin.  
 
 
4.8 Further work 
 
 
• Assess namH- susceptibility with a blaS+ strain 
 
The M. smegmatis strains investigated were both blaS-, removing the dominant b-lactamase 
(Raymond, et al. 2005), reducing the resistance of the strains to common b-lactam antibiotics such 
as ampicillin (Flores, et al. 2005). This chapter demonstrated that the blaS- namH- M. smegmatis 
strain demonstrated greater susceptibility than the solely blaS strain to ampicillin. Generation of 
both blaS+ and blaS+ namH- strains and implementation of antimicrobial assessment would 
determine the relationship between the b-lactamase enzyme and the N-glycolylation of Lipid II in 
providing increased resistance during antimicrobial therapy. 
 
 
• Explore methods of peptidoglycan intermediate labelling  
 
Biotinylation occurs at the third amino acid of the pentapeptide stem. The close proximity to the 
stem terminal may affect the interactions with antimicrobials such as vancomycin. Therefore, 
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investigation of other methods of labelling peptidoglycan intermediates that are either smaller in 
size or located elsewhere on the intermediate may be warranted. One alternative is dansylation 
(Bouhss et al. 2008) the modification of the third position amino acid of the pentapeptide stem by 
dansyl chloride to fluorescently label Lipid II.  
 
 
• Improve SPR coating 
 
Issues arose with the SPR analysis and measuring association and dissociation binding, due to over 
saturation during the coating of the SPR streptavidin coated flow cells.  Application of a lower set 
of  concentrations of each biotinylated lipid loaded onto each flow cell to achieve a set response 
unit value would increase the time period from initial antimicrobial interaction to complete 
saturation permitting binding analysis to be determined. 
 
 
• Assess further antimicrobials by BLI and SPR 
 
An avenue of investigation highlighted by the results reported here would be to expand the 
investigation into variants of Lipid II and their associated binding affinities towards a broader 
range of antimicrobials. 
 
 
4.9 Conclusion  
 
The absence of N-glycolylated peptidoglycan monosaccharides impacted the susceptibility of M. 
smegmatis cells depending on the mode of action of the antimicrobial. Compounds which targeted 
the pentapeptide stem or enzymes which interact with it will be more susceptible than those that 
targeted other structures. The binding affinity of these compounds was greater towards the N-
acetylated lipids in most cases providing an explanation for the role of the N-glycolyl modification 
in antimicrobial resistance. 
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Chapter 5. Variations in mycobacterial peptidoglycan synthesis 
enzymes 
 
 
5.1 Introduction 
 
The N-glycolylation of peptidoglycan investigated in previous chapters are modified during 
aerobic conditions (Raymond, et al. 2005) throughout the cytoplasmic formation of the 
peptidoglycan subunit Lipid II (Vollmer 2008). This alteration differs from other common 
peptidoglycan modifications such as O-acetylation (Section 1.3.8.1) and N-deacetylation (Section 
1.3.8.2) due to cellular localization of enzymes which enact these modifications (Moynihan and 
Clarke 2010). The ability of mycobacterial organisms to synthesize N-glycolylated Lipid II solely 
during aerobic conditions has led to investigations into the role of NamH on the cellular flux of 
peptidoglycan biosynthesis, with particular focus on the Mur ligases.  
 
 
5.2 M. leprae peptidoglycan biosynthesis 
 
Due to the effects of significant genomic degradation, the mycobacterial pathogen M. leprae does 
not possess a functional gene equivalent to NamH, and instead contains only a pseudogene 
(ML0085c) (Mahapatra, et al. 2008). Therefore M. leprae is unable to create N-glycolylated 
peptidoglycan, expressing only the N-acetylated variant. The implementation of N-glycolylated 
lipids within the peptidoglycan layer confers resistance to both hydrolytic enzymes and 
antimicrobials (Raymond, et al. 2005) as has been described previously in this thesis.  
 
The Mur ligases within M. leprae also possesses specific characteristics. As with other 
mycobacteria, the first enzyme in the peptidoglycan biosynthesis pathway MurA (Nasiri, et al. 
2017) demonstrates inherent resistance towards the antimicrobial fosfomycin (De Smet, et al. 
1999). The antimicrobial’s mode of action is to modify the MurA active site cysteine residue to 
inhibit activity. The mycobacterial murA gene sequence translates an aspartate residue at this 
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position to counteract inhibition. The standard amino acid sequence for a broad range of organisms 
affix the pentapeptide stem with an L-alanine residue at position one by the enzyme MurC 
(Vollmer 2008). M. leprae MurC adheres an L-lysine at the muramic acid saccharide instead 
(Mahapatra, et al. 2000). 
 
 
5.3 Experimental aims  
 
To probe the mycobacterial variations in peptidoglycan synthesis, through cloning, expression and 
characterization of a range of mycobacterial peptidoglycan enzymes within the pathway. To 
investigate the effect of N-glycolylated substrates on mycobacterial Mur ligases and PBPs to 
measure the variation on cell flux and binding affinity compared to the N-acetylated substrate. 
 
 
5.4 M. leprae MurA 
 
The murA gene of the organism Mycobacteria leprae is 1254 bp long with a comparative protein 
sequence similarity to other mycobacteria of 95.9% (M. tuberculosis) and 90.67% (M. smegmatis) 
respectively as shown in Figure 5.1 (www.ncbi.nih.gov/BLAST).  
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Figure 5.1 Protein sequence alignment of the peptidoglycan synthesis gene murA within selected mycobacteria. 
M. tuberculosis, M. leprae, and M. smegmatis demonstrate a significant amount of amino acid homology between 
organisms. (*) indicate conserved residues, (:) indicate strongly similar residues and (.) indicate weakly similar 
residues. (www.ncbi.nih.gov/BLAST). The active site aspartate at position 118 for each enzyme is highlighted in red. 
 
The murA gene was acquired from GenScript, and was synthesized to present a NdeI restriction 
site at the 5’ end and a XhoI restriction site at the 3’ end. The restriction sites are shown in Table 
2.3. The gene was selected to be optimized for expression within E. coli and inserted within a 
standard pUC57 vector (Section A1.1). The murA gene was amplified by PCR (Section 2.6.1) to 
determine its presence within the plasmid using pUC57 forward and reverse primers (Section 
2.6.8) corresponding to genetic sequences upstream and downstream of the murA gene sequence 
within the multiple cloning region of the pUC57 plasmid. The annealing temperature during PCR 
was 48°C. Results of this PCR are shown in Figure 5.2. 
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Figure 5.2 PCR amplification of M. leprae murA. 1% Agarose gel electrophoresis of M. leprae murA gene utilizing 
forward and reverse primers targeting the up- and downstream regions of the multiple cloning site with the vector 
pUC57. Lane 1. DNA marker, Lane 2. M. leprae murA. Result: observation of single amplified 1.25 kb DNA band 
corresponding to the known size of M. leprae murA 
 
DNA amplified by PCR showed a single bold band with an estimated size, based upon the DNA 
markers (Figure 5.2) of 1.25 kb corresponding to M. leprae murA. The gene contained within the 
sample plasmid was sent for sequencing analysis with the same primers and returned a positive 
and accurate genetic match for murA. 
 
 
5.4.1 Cloning of M. leprae MurA 
 
M. leprae murA gene was amplified by PCR, using the pUC57 forward and reverse primers. The 
gene and the expression plasmid pCOLD (Section A1.2) were digested by NdeI and XhoI 
restriction enzymes (Section 2.6.2). Following restriction, digested products were purified (Section 
2.6.3) to isolate the genetic material and quantified to determine the DNA concentration. Digested 
plasmid concentration was 220 ng/µL and the murA gene insert was 344 ng/µL. To prevent the 
pCOLD plasmid reannealing, 30 minutes incubation with shrimp alkaline phosphatase (SAP) was 
performed before ligation (Section 2.6.4). The ratio of murA to vector was 3:1 for ligation to 
maximize potential annealing. Samples were incubated for 1 hour and transformed into E. coli 
TOP10 cells. Successful ligations were identified through E. coli TOP10 propagation on ampicillin 
imbedded agar due to the pCOLD vector containing an ampicillin resistance cassette. Newly 
formed pCOLD-murA plasmids were evaluated for in-frame matching of the original M. leprae 
murA gene utilizing pCOLD forward and reverse primers. pCOLD plasmids lack a poly-histidine 
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tag sequence to aid purification of recombinant proteins. Primers were created, complementing the 
murA gene to adhere a C-terminal poly-histidine tag sequence and a cleavable TEV region, to 
remove the expressed tag following protein purification. Due to the size of these regions, the TEV 
and histidine tag sequences were added in stages to improve cloning efficiency. The genetic 
sequences of the TEV and histidine tag are described in Table 2.2. Once completed M. leprae 
murA genes were once again digested and ligated into pCOLD vectors as described previously, 
generating two versions of murA, one labelled and one unlabeled for further investigations. The 
resulting genes were sequenced to confirm the presence of the implemented modifications and also 
the retained murA sequence. 
 
 
5.4.2 Expression of M. leprae MurA 
 
pCOLD-M. leprae murA plasmids containing the poly-histidine tag sequence were transformed 
(Section 2.6.9) into competent (Section 2.4.2) E. coli tuner (DE3) expression cells, cultured in 
liquid media and initiated recombinant protein expression through IPTG induction (Section 2.7.1). 
Once incubation was completed cells were pelleted by centrifugation and fractionated (Section 
2.7.2). Cell debris and the insoluble fraction was isolated by centrifugation, and the soluble 
fractions were analysed by both SDS-PAGE and Western blotting. Results are demonstrated in 
Figure 5.3.  
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Figure 5.3 SDS-PAGE and Western blot analysis of expressed M. leprae MurA. Recombinant MurA protein was 
expressed in E. coli tuner (DE3) cells by the addition of 1 mM IPTG and reduction of incubation temperature from 
37°C to 16°C to induced the TEE element. Cells were pelleted, resuspended and lysed by sonication and soluble 
fractions isolated for electrophoresis separation. Proteins were run on two  SDS-PAGE gels, one (A) was Coomassie-
stained and another (B) was Western blotted onto a PVDF membrane with anti-His antibodies. Lanes A1: Protein 
marker, A2: Expression of M. leprae MurA (1), A3: Expression of M. leprae MurA (2), A4: Expression of empty 
plasmid, B1: Western blot maker, B2: Expression of M. leprae MurA (1), B3: Expression of M. leprae MurA (2), B4: 
Expression of empty plasmid. Results: Presence of histidine tagged M. leprae MurA detected in each sample.   
 
The findings of Figure 5.3 displayed that M. leprae MurA was successfully expressed in the  
E. coli tuner (DE3) cell line (Figure 5.3: A2-A3 Blue rectangle). Both the SDS-PAGE gel and the 
Western blotting x-ray produced a noticeable band correlating in size to the protein markers at 
around 46 kDa, the correct weight for the enzyme. The Western blotting x-ray shows that this 
protein bound with the anti-His antibodies due to the expression of the C-terminal poly-histidine 
tag. The expression of the empty plasmid (Figure 5.3: A4) did not lead to expression of MurA as 
expected. 
 
 
5.4.3 M. leprae MurA active site mutant 
 
To complement the investigation into M. leprae MurA, the decision was taken to create an active 
site mutant to probe the interactions between the enzyme and the antimicrobial fosfomycin (De 
Smet, et al. 1999). The active site of M. leprae MurA is resistant towards perturbation by the 
antimicrobial due to an aspartate residue at position 118 in the amino acid sequence (Figure 5.1 
Highlighted red). Fosfomycin susceptibility has been previously described in MurA enzyme which 
utilize an active site cysteine residue.  
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5.4.3.1 Site directed mutagenesis of M. leprae MurA active site 
 
The M. leprae MurA gene was optimized for E. coli, which led to the amino acid sequence 
remaining equivalent, although selected codons were altered to aid expression in E. coli. The 
original aspartate residue was transcribed from the genetic sequence GAT, to transcribe a cysteine 
residue in its place the codon substitution must be altered to either TGT or TGC. The latter was 
selected and overlapping extended primers containing this substitution were synthesized. Site 
directed mutagenesis primers were used on pCOLD-M. leprae murA (C-terminal poly-histidine 
tag) plasmids to amplify the substituted gene through PCR (Section 2.6.6). The genetic sequences 
for each primer are illustrated in Table 2.4. Resulting genetic material was sequenced to confirm 
the implementation of the mutation before digestion by NdeI and XhoI and the resulting murA 
(D118C) mutant gene was ligated into pCOLD vectors as described previously. 
 
 
5.4.3.2 Expression of M. leprae MurA active site mutant 
 
pCOLD-M. leprae murA (D118C) active site mutant plasmid was transformed into E. coli tuner 
(DE3) and cultured till cells reached OD600nm 0.5-0.7. Exponentially grown cells were then induced 
with 1 mM IPTG at 16°C overnight. Cells were isolated, fractionated and centrifuged to separate 
the soluble phase, which was then analysed by SDS-PAGE and Western blotting as displayed in 
Figure 5.4. 
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Figure 5.4 SDS-PAGE and Western blot analysis of expressed M. leprae MurA active site mutant. Recombinant 
MurA active site mutant protein was expressed in E. coli tuner (DE3) cells by the addition of 1 mM IPTG and reduction 
of incubation temperature from 37°C to 16°C to induced the TEE element. Cells were pelleted, resuspended and lysed 
by sonication and soluble fractions isolated for electrophoresis separation. Proteins were run on two  SDS-PAGE gels, 
one (A) was Coomassie-stained and another (B) was Western blotted onto a PVDF membrane with anti-His antibodies. 
Lanes A1: Protein marker, A2: Expression of M. leprae MurA mutant, A3: Expression of empty plasmid,  B1: Western 
blot maker, B2: Expression of M. leprae MurA mutant, B3: Expression of empty plasmid,. Results: Presence of 
histidine tagged M. leprae MurA detected. 
 
SDS-PAGE analysis (Figure 5.4A: Blue rectangle) noted a large protein band equivalent to the 
known 46 kDa size of M. leprae MurA. This band was confirmed to be poly-histidine tagged based 
upon the Western blot x-ray (Figure 5.4B). 
 
 
5.5 M. leprae MurC 
 
The second M. leprae Mur enzyme investigated within this chapter is MurC, the first amino acid 
ligase which attaches N-glycine at position one of the pentapeptide stem (Mahapatra, et al. 2005) 
to only N-acetylated muramic acid due to M. leprae NamH being designated as a pseudogene 
(Mahapatra, et al. 2005). The 1485 bp M. leprae murC gene was synthesized with an N-terminal 
5’ NdeI enzyme restriction site and a C-terminal 3’ XhoI restriction site, along with E. coli 
expression optimization of codon selection. The protein sequence similarity between other 
mycobacterial MurC enzymes was 71.91% (M. smegmatis) and 79.15% (M. tuberculosis) as 
shown in Figure 5.5. 
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Figure 5.5 Protein sequence alignment of the peptidoglycan synthesis gene murC within selected mycobacteria. 
M. leprae, M. tuberculosis, and M. smegmatis demonstrate a significant amount of amino acid homology between 
organisms. (*) indicate conserved residues, (:) indicate strongly similar residues and (.) indicate weakly similar 
residues. (www.ncbi.nih.gov/BLAST). 
 
 
5.5.1 Cloning of M. leprae MurC 
 
The M. leprae murC gene was initially assessed by PCR to confirm the correct gene length of the 
synthesized product. Forward and reverse primers specific for the standard pUC57 vector were 
utilized with an annealing temperature of 48°C. The findings of PCR amplification are detailed in 
Figure 5.6. 
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Figure 5.6 PCR amplification of M. leprae murC. 1% Agarose gel electrophoresis of M. leprae murC gene utilizing 
forward and reverse primers targeting the up- and downstream regions of the multiple cloning site with the vector 
pUC57. Lane 1. DNA marker, Lane 2. M. leprae murC. Result: observation of single amplified 1.48 kb DNA band 
corresponding to the known size of M. leprae murC. 
 
Results from Figure 5.6 identified a single amplified DNA band 1.5 kb in length. The synthesized 
gene was evaluated by sequencing methods employing the forward and reverse pUC57 primers. 
Results confirmed the presence of the full length M. leprae murC gene sequence correctly 
synthesized. Similarly, to the investigation into M. leprae MurA, the gene was re-cloned into 
pCOLD vector following the established protocol, and required the addition of a poly-histidine tag 
sequence and a cleavable TEV region. The primers required to modify the murC  C-terminal are 
shown in Table 2.2. Once the TEV and poly-histidine tag sequences were added to the murC gene, 
it was re-cloned into a pCOLD vector and identified by sequencing. 
 
 
5.5.2 Expression of M. leprae MurC 
 
The pCOLD-M. leprae murC (C-terminal poly-histidine tag) was transformed into E. coli tuner 
(DE3) cells and cultured at 37°C until early exponential phase. Cells were induced to express 
recombinant proteins by addition of 1 mM IPTG and further incubated at 16°C overnight. Cells 
were fractionated by sonication (Section 2.7.2) and centrifuged to isolate the soluble protein phase. 
Samples were analysed by SDS-PAGE and Western Blot as shown in Figure 5.7.  
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Figure 5.7. SDS-PAGE and Western blot analysis of expressed M. leprae MurC. Recombinant MurC protein was 
expressed in E. coli tuner (DE3) cells by the addition of 1 mM IPTG and reduction of incubation temperature from 
37°C to 16°C to induced the TEE element. Cells were pelleted, resuspended and lysed by sonication and soluble 
fractions isolated for electrophoresis separation. Proteins were run on two  SDS-PAGE gels, one (A) was Coomassie-
stained and another (B) was Western blotted onto a PVDF membrane with anti-His antibodies. Lanes A1: Protein 
marker, A2: Expression of M. leprae MurC (1), A3: Expression of M. leprae MurC (2), A4: Expression of M. leprae 
MurC (3), A5: Expression of empty plasmid,  B1: Western blot maker, B2: Expression of M. leprae MurC (1), B3: 
Expression of M. leprae MurC (2), B4: Expression of M. leprae MurC (3), B5: Expression of empty plasmid. Results: 
Presence of histidine tagged M. leprae MurC detected in each sample.  
 
Results of Figure 5.7 demonstrated that incubation conditions and IPTG concentration were 
sufficient to generate the recombinant MurC protein. SDS-PAGE findings (Figure 5.7A: Blue 
rectangle) indicated the presence of a protein which corresponded to the known 51 kDa weight of 
M. leprae MurC. Western blotting definitively identified this protein as bound to anti-His 
antibodies due to the expression of the poly-histidine tag. Soluble active protein was not able to be 
obtained from the current protocol. 
 
 
5.6 M. smegmatis Mur ligases 
 
M. smegmatis is noted as the mycobacterial standard during investigations, due to its low virulence 
and relatively rapid growth rate (He and De Buck 2010). Collaborators in the Roper laboratory at 
the University of Warwick were determining the crystal structure of M. smegmatis MurC and 
MurD and permitted the enzymes binding affinities to be assessed against the two possible 
muramic acid substrates variants, UDP-MurNAc/UDP-MurNGlyc for MurC and UDP-MurNAc-
L-ala/UDP-MurNGlyc-L-ala for MurD. Unlike M. leprae, M. smegmatis possesses a NamH 
hydroxylase and is therefore able to generate N-glycolylated substrates for Mur ligases. Binding 
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favorability of the enzymes was determined by coupled NADH-linked pyruvate kinase/lactate 
dehydrogenase assay to amino acid Mur ligase activity (Section 2.11.1). 
 
 
5.6.1 The kinetic profile of M. smegmatis MurC binding affinity towards 
muramic acid variants  
 
The Michaelis-menten enzymatic kinetics graph result for M. smegmatis MurC against UDP-
MurNAc and UDP-MurNGlyc are shown in Figure 5.8 and the kinetic parameters extrapolated 
utilizing GraphPad Prism 6 are displayed in Table 5.1. 
 
 
 
Figure 5.8. Initial rate of M. smegmatis MurC enzyme velocity against muramic acid variants. Michaelis-menten 
graphs depicting the variation in binding affinity of MurC towards UDP-MurNAc and UDP-MurNGlyc substrates at 
a varying range of concentrations between 0.1 and 2.0 mM. Reaction measured at 340 nm through coupling to the 
conversion of phosphoenolpyruvate to lactate and measuring the oxidation of NADH to NAD+. Graph constructed 
using GraphPad Prism 6. 
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Mur 
Ligase 
 
 
UDP-MurNGlyc 
 
UDP-MurNAc Ratio 
KmApp 
(µM) 
KcatApp 
(min-1) 
KcatApp/ 
KmApp 
(min-1/ 
µM)  
b 
KmApp 
(µM) 
KcatApp 
(min-1) 
KcatApp/ 
KmApp 
(min-1/ 
µM)  
a 
b/a 
MurC 1296 ± 
256 
306.5 ± 
16.09 
0.2364 30380 ± 
69010 
165.6 ± 
333.3 
0.00545 43.38 
Table 5.1.  M. smegmatis MurC kinetic activity constants comparison between binding affinity towards UDP-
MurNAc and UDP-MurNGlyc substrates. Km and Kcat extrapolated from the Michaelis-menten kinetic graph in 
Figure 5.8. 
 
 
M. smegmatis MurC demonstrated a significant variation in binding affinities towards each of the 
two possible muramic acid substrates. The investigated concentration range of 0.1-2.0 mM 
permitted a hyperbolic relationship between MurC and UDP-MurNGlyc, although the binding 
affinity did not saturate at the concentrations investigated. The UDP-MurNAc substrate however 
displayed a simple linear relationship. The enzyme showed one sided favorability towards the N-
glycolyl substrate with a 43 fold higher affinity and a Km of 1.29 mM, compared to the N-acetyl 
substrates Km of 30.38 mM. 
 
 
5.6.2 The kinetic profile of M. smegmatis MurD binding affinity towards 
muramic acid variants 
 
The Michaelis-menten enzymatic kinetics graph result for M. smegmatis MurD against UDP-
MurNAc-L-ala and UDP-MurNGlyc-L-ala are shown in Figure 5.9 and the kinetic parameters 
extrapolated utilizing GraphPad Prism 6 are displayed in Table 5.2. 
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Figure 5.9 Initial rate of M. smegmatis MurD enzyme velocity against muramic acid variants. Michaelis-menten 
graphs depicting the variation in binding affinity of MurD towards UDP-MurNAc-L-ala and UDP-MurNGlyc-L-ala 
substrates at a varying range of concentrations between 0.01 and 1.0 mM. Reaction measured at 340 nm through 
coupling to the conversion of phosphoenolpyruvate to lactate and measuring the oxidation of NADH to NAD+. Graph 
constructed using GraphPad Prism 6. 
 
 
Mur 
Ligase 
 
 
UDP-MurNGlyc-L-Ala 
 
UDP-MurNAc-L-Ala Ratio 
KmApp 
(µM) 
KcatApp 
(min-1) 
KcatApp/ 
KmApp 
(min-1/ 
µM) 
b 
KmApp 
(µM) 
KcatApp 
(min-1) 
KcatApp/ 
KmApp 
(min-1/ 
µM)  
a 
b/a 
MurD 10.83 ± 
1.71 
8109 ± 
241.1 
750.83 49.68 ± 
8.96 
7319 ± 
237.00 
147.26 5.09 
Table 5.2.  M. smegmatis MurD kinetic activity constants comparison between binding affinity towards UDP-
MurNAc and UDP-MurNGlyc substrates. Km and Kcat extrapolated from the Michaelis-menten kinetic graph in 
Figure 5.9. 
 
The relationship between MurD and both substrate variants was hyperbolic with both interactions 
plateauing at concentrations greater than 0.2 mM. The noted significant catalytic preference for 
the N-glycolyl substrate observed in Figure 5.8 for MurC was not sustained in MurD (Figure 5.9), 
although MurD still demonstrated an over five-fold higher affinity for the N-glycolyl substrate. 
The narrower variation of substrate Km values, 10.83 µM in UDP-MurNGlyc-L-ala and 49.68 µM 
in UDP-MurNAc-L-ala, led to a lower range of investigated substrate concentrations between 0.01 
mM and 1.0 mM. 
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5.7 M. tuberculosis PonA1 and PonA2  
 
M. tuberculosis utilizes two bifunctional PBPs, PonA1 (Rv0050) and PonA2 (Rv3682) to 
incorporate newly synthesized Lipid II subunits to the overall peptidoglycan architecture (Kieser, 
et al. 2015). Collaborators from the Besra laboratory at the University of Birmingham, provided 
both PBPs genes within pET21b expression vectors (Section A1.1.3). 
 
 
5.7.1 Expression of M. tuberculosis PonA1 and PonA2 
 
M. tuberculosis PonA1 and PonA2 genes were sequenced to determine the presence of the PBP, 
in frame with the addition of a C-terminal poly-histidine tag sequence. PonA1 was confirmed as 
2460 bp and PonA2 as 2430 bp in length. Vectors were then transformed into E. coli BL21 (DE3) 
expression strains (Section 2.6.9), and successful insertion of the plasmid was observed through 
ampicillin resistance selection. Recombinant PBPs were expressed as described previously 
(Section 2.7.1).  
 
 
5.7.2 Purification of M. tuberculosis PonA1 and PonA2 
 
Recombinantly expressed M. tuberculosis PonA1 and PonA2 contained a C-terminal poly-
histidine tag permitting purification by IMAC as detailed in Section 2.7.3.1 and shown in Figure 
5.10 and Figure 5.11. 
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Figure 5.10 Purification of M. tuberculosis PonA1. 12% SDS-PAGE analysis gels of Immoblised metal affinity 
chromatography (5 mL Cobalt) elutions by imidazole (IM) gradient of purified recombinantly expressed PonA1 from 
E. coli BL21 (DE3) expression cell line. Bands visualized by Coomassie blue staining. Lanes A1: Protein marker, A2: 
Flow through, A3: Wash through, A4: 0mM IM, A5: 10mM IM, A6: 30mM IM, A7: 50mM IM, A8: 100mM IM, A9: 
150mM IM, B1: Protein marker, B2: 200mM IM, B3: 250mM IM, B4: 300mM IM, B5: 350mM IM, B6: 400mM IM, 
B7: 450mM IM, B8: 500mM IM, B9: 500mM IM. Identification of PonA1 for further concentration noted by black 
rectangle. 
 
IMAC purification of M. tuberculosis PonA1 led to mostly successful isolation from other cellular 
components. PonA1 is an 85 kDa protein present during elution with imidazole concentrations 30-
150 mM in Figure 5.10 (Highlight with black rectangle). Eluted fractions corresponding to wells 
A6-9 were combined and dialyzed (Section 2.7.4) overnight at 4°C in PBP specific assay buffer 
(Section 2.10.2). The PBP was then concentrated (Section 2.7.5) below 1 mL total volume and the 
concentration quantified by BCA (Section 2.7.6.2). PonA1 concentration was 3.2 mM. Purification 
was not entirely successful with other band present in the purified sample which may impact 
binding.  
 
 
Figure 5.11 Purification of M. tuberculosis PonA2. 12% SDS-PAGE analysis gels of Immoblised metal affinity 
chromatography (5 mL Cobalt) elutions by imidazole (IM) gradient of purified recombinantly expressed PonA2 from 
E. coli BL21 (DE3) expression cell line. Bands visualized by Coomassie blue staining. Lanes A1: Protein marker, A2: 
Flow through, A3: Wash through, A4: 0mM IM, A5: 10mM IM, A6: 30mM IM, A7: 50mM IM, A8: 100mM IM, A9: 
150mM IM, B1: Protein marker, B2: 200mM IM, B3: 250mM IM, B4: 300mM IM, B5: 350mM IM, B6: 400mM IM, 
B7: 450mM IM, B8: 500mM IM, B9: 500mM IM. Identification of PonA1 for further concentration noted by black 
rectangle. 
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PonA2 was eluted from the IMAC column at a similar imidazole concentration as PonA1. The 84 
kDa PBP was removed from the column between 30-150 mM IM, fraction corresponding to wells 
A6-9 (Figure 5.11) were pooled and dialyzed overnight in PBP buffer. The recombinant protein 
was then concentrated and the resulting volume was quantified as containing 4.1 mM PonA2. 
Purification was once again not solely successful with the final elution containing more than one 
band. 
 
 
5.7.3 Binding affinity of M. tuberculosis PonA1/PonA2 to Lipid II variants 
 
PonA1 and PonA2 were assessed by BLI (2.10.2) to measure the binding affinity of the penicillin 
binding proteins to the two possible modified peptidoglycan subunits, N-acetylated Lipid II and 
N-glycolylated Lipid II. As described previously, biotinylated Lipid II variants were immobilized 
on streptavidin sensors and interactions between 0.2 µM set lipid concentrations and a range of 
PBP concentrations between 0.03 µM and 0.5 µM were evaluated. The BLI buffer solution utilized 
was altered to specify for optimal PBP activity (Section 2.10.2). The BLI sensorgrams for each 
Lipid II variant against both PonA1 and PonA2 are shown in Figure 5.12 and the KD results 
extrapolated for each PBP are shown in Table 5.3. 
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Figure 5.12. Binding affinity of biotinylated Lipid II variants against M. tuberculosis penicillin binding proteins PonA1 and PonA2. Sensorgrams of 
streptavidin coated sensors bound to N-acetylated Lipid II and N-glycolylated Lipid II were assessed by their affinity towards two-fold serial dilutions from 0.5 
µM to 0.03 µM of PonA1 and PonA2. Reference sensors were used to remove any non-specific binding. (a) N-acetylated Lipid II (DAP) and PonA1, (b) N-
acetylated Lipid II (DAP) and PonA2, (c) N-glycolylated Lipid II (DAP) and PonA1 and (d) N-glycolylated Lipid II (DAP) and PonA2. Binding constants were 
measured with the Octet Data Analysis software on an Octet Red, by global fitting the data with the 1:1 heterogenous ligand mode
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Lipid II PBP KD (M) KD 
Error 
Ka 
(1/Ms) 
Ka  
Error 
Kd 
(1/s) 
Kd 
Error 
NAc PonA1 5.39 10-8 7.17  
10-10 
9.71 
10+3 
7.59 
10+1 
5.24 
10-4 
5.63  
10-6 
NAc PonA2 5.50 10-8 8.26  
10-10 
8.81 
10+3 
7.95 
10+1 
4.84 
10-4 
5.82  
10-6 
NGlyc PonA1 1.14 10-7 1.40  
10-9 
6.89 
10+3 
6.92 
10+1 
7.82 
10-4 
5.62  
10-6 
NGlyc PonA2 8.02 10-8 1.93  
10-9 
1.00 
10+4 
1.77 
10+2 
8.05 
10-4 
1.32  
10-5 
Table 5.3. The equilibrium dissociation constants, KD for biotinylated Lipid II variants to M. 
tuberculosis PonA1 and PonA2. N-acetylated and N-glycolylated Lipid II (DAP) attached to 
streptavidin biosensors binding measured against concentrations of M. tuberculosis PBPs, PonA1 and 
PonA2 between 0.5 µM and 0.03 µM.  
 
The equilibrium dissociation constants, of both PBPs in Figure 5.12 towards the N-
acetylated Lipid II exhibited a similar binding affinity value of 53.9 nM for PonA1 and 
55.0 nM for PonA2 (Table 5.3) respectively. The rate of association for each PBP were 
comparatively close with Ka values of 971 Ms-1 (PonA1) and 881 Ms-1 (PonA2). The 
dissociation constant for each penicillin binding protein against the N-acetylated lipid 
was 0.524 ms-1 (PonA1) and 0.484 ms-1 (PonA2) respectively.   
 
The N-glycolylated Lipid II (DAP) displayed a slight preference in binding affinity 
towards PonA2 with a KD of 80.2 nM compared to PonA1 with a KD of 114.0 nM. Ka 
for each PBP was 689 Ms-1 (PonA1) and 1000 Ms-1 (PonA2) respectively. The 
dissociation constants for each PBP against the N-glycolylated lipid were 0.782 ms-1 
(PonA1) and 0.805 ms-1 (PonA2) respectively. 
 
Comparisons observed between the binding affinities of each lipid variant towards a 
single PBP, showed that PonA1 preferentially binds at half the KD to the N-acetylated 
lipid than the N-glycolylated lipid, whereas PonA2 binds with equal affinity towards 
each lipid. 
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5.8 Discussion  
 
5.8.1 M. leprae Mur enzymes 
 
Initial investigations have been implemented with M. leprae Mur enzymes. Both MurA 
and MurC were successfully obtained and re-cloned into pCOLD expression vectors 
with poly-histidine tags employed to aid recombinant protein folding at lower 
temperatures. Both enzymes were expressed and generated soluble protein. Site 
directed mutagenesis was enacted to probe the sensitivity of M. leprae MurA to 
fosfomycin through the substitution of an active site aspartate residue (De Smet, et al. 
1999). The active site mutant was also expressed and soluble. These initial experiments 
will be built upon to investigate the peptidoglycan regulation undertaken to control 
synthesis in response to external pressures such as starvation and antimicrobial therapy 
(Section 5.9 Further work). 
 
 
5.8.2 M. smegmatis Mur enzymes 
 
Previous chapters have demonstrated the importance of N-glycolylated peptidoglycan 
for mycobacteria to resist hydrolytic enzymes and antimicrobials. The binding affinities 
of M. smegmatis Mur ligases, MurC and MurD were probed to identify potential 
catalytic bias between the N-acetylated and N-glycolylated substrates. Kinetic 
assessments of binding affinities illustrated that the M. smegmatis Mur ligases 
displayed a higher affinity towards the N-glycolylated substrate. This impact was most 
significant for MurC with a 43 fold greater efficiency. The noted bias decreased 
significantly for MurD, demonstrating only a 5 fold preference. These findings were 
similar to a collaborators within the laboratory measuring the binding affinity of M. 
tuberculosis Mur ligases (Unpublished). Results showed a 30 fold preference for the 
N-glycolylated substrate by MurC, although each subsequent ligase, the preference was 
diminished until substrate affinities were equivalent for MurF. The incorporation of N-
glycolylated saccharides is therefore a priority in mycobacteria, likely attributed to the 
organisms need to rapidly respond to host’s immune responses or antimicrobial 
treatments.  
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5.8.3 M. tuberculosis PBPs 
 
M. tuberculosis implements the bifunctional PBPs, PonA1 and PonA2 to construct the 
wider peptidoglycan sacculus and insert either N-acetylated or N-glycolylated lipids 
into the architecture depending upon the external conditions and challenges to maintain 
mycobacterial cell wall integrity. The BLI assessment of M. tuberculosis PBPs showed 
that there was little difference between PonA1 and PonA2 in their binding affinities 
towards each specific version of Lipid II (DAP). There was specificity observed in each 
PBP’s own preferences. PonA1 showed twice as great affinity towards the N-acetylated 
lipid as the N-glycolylated, whereas PonA2 had similar affinities regardless of lipid 
binding partner. 
 
Chen, et al. (2013) however, directly tested PonA1 activity towards lipid II analogues 
and found that the N-glycolylated lipid II was two-fold more efficient than its N-
acetylated counterpart.  The apparent discrepancy may well result from the weaker 
binding of N-glycolylated as opposed to the N-acetylated substrate binding seen in this 
project. This might be countered by a much higher maximal velocity of N-glycolylated 
transglycosylation as seen by Chen, et al. (2013). 
 
 
5.9 Further work 
 
 
• Characterise activity of M. leprae Mur enzymes 
 
M. leprae MurA, a MurA active site mutant and MurC were successfully cloned and 
expressed. The Mur enzymes require an assessment of enzymatic activity 
characterization towards peptidoglycan intermediate synthesis of UDP-enolpyruvyl-
GlcNAc (MurA and MurA mutant) and UDP-MurNAc-L-glycine (MurC) respectively 
compared to known Mur enzymatic activities within other organisms (Munshi, et al. 
2013). Once standard M. leprae MurA activity is established, the effect of 
peptidoglycan synthesis can be perturbed by the MurA inhibitor, fosfomycin to 
determine the extent to which the active site amino acid substitution impacts 
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antimicrobial susceptibility of the commonly resistant enzyme. The M. leprae MurC 
implementation of L-glycine at position one of the pentapeptide stem should be re-
examined to reiterate the lack of binding preference between L-glycine and L-alanine 
(Mahapatra, et al. 2000). The experiment could also be expanded to include all amino 
acid. 
 
 
• CwlM 
 
Recent findings (Boutte, et al. 2016) have identified the protein CwlM as a key factor 
in the regulation of MurA activity. Association of the protein with MurA once 
phosphorylated by the serine/threonine protein kinase, PknB increased the Mur 
enzymes activity by around 30 fold. Investigations should be conducted into identifying 
an equivalent gene in M. leprae, determining if the gene can be expressed or is simply 
a pseudogene and if so have the gene synthesize and expressed to determine the impact 
of M. leprae peptidoglycan synthesis. 
 
 
• Assess M. leprae MurC catalytic bias towards muramic acid variants 
  
Investigate the potential for catalytic bias of M. leprae MurC towards the N-
glycolylated substrate compared to the N-acetylated variant as observed in M. 
smegmatis. Determine if the fact that the NamH equivalent in M. leprae is a pseudogene 
has led to no retained substrate binding preference. 
 
 
• Assess PonA1 and PonA2 binding affinity towards antimicrobials 
 
The M. tuberculosis PBPs were expressed with a poly-histidine tag, which permits the 
proteins to be bound to Ni-NTA anti-histidine antibody biosensors for BLI binding 
affinity assessment. Interactions between PonA1/PonA2 and PBP targeted 
antimicrobials such as b-lactam antibiotics and moenomycin should be investigated to 
decipher preferential binding of the antimicrobials.  
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5.10 Conclusion 
 
Mycobacterial peptidoglycan synthesis possesses a number of unique variations to aid 
resistance from antimicrobial interaction. Catalytic preferences towards the N-
glycolylated saccharide was shown within the Mur ligases though this effect diminished 
as the amino acid stem extended. Rapid implementation of peptidoglycan modification 
likely attributes to mycobacterial virulence.  
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Chapter 6. Elucidating the role of known cell wall active 
compounds 
 
 
6.1 Inhibition screening 
 
A collaboration between the University of Warwick and McMaster University was initiated 
to investigate the role of newly identified cell wall active compounds with antimicrobial 
activity. The compounds were identified through a new screening process described below 
created to avoid the issues commonly occurring in previous screens (De Pascale 2007). 
Previous screening methods utilised a vanH promoter-reporter merged to the lacZ gene to 
evaluate growth inhibition followed by targeted activity towards the bacterial cell wall. Such 
methods are incomplete in that they only target a specific step in peptidoglycan synthesis 
such as transpeptidation, although the screening process published by (Czarny, et al. 2014) 
reports on any inhibition of any step of the entire bacterial cell wall pathway.  
 
 
6.1.1 Pywac compounds 
 
The screening process performed at McMaster University by the Brown lab focused on the 
noted upregulation of the ywaC gene upon suppression of wall teichoic acid (WTA) 
synthesis (D’Elia, et al. 2009). Teichoic acids are designated as WTA due to interactions 
with peptidoglycan and lipoteichoic acids if anchored to lipids. Comprised from either 
glycerol phosphate or ribitol phosphate and attached by phosphodiester bonds, these 
bacterial polysaccharides are covalently bound to MurNAc subunits of the peptidoglycan 
sacculus (Brown, et al. 2014). WTA are major components of the bacterial cell wall, and in 
similar abundance to peptidoglycan in Gram-positive organisms, although absent from 
Gram-negative organisms (Swoboda, et al. 2010).  
 
The vast majority of previously identified anti-bacterials which are specific for the bacterial 
cell wall elicit activity towards peptidoglycan synthesis (Bush 2012) although WTA 
synthesis is currently emerging as an encouraging new target. The screen utilises the gene 
ywaC, observed to exhibit GTP pyrophosphokinase activity (Czarny, et al. 2014). This 
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generally uncharacterised protein belongs to a class of enzymes that catalyse the production 
of a bacterial “alarmone”, guanosine tetra(penta)phosphate ((p)ppGpp) during cellular 
stresses (Hauryliuk, et al. 2015). In turn by binding to both b and b’ subunits of RNA 
polymerase, the alarmone alters promoter preference, as well as upregulation and 
downregulation of genes, prompts precise transcriptional level gene expression (Merrikh, et 
al. 2009) and is part of the sw regulon, a collection of genes upregulated in the presence of 
cell wall antimicrobials. The screening process utilises a promoter-reporter system 
comprised of the promoter of ywaC and the lux genes from which the enzyme luciferase is 
expressed enabling a real-time luminescence signal. Luciferase catalyses the oxidation of a 
long-chain aliphatic aldehyde and reduced Flavin mononucleotide (FMNH2) by molecular 
oxygen to yield H2O, flavin mononucleotide (FMN) and a fatty acid (Baldwin, et al. 1975). 
This reaction leads to the emission of blue-green light at a wavelength of 490 nm (Wiles, et 
al. 2005). 
 
 
 
Figure 6.1 The enzymatic luminescence reaction of reduced flavin mononucleotide and a long chain 
aldehyde. Luciferase catalyses the oxygen dependent oxidation of FMNH2 and a long chain aldehyde to FMN 
and a fatty acid with the emission of light at 490 nm. 
 
The screen comprised wild type B. subtilis 168 (EB6) single colonies containing the Pywac-
Lux promoter-reporter plasmids cultured LB overnight, supplemented with erythromycin. 
Harvested cells were subsequently diluted and spotted onto the surface of solid LB agar 
incorporating potential inhibitors. Assay luminescence was evaluated for 19 hours, where 
emission was measured at 490 nm with the isoprenoid biosynthesis inhibitor fosmidomycin 
(Howe, et al. 2013) employed as a high emission control and DMSO as a low emission 
control. Potential inhibitors that elicited a positive luminescence response were selected for 
secondary screening. Osmoprotectants such as sucrose or divalent cations like magnesium 
chloride have been observed to mitigate the cell wall deficiencies of compromised cells as 
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well as supress PywaC activity. The secondary screen was conducted in the same manner as 
the first on solid agar with the addition of MgCl2, sucrose and maleic acid (MSM) to the 
liquid LB. Nine compounds were identified (designated as pywac 1-9 from the remainder of 
this thesis), displaying concentration dependant prominent luminescence emissions, which 
were also moderately quelled by osmoprotectants and induced morphology changes in cells 
at sub MIC levels. 
 
 
6.1.2 Pywac compound structures and MIC concentrations 
 
The chemical formulas, structures and MIC for the pywac compounds 1-9 against B. subtilis 
as outlined in Czarny, et al. (2014) are recorded in table 6.1. 
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Compound 
Name 
Chemical  
formula 
Molecular  
mass (Da) 
Chemical Structure MIC 
Pywac 1 C23H21BrN2O3 453.34 
 
4µM 
Pywac 2 C19H18N2O3S 354.42 
 
2µM 
Pywac 3 C14H14N2O3S 290.34 
 
32µM 
Pywac 4 C25H18ClFN2O5 480.88 
 
16µM 
Pywac 5 C16H15N3O5S 361.37 
 
32µM 
Pywac 6 C16H16ClNO4S 353.82 
 
8µM 
Pywac 7 C17H17ClN2O2S2 380.91 
 
16µM 
Pywac 8 C14H9ClF3N3O22- 343.69 
 
8µM 
Pywac 9 C19H20N2O2 308.38 
 
4µM 
Table 6.1 The cell wall active compounds identified by PywaC screening, designated pywac 1-9. Molecular 
weights, structures and MIC for B. subtilis (structures produced in ChemBio Draw 7) from (Czarny, et al. 
(2014)). 
 
 
Br
O
N NH
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O
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H
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(E)-5-(4-(benzyloxy)-3-ethoxybenzylidene)-2-iminothiazolidin-4-one
Chemical Formula: C19H18N2O3S
Exact Mass: 354.10
Molecular Weight: 354.42
m/z: 354.10 (100.0%), 355.11 (20.5%), 356.10 (4.5%), 356.11 (2.0%)
Elemental Analysis: C, 64.39; H, 5.12; N, 7.90; O, 13.54; S, 9.05
PyWac2
O
O
NH
S
O
NH
(Z)-5-(4-(allyloxy)-3-methoxybenzylidene)-2-iminothiazolidin-4-one
Chemical Formula: C14H14N2O3S
Exact Mass: 290.07
Molecular Weight: 290.34
m/z: 290.07 (100.0%), 291.08 (15.1%), 292.07 (4.5%), 292.08 (1.1%)
Elemental Analysis: C, 57.92; H, 4.86; N, 9.65; O, 16.53; S, 11.04
PyWac3
O
O
Cl
N
NH
F
O
O O
(Z)-5-(4-(benzyloxy)-3-chloro-5-methoxybenzylidene)-1-(2-fluorophenyl)pyrimidine-2,4,6(1H,3H,5H)-
trione
Chemical Formula: C25H18ClFN2O5
Exact Mass: 480.09
Molecular Weight: 480.88
m/z: 480.09 (100.0%), 482.09 (32.0%), 481.09 (27.0%), 483.09 (8.6%), 482.10 (3.5%), 482.09 (1.0%)
Elemental Analysis: C, 62.44; H, 3.77; Cl, 7.37; F, 3.95; N, 5.83; O, 16.64
PyWac 4
O
N O S O
O
N
O
N
2-morpholinophenyl benzo[c][1,2,5]oxadiazole-4-
sulfonate
Chemical Formula: C16H15N3O5S
Exact Mass: 361.07
Molecular Weight: 361.37
m/z: 361.07 (100.0%), 362.08 (17.3%), 363.07 
(4.5%), 363.08 (1.4%), 362.07 (1.1%), 363.08 
(1.0%)
Elemental Analysis: C, 53.18; H, 4.18; N, 11.63; O, 
22.14; S, 8.87
PyWac 5
O
N O S O
O
Cl
2-morpholinophenyl 3-chlorobenzenesulfonate
Chemical Formula: C16H16ClNO4S
Exact Mass: 353.05
Molecular Weight: 353.82
m/z: 353.05 (100.0%), 355.05 (32.0%), 354.05 (17.3%), 356.05 
(5.5%), 355.04 (4.5%), 357.04 (1.4%), 355.06 (1.4%)
Elemental Analysis: C, 54.32; H, 4.56; Cl, 10.02; N, 3.96; O, 
18.09; S, 9.06
PyWac 6
HO
S
S
N
H
N
O Cl
(E)-N'-(2-chlorobenzylidene)-4-hydroxy-3-(methylthio)-4,5,6,7-tetrahydrobenzo[c]thiophene-1-
carbohydrazide
Chemical Formula: C17H17ClN2O2S2
Exact Mass: 380.04
Molecular Weight: 380.91
m/z: 380.04 (100.0%), 382.04 (32.0%), 381.05 (18.4%), 382.04 (9.0%), 383.04 (5.9%), 384.03 (2.9%), 
383.04 (1.7%), 381.04 (1.6%), 382.05 (1.6%)
Elemental Analysis: C, 53.61; H, 4.50; Cl, 9.31; N, 7.35; O, 8.40; S, 16.83
PyWac 7
N
F
F
F
Cl
N
N
-O O-
(E)-4-((2-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-2-methylhydrazono)methyl)benzene-1,3-bis(olate)
Chemical Formula: C14H9ClF3N3O22-
Exact Mass: 343.03
Molecular Weight: 343.69
m/z: 171.52 (100.0%), 172.52 (32.0%), 172.02 (15.1%), 173.02 (4.8%), 172.02 (1.1%), 172.52 (1.1%)
Elemental Analysis: C, 48.93; H, 2.64; Cl, 10.31; F, 16.58; N, 12.23; O, 9.31O
O
N
N
H
(E)-2-(5-(tert-butyl)-2-methylfuran-3-carbonyl)-3-(phenylamino)acrylonitrile
Chemical Formula: C19H20N2O2
Exact Mass: 308.15
Molecular Weight: 308.38
m/z: 308.15 (100.0%), 309.16 (20.5%), 310.16 (2.0%)
Elemental Analysis: C, 74.00; H, 6.54; N, 9.08; O, 10.38
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6.2 Experimental aims 
 
To investigate the impact of the nine recently discovered cell wall active compounds on 
peptidoglycan synthesis as reported by evaluation of accumulated intermediates of the 
peptidoglycan cytosolic or membrane linked phases during incubation in excess of the MIC. 
 
 
6.3 DMSO tolerance of B. subtilis 
 
The nine presumptive cell wall active compounds are insoluble in aqueous solution but 
soluble in DMSO. Growth of cells are known to have certain tolerances for solvents, though 
above a certain threshold a noticeable decrease in cellular growth can be observed Therefore 
it was important to identify the tolerance of B. subtilis wild type cells to increasing 
concentrations of DMSO. Throughout this chapter to minimise the impact of highly complex 
nutrient media preventing accumulation of cellular intermediates, minimal nutrient media 
(Section 2.2.4) was used. DMSO tolerance of B. subtilis is demonstrated in Figure 6.2. 
 
 
 
Figure 6.2 DMSO tolerance of B. subtilis. Cells were grown in the presence of increasing 
concentrations of DMSO to identify optimal tolerance for the solvent, in 96 well microtiter plates in 
triplicate at 37°C with intermittent shaking. Absorbance was measured at 600nm at 3 hour intervals for 
24 hours. Each well contained 100 µL minimal media. The cultured B. subtilis cells were standardized 
to an OD600nm of 1 and diluted further by a factor of 104 prior to incubation. Error bars represent standard 
deviation of triplicate measurements. DMSO concentration: 0%  (v/v) Blue, 1% (v/v) Pink, 2% (v/v) 
Green, 3% (v/v) Orange, 4% (v/v) Purple, 5% (v/v) Red. Statistically significant results are indicated 
with * = p-value <0.05, ** = <0.01, *** = <0.001 and **** = <0.0001. Ns = not statistically significant. 
Result: DMSO percentages above 1% (v/v) slightly impacted phenotypic growth, with 5% (v/v) reducing 
overall growth curve area by 18%.  
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[DMSO]  
(v/v) 
(%) 
B. subtilis 
Apparent 
Lag 
Phase 
Duration 
(h) 
Td 
(h-1) 
AUC (% of 
0%  DMSO) 
Stationary 
Phase OD600 
nm attained 
p-values 
0 3 2.76 - 0.50 - 
1 3 2.78 92.38 0.50 >0.05 
2 3 3.20 92.38 0.49 <0.05 
3 3 3.22 90.47 0.47 <0.01 
4 3 2.94 91.13 0.47 <0.01 
5 3 3.61 82.63 0.46 <0.001 
Table 6.2 Statistical comparisons of B. subtilis growth curves in the presence of increasing 
concentrations of DMSO. B. subtilis incubated for 24 hours at 37°C with selected concentrations of 
DMSO (v/v) produced growth curves measured at OD600nm in Figure 4.1. Variations between growth 
curves were measured by time taken to exit apparent lag phase (hours), the doubling time (Td) of cells 
during exponential phase (hours-1), the area under the curve (AUC) percentage compared to the 0 % 
control (%), the OD600nm value achieved during stationary phase and whether the growth curve variations 
were statistically significant compared to each 0 % control with p-values <0.05 deemed significant.  
 
The normal growth phenotype of the wild type B. subtilis strain (Figure 6.2: 0% Blue) 
in the absence of DMSO exited apparent lag phase after 3 hours. The control data set 
produced a doubling time (Td) during exponential phase of 2.76 hours and reached an 
OD600nm of 0.5 during stationary phase after 21 hours. The addition of DMSO at any 
concentration tested against B. subtilis cells did not lead to the significant impact 
observed in M. smegmatis cells cultured in 7H9 media (Figure 4.1). Any investigated 
concentration of DMSO did not delay the exit from apparent lag phase which remained 
3 hours, however it did lead to slight variations in the Td of co-incubated cells and a 
gradual decrease in the area under the curve (AUC) from the 0% (v/v) control. The 
observed Td and AUC for each data set were 1% (v/v) DMSO: 2.78 hours, 92.38% 
(Figure 6.2: Pink), 2% (v/v) DMSO: 3.20 hours, 92.38% (Figure 6.2: Green), 3% (v/v) 
DMSO: 3.22 hours, 90.47% (Figure 6.2: Orange), 4% (v/v) DMSO: 2.94 hours, 91.13% 
(Figure 6.2: Purple) and 5% (v/v) DMSO: 3.61 hours, 82.63% (Figure 6.2: Red). A 
Student’s t-test was implemented to assess the significance of growth variation in the 
presence of each concentration of DMSO. Each of the DMSO concentrations added 
produced statistically significant variation to B. subtilis growth curves expect 1% (v/v) 
(p-value >0.05) with p-values of <0.05 (2% (v/v)) and <0.01 (3% and 4% (v/v)) and 
<0.001 (5% (v/v)) respectively. 
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Based upon the results obtained from Figure 6.2 the decision was taken to standardise 
a 2% (v/v) DMSO total concentration across all investigations within this chapter 
involving B. subtilis cells exposed to pywac compounds or just to the no compound 
DMSO control.  
 
 
6.4 B. subtilis MIC of pywac compounds 
 
To corroborate the findings of Czarny, et al. (2014) (Table 6.1) growth of B. subtilis at 
the reported MIC concentration of the nine compounds was monitored to validate the 
previous findings for subsequent MIC investigations in this chapter. Growth at the MIC 
for each individual pywac compound was determined in triplicate within minimal 
media. The phenotypic growth for B. subtilis cells against each pywac compound MIC 
is shown in Figure 6.3. 
 
 
 
Figure 6.3 MIC of cell wall active pywac compounds against B. subtilis. Cells were grown in the 
presence of proposed MICs of pywac compounds 1-9 in 2% DMSO in 96 well microtiter plates in 
triplicate at 37°C with intermittent shaking. Absorbance was measured at OD600nm at 3 hour intervals for 
24 hours. Each well contained 100 µL minimal media. The cultured B. subtilis cells were standardized 
to an OD600nm of 1 and diluted further by a factor of 104 prior to incubation. Error bars represent standard 
deviation of triplicate measurements. Control: (Blue) B. subtilis cells grown in absence of compounds 
plus 2% (v/v) DMSO. pywac MIC: pywac 1 4µM (Pink), pywac 2 2µM (Green), pywac 3 32µM 
(Orange), pywac 4 16µM (Purple), pywac 5 32µM (Yellow), pywac 6 8µM (Red), pywac 7 16µM 
(Turquoise), pywac 8 8µM (Magenta), pywac 9 4µM (Black). Result: All proposed MIC values for each 
pywac compound were either correct or overstated as reported in Czarny, et al. (2014).  
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Pywac 6   8µM
Pywac 7 16µM
Pywac 8   8µM
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The findings show that the MICs observed by Czarny et al. (2014) were consistent with 
the results shown in Figure 6.3 for all nine pywac compounds. None of the 
concentrations of each pywac compound tested permitted observable growth of B. 
subtilis cells. 
 
Building upon these results the main focus of this chapter was to observe the potential 
accumulation of cell wall intermediates during incubation with concentrations of pywac 
compounds exceeding their MIC values. Therefore, a positive control was required to 
ascertain the variation between normal cellular distribution of intermediates and 
compound specific causes of intermediate accumulation. For a positive control the 
antibiotic vancomycin was selected, which binds to the final D-alanyl-D-alanine 
residues of the PG precursor pentapeptide stem (Soetaerta, et al. 2015) inhibiting the 
subunit from incorporating into the peptidoglycan cell wall layer. The implementation 
of this control within B. subtilis cells would ultimately indicate that an increased 
concentration of vancomycin greater than the MIC would lead to an observable 
accumulation of UDP-MurNAc-pentapeptide DAP due to the further progress along the 
PG pathway being blocked by sequestration of Lipid II by vancomycin. The MIC of 
the B. subtilis wild type strain was identified as 0.03 µg.mL-1 by Fang, et al. (2014). 
The MIC of vancomycin against B. subtilis cells was assessed in Figure 6.4. 
 
 
Figure 6.4 MIC of vancomycin against B. subtilis. Cells were grown in the presence of the proposed 
MIC (Pink), 2x MIC (Green) and 4x MIC (Orange) of vancomycin in 2% (v/v) DMSO in 96 well 
microtiter plates in triplicate at 37°C with intermittent shaking. Absorbance was measured at 600nm at 
3 hour intervals for 24 hours. Each well contained 100 µL minimal media. The cultured B. subtilis cells 
were standardized diluted to an OD600nm of 10-4 prior to incubation. Error bars represent standard 
deviation of triplicate measurements. Control: (Blue) B. subtilis cells grown in absence of vancomycin 
plus 2% (v/v) DMSO. Result: The previously observed MIC value for vancomycin against B. subtilis 
was repeatable here.  
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The results found in Figure 6.4 validate the findings of Fang, et al. (2014). Incubation 
of B. subtilis cells with 0.03 µg.mL-1 vancomycin or greater (Figure 6.4) was sufficient 
to completely inhibit growth. The equivalent MIC of vancomycin in µM was 0.02 µM. 
The decision was taken to assess both 2x MIC (0.04 µM) and 5x MIC (0.1 µM) 
vancomycin on late exponentially growing B. subtilis cells to assess whether either are 
sufficient to obtain noticeable accumulation of the desired peptidoglycan precursor 
intermediates. 
 
 
6.5 Analysis of B. subtilis peptidoglycan precursor intermediate 
standards 
 
To compare and identify isolated peaks of interest from the ion exchange 
chromatography and mass spectrometry data of B. subtilis cells, known cytosolic 
peptidoglycan intermediates were processed individually to act as standards. The cell 
wall intermediates produced by B. subtilis are known to contain a DAP residue at 
position three of the pentapeptide stem (Vermeulen, et al. 1984). The structure of each 
of the seven peptidoglycan intermediates: UDP-GlcNAc, UDP-enolpyruvyl-GlcNAc, 
UDP-MurNAc, UDP-MurNAc-L-alanine, UDP-MurNAc-L-alanyl-g-D-glutamate, 
UDP-MurNAc-L-alanyl-g-D-glutamyl-meso-diaminopimelate and UDP-MurNAc-L-
alanyl-g-D-glutamyl-meso-diaminopimelyl-D-alanyl-D-alanine; abbreviated to UDP-
MurNAc, UDP-MurNAc-L-Ala, UDP-MurNAc-L-Ala-D-Glu, UDP-MurNAc-L-Ala-
D-Glu-m-DAP and UDP-MurNAc-L-Ala-D-Glu-m-DAP-D-Ala-D-Ala respectively 
are shown in Figure 6.5. 
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Figure 6.5: The structures of the cytosolic peptidoglycan intermediates of B. subtilis. (a) UDP-GlcNAc, (b) UDP- enolpyruvyl-GlcNAc, (c) UDP-MurNAc, (d) UDP-
MurNAc-L-Ala, (e) UDP-MurNAc-L-Ala-D-Glu, (f) UDP-MurNAc-L-Ala-D-Glu-m-DAP and (g) UDP-MurNAc-L-Ala-D-Glu-m-DAP-D-Ala-D-Ala. The above schematic 
was created using ChemBioDraw. 
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Known peptidoglycan intermediate standards synthesised within the lab by the 
BaCWAN facility utilising the methods outlined in Section 2.8.1 and used to identify 
the elution position of each peptidoglycan intermediate on fractionation of the B. 
subtilis cytosolic metabolite pool, by anion exchange as described in Section 2.7.3.3. 
Samples were diluted in 10 mM ammonium acetate to 1 mM and 2 mL volumes were 
loaded onto the column. Notable peaks of interest were retained for subsequent 
characterisation by mass spectrometry. The ion exchange chromatograms for each 
peptidoglycan intermediate standard are shown in Figure 6.6. 
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Figure 6.6: Anion exchange chromatography of peptidoglycan intermediate standards. Elution position defined by conductivity at the center of the peak of standard 
elution (i) UDP-GlcNAc (conductivity 16.41 mS.cm-1), (ii) UDP-enolpyruvyl-GlcNAc (conductivity 45.57 mS.cm-1), (iii) UDP-MurNAc (conductivity 40.61 mS.cm-1), (iv) 
UDP-MurNAc-L-Ala (conductivity 34.68 mS.cm-1), (v) UDP-MurNAc-L-Ala-D-Glu (conductivity 41.29 mS.cm-1), (vi) UDP-MurNAc-L-Ala-D-Glu-m-DAP (conductivity 
38.54 mS.cm-1), (vii) UDP-MurNAc-L-Ala-D-Glu-m-DAP-D-Ala-D-Ala (conductivity 34.77 mS.cm-1). Samples were fractionation by MonoQ 5/50 GL resin. Red trace is 
absorbance at 254 nm, blue trace: absorbance at 280 nm and black trace; conductivity. 
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The 254 nm and 280 nm absorbance measured for each peptidoglycan intermediate 
standard showed single distinct peaks during ion exchange chromatography 
purification (Figure 6.6). One common identifier of eluted intermediates is the 
A254nm/A280nm ratio, which for uridine is 1:2.86 (Dawson, et al. 1986). The conductivity 
mS.cm-1 at which each of the standards eluted permitted preliminary and presumptive 
identification of potential peaks of interest obtained from ion exchange of metabolite 
pool extracted from B. subtilis treated with the pywac compounds. The conductivity at 
which each standard eluted is tabulated in table 6.3.  
 
 
UDP species Conductivity mS.cm-1 
UDP-GlcNAc 16.41  
UDP-enolpyruvyl-GlcNAc 45.57 
UDP-MurNAc 40.61 
UDP-MurNAc-L-Ala 34.68 
UDP-MurNAc-L-Ala-D-Glu 41.29 
UDP-MurNAc-L-Ala-D-Glu-m-DAP 35.85 
UDP-MurNAc-L-Ala-D-Glu-m-DAP-
D-Ala-D-Ala 
34.77 
Table 6.3 Conductivity of peptidoglycan precursor intermediate standards. Eluted from monoQ 
5/50 column by ion exchange chromatography 
 
To ensure that components of peaks eluted by anion exchange could be successfully 
characterised by mass spectrometry, the eluted peaks for each standard were subjected 
to three rounds of freeze drying in 50 mL H2O to remove the ammonium acetate. 
Samples were resuspended in H2O and prepared for mass spectrometry at a final 
concentration of 50 µM in 50% (v/v) acetonitrile, and subsequently analysed by 
negative ion mode mass spectrometry. The predicted mass:charge ratios (m/z) of each 
of the peptidoglycan intermediate standards are displayed in table 6.4, and compared to 
their observed value. 
 
All mass spectrometry was carried out in this thesis were by Dr Adrian Lloyd and Mrs. 
Anita Catherwood. Full spectra results are shown in Figures A3.1 to Figure A3.7 in 
appendix 3 with embedded zoomed in  m/z ranges of interest.  
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UDP Species (m-1)/1 (m-2)/2 (m-3)-3 
Observed Expected Observed Expected Observed Expected 
UDP-GlcNAc 606.07 606.07 302.53 302.53 - 201.35 
UDP enol pyruvoyl GlcNAc 676.08 676.07 337.53 337.53 - 224.68 
UDP-MurNAc 678.09 678.09 338.54 338.54 - 225.35 
UDP-MurNAc-L-Ala 749.14 749.13 374.07 374.06 - 249.03 
UDP-MurNAc-L-Ala-D-Glu 878.18 878.17 438.59 438.58 - 292.05 
UDP-MurNAc-L-Ala-D-Glu-m-
DAP 
1050.26 1050.25 524.63 524.62 - 349.41 
UDP-MurNAc-L-Ala-D-Glu-m-
DAP-L-Ala-L-Ala 
1192.34 1192.33 595.67 595.66 - 396.77 
Table 6.4 The mass/charge ratio for the peptidoglycan cytosolic DAP intermediate standards. Singly [M-H]-, doubly [M-2H]2- and triply [M-3H]3- charged observed and 
expected species of the various peptidoglycan DAP intermediates. 
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The mass spectrometry data from Figure A3.1 to Figure A3.7 (Appendix 3) identified the 
peptidoglycan intermediate standards isolated from ion exchange chromatography (Figure 6.6). 
Singly ([M-H]-) and doubly ([M-2H]2-) charged species were located within the full spectra which 
related to the known m/z ratios outlined in table 6.4. The data obtained from processed cells in the 
absence of antimicrobials, in the presence of excess MIC of vancomycin or excess MIC of  pywac 
compounds was then compared to the known standards to identify peaks of interest that were 
potentially comprised of accumulated of peptidoglycan intermediates. These monoQ conductivity 
comparisons were only used as an initial marker for potential identification due to differing 
methods of acquiring intermediates, synthesis versus accumulation. Potential intermediates were 
confirmed by mass spectrometry. 
 
 
6.6 Normal cellular distribution of B. subtilis peptidoglycan intermediates  
 
Growth of B. subtilis in minimal media was selected as a means of accumulating quantities of cell 
wall intermediates in the presence of the pywac compounds without competition from components 
of more complex media such as nutrient rich LB media. Pywac compounds were co-incubated at 
2x MIC (Table 6.1) with B. subtilis cells once they had reached late exponential phase at 37°C, at 
this point the protocol devised by Dr. Adrian Lloyd (Section 2.9.1)  was then used to isolate a 
crude fraction containing cytoplasmic peptidoglycan precursors which were further purified by 
size exclusion (Section 2.7.3.2) and ion exchange chromatography (Section 2.7.3.3) and species 
of interest were further characterised by mass spectrometry (Section 2.12). 
 
Alongside the pywac compounds, two sets of control samples were also implemented. One control 
was a baseline examination of standard intermediate accumulation of B. subtilis cells in the 
absence of inhibitors to understand the normal cellular distribution of cell wall intermediates. The 
second set of controls were B. subtilis cells exposed to 2x and 5x MIC of vancomycin. Both sets 
of controls were incubated in minimal media and exposed to 2% (v/v) DMSO to accurately 
compare controls to investigated samples.  
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The inhibitor-free B. subtilis control sample absent of inhibitors was processed first. The 
chromatogram from size exclusion chromatography is displayed in Figure 6.7. 
 
 
 
Figure 6.7: Size exclusion chromatography of B. subtilis control cells TCA extracted cells. Noted peak at (i) 83.29 
mL. Samples were eluted by Bio-gel P2 resin. Red trace is absorbance at 254 nm, blue trace is absorbance at 280 nm 
and black trace; conductivity. 
 
 
The gel filtration of the control B. subtilis sample (Figure 6.7) displayed the normal distribution of 
eluted peaks from control lysophilised cells separated out by size alone. Wavelengths of A254nm 
(Figure 6.7: Red) and A280nm (Figure 6.7: Blue) were measured along with the conductivity (Figure 
6.7: Black). Size exclusion chromatography isolated three separate peaks. The most prominent 
peak was the first (Figure 6.7: (i)) which eluted from the column after 83.29 mL and produced the 
initial increase in both measured wavelengths and conductivity. Based on previous work 
performed in the laboratory (Dr Adrian Lloyd, personal communication) it was observed that cell 
wall intermediates are amongst the first species to elute from the gel filtration due to their large 
comparative size.  
 
The A254nm/A280nm  ratio of the species in peak (i) was 1.72, slightly lower than expected for the 
presence of uridine containing components with an expected ratio of 2.86). This initial peak was 
isolated, freeze-dried and resuspended in water when a 2 µL aliquot was taken and added to 998 
µL of H2O. The A260nm of this dilution was 0.047. Subsequent samples mentioned in this chapter 
would also be assessed in the same way. All samples were diluted based on this measurement to 
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that of the most dilute sample (A260nm 0.02) prior to monoQ ion exchange to ensure that equal 
volume loading equated to loading of the same amount of material on a nucleotide basis. Further 
fractionation of peak (i) from Figure 6.9 on this basis by anion exchange on a MonoQ 5/50 GL 
resin column is shown in Figure 6.8. 
 
 
 
Figure 6.8: Anion exchange chromatography of isolated peptidoglycan intermediate peak of B. subtilis control 
cells. Noted peaks (i) (conductivity 13.65 mS.cm-1), (ii) (conductivity 16.78 mS.cm-1), (iii) (conductivity 21.27 mS.cm-
1), (iv) (conductivity 24.14 mS.cm-1), (v) (conductivity 32.93 mS.cm-1), (vi) (conductivity 38.85 mS.cm-1) and (vii) 
(conductivity 46.13 mS.cm-1). Red trace is absorbance at 254 nm, blue trace: absorbance at 280 nm and black trace; 
conductivity. 
 
The monoQ elution profile of the B. subtilis control (Figure 6.8) indicated the presence of a number 
of isolated peaks, from the initial size exclusion eluted peak (Figure 6.7: (i)). Seven notable peaks 
were visualised. The mAu intensity of each peak decreased as the conductivity within the column 
increased. Based upon the comparative conductivity of peptidoglycan intermediate standards, B. 
subtilis control isolated peak (ii) (16.78 mS.cm-1) eluted at a similar point to UDP-GlcNAc 
standard (Figure 6.6 (i): 16.41 mS.cm-1), isolated peak (v) (32.93 mS.cm-1) eluted at a similar point 
to both standards UDP-MurNAc-monopeptide (Figure 6.6 (iv): 34.68 mS.cm-1) and UDP-
MurNAc-pentapeptide (DAP) (Figure 6.6 (vii): 34.77 mS.cm-1), isolated peak (vi) (38.85 mS.cm-
1) eluted at a similar point to standard UDP-MurNAc-tripeptide (DAP) (Figure 6.6 (vi): 38.54 
mS.cm-1) and isolated peak (vii) (46.13 mS.cm-1) eluted comparatively to standard UDP-
enolpyruvyl-GlcNAc (Figure 6.6 (ii): 45.57 mS.cm-1). However, elution conductivity is not 
sufficient to identify potential peptidoglycan intermediates, particularly because the A254/A280 
ratio for the species fractionated in Figure 6.8 were not consistent with the presence of uridine 
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nucleotides. Therefore each of the monoQ B. subtilis control peaks (Figure 6.8) were collected and 
processed by mass spectrometry to attempt confirmation of the presence of cell wall intermediates 
and their relative abundance during unimpeded cellular growth. The mass spectra for each isolated 
peak are analysed from Figure A3.8 to Figure A3.14 in Appendix 3.  
 
Mass spectrometric analysis of the first two eluted peaks (i) (Figure 6.8: (i) conductivity 13.65 
mS.cm-1) and (ii) (Figure 6.8: (ii) conductivity 16.78 mS.cm-1) from the B. subtilis control monoQ 
purification shown in Figure A3.8 and Figure A3.9. Both peaks contained the initial subunit of the 
entire peptidoglycan biosynthesis pathway, UDP-GlcNAc, consistent with the conductivity data. 
Analysis of the mass spectrum of peaks (i) and (ii) identified singly charged ([M-H]-) species of 
UDP-GlcNAc: (i) expected m/z 606.07, observed m/z 606.08, (ii) expected m/z 606.07, observed 
m/z 606.08.  
 
The potential accumulation of UDP-GlcNAc by the pywac compounds would suggest although 
not be necessarily indicative of inhibition of MurA the first enzyme in the pathway which converts 
UDP-GlcNAc into UDP-enolpyruvyl-GlcNAc. For each of the mass spec results it should be noted 
is the presence of a single peak with a m/z ratio of 237.09 (Figure A3.8) consistently found 
amongst all samples. The most likely cause is a contaminant found in the acetonitrile, though 
assumed to not interfere with the results. 
 
Mass spectrometric analysis of the next two subsequent monoQ isolated peaks (iii) (Figure 6.8: 
(iii) conductivity 21.27 mS.cm-1) and (iv) (Figure 6.8 (iv) conductivity 24.14 mS.cm-1) from the 
B. subtilis control purification both contained UDP-MurNAc-pentapeptide DAP, the final subunit 
of the cytosolic peptidoglycan biosynthesis pathway. Mass spectra analysis of peaks (iii) (Figure 
A3.10) and (iv) (Figure A3.11) identified the doubly charged ion of UDP-MurNAc-pentapeptide 
in both samples. [M-2H]2- (iii) expected 595.66 m/z, observed m/z 595.67, (iv) expected m/z 
595.66, observed m/z 595.68 respectively. No singly charged species were identified though for 
either peak.  
 
The fifth identifiable peak from the isolated monoQ fractions of the B. subtilis control sample was 
in elution (v) (Figure 6.8 (v) conductivity 32.93 mS.cm-1). Mass spectra analysis (Figure A3.12) 
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revealed that this peak contained singly ([M-H]- observed m/z 878.19, expected m/z 878.17) and 
doubly ([M-2H]2- observed m/z 438.59, expected m/z 438.58) charged species consistent with the 
presence of UDP-MurNAc-dipeptide, the product of MurD and the substrate of MurE. Proposed 
accumulation at this stage in the peptidoglycan cell wall biosynthesis would indicate that flux 
through the MurD step was in excess of that through MurE. 
 
The final two isolated peaks eluted from the control sample (vi) (Figure 6.8 (vi) conductivity 38.85 
mS.cm-1 and (vii) (Figure 6.8 (vii) conductivity 46.13 mS.cm-1) on evaluation by negative ion mass 
spectrometry ((vi) Figure A3.13 and (vii) Figure A3.14) did not detect signals comparable to any 
of the known cell wall intermediates.  
 
Overall, elutions of peptidoglycan intermediates in the Bacillus subtilis control experiment was 
similar to the elution order observed by the standards, UDP-GlcNAc, UDP-MurNAc-pentapeptide 
(DAP) and UDP-MurNAc dipeptide (Figure 6.6 and Figure 6.8). 
 
The control data set established an estimation of conductivity ranges for each peptidoglycan 
intermediate. The inability to determine the other notable intermediates, UDP-MurNAc, UDP-
MurNAc-monopeptide and UDP-MurNAc-tripeptide DAP from the eluted peaks is not believed 
to be a problem. The control sample is the observation of normal cellular growth with the 
peptidoglycan pathway unimpeded. During this time intermediates within the pathway should be 
continually turned over at normal rates so long as ATP is present. Unless the pathway was inhibited 
the amount of any one intermediate should be constant at steady state. 
 
 
6.6.1 Intermediate accumulation of B. subtilis vancomycin control 
 
Whilst the control sample illustrated that Bacillus subtilis demonstrated detectable concentrations 
of the accumulated cytosolic intermediates UDP-GlcNAc, UDP-MurNAc-dipeptide and UDP-
MurNAc-pentapeptide (DAP) under normal cellular conditions the presence of the positive control 
vancomycin in excess MIC should specifically favour the accumulation of the peptidoglycan 
intermediate UDP-MurNAc-pentapeptide (DAP). Lysophilised cell contents from both the 2x and 
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5x MIC incubation were separated by size exclusion chromatography with a Bio-gel P2 column 
with a 2 mL loading volume in Figure 6.9.  
 
 
 
Figure 6.9: Size exclusion chromatography of B. subtilis TCA extracts of cells incubated with excess MIC 
vancomycin. (a) 2x MIC chromatogram of isolated peaks by Bio-gel P2 resin. Noted peak (i) 83.29 mL. (b) 5x MIC 
chromatogram of isolated peaks by Bio-gel P2 resin. Noted peak (i) 80.75 mL. 2 mL loading volume. Red trace is 
absorbance at 254nm, blue trace: absorbance at 280nm and black trace; conductivity. 
 
Findings for the positive control were similar to the normal cellular control absent of 
antimicrobials (Figure 6.7). The primary elution peak for both concentrations (Figure 6.9: (a): (i) 
and (b): (i))) were at 83.29 mL and 80.75 mL respectively. The gel filtration of 2x and 5x MIC 
vancomycin differed solely by the intensity of the measured absorbance of the initial peaks pre 85 
mL. The 2x MIC sample peak (i) plateaued at 45 mAu for A254nm whereas the 5x MIC control peak 
(i) attained a peak height of 180 mAu at A254nm, four times the signal emitted by the potential 
intermediates found at 2x MIC vancomycin. The concentration of the inhibitor increased the 
accumulation of the primary peak and reduced the observed secondary and tertiary peaks. 
 
Primary peak elutions of both vancomycin positive controls were isolated, measured at A260nm, 
diluted to an equivalent absorbance and further separated on the monoQ column as shown in Figure 
6.10. 
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Figure 6.10: Anion exchange chromatography of gel filtration elutes (peak (i)) from B. subtilis treated with 
excess MIC vancomycin. (a) 2x MIC chromatogram of isolated peaks by MonoQ 5/50 GL resin. Noted peak (i) 
(conductivity 26.55 mS.cm-1). (b) 5x MIC chromatogram of isolated peaks by MonoQ 5/50 GL resin. Noted peak (i) 
(conductivity 25.15 mS.cm-1). Red trace is absorbance at 254nm, blue trace: absorbance at 280nm and black trace; 
conductivity. 
 
The addition of twice the MIC of vancomycin was sufficient to alter the normal distribution of 
intermediates viewed in the control (Figure 6.8), culminating in the increased absorbance of a 
single eluted peak, which eluted from the monoQ column at a conductivity of 26.55 mS.cm-1 
(Figure 6.10). This peak (i) has an absorbance of 48 mAu at A254nm, 2.5 times greater than the next 
most abundant species. Purification of the control sample showed that the initial elution peak UDP-
GlcNAc (Figure 6.8 (i)) reached a maximum absorbance of 60 mAu (A254nm). The corresponding 
UDP-GlcNAc initial elution peak in the 2x vancomycin sample amounted to only a third of that 
value at 20 mAu at A254nm. The increased accumulation of peak (i) in the presence of 2x MIC of 
vancomycin reduced the relative overall abundance of the surrounding peaks. Vancomycin is 
known to cause UDP-MurNAc-pentapeptide accumulation. This species which eluted from the 
control monoQ experiment (Figure 6.8: (iv)) at a conductivity of 24.14 mS.cm-1, was comparable 
to the conductivity at elution of peak (i) (Figure 6.10a) from the 2x MIC incubation (26.55 mS.cm-
1). The A254/A280 ratio of peak (i) at its apex was 2.78, consistent with the expected value of 2.86 
for a uridine containing nucleotide. 
 
The addition of five times the MIC of vancomycin lead to the presence of a single peak during ion 
exchange chromatography (Figure 6.10 (b): (i)) of greater magnitude than previously observed. 
The measured intensity of this peak reached 332 mAu at an absorbance of 254 nm which was 6.93 
times greater than the equivalent peak noted during monoQ purification of B. subtilis incubated 
with 2x MIC of vancomycin (Figure 6.10: (a)). The A254/A280 ratio of peak (i) in Figure 6.10 (b) 
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was 2.32. The peak eluted at a conductivity of 25.15 mS.cm-1, and dominated the elution profile. 
This observable accumulation of an intermediate diminished the absorbance of surrounding 
fractions as the proportion of the peak (i) material increased greatly. Each of the 2x and 5x MIC 
vancomycin prominent peaks from ion exchange purification were analysed by mass spectrometry 
to identify the potential presence of specific peptidoglycan intermediates. The data obtained from 
the 2x MIC vancomycin sample mass spectrometry is shown in Figure A3.15. 
 
The mass spectral analysis in Figure A3.15 indicated the detection of a UDP-MurNAc-
pentapeptide (DAP) dimeric species ([M-2H]2- observed m/z 595.6666, expected m/z 595.6629). 
The incubation of 2x MIC of the positive control is sufficient to accumulate and identify the 
specific intermediate targeted by antibiotic inhibition. The data obtained from the 5x MIC 
vancomycin sample mass spectrometry is shown in Figure A3.16. 
 
The mass spectral analysis (Figure A3.16) identifies the fraction as containing UDP-MurNAc-
pentapeptide (DAP) ([M-2H]2- observed m/z 595.6667, expected m/z 595.6629; [M-3H]3- 
observed m/z 396.774, expected m/z 396.7727). These observations mirrored what was observed 
with the 2x vancomycin MIC control (Figure A3.15). The accumulation of the intermediate was 
sufficient enough to be visible on the full mass spectra (Figure A3.16 (a)). The results for the 
positive controls indicated that this protocol is capable of investigating the potential of the pywac 
compounds to accumulate intermediates from the peptidoglycan pathway. The 2x MIC treatment 
was deemed efficient enough to measure a response and was chosen as the investigated 
concentration of the cell wall active pywac compounds. 
 
 
6.6.2 Intermediate accumulation of B. subtilis against pywac compounds 
 
Pywac compounds were incubated with a sufficient culture volume to produce a final harvested 
cell wet pellet weight of 1 g to provide sufficient material for further analysis. Each of the B. 
subtilis cultures incubated with pywac compounds were processed and peaks of interest further 
investigated. Results for pywac compounds 1-9 are combined based on similar ion exchange 
chromatography elution profile and mass spectrometry detect or lack thereof.  
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6.6.2.1 Intermediate accumulation of B. subtilis against pywac compounds 1, 3, 
5, 6 and 7 
 
The effects of pywac compounds 1, 3, 5, 6 and 7 on B. subtilis cellular contents were analysed by 
size exclusion and ion exchange chromatography in Figure 6.11. 
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Figure 6.11: Size exclusion and ion exchange chromatography of B. subtilis TCA extracts of cells incubated with 2x MIC pywac 1, 3, 5, 6 and 7. (i) Pywac 
1 (a) Size exclusion chromatogram of isolated peaks by Bio-gel P2 resin. Noted peak at (i) 95.51 mL. (b) ion exchange chromatogram of isolated peaks by MonoQ 
5/50 GL resin. Noted peak (i) (conductivity 18.12 mS.cm-1). (ii) Pywac 3 (a) Size exclusion chromatogram of isolated peaks by Bio-gel P2 resin. Noted peak at (i) 
96.34 mL. (b) ion exchange chromatogram of isolated peaks by MonoQ 5/50 GL resin. Noted peak (i) (conductivity 25.47 mS.cm-1). (iii) Pywac 5 (a) Size exclusion 
chromatogram of isolated peaks by Bio-gel P2 resin. Noted peak at (i) 133.27 mL. (b) ion exchange chromatogram of isolated peaks by MonoQ 5/50 GL resin. 
Noted peak (i) (conductivity 24.26 mS.cm-1). (iv) Pywac 6 (a) Size exclusion chromatogram of isolated peaks by Bio-gel P2 resin. Noted peak at (i) 133.28 mL. 
(b) ion exchange chromatogram of isolated peaks by MonoQ 5/50 GL resin. Noted peak (i) (conductivity 25.68 mS.cm-1). (v) Pywac 7 (a) Size exclusion 
chromatogram of isolated peaks by Bio-gel P2 resin. Noted peak at (i) 133.28 mL. (b) ion exchange chromatogram of isolated peaks by MonoQ 5/50 GL resin. 
Noted peak (i) (conductivity 24.17 mS.cm-1). Red trace is absorbance at 254nm, blue trace: absorbance at 280nm and black trace; conductivity.
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The size exclusion chromatogram (Figure 6.11: (i)-(v) (a)) of B. subtilis cells incubated 
with 2x MIC of pywac compounds 1, 3, 5, 6 and 7 differed from the B. subtilis control 
(Figure 6.7). The control chromatogram displayed isolated individual peaks whereas 
the pywac samples displayed a narrower elution profile with multiple peaks of similar 
intensities visualised. The elution of the pywac 1 and 3 samples was displaced by an 
extra 12 mL compared to the control, whereas pywac 5, 6 and 7 samples were displayed 
by an extra 49 mL. The major reason for these variations was the twice necessary 
repacking of P200 column with Bio-gel P2 resin, due to accidental damage. Each 
subsequent size exclusion chromatography in this chapter except B. subtilis incubation 
with pywac 2 (Figure 6.12) was performed with the repacked column.  
 
As with previous experiments the initial eluted peak from size exclusion 
chromatography (Figure 6.11 (a): (i)) was isolated for each sample and further 
fractionated by ion exchange chromatography (Figure 6.11 (b)). Although the gel 
filtration data differed from the control, the B. subtilis pywac compounds 
chromatograms produced during MonoQ purification were reminiscent of the peak 
distribution observed with the control data (Figure 6.8), with one exception observed 
in each. A single noted variable peak of interest, greater in intensity than during the 
control was eluted from the MonoQ column of each sample.  
 
The conductivity of the noted peak (i) for pywac 1 (Figure 6.11 (i) (b)) was 18.12 
mS.cm-1, with an absorbance three times greater than equivalent peaks found in the 
control. Based on the conductivity value alone, the accumulation of this peak is between 
conductivity results obtained for the intermediates UDP-GlcNAc (Figure 6.8 (ii) 16.78 
mS.cm-1) and UDP-MurNAc-pentapeptide (DAP) (Figure 6.8 (iii) 21.27 mS.cm-1) 
identified in the control purification. The ratio between A254nm/A280nm however was 
3.82, not the expected 2.86 ratio proposed for intermediates containing a uridine ring. 
 
The conductivity of the noted peaks (i) for pywac 3 (Figure 6.11 (ii) (b)), 5 (Figure 6.11 
(iii) (b)), 6 (Figure 6.11 (iv) (b)) and 7 (Figure 6.11 (iv) (b)) were 25.47 mS.cm-1, 24.26 
mS.cm-1, 25.68 mS.cm-1 and 24.17 mS.cm-1 respectively. Comparing these 
conductivity values to the B. subtilis control (Figure 6.8) suggests a similar conductivity 
observed in elutions containing UDP-MurNAc-pentapeptide (DAP) (Figure 6.8 (iv) 
conductivity 24.14 mS.cm-1), although the A254nm/A280nm ratios observed for each peak 
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do not demonstrate the 2.86 ratio commonly used to identify the elutions containing a 
uridine ring. 
 
The mass spectrometric analysis of these peaks are shown from Figure A3.17 to Figure 
A3.21 in Appendix 3. 
 
Based upon the m/z range investigated and the values attributed to known intermediates 
it was concluded that the incubation of B. subtilis with pywac compounds 1, 3 5, 6, and 
7 does not lead to an accumulation of cell wall peptidoglycan intermediates. The signals 
analysed from the isolated elutions (Figure 6.11 (b): (i)) did not denote any of the 
known m/z values or spectral properties of peptidoglycan intermediates, leading to the 
conclusion that the observed accumulation of the sample was not a peptidoglycan 
precursor. 
 
 
6.6.2.2 Intermediate accumulation of B. subtilis against pywac 
compound 2 
 
 
 
Figure 6.12: Size exclusion and ion exchange chromatography of B. subtilis TCA extracts of cells 
incubated with 2x MIC pywac 2. (a) Size exclusion chromatogram of isolated peaks by Bio-gel P2 
resin. Noted peak at (i) 83.30 mL. (b) ion exchange chromatogram of isolated peaks by MonoQ 5/50 GL 
resin. Noted peak (i) (conductivity 18.80 mS.cm-1) and (ii) (conductivity 22.11 mS.cm-1). Red trace is 
absorbance at 254nm, blue trace: absorbance at 280nm and black trace; conductivity. 
 
The size exclusion chromatogram of the TCA extracted sample from B. subtilis exposed 
to 2x MIC pywac 2 (Figure 6.12 (a)) was similar in elution profile to the control, with 
a notable initial peak (i). As cells incubated with pywac 2 were processed before the 
gel filtration column was repacked, leading to the elution of components of pywac 2 
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sample starting at 83.30 mL similar to that of the control (Figure 6.7). The monoQ 
purification (Figure 6.12 (b)) profile was characterised by elution of peaks (i) (Figure 
6.12 conductivity 18.80 mS.cm-1) and (ii) (Figure 6.12 conductivity 22.11 mS.cm-1). 
These peaks eluted at a conductivity similar to those that in the B. subtilis control 
contained UDP-GlcNAc (Figure 6.8: (ii)) and UDP-MurNAc-pentapeptide (DAP) 
(Figure 6.8: (iii)) respectively. The two peaks were isolated and analysed by mass 
spectrometry in Figure A3.18 and Figure A3.19 in Appendix 3. 
 
Analysis (Figure A3.18) of the first isolated peak (i) from Figure 6.12 (b) failed to 
identify a species with a mass to charge ratio consistent with that of any known cell 
wall intermediate. Therefore, this peak was not caused by accumulation of 
peptidoglycan precursors. 
 
Mass spectral analysis (Figure A3.19) of the second eluted peak of note from Figure 
6.12 (b) (ii) provided an immediately recognisable UDP-MurNAc-pentapeptide (DAP) 
doubly and triply charged signal ([M-2H]2- Observed m/z 595.66 expected m/z 595.66, 
[M-3H]3- Observed m/z 396.77, expected m/z 396.77). The increase in absorbance of 
the second isolated peak was slightly greater than the equivalent peak from the control 
sample (Figure 6.8: (iii). Proposed accumulation of UDP-MurNAc-pentapeptide by the 
pywac compounds would suggest inhibition of either the enzymes involved in lipid 
synthesis such as MraY catalysing the formation of lipid I, recycling of undecaprenyl 
pyrophosphate back to undecaprenyl phosphate or that the compounds binds directly to 
the D-Alanyl-D-Ala subunit in a similar manner to vancomycin. 
 
 
6.6.2.3 Intermediate accumulation of B. subtilis against pywac 
compounds 4 and 9 
 
The size elution and ion exchange chromatography of B. subtilis cell extracts incubated 
with pywac compounds 4 and 9 are shown in Figure 6.13. 
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Figure 6.13: Size exclusion and ion exchange chromatography of B. subtilis TCA extracts of cells 
incubated with 2x MIC pywac compounds 4 and 9. (i) Pywac 4 (a) Size exclusion chromatogram of 
isolated peaks by Bio-gel P2 resin. Noted peak at (i) 133.28 mL. (b) ion exchange chromatogram of 
isolated peaks by MonoQ 5/50 GL resin. No noted peaks were identified. (ii) Pywac 9 (a) Size exclusion 
chromatogram of isolated peaks by Bio-gel P2 resin. Noted peak at (i) 133.28 mL. (b) ion exchange 
chromatogram of isolated peaks by MonoQ 5/50 GL resin. No noted peaks were identified. Red trace is 
absorbance at 254nm, blue trace: absorbance at 280nm and black trace; conductivity. 
 
The addition of pywac compounds 4 and 9 to B. subtilis cells led to a similar size 
exclusion elution profile (Figure 6.13 (a)) observed as a result of treatment with other 
pywac compounds (Figure 6.11 (a)) with no obvious accumulation. The volume taken 
to reach the initial elution was 40 mL greater than previously observed for both 
compounds at 133.28 mL. The volume difference was due to further reconstruction of 
the Bio-gel P200 column. The initial eluted peak for both cell extracts from gel 
filtrations were further purified by ion exchange (Figure 6.13 (b)). The results appeared 
to match the control sample (Figure 6.8) leading to the conclusion that pywac 
compounds 4 and 9 did not alter the cell intermediate pool extracted and therefore no 
fractions were sent to be further analysed by mass spectrometry. Results indicated that 
the target of pywac compounds 4 and 9 in B. subtilis remains to be identified. 
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6.6.2.4 Intermediate accumulation of B. subtilis against pywac 8 
 
 
Figure 6.14: Size exclusion and ion exchange chromatography of B. subtilis TCA extracts of cells 
incubated with 2x MIC pywac 8. (a) Size exclusion chromatogram of isolated peaks by Bio-gel P2 
resin. Noted peak at (i) 133.27 mL. (b) ion exchange chromatogram of isolated peaks by MonoQ 5/50 
GL resin. Noted peak (i) (conductivity 18.85 mS.cm-1). Red trace is absorbance at 254nm, blue trace: 
absorbance at 280nm and black trace; conductivity. 
 
The penultimate compound tested, pywac 8 produced a unique size exclusion elution 
profile (Figure 6.14 (a)). Here pywac 8 treated cell extracts chromatographed in a 
similar manner reminiscent of either the control (Figure 6.7) or the vancomycin positive 
controls (Figure 6.9) with a significant initial peak separate from the subsequent peaks. 
The further purification of this fraction (Figure 6.14 (b)) led to an ion exchange 
chromatogram with a noted difference from the control sample (Figure 6.8). The first 
and major eluting peak (Figure 6.14 (b): (i)) with a conductivity of 18.85 mS.cm-1 was 
more pronounced though not equivalent to the vancomycin positive controls, with a 
marked reduction in surrounding peaks. As previously observed, the initial control peak 
(Figure 6.8 (i)) contained the UDP-GlcNAc intermediate, which if accumulated to a 
degree would decrease the concentration of UDP-MurNAc-pentapeptide (DAP) 
previously observed in the subsequent peaks. The initial elution was analysed by mass 
spectrometry in Figure A3.24 in Appendix 3 to identify the presence of potential 
intermediates.  
 
The mass spectrometry data in Figure A3.24 positively identified the fraction as 
containing the singly charged species of UDP-GlcNAc ([M-H]- observed m/z 606.08, 
expected m/z 606.07).  
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6.7 Purification of non-peptidoglycan intermediate standards 
 
A number of the ion exchange purifications identified a potential accumulation during 
pywac incubation not attributed to peptidoglycan intermediates. Other possible 
candidates for accumulation that would impact the peptidoglycan pathway include the 
nucleotides adenosine tri-phosphate (ATP), adenosine di-phosphate (ADP) and 
adenosine mono-phosphate (AMP), the structures of whom are displayed in Figure 
6.15.  
 
 
 
Figure 6.15: The structure of Adenosine mono-phosphate (AMP), Adenosine di-phosphate (ADP) 
and Adenosine tri-phosphate (ATP). Molecular weight: AMP 347.22, ADP 427.20, ATP 507.18; 
Chemical formula: AMP C10H14N5O7P, ADP C10H15N5O10P2, ATP C10H16N5O13P3. The above schematic 
was created using ChemBioDraw. 
 
A key component of peptidoglycan pathway is the utilisation of ATP for the formation 
of the pentapeptide stem to UDP-MurNAc catalysed by the Mur ligases C-F (Munshi, 
et al. 2013), generating ADP. Inhibition targeted towards an ATP synthase would 
impact the ability of the cell to generate ATP and lead to accumulation of ADP. 
Samples from monoQ fractionation of gel filtration elutes of B. subtilis sample extracts 
treated with pywac compounds 1, 3, 5, 6, and 7 displayed isolated peaks of greater 
intensity than the control sample (Figure 6.8) but analysis of these peaks revealed that 
they did not contain known species of peptidoglycan intermediates. To establish 
whether these samples contained adenosine nucleotides initially, standards of ATP, 
ADP and AMP at a ratio of 3:2:1 were chromatographed by ion exchange 
chromatography in Figure 6.16 to observe elution conductivity and amenability to mass 
spectral analysis in Figure A3.25. 
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Figure 6.16: Anion exchange chromatography of AMP, ADP and ATP standards. Noted peaks (i) 
AMP (conductivity 15.94 mS.cm-1), (ii) ADP (conductivity 31.55 mS.cm-1), (iii) ATP (conductivity 
43.21 mS.cm-1) were isolated by MonoQ 5/50 GL resin. Red trace is absorbance at 254nm, blue trace: 
absorbance at 280nm and black trace; conductivity. 
 
The three adenosine standards eluted consecutively with sufficient separation to 
distinguish between peaks. The standards eluted in the order of AMP (Figure 6.16 (i)), 
ADP (Figure 6.16 (ii)) and ATP (Figure 6.16 (iii)) with 254 nm absorbances measured 
at the stated ratio of 1:2:3. The conductivity of each standard was 15.94 mS.cm-1 
(AMP), 31.55 mS.cm-1 (ADP) and 43.21 mS.cm-1 (ATP). Standards were analysed by 
mass spectrometry in Figure A3.25 in Appendix 3. The known m/z values for each 
singly, doubly and triply charged species are presented in table 6.5 Comparing eluted 
conductivities of ATP, ADP and AMP to those peaks of interest accumulated during 
pywac incubation, it was clear that the pywac peaks were not adenosine nucleotides.  
 
 
Adenosine nucleotide (m-1)/1 (m-2)/2 (m-3)-3 
ATP 505.98 252.49 167.99 
ADP 426.02 212.51 141.34 
AMP 346.05 172.52 144.68 
Table 6.5 The mass/charge ratio for ATP, ADP and AMP. Singly (m-1)/1, doubly (m-2)/2 and triply 
(m-3)/3 charged species of the adenosine nucleotides. 
 
The mass spectral analysis of standards showed the presence of singly charged species 
of each adenosine nucleotide. ATP (Figure A3.25 (i)) ([M-H]- observed m/z 505.9882, 
expected m/z 505.9888), ADP (Figure A3.25 (ii)) ([M-H]- observed m/z 426.0229, 
expected m/z 426.0217) and AMP (Figure A3.25 (iii)) ([M-H]- observed m/z 346.0559, 
expected m/z 346.0554).  
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Another non-peptidoglycan intermediate standard to compare against the pywac 
accumulation was NADPH. The cofactor is utilized by MurB to reduce the 
enolpyruvate double bond on UDP-GlcNAc-enolpyruvate generating UDP-MurNAc. 
The structure is depicted in Figure 6.17. 
 
 
 
Figure 6.17: The structure of NADPH. Molecular weight: 727.41; Chemical formula: C21H28N7O16P32-
. The above schematic was created using ChemBioDraw. 
 
A 1000 µL aliquot 1 mM stock of NADPH was loaded onto a monoQ column to analyse 
the purity of the sample and identify the elution conductivity as described in Figure 
6.18. 
 
 
 
Figure 6.18: Anion exchange chromatography of NADPH standard. Noted peaks (i) (conductivity 
18.93 mS.cm-1) was isolated by MonoQ 5/50 GL resin. Red trace is absorbance at 254nm, blue trace: 
absorbance at 280nm and black trace; conductivity. 
 
The NADPH standard eluted (Figure 6.18) at a conductivity of 18.93 mS.cm-1. Th 
conductivity of the elution of NADPH was similar to the conductivity of the first B. 
subtilis monoQ purification peak, commonly containing UDP-GlcNAc. This 
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conductivity was too low to equate with unknown pywac accumulations. The standard 
was analysed by mass spectrometry in Figure A3.26 in Appendix 3.  
 
The mass spectra analysis of NADPH (Figure A3.26) identified the doubly ([M-2H]2- 
observed m/z 371.54, expected m/z 371.53) charged species relating to the cofactor. 
Previously isolated elutions did not match NADPH. 
 
 
6.8 Inhibition of Lipid II synthesis  
 
The activity of the pywac compounds towards the bacterial cell wall likely encompasses 
more than just the cytosolic pathway. UDP-MurNAc-pentapeptide the product of the 
cytosolic pathway is converted into lipid linked intermediates by the enzymes MraY 
and MurG (Lloyd, Brandish et al. 2004) (Section 1.3.4). In vitro Lipid II is constructed 
through the utilisation of bacterial membranes supplemented with UDP-GlcNAc and 
undecaprenyl phosphate (Breukink, van Heusden et al. 2003). Extracted bacterial 
membranes contain native MraY, the standard protocol for this technique comprises of 
M. flavus membrane due to the increased abundance of the required enzymes. This 
method is preferred to expressing the recombinant MraY protein due to the difficulty 
of purifying this enzyme which is a ten transmembrane protein (Lloyd, Brandish et al. 
2004). Small scale synthesis of Lipid II samples was prepared as outlined in Section 
2.8.4 with any alterations to the protocol mentioned. 
 
 
6.8.1 Lipid II synthesis utilising B. subtilis membranes 
 
As the activity of the pywac compounds was tested in B. subtilis cells, the protocol was 
adapted to incorporate the membranes of this organism. Membranes were extracted 
from cells grown to exponential phase within minimal media and LB as detailed in 
Section 2.8.3. The activity of the membranes harvested from cells grown under these 
conditions was trialled as a small scale Lipid II synthesis (Section 2.8.4), with all 
reagents employed scaled down to 25% of the full lipid synthesis and samples were 
incubated at 37°C overnight. The resulting lipids were analysed by Silica TLC (Section 
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2.8.4.2) accompanied by a Lipid II (DAP) positive control. The results are shown in 
Figure 6.19.  
 
 
 
Figure 6.19: TLC of fractions from lipid synthesis of Lipid II (DAP) to assess membrane activity 
in selected media. B. subtilis membranes extracted from cells in LB (1) and minimal media (2). Lipid II 
(DAP) standard 50 µM (3) identifies the migration of the lipid. Silica gel TLC plate chromatography 
with Chloroform/methanol/Water ammonia (88:48:10:1) solvent. TLC plate stained with iodine vapour. 
(a) Lipid II, (b) the origin and (c) denotes the solvent front. 
 
The migration of the lipids was indicated by the location of the Lipid II (DAP) positive 
control (Figure 6.19 (3a)) Lipids (Figure 6.19 (1a) and (2a)) were synthesised from each 
of the small scale synthesises. The utility of minimal media for growth did not impact 
on the efficacy of the membranes with respect to lipid synthesis (Figure 6.19 (2)) 
compared to membranes prepared from cells grown in nutrient LB media (Figure 6.19 
(1)). Based on this result all lipid synthesis experiments used B. subtilis membranes 
grown from minimal media to aid in determining inhibition. 
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6.8.2 Lipid synthesis in the presence of pywac compounds  
 
The full scale synthesis of lipid II was performed in the presence of 50 µM of each 
pywac compound for 4 hours at 37°C. A control synthesis in the absence of compound 
was also performed as a comparison. The reduced time frame from overnight 
incubation to 4 hours was decided upon to maximise the sensitivity of the technique to 
detection of inhibition of lipid synthesis by the pywac compounds. Once the incubation 
was complete the lipid phase was extracted by pyridinium acetate, N-butanol and H2O 
additions (Section 2.8.4). A small amount of each synthesis was separated from the 
main volume and all volumes were desiccated to remove liquid. The small unpurified 
aliquots were resuspended in a small amount of solvent A (2:3:1 
Chloroform:Methanol:Water) and spotted onto warmed TLC plates to monitor lipid 
synthesis utilising TLC chromatography (Section 2.8.4.2). TLC plates were stained 
with iodine vapours and imaged as shown in Figure 6.20.  
 
 
 
Figure 6.20: TLC of unpurified fractions from lipid synthesis of Lipid II (DAP) co-incubated with 
50µM of pywac compounds 1-9 and no compound control C. Silica gel TLC plate chromatography 
with Chloroform/methanol/Water ammonia (88:48:10:1) solvent. TLC plate stained with iodine vapour. 
(a) Synthesised lipid, (b) undecaprenyl phosphate, (c) undecaprenyl pyrophosphate, (d) the origin and 
(e) denotes the solvent front. 1-9 refers to pywac compounds 1-9. C refers to lipid control. 
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Results from Figure 6.20 indicate the presence of lipids in all synthesised samples 
(Figure 6.20 (a)). The variation in the migration of these lipids was caused be the 
uneven absorption of the TLC running buffer to the silica plate, preferentially migrating 
at an accelerated rate in the centre of the plate. The ability of the B. subtilis membranes 
to synthesise lipids was observed to be successful in the presence of all pywac 
compounds although this result alone does not identify the type of lipid produced. The 
absence of any form of inhibition would lead to the formation of Lipid II. Inhibition 
solely of MurG by the pywac compounds would lead to the creation of Lipid I, which 
would migrate to a similar extent as Lipid II on silica TLC. The results suggested that 
the nine pywac compounds do not elicit activity towards MraY, as hindrance would 
culminate in the absence of synthesised lipid and the presence of UDP-MurNAc-
pentapeptide.  
 
 
6.8.2.1 Purification of synthesised lipids co-incubated with pywac 
compounds 
 
The extracted unpurified aliquots identified the synthesis of lipids when B. subtilis was 
co-incubated with pywac compounds. The remaining desiccated synthesised lipids 
samples were purified by anion exchange chromatography on DEAE Sephacel as 
described in Section 2.8.4.1. Previous investigations from other members of the 
laboratory (Julie Tod, personal communication) have indicated that Lipid II DAP 
remained bound to the column at high ammonium bicarbonate (AB) concentrations (0.2 
M) and required a second 1 M wash to elute. Based upon this knowledge once all 
synthesised lipid samples were purified isocratically by AB concentrations ranging 
from 50 mM to 1 M, small aliquots were taken of the three most concentrated elutions 
of AB (500 mM, 1 M and 1 M repeat) for each pywac incubated sample. The three 
aliquots were resuspended in chloroform/methanol/water (2:3:1) (solvent A) and 
loaded onto Silica TLC plates. Figure 6.21 displays the TLC of purified lipids incubated 
with pywac compounds 1-3 as well as the compound absent control. Figure 6.22 
displays the TLC of purified lipids incubated with pywac compounds 4-9. 
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Figure 6.21: Thin-layer chromatography of purified lipid fractions co-incubated with 50 µM 
pywac compounds 1, 2 3 and no compound control. Lipid synthesis utilizing B. subtilis membranes 
extracted from cells in minimal media co-incubated with compounds pywac 1 (1a-c), pywac 2 (2a-c) 
pywac 3 (3a-c) or without compound control (C1-3). Lipids eluted from DEAE sephacel fast flow resin 
column by isocratic additions of ammonium bicarbonate 50 mM to 1 M. Silica gel TLC plate 
chromatography with Chloroform/methanol/Water ammonia (88:48:10:1) solvent. TLC plate stained 
with iodine vapour. (a) Lipid II, (b) the origin and (c) denotes the solvent front. Lipids eluted during the 
second 1M AB wash highlighted by black squares. 
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Figure 6.22: Thin-layer chromatography of purified lipid fractions co-incubated with 50 µM 
pywac compounds 4, 5, 6, 7, 8 and 9. Lipid synthesis utilizing B. subtilis membranes extracted from 
cells in minimal media co-incubated with compounds pywac 4 (4a-c), pywac 5 (5a-c), pywac 6 (6a-c), 
pywac 7 (7a-c), pywac 8 (8a-c) and pywac 9 (9a-c). Lipids eluted from DEAE sephacel fast flow resin 
column by isocratic additions of ammonium bicarbonate 50 mM to 1 M. Silica gel TLC plate 
chromatography with Chloroform/methanol/Water ammonia (88:48:10:1) solvent. TLC plate stained 
with iodine vapour. (a) Lipid II, (b) the origin and (c) denotes the solvent front. Lipids eluted during the 
second 1M AB wash highlighted by black squares. 
 
TLC of the purified pywac lipid samples (Figure 6.21 (a), Figure 6.22 (a)), identified 
the presence of purified lipids within the repeat 1 M ammonium bicarbonate elution. 
None of the purified lipids or any excess reagents or impurities were observed within 
the 500 mM and the first 1 M elution. Each of the synthesised lipids migrated to a 
comparable degree as the control (Figure 6.21: control (a)) with only minor variation 
most notably pywac sample 7. The solvents present in purified lipid samples were 
removed by desiccation and samples were submitted for negative ion mass 
spectrometry analysis.  
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6.8.2.2 Identification of lipids co-incubated with pywac compounds 
 
Lipids were synthesised by the displacement of UMP from UDP-MurNAc-
pentapeptide (DAP) by undecaprenyl phosphate to form Lipid I, which was 
subsequently glucosaminylated with UDP-GlcNAc to form Lipid II. These reactions 
were catalysed by MraY and MurG respectively. The expected m/z ratios for negative 
ion singly, doubly and triply charged species of Lipid I (DAP) and Lipid II (DAP) are 
recorded in table 6.6.  
 
 
Lipid species Expected m/z 
(m-1)/1 (m-2)/2 (m-3)-3 
Lipid I DAP (MurNAc) 1714.97 856.98 570.99 
Lipid II DAP (MurNAc) 1918.04 958.51 638.67 
Table 6.6 The mass/charge ratio for N-acetylated Lipid I DAP and N-acetylated Lipid II DAP. 
Singly (m-1)/1, doubly (m-2)/2 and triply (m-3)/3 charged species stated. 
 
Each of the small scale synthesis were successful in producing lipids in the presence of 
all pywac compounds as observed by the TLC results (Figure 6.21 and Figure 6.22). 
To distinguish between the two possible variants, Lipid I and Lipid II each sample was 
subjected to mass spectrometric analysis beginning with the compound absent control 
in Figure A3.27.  
 
The mass spectral analysis (Figure A3.27) of the control Lipid II synthesis sample 
detected the singly ([M-H]- observed m/z 1918.03 expected m/z 1918.04) and doubly 
([M-2H]2- observed m/z 958.51 expected m/z 958.51) charged species of Lipid II DAP, 
confirming the accuracy of the protocol utilised (Section 2.8.4). The purified pywac 
incubated lipid samples were subsequently analysed by mass spectrometry from Figure 
A3.28 to Figure A3.36. 
 
The synthesis of Lipid II (DAP) by B. subtilis membranes despite the presence of  each 
pywac compound was confirmed by negative ion mass spectrometry (Figure A3.28 to 
Figure A3.36). The doubly (expected m/z 958.51) and triply (expected m/z 638.67) 
charged m/z ratios for each species agreed with the expected values for with Lipid II 
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(DAP). The mass spectral analysis confirmed that the activity of pywac compounds 1-
9 was likely not targeted towards either MraY or MurG, with potentially one exception. 
Analysis of pywac 7 lipid synthesis (Figure A3.34) determined that the relative 
abundance of the lipid was dramatically reduced compared to the other samples. 
Relating the intensity of the doubly charged [M-2H]2- ion of Lipid II DAP to that of the 
constant presence of the unknown solvent contaminant (255.2346 m/z). The signal for 
the pywac 7 sample was negligible relative to that of other lipid samples.  
 
Lipid II was not the sole cellular structure observed in all samples. The presence of 
other peptidoglycan precursors in pywac 2 and 3 samples during mass spectrometry 
analysis was shown in Figure A3.37 and Figure A3.38 respectively. 
 
Two of the analysed samples incubated with pywac 2 (Figure A3.37) and pywac 3 
(Figure A3.38) were also determined to contain singly ([M-H]- expected m/z 606.07) 
and doubly ([M-2H]2- expected m/z 302.53) charged species of UDP-GlcNAc. Both 
samples were analysed (Figure A3.29 and Figure A3.30) and as previously mentioned 
a significant abundance of both dimeric and trimeric species characterising Lipid II 
(DAP) were detected. Detection of UDP-GlcNAc in these samples is likely attributed 
to errors during purification and collection of separated phases, as Lipid I was not 
detected by mass spectrometry in either sample which would be observed during MurG 
inhibition.  
 
Quantification of the purified lipid samples was undertaken to assess the comparative 
concentration of Lipid II once incubated with pywac compounds. The method used is 
described in Section 2.8.4.3. The concentration of each synthesised lipid II is stated in 
table 6.7 
 
 
 
 
 
 
 
 285 
Lipid sample Lipid concentration 
Control 120 µM 
Pywac 1 110µM 
Pywac 2 128 µM 
Pywac 3 139 µM 
Pywac 4 111 µM 
Pywac 5 121 µM 
Pywac 6 105 µM 
Pywac 7 27 µM 
Pywac 8 116 µM 
Pywac 9 123 µM 
Table 6.7 Concentrations of synthesised Lipid II co-incubated with 50 µM of pywac compounds 1-
9. Small scale lipid synthesis of 200 µL final volume. Lipids were purified on a DEAE Sepharose Fast 
Flow resin column with isocratic increases in ammonium bicarbonate from 50 mM to 1 M. Quantification 
of lipids by measurement of phosphate release assay at A360nm. Control sample is synthesised in the 
absence of pywac compounds. 
 
The concentrations quantified in table 6.7 clearly demonstrate that in the presence of 
pywac 7 B. subtilis membranes produced 22% of the concentration of Lipid II DAP 
relative to that accumulated in the compound absent control. This disparity explains the 
noted variation in mass spectra analysis utilising equal final volumes from the final 
DEAE sepharose column elution. This data may indicate that pywac 7 is targeted 
towards hindrance of lipid synthesis, although further investigations are required to 
confirm findings.  
 
In all other pywac incubations, Lipid II DAP was synthesised to quantities that were 
within 10% of the control leading to the conclusion that pywac compounds 1-6 and 8-
9 did not impact Lipid II DAP synthesis significantly. 
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The concentrations measured for pywac compounds 2 and 3 were likely artificially 
inflated slightly due to the presence of UDP-GlcNAc contaminants which can also 
release phosphate groups, increasing the determined Lipid II concentration. 
 
 
6.9 Intermediate accumulation of S. aureus  
 
Preceding the initial investigation into the mode of action of the pywac compounds 
with respect to B. subtilis, the decision was taken to expand the investigation into 
another organism. As the peptidoglycan pentapeptide stem of B. subtilis contains the 
residue DAP at position three, the Gram-positive organism S. aureus was selected due 
to the incorporation of L-Lysine at position three. 
 
The intension was to repeat the accumulation protocol with a Gram-positive organism 
in order to evaluate potential differences in peptidoglycan biosynthesis with cells that 
incorporate L-lysine into position 3 of the peptidoglycan peptide stem, which may aid 
in determining the role of each pywac compound. 
 
Unfortunately due to health issues and time constraints a complete investigation could 
not be completed. The experiment data reported in this section are therefore intended 
as a marker for subsequent exploration. The MIC values for S. aureus were not 
established and experiments within this section utilised previously observed MIC 
values for B. subtilis (Table 6.1). Therefore these results cannot be accurately compared 
to equivalent B. subtilis experiments. Due to the high MIC values of pywac compounds 
3, 4, 5 and 7 and the limited availability of these compounds, they were omitted from 
further investigation.  
 
S. aureus was evaluated to determine its response to pywac compounds 1, 2, 6, 8, 9 as 
well as a 2x MIC vancomycin positive control.  
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6.9.1 DMSO tolerance of S. aureus 
 
In a similar manner to B. subtilis (Figure 6.2) the tolerance of S. aureus cells towards 
DMSO was assessed. Increasing percentages of DMSO were added to diluted 
exponentially grown cells to evaluate the effect the presence of DMSO has on normal 
observed growth. The results are depicted in Figure 6.23.  
 
 
 
Figure 6.23 DMSO tolerance of S. aureus. Cells were grown in the presence of increasing 
concentrations of DMSO to determine the tolerance of staphylococcus proliferation for the solvent, in 
96 well microtiter plates in triplicate at 37°C with intermittent shaking. Absorbance was measured at 
OD600nm at 3 hour intervals for 24 hours. Each well contained 100 µL minimal media. S. aureus cells 
were standardized to an OD600nm of 1 and diluted further by a factor of 104 prior to incubation. Error bars 
represent standard deviation of triplicate measurements. DMSO concentration: 0% (v/v) Blue, 1% (v/v) 
Pink, 2% (v/v) Green, 3% (v/v) Orange, 4% (v/v) Purple, 5% (v/v) Red. Result: DMSO percentages 
between 1-3% (v/v) slightly impacted phenotypic growth equally, with 4-5% (v/v) reducing growth by a 
greater degree. 
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[DMSO] 
(%) 
S. aureus 
Apparent 
Lag 
Phase 
Duration 
(h) 
Td 
(h-1) 
AUC (% of 
0%  DMSO) 
Stationary 
Phase OD600 
nm attained 
p-values 
0 3 1.72 - 1.04 - 
1 3 1.89 93.16 1.00 <0.05 
2 3 1.91 92..53 1.03 <0.05 
3 3 1.99 90.65 1.06 <0.05 
4 3 2.07 81.49 0.927 <0.01 
5 3 2.29 75.78 0.909 <0.01 
Table 6.8 Statistical comparisons of S. aureus growth curves in the presence of increasing 
concentrations of DMSO. S. aureus incubated for 24 hours at 37°C with selected concentrations of 
DMSO (v/v) produced growth curves measured at OD600nm in Figure 4.1. Variations between growth 
curves were measured by time taken to exit apparent lag phase (hours), the doubling time (Td) of cells 
during exponential phase (hours-1), the area under the curve (AUC) percentage compared to the 0 % 
control (%), the OD600nm value achieved during stationary phase and whether the growth curve variations 
were statistically significant compared to each 0 % control with p-values <0.05 deemed significant.  
 
Results show that staphylococcal cells were less tolerant to concentrations of DMSO 
than B. subtilis (Figure 6.2). In the absence of DMSO (Figure 6.23: Blue) S. aureus 
exited apparent lag phase after 3 hours, multiplied with a  Td of 1.72 hours during 
exponential phase and entered stationary phase after 15 hours at an OD600nm of 1.0. The 
addition of DMSO regardless of concentration did not impede the exit from apparent 
lag phase which remained at 3 hours. The doubling time increased slightly with each 
increase in total percentage of DMSO present. The Td results were: 1% (v/v) 1.89 hours 
(Figure 6.23: Pink), 2% (v/v) 1.91 hours (Figure 6.23: Green), 3% (v/v) 1.99 hours 
(Figure 6.23: Orange), 4% (v/v) 2.07 hours (Figure 6.23: Purple), 5% (v/v) 2.29 hours 
(Figure 6.23: Red). Similarly, to the doubling time, the increased addition DMSO 
caused a gradual decrease in AUC: 1% (v/v) 93.16%, 2% (v/v) 92.53%, 3% (v/v) 
90.65%, 4% (v/v) 81.49%, 5% (v/v) 75.78%. The statistical significance of each 
concentration was <0.05 (1%, 2% and 3% (v/v)) and <0.01 (4% and 5% (v/v)) 
respectively. 
 
Based upon these results the decision was taken to continue utilising 2% (v/v) DMSO 
to solubilise the pywac compounds. Controls incubated in the absence of these 
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compounds contained the equivalent percentage of DMSO to account for the impact of 
DMSO alone. 
 
 
6.9.2 Analysis of S. aureus peptidoglycan intermediate standards 
 
The examination of S. aureus permitted a comparison between the implementation of 
the third residue of the UDP-MurNAc peptide stem. The MurE ligase of most Gram 
positive organisms adds a L-lysine to the third position whereas B. subtilis MurE 
utilises DAP. The incorporation of L-lysine required the evaluation of new UDP-
MurNAc-tri and pentapeptide (Lys) standards. Previously evaluated peptidoglycan 
intermediate standards (Figure 6.6) minus the UDP-MurNAc-tripeptide (DAP) and 
UDP-MurNAc-pentapeptide (DAP) were still applicable to this investigation. The 
structures of both UDP-MurNAc-tripeptide (Lys) and UDP-MurNAc-pentapeptide 
(Lys) were presented in Figure 6.24. 
 
 
 
Figure 6.24: The structures of cytosolic peptidoglycan intermediates of S. aureus. (a) UDP-
MurNAc-tripeptide Lys (L-Ala-D-Glu-L-Lys) (b) UDP-MurNAc-pentapeptide Lys (L-Ala-D-Glu-L-
Lys-D-Ala-D-Ala). The above schematic was created using ChemBioDraw. 
 
UDP-MurNAc-tripeptide (Lys) and UDP-MurNAc-pentapeptide (Lys) standards at a 
final concentration of 1 mM were synthesised as outlined in Section 2.8.1 and were 
characterised by ion exchange chromatography to establish the estimated conductivity 
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required for the elution of each species. The chromatogram for each standard is shown 
in Figure 6.25.   
 
 
 
Figure 6.25: Anion exchange chromatography of S. aureus peptidoglycan intermediate standards. 
Noted peak (a) UDP-MurNAc-tripeptide (L-Ala-D-Glu-L-Lys) (conductivity 25.21 mS.cm-1), (b) UDP-
MurNAc-pentapeptide (L-Ala-D-Glu-L-Lys-D-Ala-D-Ala) (conductivity 26.31 mS.cm-1). Samples were 
analysed using a MonoQ 5/50 GL resin. Red trace is absorbance at 254 nm, blue trace: absorbance at 
280 nm and black trace; conductivity. 
 
Both the tripeptide and pentapeptide standards eluted similarly from the monoQ column 
(Figure 6.25) with conductivities of 25.21 mS.cm-1 (Figure 6.25 (a)) and 26.31 mS.cm-
1 (Figure 6.25 (b)) respectively. Both standards produced only a single significant peak 
which was analysed by mass spectrometry in Figure A3.39 (tripeptide) and Figure 
A3.40 (pentapeptide) in Appendix 3. The known m/z ratios for each S. aureus 
peptidoglycan intermediate are stated in table 6.9. 
 
 
UDP Species (m-1)/1 (m-2)/2 (m-3)-3 
UDP-GlcNAc 606.07 302.53 201.35 
UDP-GlcNAc-enolpyruvyl 676.07 337.53 224.68 
UDP-MurNAc 678.09 338.54 225.35 
UDP-MurNAc-L-Ala 749.13 374.06 249.03 
UDP-MurNAc-L-Ala-D-Glu 878.17 438.58 292.05 
UDP-MurNAc-L-Ala-D-Glu-L-Lys 1006.26 502.63 334.75 
UDP-MurNAc-L-Ala-D-Glu-L-
Lys-D-Ala-D-Ala 
1148.34 573.66 382.10 
Table 6.9 The mass/charge ratio for the peptidoglycan cytosolic gram-positive lysine intermediates. 
Singly (m-1)/1, doubly (m-2)/2 and triply (m-3)/3 charged species of the various peptidoglycan 
intermediates. 
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The mass spectral analysis (Figure A3.39) of the UDP-MurNAc-tripeptide (Lys) 
standard elution (Figure 6.25 (a)) identified the singly ([M-H]- observed m/z 1006.27, 
expected m/z 1006.269), doubly ([M-2H]2- observed m/z 502.63, expected m/z 
502.630) and triply ([M-3H]3- observed m/z 334.75, expected m/z 334.751) charged 
species matching the known values attributed to the intermediate. 
 
The mass spectral analysis (Figure A3.40) of the UDP-MurNAc-pentapeptide (Lys) 
standard elution (Figure 6.25 (b)) identified the singly ([M-H]- observed m/z 1148.34, 
expected m/z 1148.343), doubly ([M-2H]2- observed m/z 573.67, expected m/z 
573.667) and triply ([M-3H]3- observed m/z 382.11, expected m/z 382.109) charged 
species matching the known values attributed to the intermediate. 
 
 
6.9.3 Normal cellular distribution of S. aureus peptidoglycan 
intermediates  
 
Utilising the protocol outlined in Section 2.9 S. aureus cells in the absence of inhibitors 
were grown to late exponential phase and whilst other S. aureus cells were then 
incubated with pywac compounds or vancomycin, the control sample continued 
incubation for the remaining three hours with the addition of equivalent DMSO 
percentage to that added with the pywac compound samples. Cellular extracts for 
chromatographic purification were prepared according to Section 2.9.2 and Section 
2.9.3 and were fractionated by size exclusion chromatography followed by ion 
exchange chromatography. These results are shown in Figure 6.26.  
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Figure 6.26: Size exclusion and ion exchange chromatography of S. aureus TCA extracted control 
cells. (a) Size exclusion chromatogram of isolated peaks by Bio-gel P2 resin. Noted peak at (i) 83.55 
mL. (b) ion exchange chromatogram of isolated peaks by MonoQ 5/50 GL resin. Noted peaks (i) 
(conductivity 15.49 mS.cm-1), (ii) (conductivity 18.63 mS.cm-1), (iii) (conductivity 22.49 mS.cm-1), (iv) 
(conductivity 28.33 mS.cm-1), (v) (conductivity 33.38 mS.cm-1), (vi) (conductivity 39.03 mS.cm-1), (vii) 
(conductivity 46.05 mS.cm-1), (viii) (conductivity 49.74 mS.cm-1), (ix) (conductivity 57.84 mS.cm-1) and 
(x) (conductivity 70.31 mS.cm-1). Red trace is absorbance at 254nm, blue trace: absorbance at 280nm 
and black trace; conductivity. 
 
The size exclusion chromatogram of the S. aureus control (Figure 6.26 (a)) separated 
lysed cell contents in a similar manner to B. subtilis samples. Initial conductivity 
increase correlated with a measurable A254nm/A280nm increase in absorbance which 
eluted from the column after 83.55 mL. The significant fraction (i) was isolated and 
freeze-dried. The S. aureus control sample was resuspended in monoQ buffer A 
(Section 2.7.3.3), a A260nm reading was taken from each sample and was diluted to a 
standard absorbance of 0.03 before purification on an equilibrated monoQ 5/50 column. 
The elution profile of S. aureus cells shows similarity to the equivalent result in B. 
subtilis cells (Figure 6.7), with a significant initial peak and a subsequent gradual 
decrease in peak intensities. The initial peak reached 270 mAu at an absorbance of 254 
nm. Ten noted peaks (Figure 6.26 (b): (i) - (x)) were eluted from the monoQ column of 
the initial S. aureus gel filtration peak. These elutions were isolated and analysed by 
negative ion mass spectrometry to identify peptidoglycan intermediates in the standard 
elution profile as shown from Figure A3.41 to Figure A3.50. 
 
The first five eluted peaks from ion exchange chromatography (Figure 6.26 (b)) all 
contained peptidoglycan intermediates as detected by mass spectrometry (Figure A3.41 
to Figure A3.45). The first eluted peak (Figure 6.26 (b): (i)) with a conductivity of 15.49 
mS.cm-1 contained the UDP-GlcNAc, the first precursor of the peptidoglycan pathway 
([M-H]- (observed m/z 606.0739, expected m/z 606.0738). The second eluted peak 
(Figure 6.26 (b): (ii)) with a conductivity of 18.63 mS.cm-1 also contained UDP-
GlcNAc ([M-H]- (observed m/z 606.0738, expected m/z 606.0738). The conductivity 
 293 
of the first two eluted peaks were either side of the conductivity obtained by the UDP-
GlcNAc standard (Figure 6.6 (i): conductivity 16.41 mS.cm-1) although this might 
reflect the variation in the gradient of ammonium acetate between the two runs. The 
remaining three eluted peaks analysed in (Figure A3.43 to Figure A3.45) were 
evaluated to all contain UDP-MurNAc-pentapeptide (Lys). The standard for this 
intermediate eluted at a conductivity of 26.31 mS.cm-1 (Figure 6.25 (b)). The elution 
conductivity of these S. aureus control peaks was 22.49 mS.cm-1 (Figure 6.26 (b): (iii)), 
28.33 mS.cm-1 (Figure 6.26 (b): (iv)) and 33.38 mS.cm-1 (Figure 6.26 (b): (v)). As with 
the UDP-GlcNAc standard, two of these peaks fell either side of the elution value 
produced by the pentapeptide (Lys) standard. Mass spectra analysis identified the 
doubly charged UDP-MurNAc-pentapeptide (Lys) species within the three peaks, 
(Figure A3.43) (iii) ([M-2H]2- (observed m/z 573.6703, expected m/z 573.6679), 
(Figure A3.44) (iv) ([M-2H]2- (observed m/z 1148.3480, expected m/z 1148.3437) and 
(Figure A3.45) (v) ([M-2H]2- (observed m/z 1148.3492, expected m/z 1148.3437) 
respectively.  
 
From the isolated S. aureus control peaks (vi) (conductivity 39.03 mS.cm-1) to (x) 
(conductivity 70.31 mS.cm-1) the mass spectra analysis (Figure A3.46 to Figure A3.50) 
produced no further evidence of peptidoglycan intermediates, therefore all eluted peaks 
with conductivity greater than 39.03 mS.cm-1 were eliminated from further 
consideration.  
 
The absence of either UDP-MurNAc-monopeptide, -dipeptide or -tripeptide was not 
unexpected as similar findings were found with B. subtilis (Figure 6.8). This might 
suggest these intermediates were being consumed as fast as they were formed in the 
pathway under normal conditions. 
 
 
6.9.4 Intermediate accumulation of S. aureus vancomycin control 
 
Cell wall active pywac compounds were previously incubated with B. subtilis cells at 
twice the MIC (µM) of the positive control vancomycin (Figure 6.10). The stated 
vancomycin MIC for S. aureus strains is between 0.5-2 µg.mL-1 (Prakash, et al. 2008). 
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To assess the MIC of the S. aureus strain used here, the impact of growth of vancomycin 
concentrations between 0.5-2 µg.mL-1 was assessed (Figure 6.27).  
 
 
 
Figure 6.27 MIC of vancomycin against S. aureus. Cells were grown in the presence of the 
vancomycin 0.5 µg.mL-1 (Pink), 1 µg.mL-1 (Green) and 2 µg.mL-1 (Orange) in 2% (v/v) DMSO in 96 
well microtiter plates in triplicate at 37°C with intermittent shaking. Absorbance was measured at 
OD600nm at 3 hour intervals for 24 hours. Each well contained 100 µL minimal media. S. aureus cells 
were standardized to an OD600nm of 1 and diluted further by a factor of 104 prior to incubation. Error bars 
represent standard deviation of triplicate measurements. Control: (Blue) S. aureus cells grown in absence 
of vancomycin plus 2% (v/v) DMSO. Result: The proposed MIC values for vancomycin against S. aureus 
was correct.  
 
Each of the vancomycin concentrations investigated (Figure 6.27) were sufficient to 
completely inhibit observable growth. Therefore 1 µg.mL-1 was selected as ³ 2x MIC 
against S. aureus cells. Following incubation and extraction by TCA/Di-ethyl ether the 
2x MIC positive control sample was processed by size exclusion chromatography and 
ion exchange chromatography. The chromatograms for each purification step are 
presented in Figure 6.28. 
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Figure 6.28: Size exclusion and ion exchange chromatography of S. aureus TCA extracts of cells 
incubated with 2x MIC vancomycin. (a) Size exclusion chromatogram of isolated peaks by Bio-gel P2 
resin. Noted peak at (i) 81.47 mL. (b) ion exchange chromatogram of isolated peaks by MonoQ 5/50 GL 
resin. Noted peak (i) (conductivity 18.97 mS.cm-1). Red trace is absorbance at 254nm, blue trace: 
absorbance at 280nm and black trace; conductivity. 
 
The positive control gel filtration (Figure 6.28 (a)) lead to separation of two distinctive 
elution peaks. The first was the standard elution after 81.47 mL measured to coincide 
with the increase in conductivity and the second larger and broader peak eluting after 
175 mL. As with the standard protocol the first peak was further purified by a monoQ 
column (Figure 6.28 (b)) which led to a very different elution profile than observed in 
the control sample (Figure 6.26 (b)). Instead for the distribution of a number of 
individual elution peaks the 2x MIC positive control displayed a single prominent peak 
with conductivity 18.97 mS.cm-1 with the surrounding peaks severely diminished. The 
proposed intermediate contained within the elution should be UDP-MurNAc-
pentapeptide (Lys) although the elution conductivity does not accurately match the 
equivalent for the standard (Figure 6.25 26.31 mS.cm-1) but is closer to one of the 
control peaks containing the pentapeptide with a conductivity of 22.49 mS.cm-1 (Figure 
6.26 (b): (iii)). This variation potentially shows the difference from cellular and in vitro 
synthesis of peptidoglycan intermediates but more likely may result from the fact the 
ammonium acetates gradients differ in conductivity.min-1. The monoQ purified peak 
was analysed by mass spectrometry and the data is displayed in Figure A3.51.  
 
Mass spectra analysis (Figure A3.51) identified the 2x vancomycin MIC positive 
control peak as containing UDP-MurNAc-pentapeptide (Lys). The singly ([M-H]- 
observed m/z 1148.34, expected m/z 1148.343) and doubly ([M-2H]2- observed m/z 
573.67, expected m/z 573.667) charged species were detected. These data indicated that 
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the expected accumulation of UDP-MurNAc-pentapeptide (Lys), resulting from 
vancomycin-challenge could be easily detected in S. aureus.  
 
 
6.9.5 Intermediate accumulation of S. aureus against pywac 
compounds 
 
Once again as outlined during the investigation with B. subtilis (Section 6.6.2), pywac 
compounds were incubated with a sufficient culture volume to produce a final harvested 
wet pellet cell weight of 1 g to aid the investigation. Each of the S. aureus cultures 
incubated with the remaining pywac compounds were processed and peaks of interest 
further investigated. 
 
 
6.9.5.1 Intermediate accumulation of S. aureus against pywac 1 
 
 
Figure 6.29: Size exclusion and ion exchange chromatography of S. aureus TCA extracts of cells 
incubated with 4 µM pywac 1. (a) Size exclusion chromatogram of isolated peaks by Bio-gel P2 resin. 
Noted peak at (i) 84.99 mL. (b) ion exchange chromatogram of isolated peaks by MonoQ 5/50 GL resin. 
Noted peak (i) (conductivity 25.46 mS.cm-1). Red trace is absorbance at 254nm, blue trace: absorbance 
at 280nm and black trace; conductivity. 
 
Incubation of the gram-positive S. aureus cells with pywac 1 led to a size exclusion 
elution profile (Figure 6.29 (a)) similar in distribution to the control sample but with a 
significant increase in the 254 nm absorbance measured from the initial elution (Figure 
6.29 (a): (i)). The peak plateaued around 240 mAu and eluted after 84.99 mL, compared 
to the equivalent control peak of 60 mAu after 85.55 mL (Figure 6.26 (a): (i)). The 
further purification by ion exchange chromatography (Figure 6.29 (b)) of this peak led 
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to an elution profile similar in nature to the 2x MIC vancomycin control (Figure 6.28 
(b)) with a single prominent elution of over 2.5 times greater than the next greatest 
peak, eluting with a conductivity of 25.46 mS.cm-1. Comparing this value to the 
standard elution peaks of the control situates the pywac 1 accumulated peak between 
two control peaks which both contained UDP-MurNAc-pentapeptide (Lys) (Figure 
6.26 (b)) with conductivities of 22.49 mS.cm-1 (Figure 6.26 (b): (iii)) and 28.33 mS.cm-
1 (Figure 6.26 (b): (iv)). The peak of interest was analysed by mass spectrometry in 
Figure A3.52. 
 
Mass spectral analysis of the pywac 1 accumulated peak (Figure A3.52) did not identify 
the presence of any peptidoglycan cell wall intermediates, although an abundant signal 
was measured at 474.1960 m/z relating to an unknown compound.  
 
 
6.9.5.2 Intermediate accumulation of S. aureus against pywac 2 
 
 
Figure 6.30: Size exclusion and ion exchange chromatography of S. aureus TCA extracts of cells 
incubated with 2 µM pywac 2. (a) Size exclusion chromatogram of isolated peaks by Bio-gel P2 resin. 
Noted peak at (i) 95.93 mL. (b) ion exchange chromatogram of isolated peaks by MonoQ 5/50 GL resin. 
Noted peak (i) (conductivity 20.99 mS.cm-1). Red trace is absorbance at 254nm, blue trace: absorbance 
at 280nm and black trace; conductivity. 
 
The size exclusion chromatography (Figure 6.30 (a)) of S. aureus cells incubated with 
pywac 2 produced a similar elution profile to incubation with pywac 1 (Figure 6.29 (a)) 
displaying a single prominent initial peak after 95.93 mL with a 254 nm absorbance of 
580 mAu. Further purification of this elution led to an ion exchange chromatogram 
(Figure 6.30 (b)) which contained a solitary eluted peak with a 254 nm absorbance of 
over 1200 mAu. There was no observed distribution of peaks surrounding the 
prominent elution. The conductivity of this peak was 20.99 mS.cm-1, which when 
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compared to the control profile (Figure 6.26 (b) fells between the second (18.63 mS.cm-
1) and third (22.49 mS.cm-1) eluted peaks containing UDP-GlcNAc and UDP-MurNAc-
pentapeptide (Lys) respectively. The peak was analysed by mass spectrometry in Figure 
A3.53. 
 
Mass spectral analysis of the eluted sample (Figure A3.53) identified the singly ([M-
H]- observed m/z 1006.27, expected m/z 1006.26), doubly ([M-2H]2- observed m/z 
505.63, expected m/z 502.63) and triply ([M-3H]3- observed m/z 334.75, expected m/z 
334.75) charged species of UDP-MurNAc tripeptide (Lys), the substrate for amino acid 
ligase MurF. The tripeptide was not identified in the S. aureus control ion exchange 
chromatogram (Figure 6.26 (b)) and the tripeptide (Lys) standard (Figure 6.25 (a)) 
eluted with a greater conductivity of 25.21 mS.cm-1.  
 
The presence of the tripeptide moiety means that intermediate accumulation must have 
occurred and was solely due to the presence of the compound. As the tripeptide is 
accumulated it means that the compound inhibited one of three enzymes. MurF, the 
final Mur ligase in the addition of the pentapeptide stem to the UDP-MurNAc moiety 
which adheres the terminal D-alanyl-D-alanine. D-alanine racemase (Alr) which 
converts L-alanine to D-alanine or D-alanine-D-alanine ligase (DdlB), the enzyme that 
catalyses D-alanyl-D-alanine from two D-alanine residues. 
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6.9.5.3 Intermediate accumulation of S. aureus against pywac 6 
 
 
Figure 6.31: Size exclusion and ion exchange chromatography of S. aureus TCA extracts of cells 
incubated with 8 µM pywac 6. (a) Size exclusion chromatogram of isolated peaks by Bio-gel P2 resin. 
Noted peak at (i) 86.50 mL. (b) ion exchange chromatogram of isolated peaks by MonoQ 5/50 GL resin. 
Noted peak (i) (conductivity 62.04 mS.cm-1). Red trace is absorbance at 254nm, blue trace: absorbance 
at 280nm and black trace; conductivity. 
 
The size exclusion chromatogram (Figure 6.31 (a)) of the pywac 6 sample displayed an 
initial elution peak after 86.50 mL. The sharp second peak is an artefact of pausing the 
AKTA during the run. Further purification of this initial peak lead to an ion exchange 
chromatogram (Figure 6.31 (b)) similar in distribution to the control sample (Figure 
6.26 (b)) with one exception. Once the monoQ was exposed to 100% monoQ buffer B 
(1 M ammonium acetate) and the conductivity plateaued at 62.04 mS.cm-1, a significant 
eluted peak was observed. This peak had a greater conductivity value than any of the 
peptidoglycan cell wall intermediates or the ATP standard control (Figure 6.16). The 
peak was analysed by mass spectrometry to determine the presence of peptidoglycan 
precursors in Figure A3.54. 
 
Mass spectral analysis in Figure A3.54, exploring the species contained within the 
noted peak of interest (Figure 6.31 (b)) determined as expected that the intensity of the 
elution was not attributed to the presence of any investigated cell wall intermediate. 
Based upon the m/z range investigated no known cellular metabolites were identified. 
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6.9.5.4 Intermediate accumulation of S. aureus against pywac 8 
 
 
Figure 6.32: Size exclusion and ion exchange chromatography of S. aureus TCA extracts of cells 
incubated with 8 µM pywac 8. (a) Size exclusion chromatogram of isolated peaks by Bio-gel P2 resin. 
Noted peak at (i) 82.48 mL. (b) ion exchange chromatogram of isolated peaks by MonoQ 5/50 GL resin. 
Noted peak (i) (conductivity 16.02 mS.cm-1). Red trace is absorbance at 254nm, blue trace: absorbance 
at 280nm and black trace; conductivity. 
 
The addition of pywac 8 to S. aureus cells lead to an overall similar size exclusion 
profile (Figure 6.32 (a)) to the control (Figure 6.26 (a)) with a smaller than average 
initial elution. Further purification of this isolated peak by ion exchange 
chromatography (Figure 6.32 (b)) demonstrated the same elution profile against pywac 
compound 8 exposed to B. subtilis cells (Figure 6.14). The similarity stems from the 
initial elution peak appearing more pronounced and acute that the equivalent displayed 
by the control peak, with fewer surrounding elution peaks. The peak eluted with a 
conductivity of 16.02 mS.cm-1, which falls between the conductivity of two control 
elutions, 15.49 mS.cm-1 and 18.63 mS.cm-1 respectively, containing UDP-GlcNAc. The 
intensity of the peak was not significantly different from other observed elutions in the 
profile so significant accumulation does not appear to be the cause of the distribution 
seen in the profile. The peak was analysed by mass spectrometry in Figure A3.55. 
 
Mass spectral analysis (Figure A3.55) of the isolated peak determined the presence of 
UDP-GlcNAc ([M-H]- observed m/z 606.08, expected m/z 606.07). This result 
mirrored the equivalent result obtained in B. subtilis cell against 2x MIC of pywac 2 
(Figure 6.14). 
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6.9.5.5 Intermediate accumulation of S. aureus against pywac 9 
 
 
Figure 6.33: Size exclusion and ion exchange chromatography of S. aureus TCA extracts of cells 
incubated with 4 µM pywac 9. (a) Size exclusion chromatogram of isolated peaks by Bio-gel P2 resin. 
Noted peak at (i) 84.39 mL. (b) ion exchange chromatogram of isolated peaks by MonoQ 5/50 GL resin. 
Noted peak (i) (conductivity 64.74 mS.cm-1). Red trace is absorbance at 254nm, blue trace: absorbance 
at 280nm and black trace; conductivity. 
 
The final compound investigated was pywac 9, which produced a similar ion exchange 
chromatogram (Figure 6.33 (b)) to another purification elution profile observed in cells 
incubated with pywac 6 (Figure 6.31 (b)). The standard distribution of elution peak 
followed the control chromatogram closely but once monoQ buffer B percentage was 
increased to 100% and the conductivity plateaued at 64.74 mS.cm-1 a noted eluted peak 
(Figure 6.33 (b): (i)) was measured. This level of conductivity is not attributed to any 
of the investigated peptidoglycan intermediates or any or the non-intermediate 
standards. The pywac 9 chromatogram mirrored the chromatogram observed for pywac 
6 cellular extracts. The pywac 9 peak (i) was analysed by mass spectrometry in Figure 
A3.56. 
 
Mass spectra analysis of pywac 9 incubated cells (Figure A3.56) could not locate 
charged species relating to any of the peptidoglycan intermediates, leaving the elution 
as currently unidentified.    
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6.10 Discussion 
 
Cell wall active compounds with unknown mode of action were identified by the 
upregulation of the ywac gene based on a reduction in the measured synthesis of wall 
teichoic acids (D’Elia, et al. 2009). These nine pywac compounds were acquired to 
ascertain whether the peptidoglycan biosynthesis pathway contained the proposed 
targets. Previously stated MIC of these compounds (Czarny, et al. 2014) was 
successfully confirmed (Figure 6.3) and DMSO tolerance of the B. subtilis control was 
established because of the requirement of these compounds for DMSO as the vehicle 
(Figure 6.2).  
 
 
6.10.1 B. subtilis cytosolic phase intermediate accumulation 
assessment  
 
The initial probing of the B. subtilis cytosolic phase of peptidoglycan synthesis utilised 
the assessment of peptidoglycan intermediate accumulation in the presence of 2x MIC 
of pywac compounds compared to a control. Pywac compounds 4 and 9 produced 
similar anion exchange elution profiles to the control. Pywac compounds 1, 3, 5, 6 and 
7 generated single isolated peaks not found within the control, although mass 
spectrometric analysis could not identify peptidoglycan intermediates within these 
elutions. Expanding the possible range of targets to include alternative metabolites such 
as ATP and NADH did not lead to a positive identification of these species. These six 
pywac compounds were therefore assumed to not elicit their mode of action within the 
cytosolic phase of peptidoglycan biosynthesis.  
 
Only two of the pywac compounds (2 and 8) impacted the growth of B. subtilis relative 
to that seen in the presence of DMSO alone.  Pywac 2 also caused accumulation of a 
species which registered as a slight increase in the intensity of one of the species 
detected on ion exchange fractionation of B. subtilis metabolites (Figure 6.12), which 
was identified as UDP-MurNAc-pentapeptide, the final precursor of the cytosolic phase 
of peptidoglycan biosynthesis. Accumulation of this intermediate was also observed 
during incubation with the positive control, vancomycin. Although at 2x MIC of 
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vancomycin accumulation of UDP-MurNAc-pentapeptide was so prominent that it 
dominated the ion exchange chromatogram (Figure 6.10)., This was not observed with 
pywac compound 2. Accumulation of UDP-MurNAc-pentapeptide could therefore 
have arisen through the inhibition of MraY (Alderwick, et al. 2015) (which consumes 
UDP-MurNAc-pentapeptide to generate Lipid I).  Alternatively, and in a similar 
manner to vancomycin, pywac compound 2 might have bound directly to the terminal 
D-alanyl-D-alanine of the pentapeptide stem impeding further enzymatic interaction 
(Soetaerta, et al. 2015). Incubation with excess concentrations of pywac 8 led to the 
accumulation of the first peptidoglycan intermediate of the pathway, UDP-GlcNAc 
(Figure 6.14). This might have arisen through inhibition of the enzyme catalysing the 
first committed  step of the peptidoglycan pathway, MurA.  This enzyme is also the 
target of the antimicrobial fosfomycin, which inhibits MurA through modification of a 
cysteine within the active site of the enzyme.(Nasiri, et al. 2017). 
 
 
6.10.2 Pywac inhibition of B. subtilis lipid synthesis 
 
Based upon the utilisation of B. subtilis as the test organism, the standard protocol for 
lipid synthesis was altered to include membranes extracted from the Gram-positive 
organism. The ability to generate lipids was not impeded by this deviation, permitting 
the investigation to probe the membrane associated enzymes required for lipid synthesis 
in B. subtilis. Co-incubation of 2x MIC of each pywac compound during lipid synthesis 
still led to formation of Lipid II. Lipids once purified were each identified as solely 
Lipid II. Quantification of lipids synthesised (Figure 6.7) demonstrated that co-
incubation with each pywac compound except pywac 7 failed to modify the extent of 
Lipid II synthesis. These results likely indicate that these eight compounds did not 
inhibit either of the two enzymatic steps involving MraY and MurG in the formation of 
Lipid II.  
 
The protocol for lipid synthesis involved an incubation overnight. To better evaluate 
synthesis, the protocol was shortened to four hours. Results showed no inhibition 
amongst eight of the nine compounds during this time period, though the rate of lipid 
synthesis before it plateaus was unknown. Further work would require reducing the 
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time frame of synthesis by hourly increments to ascertain when synthesis plateau 
occurs. The investigation will definitively show that whether there was zero inhibition 
in the previous experiment or whether the control rate of synthesis was rapid but the 
four hour time frame was sufficient for inhibited samples to generate equivalent 
concentrations of lipid. 
 
Quantification of lipid synthesis co-incubated with pywac compound 7 reduced the 
concentration of Lipid II by almost 80%. The target of pywac 7 is likely one the two 
enzymes vital for lipid synthesis, MraY which catalyses the addition of undecaprenyl 
phosphate to UDP-MurNAc pentapeptide forming Lipid I or MurG which appends a 
GlcNAc subunit onto Lipid I (Bouhss, et al. 2008). Since based upon the TLC, Lipid II 
was generated but at a lesser concentration and Lipid I did not appear to be generated 
as assessed by mass spectrometry, the likely target is MraY. 
 
 
6.10.3 S. aureus cytosolic phase intermediate accumulation assessment 
 
Pywac active compounds were additionally exploited for initial probing of the 
peptidoglycan synthesis pathway of a second Gram-positive organism, S. aureus. The 
reason for the selection was to ascertain whether previously investigated cell wall active 
compounds which did not lead to observable accumulation of intermediates were 
targeted towards other cellular structures or if variations in the amino acids composition 
of the pentapeptide stem would increase accumulation and aid identification. B. subtilis 
cells implement m-DAP at position three of the stem whereas S. aureus insert L-lysine. 
The pywac compounds were identified as cell wall active in B. subtilis (Czarny, et al. 
2014), although potential targets such as UDP-MurNAc-tripeptide (L-lys) and its 
synthesis may be better substrates for the compounds.  
 
Intermediate accumulation utilising B. subtilis MIC values of S. aureus cells by pywac 
compounds 1 6 and 9 led to the accumulation of an individual peak not observed 
through the elution profile of the DMSO control.  For both pywac compounds 6 and 9, 
this species eluted at a similar conductivity value, although neither of these nor the 
species detected in the presence of pywac compound 1 contained  cell wall 
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intermediates. As previously investigated, the incubation of a Gram-positive organism 
with 2x MIC pywac compound 8 led to a variable elution profile within the initial eluted 
peaks, with mass spectrometric analysis identifying the presence of UDP-GlcNAc 
(Figure 6.32). Investigations into S. aureus with pywac compound were performed 
without the knowledge of the S. aureus MIC, therefore these results must be established 
before broad conclusions can be drawn and compared to the findings against B. subtilis 
cells.  
 
The final compound initially probed against S. aureus was pywac 2. A significant 
accumulation of UDP-MurNAc-tripeptide (L-Lys) was identified with consequent and 
dramatic suppression of the contribution to the elution profile of other species (Figure 
6.30). The accumulated elution against B. subtilis was measured to contain UDP-
MurNAc-pentapeptide (DAP) (Figure 6.12). Comparisons between the two elution 
profiles demonstrates that although the pentapeptide peak of B. subtilis is slightly more 
pronounced that the equivalent in the compound absent control, the S. aureus 
accumulation attributed to pywac 2 incubation was far more significant.   
 
Accumulation the tripeptide would indicate an inability to attach the terminal D-alanyl-
D-alanine residues, leading to the potential compound targets being either MurF, Alr 
or DdlB. The amino acid ligase MurC-F possess equivalent reaction mechanism 
attaching the specific amino acid to high-energy tetrahedral intermediates. This 
uniformity in function commonly equates to all four mur ligases being susceptible to 
the same antimicrobials, such as phosphinate inhibitors (El Zoeiby et al. 2003). 
Therefore, the target for pywac compound 2 would likely be the terminal D-alanyl-D-
alanine to the peptide stem in a similar mode of action to vancomycin. The second 
potential target, the formation of D-alanyl-D-alanine by Alr and DdlB are known to be 
the cellular targets of the antimicrobial D-cycloserine (Feng, et al. 2003). Comparisons 
between pywac compound 2 and D-cycloserine in future investigation could lead to a 
positive identification of the cellular target. 
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6.10.4 Potential isolation of incomplete gel filtration intermediate 
pools 
 
Once the intermediate accumulation protocol was concluded a number of potential 
issues arose surrounding the method used. The acquisition of the initially eluted peak 
from gel filtration of B. subtilis cell contents was isolated based upon previous 
purifications undertaken by Dr. Adrian Lloyd during purification of UDP-MurNAc-
pentapeptide, known to elute earlier than other cellular low molecular weight 
components. Purification of B. subtilis lysed cell material commonly generated a 
primary broad peak corresponding to an increase in conductivity. Secondary and 
tertiary peaks were discarded based upon initial recommendation. Peptidoglycan 
intermediate standards were purified by anion exchange to establish the possible 
conductivity range of elution, although these initial investigations were not conducted 
to establish common elution volumes for the peptidoglycan intermediate standards 
during gel filtration. Results obtained within this chapter are valid comparisons of the 
initial eluted peak and there was no evidence that the intermediate pools were being 
split from the purified totals, although this potential oversight will be rectified in further 
work. 
 
 
6.11 Further work 
 
 
• Redesign accumulation protocol 
 
Standardise initial gel filtration step by calibrating the Biogel P200 with UDP-
MurNAc-pentapeptide, tripeptide, dipeptide, monopeptide and UDP-MurNAc, to know 
that those fractions on the Biogel P200 elution will in an unbiased way contain the 
maximum available concentration of the precursor under consideration because it is 
possible that Pywac compounds that did not generate a UDP precursor response may 
have appeared to do so because the relevant precursor pool was missed on gel filtration. 
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• Establish pywac compounds MIC against S. aureus and repeat intermediate 
accumulation 
 
Determine the MIC values for each pywac compound against S. aureus. Repeating the 
accumulation protocol with known 2x MIC of the pywac active compounds against S. 
aureus will allow a direct comparison between both investigated Gram-positive 
organisms. The protocol will also permit further probing into pywac compound 
targeting and the role of specific peptidoglycan pentapeptide stem variations on 
compound activity. 
 
 
• Investigate PBP inhibition 
 
One unexplored phase of peptidoglycan synthesis to investigate is the activity of the 
cell wall active compounds against the penicillin binding proteins (PBPs). After lipid 
synthesis, the final steps of peptidoglycan synthesis lead to incorporation of Lipid II 
precursors into the overall cell wall sacculus which involves a number of PBPs utilising 
transglycosylase and transpeptidase activity. The transglycosylase activity of PBPs 
polymerises Lipid II subunits together to increase the overall sacculi. This process has 
known inhibitors such as moenomycin a mimic of Lipid IV (Ostash, et al. 2009), the 
designation for the combination of two bound Lipid II molecules, which fit in the 
transglycosylase pocket. It is worth testing the pywac compounds on this enzymatic 
step to find out if they mimic moenomycin (based on structural similarities) or possibly 
lead to inhibition through binding to another site. The transpeptidase activity of PBPs 
where by the amino acid stems of the Lipid II moieties are cross-linked at the 3-4 
position, releasing D-Ala residues would also be impacted by transglycosylase 
inhibition in the bifunctional transglycosylase/transpeptidase PBPs, however it is also 
possible that the transpeptidase function might itself be uniquely targeted . Assays to 
assess both PBP functions are vital to identifying modes of action against the currently 
unknown targets of half of the investigated pywac compounds. 
 
 
 
 308 
• Assess inhibition of cytosolic Mur enzymes 
 
A selected number of pywac compound appear to contribute to the accumulation of 
certain peptidoglycan intermediates. Individual Mur enzyme assays exist for synthesis 
of the intermediates (Section 2.8.1). Incubation with excess concentrations of pywac 
compounds will establish whether inhibition of individual enzymes occurs through 
utility of a coupled NADH-linked pyruvate kinase/lactate dehydrogenase assay for 
amino acid Mur ligase activity (Section 2.11.1). Once established, concentration 
specific investigation to probe the efficacy of each compound against the targeted 
enzymes will be undertaken using such an assay, taking care to ensure the coupling 
system was not compromised by the Pywac compounds. 
 
 
• Pywac synergy with other antimicrobials 
 
Assessing potential synergy between pywac compounds and standard antimicrobials 
that target peptidoglycan (Vancomycin, Fosfomycin and Clavulanic acid), protein 
(Chloramphenicol) and DNA (Ciprofloxacin) synthesis may aid in determining pywac 
mode of action towards cellular structures. 
 
 
6.12 Conclusion 
 
Newly discovered pywac compounds 1-9 are known to be active against the bacterial 
cell wall but their exact targets were unknown. Initial investigations against B. subtilis 
cells determined their MIC values and the range of possible targets for each pywac 
compound was narrowed down by probing two of the three distinct phases during the 
biosynthesis of peptidoglycan. Further probing of these targets is required before exact 
identification can be determined but these discoveries are important for identifying new 
interactions with new and extant targets to aid against the rise in antimicrobial 
resistance of standard therapies. 
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Chapter 7. General discussion and final conclusions 
 
The global threat of tuberculosis affects approximately one third of the world’s 
population (Houben and Dodd 2016). The increased prevalence of mycobacterial 
infection is due to insufficient drug therapy options attributed to multi-drug resistance 
towards standard mycobacterial antimicrobials (Zhang and Yew 2009). Mycobacteria 
are also inherently resistant to treatment by antimicrobials due to the expression of b-
lactamases (Heesemann 1993) as well as the composition of their cell wall. The mAGP 
complex provides protection from external threats such as the administered 
antimicrobials and the secretion of host hydrolytic enzymes, through modifications 
made to cell wall structure. Mycobacteria and other representatives of the 
Actinobacteria modify the peptidoglycan layer through incorporation of N-acetylated 
and N-glycolylated lipids, the latter by utilisation of a NamH hydroxylase within an 
aerobic environment (Mahapatra, et al. 2008). The inclusion of the N-glycolylated lipid 
has previously been determined to increase mycobacterial resilience towards challenge 
by both lysozyme and b-lactam antibiotics (Raymond, et al. 2005).  
 
The purpose of this thesis was to expand the current understanding of the function of 
N-glycolylation, especially with respect to mycobacterial responses to antibiotics and 
to external stresses during host invasion that cause lysis as well as to document the 
impact of N-glycolylation on  peptidoglycan synthesis. The utilisation of a M. 
smegmatis DnamH mutant which produces solely N-acetylated peptidoglycan was key 
in this regard. 
 
 
7.1 Impact of N-glycolylation on standard mycobacterial growth 
 
Standard mycobacterial phenotypic growth remained unaltered by the absence of N-
glycolylated saccharides in typical aerobic conditions (Section 3.4). Furthermore, 
exposure of DNamH M. smegmatis to an extended anaerobic incubation to mimic in 
vitro, the environment created within an enclosed granuloma in vivo, was consistant 
with the view that  illustrated the discovery that namH expression was not vital to 
resuscitation of the mycobacteria during re-exposure to aerobic conditions.  This 
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conclusion was supported by the observation that wild type and DNamH strains 
exhibited equivalent propagation on both nutrient rich and deficient media on return to 
aerobic conditions (Section 3.5). 
 
 
7.2 Impact of N-glycolylation on hydrolytic enzymes interaction 
 
Previous investigations into the expression of solely N-acetylated mycobacterial 
peptidoglycan (Raymond, et al. 2005) revealed an increase in the susceptibility of M. 
smegmatis to lysozyme, a key secretion of the host immune response (Callewaert and 
Michiels 2010). The MIC of human lysozyme was two-fold greater in mycobacterial 
cells utilising N-glycolylated components, and these results were confirmed in this 
thesis (Section 3.6.1.1). Activity of the enzyme against mycobacterial peptidoglycan 
was concluded to be optimal at pH 7.0, and decline in lysis was observed when the pH 
was reduced to 6.0. Between pH 6.0 and 5.0 the activity of human lysozyme remained 
constant (Section 3.6.1.2) illustrating the efficacy of the enzyme as the pH within the 
phagolysosome is reduced to aid lysis. The increased susceptibility of the N-glycolyl 
deficient mycobacteria was noted as constant across each investigated pH.  
 
The impact of the duration of exposure to  lysozyme on mycobacterial survival was 
examined with a two and three-fold increase in duration (Section 3.6.1.3). Comparisons 
between these two time increases led to minimal variation with mycobacterial lysis 
plateauing at investigated concentrations and the divide between strain susceptibility 
remained constant. Increases to incubation time frame exacerbated mycobacterial cell 
lysis on both strains equally at lysozyme concentrations above 1024 µg.ml. In 
conclusion, N-glycolyl deficient mycobacteria remained more susceptible to human 
lysozyme, with the enzymatic activity being (a) stable at phagolysosome pH conditions 
and (b) more effective during longer exposure. 
 
The investigation of host-mediated challenge to mycobacterial proliferation extended 
to include b-hexosaminidase, a hydrolytic enzyme previously observed as being 
expressed specifically during mycobacterial infection in humans (Koo, et al. 2008). 
Human b-hexosaminidase (which hydrolyses the b-1,4 glycosidic bond between 
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peptidoglycan subunits in a similar manner to lysozyme) generated a two-fold lower 
MIC and MBC in the exclusively N-acetylated mycobacteria (Section 3.7.2).  This 
result was consistant with the data of Koo, et al. (2008) who identified b-
hexosaminidase during mycobacterial infection close to the host macrophage plasma 
membrane at a more neutral pH environment as well as the acidic phagolysosome.  
Here, the activity of the enzyme was unaltered at either condition (Section 3.7.2.1) and 
at both conditions the NamH deficient strain was equally susceptible to lysis. 
 
The focus of further work should be on potential synergistic interactions between host 
hydrolytic enzymes, to ascertain the impact of equivalent activities of different 
peptidoglycan-hydrolytic enzymes encompassing the range of pH conditions present 
within macrophage, as well as the binding affinities of each enzyme to N-acetylated 
and N-glycolylated lipids to confirm preferential binding and explain increased 
susceptibility.    
 
 
7.3 Impact of N-glycolylation on antimicrobial therapy 
 
The generation of a namH and blaS deficient M. smegmatis mutant permitted the 
evaluation of antimicrobial mycobacterial therapies and the implementation of N-
glycolylated peptidoglycan to oppose lysis. Previously published studies (Raymond, et 
al. 2005) showcased the increased susceptibility of DNamH to b-lactam antibiotics and 
the unaltered sensitivity towards non-peptidoglycan targeted antimicrobials. These 
findings were confirmed and extended within this thesis (Section 4.4). Both 
investigated mycobacterial strains lacked the BlaS b-lactamase to assess the impact of 
b-lactams on N-glycolylated deficient mycobacteria. The blaS- namH- double mutant 
was two-fold more susceptible to ampicillin than the solely blaS- mutant, whereas both 
strains were equally sensitive to isoniazid. The N-glycolylated lipid may aid against b-
lactam interaction due to the reduced time frame observed to synthesis the N-
glycolylated version of Lipid II (Chapter 5), or through aiding substrate recognition of 
PBPs. 
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MIC and MBC susceptibility of N-glycolyl deficient mycobacteria were equivalent to 
the wild type during exposure to antimicrobials targeting transglycosylase activity. 
Although ramoplanin and mersacidin which both bind directly to Lipid II, demonstrated 
increased activity towards the DNamH strain at sub MIC values (Section 4.4). The 
susceptibility was explained through measuring of antimicrobial binding affinities 
towards modified variants of Lipid II. Both antimicrobials demonstrated a greater 
binding response in the presence of N-acetylated substrates than N-glycolylated at 
equivalent concentrations (Section 4.6). Preference towards the N-acetyl group 
establishes a possible raison d’etre for maintenance by  M. smegmatis of a 7:3 ratio of 
MurNGlyc to MurNAc saccharides within the peptidoglycan layer during aerobic 
conditions. N-glycolylation occurs prior to the lipid linked steps of peptidoglycan 
synthesis that occur on the inner and outer faces of the cytoplasmic membrane.  
However, results indicated the administration of tunicamycin, an active site inhibitor of 
MraY (MurX), did not lead to an alteration in antimicrobial susceptibility dependent 
upon the presence of the N-acetyl/N-glycolyl group (Section 4.4).   Moenomycin which 
mimics Lipid IV and blocks binding to the TP and TG domains of bifunctional PBPs 
such as mycobacterial PonA1 and PonA2, displayed increased activity towards NamH 
deficient mycobacteria (Section 4.4). This would potentially indicate that 
implementation of the N-glycolyl group on Lipid II substrates may improve PBP 
binding to outcompete moenomycin. This hypothesis was counteracted by binding 
affinity assessments of M. tuberculosis PonA1 and PonA2 (Chapter 5) which 
demonstrated that the binding affinities towards Lipid II of PonA1 were two-fold 
greater with the N-acetylated lipid and PonA2 demonstrated equivalent affinities 
towards each lipid.    
 
Due to the expansion of multidrug resistant mycobacterial strains to primary treatments, 
the requirement for secondary therapies such as vancomycin has increased. The N-
glycolylation of peptidoglycan of the wild type strain assists in mitigating the activity 
of the antimicrobial, as registered by the decreased survival of the DNamH strain 
(Section 4.4). Assessment of lipid binding affinities towards vancomycin supports the 
hypothesis that mycobacteria include high percentages of N-glycolylated lipids to 
decrease recognition and reduce cell lysis (Section 4.6).   
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The proliferation of resistance has led to a requirement for newly antimicrobial 
therapies. Teixobactin has been touted as a break through, due to its unique targeting 
towards the prenyl-pyrophosphate-GlcNAc region of Lipid II (Ling, et al. 2015), and 
the current lack of observable resistance. MIC assessment of both investigated strains 
concluded that the mycobacterial composition of the peptidoglycan layer did not impact 
the susceptibility of M. smegmatis to teixobactin with equivalent MIC values (Section 
4.4). Binding affinity of the antimicrobial towards the peptidoglycan lipid precursors 
demonstrated a five-fold preference  towards the binding of N-acetylated lipid II 
compared to its N-glycolylated variant, although this interaction appeared to not have 
impact susceptibility. Due to the lack of current observable resistance, teixobactin 
analogues have been created by a number of collaborators to evaluate key structural 
components of the antimicrobial (Jad, et al. 2015). Arg-teixobactin displayed a four-
fold reduction in MIC activity towards mycobacteria (Section 4.4), due in part to the 
substitution of the L-allo-endurcididine residue with L-arginine, which impacted the 
preferential binding affinity observed for the original teixobactin towards N-acetylated 
lipids.  
 
Future experiments should focus on overcoming difficulties noted during assessment 
of binding affinities, especially the use of less intrusive lipid labelling and discovery 
into the optimal SPR chip coating concentrations to reduce the time frame of binding 
saturation. Expanding the range of antimicrobials investigated to examining 
antimicrobial synergy to circumvent resistance. 
 
 
7.4 Impact of N-glycolylation on peptidoglycan synthesis 
 
The main focus of this thesis was the impact of N-glycolylated lipids embedded with 
the peptidoglycan on response to   external agents such as enzymatic and antimicrobial 
activity. A number of mycobacteria possess more unique variation in relation to 
peptidoglycan synthesis. Chapter 5 illustrated the initial investigations into a wide range 
of mycobacterial enzymes and the role of each enzymatic deviation from the common 
procedure. 
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Mycobacterial MurA species are inherently resistant to fosfomycin due to an aspartate 
substitution of the more common active site residue cysteine (De Smet, et al. 1999). 
One aspect of this chapter was to re-sensitise M. leprae MurA to fosfomycin. The 
mycobacterial enzyme was acquired and cloned within a pCOLD expression vector, to 
aid expression at decreased temperatures. The gene was modified append a C-terminal 
poly-histidine tag to the murA coding sequence. Site directed mutagenesis was 
implemented to alter the DNA sequence to replace an aspartate residue with  a cysteine 
residue. Genes encoding both potentially fosfomycin sensitive and resistant MurA 
proteins were successfully expressed and identified through Western blotting. Further 
work would compare the activity of the enzymes in the presence of fosfomycin as well 
as the binding affinity of the antimicrobial to the enzymes.   This work will be greatly 
facilitated by the recent discovery of a protein cofactor (CwlM,  Boutte et al., 2016) 
that when phosphorylated, activates mycobacterial MurA activity. 
 
M. leprae MurC inserts L-glycine at position one of the pentapeptide stem instead of 
the commonly observed L-alanine (Mahapatra, et al. 2000). Previous studies have 
determined that there is no enzymatic preference for the amino acid, but the reason for 
this deviation remains unknown. Due to genomic degradation, M. leprae does not 
utilise N-glycolylated peptidoglycan, as NamH encodes only for a pseudogene (Muro, 
et al. 2011). N-glycolylation occurs on UDP-N-acetyl muramic acid product of MurB, 
and therefore each of the Mur ligases can utilise an N-glycolylated substrate. The 
purpose of this investigation was to determine whether M. leprae Mur ligases have a 
catalytic preference for muramic acid substrates as unable to generate N-glycolylation 
precursors. M. leprae MurC was cloned in a similar manner to M. leprae MurA, within 
a pCOLD expression vector with a C-terminal poly-histidine tag. Successful expression 
was confirmed by Western blot. 
 
The investigation into Mur ligases and catalytic preference of substrates was expanded 
through acquisition of M. smegmatis MurC and MurD. Results demonstrated a 
significant substrate preference for the N-glycolylated muramic acid at a ratio of 43:1 
compared to the N-acetylated variant for MurC. This ratio decreased significantly to 
5:1 during assessment of MurD. This decrease in favourability as the amino acid stem 
was extended has also been observed in M. tuberculosis (Unpublished). Each 
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subsequent Mur ligase demonstrated a reduced catalytic preference until the ratio was 
almost 1:1 for M. tuberculosis MurF.  
 
The reason for this catalytic bias can potentially be narrowed down based upon previous 
investigations within this thesis. The M. smegmatis wild type and DNamH strains 
displayed matching phenotypic growth during aerobic conditions (Section 3.4). 
Extended anaerobic incubation to replicate dormancy followed by aerobic incubation 
to replicate resuscitation also produced equivalent propagation in both the wild type 
and NamH strains. These two results indicate that implementation of N-glycolylated 
peptidoglycan does not appear to be to either aid standard mycobacterial growth during 
aerobic conditions or aid growth from dormancy. Based upon chapter 3 and 4, N-
glycolylation appears to be utilised specifically against external enzymatic and 
antimicrobial recognition and lysis, and the catalytic bias of Mur ligases maybe to 
rapidly alter the peptidoglycan layer composition to resist these interactions. 
 
The binding affinity towards both N-glycolylated and N-acetylated Lipid II was 
expanded to include the primary PBPs of M. tuberculosis, PonA1 and PonA2. A two-
fold increase in affinity was noted for PonA1 towards the N-acetylated lipid over the 
N-glycolylated lipid, whereas binding affinity for PonA2 for either substrate was almost 
equal.   
 
 
7.5 Cell wall active drug discovery 
 
The pursuit of new antimicrobials to combat antimicrobial resistance has led to the 
generation of new screening techniques. The utilisation of ywaC, a gene which encoded 
an enzyme important in the catalysis of the bacterial alarmone (p)ppGpp were coupled 
with lux genes to produced real-time luminescence signals during bacterial stress 
(Czarny, et al. 2014) and screen potential antimicrobials. Nine cell wall active 
compounds, termed Pywac 1-9 were identified as impacting the mAGP complex in B. 
subtilis, through the exact targets were unknown.  
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The Pywac compounds MIC (Czarny, et al. 2014) values against B. subtilis were 
accurately confirmed in chapter 6, and an intermediate accumulation protocol was 
implemented to probe the cytosolic peptidoglycan precursor intermediates as potential 
targets (Section 6.6.2). Pywac 4 and 9 did not alter the intermediate elution profile 
produced by the compound free control. Pywac 1, 3, 5, 6 and 7 each produced a single 
previously unforeseen elution, though none of these peaks contained peptidoglycan 
precursors or co-factors. Pywac 8 increased the elution peak containing UDP-GlcNAc 
and Pywac 2 did the same for UDP-MurNAc-pentapeptide (DAP). With the targets of 
the majority of the Pywac compounds still unknown, the lipid synthesis portion of the 
pathway was also probed (Section 6.8.2). TLC analysis of 2x Pywac MIC incubation 
during lipid synthesis utilising B. subtilis cell membranes, identified the presence of 
lipids within each sample which when purified were all found to contain Lipid II. All 
Pywac compounds were determined to not impede lipid synthesis once equivalent lipid 
synthesis concentrations were established in each sample compared to the control, 
except Pywac 7 which reduced the lipid synthesised concentration by 80%. The 
presence of reduced quantities of Lipid II within the Pywac 7 sample indicate that the 
compound likely elicits its actions on either MraY or MurG. Further investigations are 
required. 
 
Initial investigations with a secondary Gram-positive organism, S. aureus was used due 
the variation in the amino acid attached to the third position compared to B. subtilis.  
This led to a noted accumulation attributed to two Pywac compounds (Section 6.9). 
Once again Pywac 8 led to an increase in the elution of a peak containing UDP-GlcNAc 
and Pywac 2 caused a significant single eluted peak containing UDP-MurNAc-
tripeptide (Lys). Inhibition of MurA by Pywac compound 2 would lead to accumulation 
of UDP-GlcNAc, other inhibitors with this target include fosfomycin (Bugg, 1999). 
Inhibition of MurF, DdlB or Alr would lead to accumulation of UDP-MurNAc-
tripeptide (Lys) (Bugg, 1999). D-cycloserine is an antimicrobial which also targets 
DdlB and Alr whereas MurF inhibition is caused by phosphinate inhibitors (Bugg, 
1999). Further investigations expanding the scope of possible targets to include the 
extracellular components of peptidoglycan biosynthesis such as PBPs, and investigate 
potential synergy and antagonism with other known antimicrobial to narrow possible 
targets. 
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7.6 Final conclusion 
 
The purpose of this thesis was to increase current understanding of a unique structural 
modification within the mycobacterial genus and the impact it elicits to aid in the 
virulence of the organism which is a global issue. Initial findings made throughout this 
thesis will provide a broader platform to examine N-glycolylation and the key traits 
which lead to its continued prevalence with the mycobacterial cell wall. 
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Appendix 1 
 
Plasmids and constructed vectors utilising acquired mycobacterial genes optimised for 
expression in E. coli mentioned in chapter 5. 
 
 
A1.1 Plasmids  
 
A1.1.1 pUC57 
 
The standard plasmid utilised for synthesised gene amplification within E. coli. The 
2710 base pair vector contained an Ampicillin resistance gene and a multiple cloning 
site (MCS). Restriction enzymes BsaI/NdeI and XhoI were used to insert synthesised 
genes. Genes synthesized by GenScript were acquired within this vector. The Vector 
map of pUC57 is presented in figure A1.1. 
 
 
 
Figure A1.1 The vector map of pUC57. The plasmid contained an Ampicillin resistance gene, a lacZ 
operon and a multiple cloning site (MCS). Modified from www.genscript.com 
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A1.1.2 pCOLD 
 
The pCOLD plasmid (4392 bp) was specifically applied to aid in expression of difficult 
to solubilise, low yield proteins. The vector contained an ampicillin resistance gene, a 
cold shock protein A (cspA) promoter, a translation enhancing element (TEE) and an 
N-terminal poly-histidine tag. The vector promoter cspA up-regulated downstream 
genes during cold-shock, which was an instant temperature decrease during incubation 
from 37°C to 15°C. The TEE was a five amino acid sequence (MNHKV) which 
enhances the translation of expressed proteins within E. coli. Incubation in cold 
conditions reduced expression of unwanted proteins, focusing expression of plasmid 
genes, increasing yield and solubility in comparison to standard strategies of E. coli 
expression. Restriction enzymes employed during this thesis on the pCOLD 
cloning/expression region were NdeI and XhoI. The vector map for pCOLD is 
exhibited in figure A1.2. 
 
 
 
Figure A1.2 The vector map of pCOLD. The plasmid contained an Ampicillin resistance gene, a 
multiple cloning site, an N-terminal poly-histidine tag sequence, a lac operator, a translation enhanced 
element (TEE) and a cold shock cspA promoter. Modified from www.clontech.com 
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A1.1.3 pET21b 
 
The T7 expression vector pET21b was 5442 bp containing a lac operator, an ampicillin 
resistance gene, a N-terminal T7 tag sequence and an optional C-terminal poly-histidine 
tag. Restriction enzymes utilised within the cloning/expression region of pET21b were 
NdeI and XhoI to excise the T7 tag. The vector map for pET21b is depicted in figure 
A1.3. 
 
 
 
Figure A1.3 Vector map of pET21b. The expression plasmid contained an Ampicillin resistance gene, 
a multiple cloning site, a C-terminal poly-histidine tag sequence and a lac operator. Adapted from 
www.merckmillipore.com 
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A1.2 Gene plasmid constructs  
 
Construct Description Selection Affinity tag Source 
pUC57:murA M. leprae murA (full 
length) in pUC57 
vector 
Optimised for 
expression in E. coli 
Ampicillin Untagged GenScript 
pUC57:murC M. leprae murC (full 
length) in pUC57 
vector Optimised for 
expression in E. coli 
Ampicillin Untagged GenScript 
Table A1.1 Gene constructs obtained in this project 
 
 
Construct Description Selection Affinity tag Source 
pCOLD:murA 
N-term 
M. leprae murA (full 
length) in pCOLD 
vector 
Ampicillin TEV-cleavable 
N-term 6-His 
Cloned for  
this project 
pCOLD:murA 
C-term 
M. leprae murA (full 
length) in pCOLD 
vector 
Ampicillin TEV-cleavable 
C-term 6-His 
Cloned for  
this project 
pCOLD:murA 
(mutant) 
N-term 
M. leprae murA 
D118C (full  
length) in pCOLD 
vector 
Ampicillin TEV-cleavable 
N-term 6-His 
Cloned for  
this project 
pCOLD:murA 
(Mutant) 
C-term 
M. leprae murA 
D118C (full  
length) in pCOLD 
vector 
Ampicillin TEV-cleavable 
C-term 6-His 
Cloned for  
this project 
pCOLD:murC 
N-term 
M. leprae murC (full 
length) in pCOLD 
vector 
Ampicillin TEV-cleavable 
N-term 6-His 
Cloned for  
this project 
pCOLD:murC 
C-term 
M. leprae murC (full 
length)  
in pCOLD vector 
Ampicillin TEV-cleavable 
C-term 6-His 
Cloned for  
this project 
pET21b:ponA1 M. tuberculosis 
ponA1 
(full length) in  
pET21b vector 
Ampicillin TEV-cleavable 
C-term 6-His 
Cloned for  
this project 
pET21b:ponA2 M. tuberculosis 
ponA2 
(full length) in  
pET21b vector 
Ampicillin TEV-cleavable 
C-term 6-His 
Cloned for  
this project 
Table A1.2 Gene constructs created in this project 
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Appendix 2 
 
Mass spectrometric analysis of synthesised peptidoglycan precursors, generated in the 
formation of biotinylated N-acetylated Lipid II (DAP) and biotinylated N-glycolylated 
Lipid II (DAP) in Chapter 4. 
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Figure A2.1: Negative ion mass spectra of synthesized UDP-MurNAc-pentapeptide DAP. (a): mass spectra with [M-H]- (observed 1192.34, expected 1192.33) 
and [M-2H]2- (observed 595.67, expected 595.66). (b): Zoomed in view of [M-3H]3- (observed 396.77, expected 396.77) (deconvoluted by MassLynxTM software 
(Waters, USA).  
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Figure A2.2: Negative ion mass spectra of synthesized UDP-MurNGlyc-pentapeptide DAP. (a): mass spectra with [M-2H]2- (observed 603.66, expected 
603.66) and [M-3H]3- (observed 402.10, expected 402.10). (b): Zoomed in view of [M-H]- (observed 1208.33 expected 1208.32) (deconvoluted by MassLynxTM 
software (Waters, USA).  
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Figure A2.3: Negative ion mass spectra of unlabelled UDP-MurNAc-pentapeptide DAP. (a): mass spectra with [M-H]- (observed 1192.34, expected 1192.33) 
and [M-2H]2- (observed 595.67, expected 595.66). (b): Zoomed in view of [M-3H]3- (observed 396.77, expected 396.77) (deconvoluted by MassLynxTM software 
(Waters, USA).  
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Figure A2.4: Negative ion mass spectra of biotinylated UDP-MurNAc-pentapeptide DAP. (a): mass spectra with [M-2H]2- (observed 708.70, expected 708.70). 
(b): Zoomed in view of [M-H]- (observed 1418.41, expected 1418.41) (deconvoluted by MassLynxTM software (Waters, USA). 
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Figure A2.5: Negative ion mass spectra of unlabelled UDP-MurNGlyc-pentapeptide DAP. (a): mass spectra with [M-2H]2- (observed 603.66, expected 603.66) 
and [M-3H]3- (observed 402.10, expected 402.10). (b): Zoomed in view of [M-3H]3- (deconvoluted by MassLynxTM software (Waters, USA). 
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Figure A2.6: Negative ion mass spectra of biotinylated UDP-MurNGlyc-pentapeptide DAP. (a): mass spectra with [M-2H]2- (observed 603.66, expected 
603.66) and [M-3H]3- (observed 402.10, expected 402.10). (b): Zoomed in view of [M-3H]3- (deconvoluted by MassLynxTM software (Waters, USA). 
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Figure A2.7: Negative ion mass spectra of biotinylated N-Acetylated Lipid II DAP. (a): mass spectra with [M-2H]2- (observed 1071.56, expected 1071.56) and 
[M-3H]3- (observed 714.04, expected 714.04). (b): Zoomed in view of [M-H]- (observed 2144.13, expected 2144.13) (deconvoluted by MassLynxTM software 
(Waters, USA).   
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Figure A2.8: Negative ion mass spectra of biotinylated N-Glycolylated Lipid II DAP. (a): mass spectra with [M-2H]2- (observed 1080.05, expected 1080.05) 
and [M-3H]3- (observed 719.70, expected 719.70). (b): Zoomed in view of [M-H]- (observed 2161.11, expected 2161.11) (deconvoluted by MassLynxTM software 
(Waters, USA).   
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Appendix 3 
 
Mass spectrometric analysis of potential peptidoglycan intermediate accumulated elutions, 
isolated by size exclusion chromatography and ion exchange chromatography from chapter 6. 
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Figure A3.1: Negative ion mass spectrometry of peptidoglycan standard UDP-GlcNAc. (a): mass spectra with [M-H]- (observed 606.07, expected 606.07) and [M-2H]2- 
(observed 302.53, expected 302.53). (b): Zoomed in view of [M-H]- peak shown in (a). (deconvoluted by MassLynxTM software (Waters, USA). 
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Figure A3.2: Negative ion mass spectrometry of peptidoglycan standard UDP- enolpyruvyl-GlcNAc. (a): mass spectra with [M-H]- (observed 676.08, expected 676.07) 
and [M-2H]2- (observed 337.53, expected 337.53). (b): Zoomed in view of [M-2H]2- peak shown in (a). (deconvoluted by MassLynxTM software (Waters, USA). 
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Figure A3.3: Negative ion mass spectrometry of peptidoglycan standard UDP-MurNAc. (a): mass spectra with [M-H]- (observed 678.09, expected 678.09). (b): Zoomed 
in view of [M-2H]2- (observed 338.54, expected 338.54). (deconvoluted by MassLynxTM software (Waters, USA). 
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Figure A3.4: Negative ion mass spectrometry of peptidoglycan standard UDP-MurNAc-monopeptide (L-Alanine). (a): mass spectra with [M-H]- (observed 749.14, 
expected 749.13). (b): Zoomed in view of [M-2H]2- (observed 374.07, expected 374.06). (deconvoluted by MassLynxTM software (Waters, USA). 
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Figure A3.5: Negative ion mass spectrometry of peptidoglycan standard UDP-MurNAc-dipeptide (L-Ala-D-Glu). (a): mass spectra with [M-H]- (observed 878.18, 
expected 878.17) [M-2H]2- (observed 438.59, expected 438.58). (b): Zoomed in view of [M-2H]2- peak shown in (a). (deconvoluted by MassLynxTM software (Waters, USA).
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Figure A3.6: Negative ion mass spectrometry of peptidoglycan standard UDP-MurNAc-tripeptide (L-Ala-D-Glu-m-DAP). (a): mass spectra with [M-H]- (observed 
1050.26, expected 1050.25) [M-2H]2- (observed 524.63, expected 524.62). (b): Zoomed in view of [M-3H]3- (observed 349.41, expected 349.41). (deconvoluted by 
MassLynxTM software (Waters, USA).
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Figure A3.7: Negative ion mass spectrometry of peptidoglycan standard UDP-MurNAc-pentapeptide (L-Ala-D-Glu-m-DAP-D-Ala-D-Ala). (a): mass spectra with [M-
H]- (observed 1192.34, expected 1192.33) and [M-2H]2- (observed 595.67, expected 595.66) (b): Zoomed in view of [M-3H]3- (observed 396.77, expected 396.77). 
(deconvoluted by MassLynxTM software (Waters, USA).
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Figure A3.8: Negative ion mass spectrometry of the isolated accumulated peak (i) from B. subtilis control. (a): full mass spectra (no identifiable m/z). (b): 
mass spectra of UDP-GlcNAc [M-H]- (observed 606.08, expected 606.07) (zoomed in view of (a)). (deconvoluted by MassLynxTM software (Waters, USA). 
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Figure A3.9: Negative ion mass spectrometry of the isolated accumulated peak (ii) from B. subtilis control. (a): full mass spectra (no identifiable m/z). (b): 
mass spectra of UDP-GlcNAc [M-H]- (observed 606.08, expected 606.07) (zoomed in view of (a)). (deconvoluted by MassLynxTM software (Waters, USA). 
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Figure A3.10: Negative ion mass spectrometry of the isolated accumulated peak (iii) from B. subtilis control. (a): full mass spectra (no identifiable m/z). (b): 
mass spectra of UDP-MurNAc-pentapeptide (DAP) [M-2H]2- (observed 595.67, expected 595.66) (zoomed in view of (a)). (deconvoluted by MassLynxTM 
software (Waters, USA). 
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Figure A3.11: Negative ion mass spectrometry of the isolated accumulated peak (iv) from B. subtilis control. Peak (iv): (a): full mass spectra (no identifiable 
m/z). (b): mass spectra of UDP-MurNAc-pentapeptide (DAP) [M-2H]2- (observed 595.68, expected 595.66) (zoomed in view of (a)). (deconvoluted by 
MassLynxTM software (Waters, USA). 
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Figure A3.12: Negative ion mass spectrometry of the isolated accumulated peak (v) from B. subtilis control. (a): full mass spectra (no identifiable m/z). (b): 
mass spectra of UDP-MurNAc-dipeptide [M-H]- (observed 878.19, expected 878.17) (zoomed in view of (a)). (c): Mass spectra of [M-2H]2- (observed 438.59, 
expected 438.58). (deconvoluted by MassLynxTM software (Waters, USA). 
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Figure A3.13: Negative ion mass spectrometry of the isolated accumulated peak (vi) from B. subtilis control. Full mass spectra (no identifiable m/z). 
(deconvoluted by MassLynxTM software (Waters, USA). 
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Figure A3.14: Negative ion mass spectrometry of the isolated accumulated peak (vii) from B. subtilis control. Full mass spectra (no identifiable m/z) 
(deconvoluted by MassLynxTM software (Waters, USA). 
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Figure A3.15: Negative ion mass spectrometry of the isolated accumulated peak of UDP-MurNAc-pentapeptide (DAP) from B. subtilis incubated with 2x 
MIC vancomycin. (a): mass spectra of [M-2H]2- (observed 595.66, expected 595.66). (b): Observed isotope distribution of [M-2H]2- (deconvoluted by 
MassLynxTM software (Waters, USA). 
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Figure A3.16: Negative ion mass spectrometry of the isolated accumulated peak of UDP-MurNAc-pentapeptide (DAP) from B. subtilis incubated with 5x 
MIC vancomycin. (a): mass spectra with [M-2H]2- (observed 595.67, expected 595.66) and [M-3H]3- (observed 396.77, expected 396.77) (deconvoluted by 
MassLynxTM software (Waters, USA). (b): Observed isotope distribution of [M-2H]2- (zoomed in view of [M-2H]2- peak shown in (a)). (c): Mass spectra of [M-
3H]3-. 
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Figure A3.17: Negative ion mass spectrometry of the isolated accumulated peak (i) from B. subtilis cells incubated with 2x MIC pywac 1. Full mass spectra, 
no identifiable peptidoglycan intermediate m/z (deconvoluted by MassLynxTM software (Waters, USA). 
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Figure A3.18: Negative ion mass spectrometry of the isolated accumulated peak from B. subtilis incubated with 2x MIC pywac 3. Full mass spectra, no 
identifiable peptidoglycan intermediate m/z (deconvoluted by MassLynxTM software (Waters, USA). 
 
  
 
 
 
 
 378 
 
Figure A3.19: Negative ion mass spectrometry of the isolated accumulated peak from B. subtilis incubated with 2x MIC pywac 5. Full mass spectra (no 
identifiable m/z) (deconvoluted by MassLynxTM software (Waters, USA). 
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Figure A3.20: Negative ion mass spectrometry of the isolated accumulated peak from B. subtilis incubated with 2x MIC pywac 6. Full mass spectra (no 
identifiable m/z) (deconvoluted by MassLynxTM software (Waters, USA). 
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Figure A3.21: Negative ion mass spectrometry of the isolated accumulated peak from B. subtilis incubated with 2x MIC pywac 7. Full mass spectra (no 
identifiable m/z) (deconvoluted by MassLynxTM software (Waters, USA). 
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Figure A3.22: Negative ion mass spectrometry of the isolated accumulated peak (i) from B. subtilis incubated with 2x MIC pywac 2. Full mass spectra, (no 
identifiable peptidoglycan intermediate m/z) (deconvoluted by MassLynxTM software (Waters, USA). 
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Figure A3.23: Negative ion mass spectrometry of the isolated accumulated peak (ii) from B. subtilis incubated with 2x MIC pywac 2. (a): full mass spectra 
of UDP-MurNAc-pentapeptide (DAP) with [M-2H]2- (observed 595.67, expected 595.66) and [M-3H]3- (observed 396.77, expected 396.77). (deconvoluted by 
MassLynxTM software (Waters, USA). (b): Observed isotope distribution of [M-2H]2- (zoomed in view of [M-2H]2- peak shown in (a)). (c): Mass spectra of [M-
3H]3-.  
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Figure A3.24: Negative ion mass spectrometry of the isolated accumulated peak of B. subtilis cells incubated with 2x MIC pywac 8. (a): mass spectra (no 
identifiable m/z). (b): Observed isotope distribution of UDP-GlcNAc [M-H]- (zoomed in view of [M-H]- peak shown in (a)) (observed 606.08, expected 606.07) 
(deconvoluted by MassLynxTM software (Waters, USA). 
 
 
 
 
 
 384 
 
Figure A3.25: Negative ion mass spectrometry of ATP ADP and AMP standards. (a): mass spectra with (i) ATP [M-H]- (observed 505.98, expected 505.98), 
(ii) ADP [M-H]- (observed 426.02, expected 426.02) and (iii) AMP [M-H]- (observed 346.05, expected 346.05). (b): Zoomed in view of ATP [M-H]- peak shown 
in (a)). (deconvoluted by MassLynxTM software (Waters, USA). 
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Figure A3.26: Negative ion mass spectrometry of NADPH. (a): mass spectra with [M-2H]2- (observed 371.54, expected 371.53) (deconvoluted by MassLynxTM 
software (Waters, USA). (b): Zoomed in view of [M-2H]2- peak shown in (a)).  
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Figure A3.27: Negative ion mass spectrometry of control Lipid II DAP synthesis. (a): mass spectra with Lipid II DAP [M-2H]2- (observed 958.51, expected 
958.51) (deconvoluted by MassLynxTM software (Waters, USA). (b): mass spectra with [M-H]- (observed 1918.03, expected 1918.04).  
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Figure A3.28: Negative ion mass spectrometry of Lipid II (DAP) synthesis sample incubated with 50 µM pywac compound 1.  (a): mass spectra with [M-
2H]2- (observed 958.51, expected 958.51). (b): Observed isotope distribution of [M-2H]2- (zoomed in view of [M-2H]2- peak shown in (a)). (b): Mass spectra of [M-
3H]3- (observed 638.67, expected 638.67). (deconvoluted by MassLynxTM software (Waters, USA). 
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Figure A3.29: Negative ion mass spectrometry of Lipid II (DAP) synthesis sample incubated with 50 µM pywac compound 2. (a): mass spectra with [M-
2H]2- (observed 958.52, expected 958.51). (b): Observed isotope distribution of [M-2H]2- (zoomed in view of [M-2H]2- peak shown in (a)). (c): Mass spectra of [M-
3H]3- (observed 638.68, expected 638.67).  (deconvoluted by MassLynxTM software (Waters, USA). 
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Figure A3.30: Negative ion mass spectrometry of Lipid II (DAP) synthesis sample incubated with 50 µM pywac compound 3. (a): mass spectra with [M-
2H]2- (observed 958.52, expected 958.51). (b): Observed isotope distribution of [M-2H]2- (zoomed in view of [M-2H]2- peak shown in (a)). (c): Mass spectra of [M-
3H]3- (observed 638.68, expected 638.67). (deconvoluted by MassLynxTM software (Waters, USA). 
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Figure A3.31: Negative ion mass spectrometry of Lipid II (DAP) synthesis sample incubated with 50 µM pywac compound 4. (a): mass spectra with [M-
2H]2- (observed 958.52, expected 958.51). (b): Observed isotope distribution of [M-2H]2- (zoomed in view of [M-2H]2- peak shown in (a)). (c): Mass spectra of [M-
3H]3- (observed 638.67, expected 638.67). (deconvoluted by MassLynxTM software (Waters, USA). 
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Figure A3.32: Negative ion mass spectrometry of Lipid II (DAP) synthesis sample incubated with 50 µM pywac compound 5. (a): mass spectra with [M-
2H]2- (observed 958.52, expected 958.51). (b): Observed isotope distribution of [M-2H]2- (zoomed in view of [M-2H]2- peak shown in (a)). (c): Mass spectra of [M-
3H]3- (observed 638.68, expected 638.67). (deconvoluted by MassLynxTM software (Waters, USA). 
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Figure A3.33: Negative ion mass spectrometry of Lipid II (DAP) synthesis sample incubated with 50 µM pywac compound 6. (a): mass spectra with [M-
2H]2- (observed 958.52, expected 958.51). (b): Observed isotope distribution of [M-2H]2- (zoomed in view of [M-2H]2- peak shown in (a)). (c): Mass spectra of [M-
3H]3- (observed 638.68, expected 638.67). (deconvoluted by MassLynxTM software (Waters, USA). 
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Figure A3.34: Negative ion mass spectrometry of Lipid II (DAP) synthesis sample incubated with 50 µM pywac compound 7. (a): mass spectra with [M-
2H]2- (observed 958.52, expected 958.51). (b): Observed isotope distribution of [M-2H]2- (zoomed in view of [M-2H]2- peak shown in (a)). (deconvoluted by 
MassLynxTM software (Waters, USA). 
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Figure A3.35: Negative ion mass spectrometry of Lipid II (DAP) synthesis sample incubated with 50 µM pywac compound 8. (a): mass spectra with [M-
2H]2- (observed 958.52, expected 958.51). (b): Observed isotope distribution of [M-2H]2- (zoomed in view of [M-2H]2- peak shown in (a)). (c): Mass spectra of [M-
3H]3- (observed 638.68, expected 638.67). (deconvoluted by MassLynxTM software (Waters, USA). 
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Figure A3.36: Negative ion mass spectrometry of Lipid II (DAP) synthesis sample incubated with 50 µM pywac compound 9. (a): mass spectra with [M-
2H]2- (observed 958.52, expected 958.51) [M-3H]3- (observed 638.68, expected 638.67). (b): Observed isotope distribution of [M-2H]2- (zoomed in view of [M-
2H]2- peak shown in (a)). (c): Mass spectra of [M-3H]3-. (deconvoluted by MassLynxTM software (Waters, USA). 
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Figure A3.37: Negative ion mass spectrometry of UDP-GlcNAc present during Lipid II DAP synthesis incubated with 50 µM pywac 2. UDP-GlcNAc (a): 
mass spectra with [M-H]- (observed 606.07, expected 606.07) and [M-2H]2- (observed 302.53, expected 302.53) (deconvoluted by MassLynxTM software (Waters, 
USA). (b): Observed isotope distribution of [M-H]- (zoomed in view of [M-H]- peak shown in (a)). (c): Observed isotope distribution of [M-2H]2- (zoomed in view 
of [M-2H]2- peak shown in (a)). 
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Figure A3.38: Negative ion mass spectrometry of UDP-GlcNAc present during Lipid II DAP synthesis incubated with 50 µM pywac 3. UDP-GlcNAc (a): 
mass spectra with [M-H]- (observed 606.07, expected 606.07) and [M-2H]2- (observed 302.53, expected 302.53) (deconvoluted by MassLynxTM software (Waters, 
USA). (b): Observed isotope distribution of [M-H]- (zoomed in view of [M-H]- peak shown in (a)). (c): Observed isotope distribution of [M-2H]2- (zoomed in view 
of [M-2H]2- peak shown in (a)). 
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Figure A3.39: Negative ion mass spectrometry of MurNAc-tripeptide Lys standard. (a): mass spectra with [M-H]- (observed 1006.27, expected 1006.26) and 
[M-2H]2- (observed 502.63, expected 502.63) (deconvoluted) by MassLynxTM software (Waters, USA). (b): Zoomed in view of [M-3H]3- (observed 334.75, 
expected 334.75) peak shown in (a). 
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Figure A3.40: Negative ion mass spectrometry of MurNAc-pentapeptide Lys standard. (a): mass spectra with [M-H]- (observed 1148.34, expected 1148.34), 
[M-2H]2- (observed 573.67, expected 573.66) (deconvoluted by MassLynxTM software (Waters, USA). (b): Zoomed in view of [M-3H]3- (observed 382.11, 
expected 382.10). 
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Figure A3.41: Negative ion mass spectrometry of the isolated accumulated peak (i) from S. aureus control. (a): full mass spectra of accumulated peak (i), no 
identifiable m/z. (b): mass spectra of UDP-GlcNAc [M-H]- (observed 606.07, expected 606.07) (zoomed in view of (a)). (deconvoluted by MassLynxTM software 
(Waters, USA). 
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Figure A3.42: Negative ion mass spectrometry of the isolated accumulated peak (ii) from S. aureus control. (a): full mass spectra of accumulated peak (ii), 
no identifiable m/z. (b): mass spectra of UDP-GlcNAc [M-H]- (observed 606.07, expected 606.07) (zoomed in view of (a)). (deconvoluted by MassLynxTM 
software (Waters, USA). 
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Figure A3.43: Negative ion mass spectrometry of the isolated accumulated peak (iii) from S. aureus control. (a): full mass spectra of accumulated peak (iii), 
no identifiable m/z. (b): mass spectra of UDP-MurNAc-pentapeptide Lys [M-2H]2- (observed 573.67, expected 573.66) (zoomed in view of (a)). (deconvoluted by 
MassLynxTM software (Waters, USA). 
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Figure A3.44: Negative ion mass spectrometry of the isolated accumulated peak (iv) from S. aureus control. (a): full mass spectra of accumulated peak (iv), 
no identifiable m/z. (b): mass spectra of UDP-MurNAc-pentapeptide Lys [M-H]- (observed 1148.34, expected 1148.34) (zoomed in view of (a)). (deconvoluted by 
MassLynxTM software (Waters, USA). 
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Figure A3.45: Negative ion mass spectrometry of the isolated accumulated peak (v) from S. aureus control. (a): full mass spectra of accumulated peak (v), 
no identifiable m/z. (b): mass spectra of UDP-MurNAc-pentapeptide Lys [M-H]- (observed 1148.34, expected 1148.34) (zoomed in view of (a)). (deconvoluted by 
MassLynxTM software (Waters, USA). 
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Figure A3.46: Negative ion mass spectrometry of the isolated accumulated peak (vi) from S. aureus control. No identifiable m/z observed. (deconvoluted by 
MassLynxTM software (Waters, USA).  
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Figure A3.47 Negative ion mass spectrometry of the isolated accumulated peak (vii) from S. aureus control. No identifiable m/z observed. (deconvoluted by 
MassLynxTM software (Waters, USA).  
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Figure A3.48: Negative ion mass spectrometry of the isolated accumulated peak (viii) from S. aureus control. No identifiable m/z observed. (deconvoluted 
by MassLynxTM software (Waters, USA).  
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Figure A3.49: Negative ion mass spectrometry of the isolated accumulated peak (ix) from S. aureus control. No identifiable m/z observed. (deconvoluted by 
MassLynxTM software (Waters, USA).  
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Figure A3.50: Negative ion mass spectrometry of the isolated accumulated peak (x) from S. aureus control. No identifiable m/z observed. (deconvoluted by 
MassLynxTM software (Waters, USA).  
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Figure A3.51: Negative ion mass spectrometry of the isolated accumulated peak of UDP-MurNAc-pentapeptide (Lys) from S. aureus incubated with 2x 
MIC vancomycin monoQ fraction. (a): mass spectra with [M-H]- (observed 1148.34, expected 1148.34), [M-2H]2- (observed 573.67, expected 573.66) 
(deconvoluted by MassLynxTM software (Waters, USA). (b): Zoomed in view of [M-H]- peak shown in (a). 
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Figure A3.52: Negative ion mass spectrometry of the isolated accumulated peak from S. aureus incubated with 4 µM pywac 1. Full mass spectra (no 
identifiable m/z) (deconvoluted by MassLynxTM software (Waters, USA). 
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Figure A3.53: Negative ion mass spectrometry of the isolated accumulated peak of UDP-MurNAc-tripeptide (Lys) from S. aureus incubated with 2 µM 
pywac 2. (a): mass spectra with [M-2H]2- (observed 502.63, expected 502.63) (deconvoluted by MassLynxTM software (Waters, USA). (b): Mass spectra of [M-
H]- (observed 1006.27, expected 1006.26). (c): Observed isotope distribution of [M-2H]2- (zoomed in view of [M-2H]2- peak shown in (a)).  
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Figure A3.54: Negative ion mass spectrometry of the isolated accumulated peak from S. aureus incubated with 8 µM pywac 6. Full mass spectra (no 
identifiable m/z) (deconvoluted by MassLynxTM software (Waters, USA). 
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Figure A3.55: Negative ion mass spectrometry of the isolated accumulated peak of UDP-GlcNAc from S. aureus incubated with 8 µM pywac 8. (a): mass 
spectra (no identifiable m/z). (b): Observed isotope distribution of UDP-GlcNAc [M-H]- (zoomed in view of [M-H]- peak shown in (a)) (observed 606.08, expected 
606.07) (deconvoluted by MassLynxTM software (Waters, USA). 
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Figure A3.56: Negative ion mass spectrometry of the isolated accumulated peak from S. aureus incubated with 4 µM pywac 9. Full mass spectra (no 
identifiable m/z) (deconvoluted by MassLynxTM software (Waters, USA). 
 
 
 
 
 
 
 
